text,title,id,project_number,terms,administration,organization,mechanism,year,award_amount,cong_dist,score
"Population Genetics Theory    DESCRIPTION (provided by applicant): Four areas of theoretical population genetics will be studied. In the first, we will develop mathematical and statistical framework for studying the evolution of genes that affect how other sets of genes interact with one another. This theory helps in understanding conditions under which the genome can be expected to become modular in its production of phenotypes, as well as when synergy between mutations in different genes should be produced by evolution. We shall study how the pattern of interaction between deleterious mutations evolves as a function of the mutation rate, the recombination rate, and the degree of fitness loss of each mutation. We shall also study buildup of statistical association between genes that influence culturally transmitted traits that are associated either through transmission or through fitness. The second area of study concerns the evolution of pathogens such as influenza. Here we build models to predict the accumulation of mutations during epidemics and pandemics in a way that can assist in guiding vaccination strategies. We will develop algorithms that search for potential recombinants and reassortants among a collection of up to 1000 viral sequences. Here we aim to devise a statistical test to indicate whether identified recombinants or reassortants are spurious or statistically significant. Our recent theory of niche construction will form the basis of studies of how pathogens might evolve in response to human actions that they induce, such as use of antibiotics. The final research area will develop multiple-gene models for sex-linked control of genomic imprinting. These will include cis and trans modifiers of imprinting. Fertility selection as well as sex- specific viabilities will be studied in order to clarify the role of multiple paternities, which has been proposed as a driving force in the evolution of genomic imprinting. Genomic data from mammalian species will be analyzed using tools from statistical learning in order to predict which genes are likely to be imprinted. Correlations between DMA sequence properties and predicted imprinting status based on life history characteristics will also be sought.           ",Population Genetics Theory,7986659,R01GM028016,"['genome sequencing ', ' Epidemic ', ' fitness ', ' Genetic Epistasis ', ' genetic epistases ', ' gene x gene interaction ', ' Interaction Deviation ', ' Epistatic Deviation ', ' Epistasis ', ' Data ', ' Recombinants ', ' Taxon ', ' Collection ', ' transmission process ', ' Transmission ', ' Evolution ', ' Characteristics ', ' sex ', ' Modification ', ' Development ', ' developmental ', ' Fertility ', ' Fecundity ', ' Fecundability ', ' pandemic disease ', ' pandemic ', ' DNA Sequence ', ' Affect ', ' Genes ', ' Population Genetics ', ' Genome ', ' base ', ' Haploidy ', ' Haploid ', ' Human ', ' Modern Man ', ' Man (Taxonomy) ', ' Algorithms ', ' Area ', ' Specific qualifier value ', ' Specified ', ' Variant ', ' Variation ', ' Alleles ', ' Allelomorphs ', ' Link ', ' Influenza ', ' influenza infection ', ' flu infection ', ' Grippe ', ' Laboratories ', ' Genomic Imprinting ', ' Parental Imprinting ', ' Genetic Imprinting ', ' Mammals ', ' Mammalia ', ' Genetic Models ', ' Mutation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Organism ', ' living system ', ' Phenotype ', ' Genetic ', ' gene function ', ' Antibiotics ', ' Miscellaneous Antibiotic ', ' Antibiotic Drugs ', ' Antibiotic Agents ', ' Antigens ', ' immunogen ', ' ATGN ', ' Production ', ' tool ', ' Genetic Recombination ', ' Recombination ', ' DNA recombination (naturally occurring) ', ' DNA Recombination ', ' Research ', ' Role ', ' social role ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Testing ', ' Time ', ' Tweens ', ' Vaccination ', ' Virus ', ' General Viruses ', ' Complex ', ' Pattern ', ' Bacteria ', ' Bacteriophages ', ' bacterial virus ', ' Phages ', ' Viral ', ' Drug Formulations ', ' Formulation ', ' life history ', ' trait ', ' father role ', ' paternity ', ' research study ', ' experimental study ', ' experimental research ', ' experiment ', ' social ', ' influenza epidemic ', ' Flu epidemic ', ' Modeling ', ' Property ', ' LOINC Axis 2 Property ', ' response ', ' theories ', ' Genomics ', ' vaccination strategy ', ' pathogen ', ' driving force ', ' imprint ', ' Computers ', ' ']",NIGMS,STANFORD UNIVERSITY,R01,2010,142237,CA-18,0.14029551827638234
"Population Genetics Theory    DESCRIPTION (provided by applicant): Four areas of theoretical population genetics will be studied. In the first, we will develop mathematical and statistical framework for studying the evolution of genes that affect how other sets of genes interact with one another. This theory helps in understanding conditions under which the genome can be expected to become modular in its production of phenotypes, as well as when synergy between mutations in different genes should be produced by evolution. We shall study how the pattern of interaction between deleterious mutations evolves as a function of the mutation rate, the recombination rate, and the degree of fitness loss of each mutation. We shall also study buildup of statistical association between genes that influence culturally transmitted traits that are associated either through transmission or through fitness. The second area of study concerns the evolution of pathogens such as influenza. Here we build models to predict the accumulation of mutations during epidemics and pandemics in a way that can assist in guiding vaccination strategies. We will develop algorithms that search for potential recombinants and reassortants among a collection of up to 1000 viral sequences. Here we aim to devise a statistical test to indicate whether identified recombinants or reassortants are spurious or statistically significant. Our recent theory of niche construction will form the basis of studies of how pathogens might evolve in response to human actions that they induce, such as use of antibiotics. The final research area will develop multiple-gene models for sex-linked control of genomic imprinting. These will include cis and trans modifiers of imprinting. Fertility selection as well as sex- specific viabilities will be studied in order to clarify the role of multiple paternities, which has been proposed as a driving force in the evolution of genomic imprinting. Genomic data from mammalian species will be analyzed using tools from statistical learning in order to predict which genes are likely to be imprinted. Correlations between DMA sequence properties and predicted imprinting status based on life history characteristics will also be sought.           ",Population Genetics Theory,7869395,R01GM028016,"['genome sequencing ', ' Epidemic ', ' fitness ', ' Genetic Epistasis ', ' genetic epistases ', ' gene x gene interaction ', ' Interaction Deviation ', ' Epistatic Deviation ', ' Epistasis ', ' Data ', ' Recombinants ', ' Taxon ', ' Collection ', ' transmission process ', ' Transmission ', ' Evolution ', ' Characteristics ', ' sex ', ' Modification ', ' Development ', ' developmental ', ' Fertility ', ' Fecundity ', ' Fecundability ', ' pandemic disease ', ' pandemic ', ' DNA Sequence ', ' Affect ', ' Genes ', ' Population Genetics ', ' Genome ', ' base ', ' Haploidy ', ' Haploid ', ' Human ', ' Modern Man ', ' Man (Taxonomy) ', ' Algorithms ', ' Area ', ' Specific qualifier value ', ' Specified ', ' Variant ', ' Variation ', ' Alleles ', ' Allelomorphs ', ' Link ', ' Influenza ', ' influenza infection ', ' flu infection ', ' Grippe ', ' Laboratories ', ' Genomic Imprinting ', ' Parental Imprinting ', ' Genetic Imprinting ', ' Mammals ', ' Mammalia ', ' Genetic Models ', ' Mutation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Organism ', ' living system ', ' Phenotype ', ' Genetic ', ' gene function ', ' Antibiotics ', ' Miscellaneous Antibiotic ', ' Antibiotic Drugs ', ' Antibiotic Agents ', ' Antigens ', ' immunogen ', ' ATGN ', ' Production ', ' tool ', ' Genetic Recombination ', ' Recombination ', ' DNA recombination (naturally occurring) ', ' DNA Recombination ', ' Research ', ' Role ', ' social role ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Testing ', ' Time ', ' Tweens ', ' Vaccination ', ' Virus ', ' General Viruses ', ' Complex ', ' Pattern ', ' Bacteria ', ' Bacteriophages ', ' bacterial virus ', ' Phages ', ' Viral ', ' Drug Formulations ', ' Formulation ', ' life history ', ' trait ', ' father role ', ' paternity ', ' research study ', ' experimental study ', ' experimental research ', ' experiment ', ' social ', ' influenza epidemic ', ' Flu epidemic ', ' Modeling ', ' Property ', ' LOINC Axis 2 Property ', ' response ', ' theories ', ' Genomics ', ' vaccination strategy ', ' pathogen ', ' driving force ', ' imprint ', ' Computers ', ' ']",NIGMS,STANFORD UNIVERSITY,R01,2010,261556,CA-18,0.14029551827638234
"Informatic profiling of clinically relevant mutation    DESCRIPTION (provided by applicant):       Informatic profiling of clinically relevant mutation      Many approaches have been developed to predict whether a mutation associated with a disease is actually causative. In contrast to other approaches to predicting deleterious mutations, our approach, called in silico functional profiling, starts with learning residue-specific protein function and then estimates when it is disrupted. This research will continue our efforts to characterize what the underlying molecular disruption a mutation is causing and thereby improve accuracy of these approaches. We will do this by building a database that links clinical observation with molecular phenotype and using this to develop bioinformatic models of mutation. This is particularly relevant to cancer, since many mutations in cancer are both poorly understood and simply associated with cancer. The hypothesis of this proposal is that computational methods that predict a specific residue function using protein sequence and structure can classify known disease-associated mutations based on their function better than existing computational methods, and less expensively than experimental assays. In short, we will describe each phenotypically annotated mutation as possibly affecting catalysis, protein interactions, posttranslational modification and stability of the protein. The structural environments around disease associated mutations can be characterized using a combination of computational biochemical methods based on first principles of biomolecular structure and function and statistical informatics methods. We will continue this research by implementing the following steps: First, we will build a database of how often mutations in cancer, pharmacogenetics, Mendelian and complex disease are disrupted by phosphorylation, stability, catalysis, protein interaction and other posttranslational modifications. Second, we will build a bioinformatic model of disruption using machine learning methods trained with these and other commonly used features. Finally, we will link these to clinical observation by annotating disease causing mutation with an ontology of diseases and integrate these predictions into databases of mutation. Thus, we will link clinical observation with molecular phenotypes by building a useful database and new models of how mutations cause disease.          ",Informatic profiling of clinically relevant mutation,7929905,R01LM009722,"['Acetylation ', ' Bioinformatics ', ' Bio-Informatics ', ' Disease ', ' disease/disorder ', ' Disorder ', ' DNA-Binding Proteins ', ' Environment ', ' Address ', ' Data Set ', ' Dataset ', ' protein structure ', ' Data ', ' Mutation Spectra ', ' Ontology ', ' Ubiquitination ', ' ubiquitin conjugation ', ' ubiquination ', ' Ubiquitinoylation ', ' Ubiquitilation ', ' Principal Investigator ', ' Molecular ', ' protein function ', ' Affect ', ' base ', ' Goals ', ' improved ', ' Hereditary Disease ', ' hereditary disorder ', ' genetic disorder ', ' Molecular Disease ', ' Genetic Diseases ', ' Genetic Condition ', ' Site ', ' Clinical ', ' Variant ', ' Variation ', ' Biochemical ', ' Link ', ' Training ', ' Laboratories ', ' Laboratory Research ', ' Learning ', ' Databases ', ' data repository ', ' clinical data repository ', ' Electronic Database ', ' Electronic Databank ', ' Databanks ', ' Data Bases ', ' Data Banks ', ' Funding ', ' Medicine ', ' Amino Acid Sequence ', ' protein sequence ', ' Primary Protein Structure ', ' Methods ', ' Mutation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Collaborations ', ' Pharmacogenetics ', ' Genetic ', ' Phosphorylation ', ' Protein Phosphorylation ', ' Productivity ', ' Post-Translational Protein Processing ', ' Protein Modification ', ' Posttranslational Protein Processing ', ' Posttranslational Modifications ', ' Post-Translational Protein Modification ', ' Post-Translational Modifications ', ' Post-Translational Modification Protein/Amino Acid Biochemistry ', ' tool ', ' Proteins ', ' gene product ', ' Research ', ' Research Personnel ', ' Researchers ', ' Investigators ', ' Resources ', ' Research Resources ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Computational Biology ', ' programs ', ' Testing ', ' Variation (Genetics) ', ' allelic variant ', ' Genetic Variation ', ' Genetic Diversity ', ' Gene variant ', ' Work ', ' Inherited ', ' Hereditary ', ' Complex ', ' Amino Acid Substitution ', ' Biological Assay ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' Biology ', ' experience ', ' protein structure function ', ' computer science ', ' Informatics ', ' Catalytic Domain ', ' Catalytic Subunit ', ' Catalytic Site ', ' Catalytic Region ', ' Catalytic Core ', ' Structure ', ' Basic Science ', ' Basic Research ', ' Malignant Neoplasms ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Human Resources ', ' personnel ', ' Manpower ', ' Positioning Attribute ', ' Position ', ' Catalysis ', ' Peptide Sequence Determination ', ' Protein Sequencing Molecular Biology ', ' Protein Sequencing ', ' Protein Sequence Determinations ', ' Amino Acid Sequence Determinations ', ' falls ', ' Modeling ', ' protein protein interaction ', ' Clinical Informatics ', ' cancer classification ', ' disease phenotype ', ' computerized tools ', ' computational tools ', ' novel strategies ', ' novel strategy ', ' novel approaches ', ' new approaches ', ' innovation ', ' innovative ', ' innovate ', ' clinically relevant ', ' clinical relevance ', ' translational medicine ', ' disease-causing mutation ', ' clinical care ', ' molecular phenotype ', ' Computer Simulation ', ' virtual simulation ', ' in silico ', ' computerized simulation ', ' computerized modeling ', ' computer based models ', ' computational simulation ', ' computational models ', ' computational modeling ', ' Mathematical Models and Simulations ', ' Mathematical Model Simulation ', ' Computerized Models ', ' Computer based Simulation ', ' Computer Models ', ' Computing Methodologies ', ' computer methods ', ' computational methods ', ' computational methodology ', ' ']",NLM,BUCK INSTITUTE FOR RESEARCH ON AGING,R01,2010,383293,CA-02,0.2831497919721447
"Improve predictions of structure and function by PredictProtein    DESCRIPTION (provided by applicant):       SUMMARY: Over 25,000 researchers in the US and over 50,000 in 120 other countries have exploited the PredictProtein (PP) Internet server to analyze proteins by homology-transfer and by eye novo predictions of protein structure and function. Here, we propose technical and scientific solutions that will improve the functionality of PP and its extension portal META-PP. Many technical changes will remain hidden to users and are required to increase the maintainability, scalability, and portability of these servers. New Graphical User Interfaces are one proposed solution that will visibly impact the service. The scientific solutions address two related tasks pertaining to the prediction of structure and function. The first is to predict the effect of mutations. We propose the development of novel machine learning-based methods to distinguish between mutations that affect structure, function, or have no apparent phenotype. Our final method will be applied to the screening of SNP data from our experimental colleagues at Columbia, as well as to the prediction of SNP effects in public databases. The second major task is the identification of natively unstructured regions and their functional classification. Proteins that do not adopt regular structures in isolation are increasingly becoming an important research area; they may provide a key to the evolution of complexity from prokaryotes to eukaryotes. We propose the development of a machine learning-based identification of features specific to this important class of molecules. We also plan to attack the problem from a very different angle by using predictions of interaction densities inside proteins. The resulting novel tools will allow a proteome-wide analysis of the role of these molecules. All methods will be made available through PP.      RELEVANCE: Information about protein structure adds an entire dimension to protein analysis and genome annotation. This addition is often essential to infer function even for natively unstructured proteins. The PredictProtein server is unique in its combination and exploitation of evolution, structure, and function; many thousands of theoretical, experimental, and clinical researches have benefited from this. The long-term goal of the research proposed here is to improve our ability to use the evolutionary record of amino acid substitutions, i.e. to ultimately understand the amino acid ""language"". The short-term goal is to address two tasks that are closely related to human diseases, namely the distinction between silent and important mutations and the mapping of unstructured proteins onto networks and diseases.          ",Improve predictions of structure and function by PredictProtein,7842572,R01LM007329,"['Services ', ' Membrane ', ' membrane structure ', ' protein structure function ', ' Budgets ', ' Structure ', ' novel ', ' Eukaryota ', ' Eukaryote ', ' Devices ', ' Proteome ', ' Code ', ' Coding System ', ' Property ', ' LOINC Axis 2 Property ', ' protein protein interaction ', ' portability ', ' Genomics ', ' Classification ', ' Systematics ', ' Clinical Research ', ' Clinical Study ', ' Communities ', ' data modeling ', ' protein structure prediction ', ' design ', ' designing ', ' Linux ', ' Plug-in ', ' graphical user interface ', ' graphic user interface ', ' Graphical interface ', ' human disease ', ' density ', ' Goals ', ' Grant ', ' improved ', ' Area ', ' Medical ', ' Screening procedure ', ' screenings ', ' screening ', ' Training ', ' Language ', ' Databases ', ' data repository ', ' clinical data repository ', ' Electronic Database ', ' Electronic Databank ', ' Databanks ', ' Data Bases ', ' Data Banks ', ' Progress Reports ', ' Funding ', ' Maintenance ', ' Maps ', ' Amino Acids ', ' aminoacid ', ' Methods ', ' Mutation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Internet ', ' world wide web ', ' web ', ' WWW ', ' Nucleotides ', ' Phenotype ', ' Prokaryotic Cells ', ' prokaryote ', ' Prokaryotae ', ' tool ', ' Proteins ', ' gene product ', ' Research ', ' Research Personnel ', ' Researchers ', ' Investigators ', ' Role ', ' social role ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Solutions ', ' Testing ', ' Adopted ', ' Investigation ', ' Dimensions ', ' Country ', ' Amino Acid Substitution ', ' Biology ', ' Disease ', ' disease/disorder ', ' Disorder ', ' Address ', ' Data Set ', ' Dataset ', ' protein structure ', ' Data ', ' Induced Mutation ', ' Induced Sequence Alteration ', ' Induced DNA Alteration ', ' Protein Analysis ', ' Resolution ', ' Evolution ', ' protein function ', ' Development ', ' developmental ', ' Eye ', ' Eyeball ', ' Point Mutation ', ' Sequence Analysis ', ' Sequence Analyses ', ' SEQ-AN ', ' Output ', ' Affect ', ' Genome ', ' base ', ' ']",NLM,COLUMBIA UNIV NEW YORK MORNINGSIDE,R01,2010,327180,NY-13,0.09494687745204326
"Informatic profiling of clinically relevant mutation    DESCRIPTION (provided by applicant): Our group focuses on genetic variants that disrupt molecular functions that cause human disease. In this renewal R01 application, we propose to begin the process of realizing our long-term goals, and to expand our original scope of research to include the challenge of understanding genetic disease mutations and polymorphisms that affect gene expression regulation in noncoding regions. Additionally, we have formed collaborations with genetic data managers and will apply these methods to aid in their research and identify new testable hypotheses. We will do this in three aims. First, we will integrate predictions of protein-disease associations with mutation predictions to develop a new quantitative model of genotype and phenotype. Second, we will integrate each of these together to develop a systems level, molecular function genome annotator with functionality to import into the genome databases. Finally, we will continue to build new methods for characterization of mutations using sequence, function and structure and begin testing our published hypotheses. Each of these aims will include collaboration with the maintainers of genetic datasets to better understand their underlying molecular effects.           PrjctNrrative Tis cmetigrnwlR1aims t nerstn owgntic vritindat iscvrdi gnom sqecin  effortsdisrpts mlclr fnctinad te tsts wetertesemlclr fnctindisrptigvrintsar  mreliklytola to umn gneticdisaseusigbiiformtics.",Informatic profiling of clinically relevant mutation,8238173,R01LM009722,"['cancer genome ', ' Amino Acid Substitution ', ' Untranslated Regions ', ' UTRs ', ' Pharmacogenetics ', ' disease-causing mutation ', ' Computer software ', ' computer program/software ', ' Software ', ' multidisciplinary ', ' Leadership ', ' Left ', ' Bioinformatics ', ' Bio-Informatics ', ' Structure ', ' Individual ', ' protein structure function ', ' Variant ', ' Variation ', ' career ', ' Feedback ', ' Letters ', ' Inherited ', ' Hereditary ', ' Science ', ' genetic regulatory protein ', ' regulatory gene product ', ' Regulatory Protein ', ' human disease ', ' Disease ', ' disease/disorder ', ' Disorder ', ' Internet ', ' world wide web ', ' web ', ' WWW ', ' Molecular ', ' Modeling ', ' Genomics ', ' Genes ', ' Laboratories ', ' Meta-Analysis ', ' Meta-Analyses ', ' Data Pooling ', ' Clinical Trial Overviews ', ' Genome ', ' clinically relevant ', ' clinical relevance ', ' genome database ', ' Genetic ', ' Affect ', ' Genotype ', ' Mutation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Methods ', ' Informatics ', ' tool ', ' Publishing ', ' innovation ', ' innovative ', ' innovate ', ' Algorithms ', ' Staging ', ' Phenotype ', ' Performance ', ' Code ', ' Coding System ', ' Resources ', ' Research Resources ', ' System ', ' LOINC Axis 4 System ', ' Focus Groups ', ' Funding ', ' Goals ', ' novel strategies ', ' novel strategy ', ' novel approaches ', ' new approaches ', ' Malignant Neoplasms ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Proteins ', ' gene product ', ' Scientist ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Disease Association ', ' genome sequencing ', ' software development ', ' developing computer software ', ' develop software ', ' disease phenotype ', ' DNA Resequencing ', ' Resequencing ', ' exome ', ' exomes ', ' Classification ', ' Systematics ', ' Human Genome ', ' human whole genome ', ' Biomedical Research ', ' data management ', ' Functional RNA ', ' Non-Coding RNA ', ' Non-Coding ', ' Genetic Polymorphism ', ' polymorphism ', ' Polymorphism (Genetics) ', ' user-friendly ', ' Disease model ', ' disorder model ', ' Paper ', ' Research Proposals ', ' Hereditary Disease ', ' hereditary disorder ', ' genetic disorder ', ' Molecular Disease ', ' Genetic Diseases ', ' Genetic Condition ', ' genetic variant ', ' Human ', ' Modern Man ', ' Man (Taxonomy) ', ' Testing ', ' Transcript ', ' Collaborations ', ' Process ', ' Data ', ' Area ', ' novel ', ' Research Personnel ', ' improved ', ' Research ', ' Researchers ', ' Investigators ', ' base ', ' Gene Expression Regulation ', ' Gene Regulation Process ', ' Gene Regulation ', ' Gene Action Regulation ', ' Data Set ', ' Dataset ', ' Work ', ' Role ', ' social role ', ' Complex ', ' Mutation Analysis ', ' Genetic Sequence Databases ', ' ']",NLM,BUCK INSTITUTE FOR RESEARCH ON AGING,R01,2011,500661,CA-02,0.1954144328615251
"Integrated Genomic Discovery and Functional Validation of Colorectal Cancer Loci    DESCRIPTION (provided by applicant): Colorectal carcinoma (CRC) arises from multiple mutations and genomic aberrations in distinct driver cancer genes that that in concert to spur neoplastic development and phenotype. This inherent genetic complexity greatly complicates both personalized diagnosis and treatment. Previously published studies have confined that large numbers of genes will be mutated or subject to genomic aberrations in CRC. A significant and emerging challenge for the post-genomic era is to identify which of these mutated genes are ""driver"" loci that functionally drive colon cancer development, versus ""passenger"" loci without functional relevance. Finally, it is of the highest priority that one forges these genetic observations with correlations of prognosis and clinical outcome. This can only be done if we better understand the unified biological ramifications of the combined and diverse multigenic driver background which act synergistically to promote CRC tumorigenesis. This proposal details an integrated analysis that will rely on the CRC genomic data generated by the Cancer Genome Atlas Project (TCGA) to discover novel candidate CRC genes and study multigenic CRC driver gene co-mutated / dysregulated modules within the genetic context of other drivers and provide biological validation in a powerful in vitro primary culture CRC model which can be engineered for multiple genetic events.  To accomplish these goals, we will develop and implement novel statistical methodologies for the integrative analysis of multiple TCGA genomic and clinical data sets. The goal is to identify and prioritize novel CRC genes either singly or as co-mutated modules in combination with other known ""driver"" CRC genes. We will use the rich TCGA data set to conduct an integrated CRC genomic analysis of point mutations, gene expression, copy number aberrations and methylation data. We will prioritize the discovery of mutations and other genomic aberrations of these novel CRC genes that are associated with specific clinical stages of disease and other clinical parameters.  These statistical and computational studies will then be directly coupled to rapid and robust functional target validation of candidate loci using our rigorously characterized in vitro primary intestinal culture methodology (Gotani et al, Nature Medicine, 2009), in which we have recently established the transforming activity of established CRC loci such as APC, KRAS and TP53. Genetic deletion and retroviral expression of shRNA, cDNA or mutants thereof will be utilized to evaluate putative individual driver loci, as well as combinatorial oncogene modules. This proposal directly addresses fundamental problems in the exploration and translation of novel colorectal cancer gene discovery in the context of clinical data which is available from TCGA. RELEVANCE (See instructions): Colorectal cancer (CRC) represents the third most commonly diagnosed cancer in the United States. This proposal utilizes a fusion of genomic analysis of a large population of patients, mathematical modeling and culture of intestinal fragments to functionally identify genes that are critical for colon cancer development. These studies have implications for generation of novel diagnostic and therapeutic strategies for colon cancer.           ",Integrated Genomic Discovery and Functional Validation of Colorectal Cancer Loci,8178935,U01CA151920,"['cancer genome ', ' Copy Number Polymorphism ', ' copy number variation ', ' Point Mutation ', ' Complementary DNA ', ' cDNA ', ' TP53 gene ', ' p53 Genes ', ' Tumor Protein p53 Gene ', ' TRP53 ', ' TP53 ', ' P53 ', ' intestinal epithelium ', ' cancer genomics ', ' oncogenomics ', ' segregation ', ' Racial Segregation ', ' exome ', ' exomes ', ' Somatic Mutation ', ' Atlases ', ' candidate validation ', ' forging ', ' Statistical Study ', ' neoplastic ', ' Colon Carcinoma ', ' Colonic Carcinoma ', ' Colon Cancer ', ' combinatorial ', ' Gene Mutation ', ' Sequence Alteration ', ' Genetic mutation ', ' Gene Alteration ', ' DNA mutation ', ' DNA Alteration ', ' Systems Biology ', ' cancer diagnosis ', ' Intestines ', ' bowel ', ' Intestinal ', ' authority ', ' small hairpin RNA ', ' short hairpin RNA ', ' shRNA ', ' mathematical model ', ' mathematical modeling ', ' Math Models ', ' Clinical Data ', ' clinical phenotype ', ' Mutate ', ' Medicine ', ' Oncogenes ', ' Transforming Genes ', ' Cancer-Promoting Gene ', ' Cancer Genes ', ' Oncologist ', ' Methylation ', ' Protein Methylation ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Instruction ', ' Publications ', ' Scientific Publication ', ' statistics ', ' patient population ', ' novel diagnostics ', ' next generation diagnostics ', ' new diagnostics ', ' gene discovery ', ' discover genes ', ' Methods ', ' Modeling ', ' Data Set ', ' Dataset ', ' Malignant Neoplasms ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Outcome ', ' outcome forecast ', ' Prognosis ', ' Genetic ', ' In Vitro ', ' Algorithms ', ' Biological ', ' Evaluation ', ' Phenotype ', ' Validation ', ' Clinical ', ' Genes ', ' Diagnostic ', ' Disease ', ' disease/disorder ', ' Disorder ', ' Methodology ', ' Method LOINC Axis 6 ', ' Publishing ', ' novel strategies ', ' novel strategy ', ' novel approaches ', ' new approaches ', ' Measurement ', ' Diagnosis ', ' United States ', ' Event ', ' Generations ', ' Translations ', ' Data ', ' Biology ', ' mutant ', ' Gene Expression ', ' Surveys ', ' Survey Instrument ', ' Research ', ' Nature ', ' Coupled ', ' Future ', ' tumorigenesis ', ' Oncogenesis ', ' Principal Investigator ', ' novel ', ' Individual ', ' Technology ', ' Mutation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Goals ', ' Address ', ' Staging ', ' Development ', ' developmental ', ' Engineering ', ' Colorectal Cancer ', ' novel therapeutics ', ' next generation therapeutics ', ' new therapeutics ', ' Variant ', ' Variation ', ' Genomics ', ' experience ', ' Literature ', ' Genome ', ' design ', ' designing ', ' The Cancer Genome Atlas ', ' TCGA ', ' KRAS2 gene ', ' v-Ki-RAS2 Kirsten Rat Sarcoma 2 Viral Oncogene Homolog ', ' RASK2 ', ' Oncogene K-Ras ', ' Ki-RAS ', ' KRAS2 ', ' KRAS ', ' K-Ras-2 Oncogene ', ' K-Ras 2A ', ' K-RAS2B ', ' K-RAS2A ', ' C-K-RAS ', ' Bayesian Analysis ', ' computer studies ', ' computational studies ', ' Large Intestine Carcinoma ', ' Large Bowel Carcinoma ', ' Colorectal Carcinomas ', ' ']",NCI,STANFORD UNIVERSITY,U01,2011,537462,CA-18,0.09622183646985695
"Rewiring the yeast brain:  Redundancy and interference in genetic networks    DESCRIPTION (Provided by the applicant)   Abstract: Similar to neural networks in animals, molecular networks in cells can generate bistable or oscillatory dynamics that maintain memories of previous events (e.g. epigenetic switch) or order periodic events (e.g. cell cycle), respectively. In cells, networks of genes interacting with one another through regulatory feedback implement such dynamics. Analogous to learning in brains, cells can """"learn"""" correlations in their environmental signals by encoding such correlations into their gene network dynamics through mutation, a """"re-wiring"""" process that occurs on the timescale of generations. The issue of learning the statistical regularities and correlations of environmental signals is best exemplified by the evolution of """"circadian clocks"""", which are oscillatory gene circuits that have learned to internalize the 24-hour light-dark circadian cycle. Strikingly, circadian clocks have evolved independently multiple times, which suggests there exists some selection pressure and/or evolutionary mechanism that repeatedly favor the convergent evolution of autonomous oscillation. The hypothesis of my research proposal is that certain types of loss-of-function mutations in duplicated genes (known as dominant-negative mutations) can easily generate bistability and oscillation in existing regulatory networks. Gene duplication followed by a loss-of-function mutation can generate a dominant-negative. A dominant negative mutation is a partial loss-of-function mutation that renders a gene duplicate functionally inactive, yet still capable of interacting with the original duplicate, the upstream effectors, and/or downstream targets. Thus, dominant-negatives can easily interfere with the proper regulation and activity of the original duplicate. Because both gene duplication and loss-of-function mutations occur frequently in evolution, this presents an evolutionary mechanism for rapidly generating bistability and autonomous oscillation in gene regulatory networks. My proposed research over the next five years will integrate experiment and theory to understand the extent to which gene duplication and dominant-negative mutations facilitate the evolution of epigenetic switches and circadian clocks in regulatory networks. We will use computer simulation and an experimental directed evolution approach in a tractable, model eukaryote (Saccharomyces cerevisiae) to test the ability of cells to learn the statistical regularities of their coupled environmental signals. Understanding how and why single-cell microbes and parasites have learned to predict their environment is essential for understanding their future evolution to changing host conditions.   Public Health Relevance: The ability of parasites to learn and adapt to changing host conditions and environments presents a challenge to human health. The objective of my research proposal is to understand the capacity of gene networks in single cells to learn and predict the statistical regularities of their environment. Discovering the limitations and abilities of parasites to evolve and anticipate changes in their host environment will be invaluable for the treatment of many human diseases.       ",Rewiring the yeast brain:  Redundancy and interference in genetic networks,8146626,DP2OD008654,"['Duplicate Genes ', ' brain cell ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Regulator Genes ', ' trans acting element ', ' regulatory gene ', ' Transcriptional Regulatory Elements ', ' Yeasts ', ' Circadian Rhythms ', ' diurnal variation ', ' daily biorhythm ', ' circadian process ', ' circadian ', ' Twenty-Four Hour Rhythm ', ' Nyctohemeral Rhythm ', ' Diurnal Rhythm ', ' Dominant-Negative Mutation ', ' Dominant-Negative Mutant ', ' Dominant Negative ', ' Antimorphic mutation ', ' Cell Cycle ', ' Cell Division Cycle ', ' Evolution ', ' loss of function mutation ', ' Eukaryota ', ' Eukaryote ', ' Saccharomyces cerevisiae ', ' S. cerevisiae ', ' S. Cerevisiae [{C0036025}] ', ' S cerevisiae ', "" Brewer's Yeast "", "" Baker's Yeast "", ' Biological Neural Networks ', ' neural network ', ' Learning ', ' Parasites ', ' Human ', ' Modern Man ', ' Man (Taxonomy) ', ' Computer Simulation ', ' virtual simulation ', ' in silico ', ' computerized simulation ', ' computerized modeling ', ' computer based models ', ' computational simulation ', ' computational models ', ' computational modeling ', ' Mathematical Models and Simulations ', ' Mathematical Model Simulation ', ' Computerized Models ', ' Computer based Simulation ', ' Computer Models ', ' Memory ', ' Regulation ', ' Testing ', ' Process ', ' Signal Transduction ', ' biological signal transduction ', ' Signaling ', ' Signal Transduction Systems ', ' Intracellular Communication and Signaling ', ' Cell Signaling ', ' Cell Communication and Signaling ', ' theories ', ' Environment ', ' Hour ', ' research study ', ' experimental study ', ' experimental research ', ' experiment ', ' Genetic ', ' Modeling ', ' Research Proposals ', ' Event ', ' Research ', ' Future ', ' Animals ', ' Feedback ', ' human disease ', ' Cells ', ' abstracting ', ' Coupled ', ' Microbe ', ' Light ', ' Photoradiation ', ' public health relevance ', ' Mutation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Generations ', ' Time ', ' Health ', ' Brain ', ' Encephalon ', ' Brain Nervous System ', ' Epigenetic Process ', ' Epigenetic Mechanism ', ' Epigenetic Change ', ' Epigenetic ', ' pressure ', ' Molecular ', ' Genes ', ' circadian pacemaker ', ' circadian clock ', ' Gene Duplication ', ' directed evolution ', ' ']",OD,DUKE UNIVERSITY,DP2,2011,2355000,NC-04,0.1446367921825284
"Integrated Genomic Discovery and Functional Validation of Colorectal Cancer Loci    DESCRIPTION (provided by applicant): Colorectal carcinoma (CRC) arises from multiple mutations and genomic aberrations in distinct driver cancer genes that that in concert to spur neoplastic development and phenotype. This inherent genetic complexity greatly complicates both personalized diagnosis and treatment. Previously published studies have confined that large numbers of genes will be mutated or subject to genomic aberrations in CRC. A significant and emerging challenge for the post-genomic era is to identify which of these mutated genes are ""driver"" loci that functionally drive colon cancer development, versus ""passenger"" loci without functional relevance. Finally, it is of the highest priority that one forges these genetic observations with correlations of prognosis and clinical outcome. This can only be done if we better understand the unified biological ramifications of the combined and diverse multigenic driver background which act synergistically to promote CRC tumorigenesis. This proposal details an integrated analysis that will rely on the CRC genomic data generated by the Cancer Genome Atlas Project (TCGA) to discover novel candidate CRC genes and study multigenic CRC driver gene co-mutated / dysregulated modules within the genetic context of other drivers and provide biological validation in a powerful in vitro primary culture CRC model which can be engineered for multiple genetic events.  To accomplish these goals, we will develop and implement novel statistical methodologies for the integrative analysis of multiple TCGA genomic and clinical data sets. The goal is to identify and prioritize novel CRC genes either singly or as co-mutated modules in combination with other known ""driver"" CRC genes. We will use the rich TCGA data set to conduct an integrated CRC genomic analysis of point mutations, gene expression, copy number aberrations and methylation data. We will prioritize the discovery of mutations and other genomic aberrations of these novel CRC genes that are associated with specific clinical stages of disease and other clinical parameters.  These statistical and computational studies will then be directly coupled to rapid and robust functional target validation of candidate loci using our rigorously characterized in vitro primary intestinal culture methodology (Gotani et al, Nature Medicine, 2009), in which we have recently established the transforming activity of established CRC loci such as APC, KRAS and TP53. Genetic deletion and retroviral expression of shRNA, cDNA or mutants thereof will be utilized to evaluate putative individual driver loci, as well as combinatorial oncogene modules. This proposal directly addresses fundamental problems in the exploration and translation of novel colorectal cancer gene discovery in the context of clinical data which is available from TCGA. RELEVANCE (See instructions): Colorectal cancer (CRC) represents the third most commonly diagnosed cancer in the United States. This proposal utilizes a fusion of genomic analysis of a large population of patients, mathematical modeling and culture of intestinal fragments to functionally identify genes that are critical for colon cancer development. These studies have implications for generation of novel diagnostic and therapeutic strategies for colon cancer.           ",Integrated Genomic Discovery and Functional Validation of Colorectal Cancer Loci,8329613,U01CA151920,"['Algorithms ', ' Atlases ', ' Biology ', ' cDNA ', ' Complementary DNA ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Malignant Neoplasms ', ' Large Bowel Carcinoma ', ' Colorectal Carcinomas ', ' Large Intestine Carcinoma ', ' Diagnosis ', ' disease/disorder ', ' Disorder ', ' Disease ', ' Engineering ', ' Future ', ' Gene Expression ', ' Genes ', ' Genome ', ' Goals ', ' In Vitro ', ' bowel ', ' Intestinal ', ' Intestines ', ' Literature ', ' Medicine ', ' Methods ', ' Method LOINC Axis 6 ', ' Methodology ', ' Protein Methylation ', ' Methylation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' Transforming Genes ', ' Cancer-Promoting Gene ', ' Cancer Genes ', ' Oncogenes ', ' Phenotype ', ' Prognosis ', ' outcome forecast ', ' Scientific Publication ', ' Publications ', ' Publishing ', ' Research ', ' Statistical Study ', ' statistics ', ' Survey Instrument ', ' Surveys ', ' Technology ', ' Translations ', ' United States ', ' Generations ', ' p53 Genes ', ' Tumor Protein p53 Gene ', ' TRP53 ', ' TP53 ', ' P53 ', ' TP53 gene ', ' Racial Segregation ', ' segregation ', ' Dataset ', ' Data Set ', ' Point Mutation ', ' Clinical ', ' Variation ', ' Variant ', ' Biological ', ' Evaluation ', ' intestinal epithelium ', ' Individual ', ' Bayesian Analysis ', ' Measurement ', ' Oncologist ', ' Genetic ', ' Staging ', ' Diagnostic ', ' Nature ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Event ', ' Somatic Mutation ', ' experience ', ' Sequence Alteration ', ' Genetic mutation ', ' Gene Alteration ', ' DNA mutation ', ' DNA Alteration ', ' Gene Mutation ', ' mutant ', ' authority ', ' novel ', ' Colonic Carcinoma ', ' Colon Cancer ', ' Colon Carcinoma ', ' Modeling ', ' mathematical modeling ', ' Math Models ', ' mathematical model ', ' Genomics ', ' cancer diagnosis ', ' Oncogenesis ', ' tumorigenesis ', ' v-Ki-RAS2 Kirsten Rat Sarcoma 2 Viral Oncogene Homolog ', ' RASK2 ', ' Oncogene K-Ras ', ' Ki-RAS ', ' KRAS2 ', ' KRAS ', ' K-Ras-2 Oncogene ', ' K-Ras 2A ', ' K-RAS2B ', ' K-RAS2A ', ' C-K-RAS ', ' KRAS2 gene ', ' Address ', ' Systems Biology ', ' copy number variation ', ' Copy Number Polymorphism ', ' Data ', ' Mutate ', ' Clinical Data ', ' Validation ', ' Principal Investigator ', ' developmental ', ' Development ', ' Colorectal Cancer ', ' neoplastic ', ' Instruction ', ' clinical phenotype ', ' oncogenomics ', ' cancer genomics ', ' forging ', ' cancer genome ', ' computational studies ', ' computer studies ', ' designing ', ' design ', ' novel strategy ', ' novel approaches ', ' new approaches ', ' novel strategies ', ' Outcome ', ' Coupled ', ' short hairpin RNA ', ' shRNA ', ' small hairpin RNA ', ' combinatorial ', ' next generation therapeutics ', ' new therapeutics ', ' novel therapeutics ', ' next generation diagnostics ', ' new diagnostics ', ' novel diagnostics ', ' discover genes ', ' gene discovery ', ' patient population ', ' candidate validation ', ' exomes ', ' exome ', ' TCGA ', ' The Cancer Genome Atlas ', ' ']",NCI,STANFORD UNIVERSITY,U01,2012,541494,CA-18,0.09622183646985695
"Informatic profiling of clinically relevant mutation    DESCRIPTION (provided by applicant): Our group focuses on genetic variants that disrupt molecular functions that cause human disease. In this renewal R01 application, we propose to begin the process of realizing our long-term goals, and to expand our original scope of research to include the challenge of understanding genetic disease mutations and polymorphisms that affect gene expression regulation in noncoding regions. Additionally, we have formed collaborations with genetic data managers and will apply these methods to aid in their research and identify new testable hypotheses. We will do this in three aims. First, we will integrate predictions of protein-disease associations with mutation predictions to develop a new quantitative model of genotype and phenotype. Second, we will integrate each of these together to develop a systems level, molecular function genome annotator with functionality to import into the genome databases. Finally, we will continue to build new methods for characterization of mutations using sequence, function and structure and begin testing our published hypotheses. Each of these aims will include collaboration with the maintainers of genetic datasets to better understand their underlying molecular effects.           PrjctNrrative Tis cmetigrnwlR1aims t nerstn owgntic vritindat iscvrdi gnom sqecin  effortsdisrpts mlclr fnctinad te tsts wetertesemlclr fnctindisrptigvrintsar  mreliklytola to umn gneticdisaseusigbiiformtics.",Informatic profiling of clinically relevant mutation,8328943,R01LM009722,"['Affect ', ' Algorithms ', ' Biomedical Research ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Malignant Neoplasms ', ' Systematics ', ' Classification ', ' disease/disorder ', ' Disorder ', ' Disease ', ' Feedback ', ' Focus Groups ', ' Gene Regulation Process ', ' Gene Regulation ', ' Gene Action Regulation ', ' Gene Expression Regulation ', ' Genes ', ' Genome ', ' human whole genome ', ' Human Genome ', ' Genotype ', ' Goals ', ' hereditary disorder ', ' genetic disorder ', ' Molecular Disease ', ' Genetic Diseases ', ' Genetic Condition ', ' Hereditary Disease ', ' Modern Man ', ' Man (Taxonomy) ', ' Human ', ' Laboratories ', ' Leadership ', ' Methods ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' Paper ', ' Pharmacogenetics ', ' Phenotype ', ' polymorphism ', ' Polymorphism (Genetics) ', ' Genetic Polymorphism ', ' gene product ', ' Proteins ', ' Publishing ', ' Research ', ' Researchers ', ' Investigators ', ' Research Personnel ', ' Research Proposals ', ' Research Resources ', ' Resources ', ' social role ', ' Role ', ' Science ', ' computer program/software ', ' Software ', ' Computer software ', ' Testing ', ' Work ', ' Dataset ', ' Data Set ', ' base ', ' career ', ' improved ', ' Left ', ' Area ', ' Variation ', ' Variant ', ' Individual ', ' Funding ', ' world wide web ', ' web ', ' WWW ', ' Internet ', ' Collaborations ', ' Letters ', ' Genetic ', ' Staging ', ' tool ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Scientist ', ' Hereditary ', ' Inherited ', ' Complex ', ' LOINC Axis 4 System ', ' System ', ' Amino Acid Substitution ', ' data management ', ' Performance ', ' protein structure function ', ' Informatics ', ' UTRs ', ' Untranslated Regions ', ' Structure ', ' novel ', ' disorder model ', ' Disease model ', ' Mutation Analysis ', ' Coding System ', ' Code ', ' regulatory gene product ', ' Regulatory Protein ', ' genetic regulatory protein ', ' Modeling ', ' developing computer software ', ' develop software ', ' software development ', ' genome database ', ' Genomics ', ' Meta-Analyses ', ' Data Pooling ', ' Clinical Trial Overviews ', ' Meta-Analysis ', ' Genetic Sequence Databases ', ' Bio-Informatics ', ' Bioinformatics ', ' genome sequencing ', ' Non-Coding RNA ', ' Non-Coding ', ' Functional RNA ', ' Resequencing ', ' DNA Resequencing ', ' Data ', ' Disease Association ', ' Transcript ', ' Molecular ', ' Process ', ' disease phenotype ', ' cancer genome ', ' genetic variant ', ' novel strategy ', ' novel approaches ', ' new approaches ', ' novel strategies ', ' innovative ', ' innovate ', ' innovation ', ' clinical relevance ', ' clinically relevant ', ' multidisciplinary ', ' user-friendly ', ' human disease ', ' disease-causing mutation ', ' exomes ', ' exome ', ' ']",NLM,BUCK INSTITUTE FOR RESEARCH ON AGING,R01,2012,461516,CA-02,0.1954144328615251
"Informatic profiling of clinically relevant mutation    DESCRIPTION (provided by applicant): Our group focuses on genetic variants that disrupt molecular functions that cause human disease. In this renewal R01 application, we propose to begin the process of realizing our long-term goals, and to expand our original scope of research to include the challenge of understanding genetic disease mutations and polymorphisms that affect gene expression regulation in noncoding regions. Additionally, we have formed collaborations with genetic data managers and will apply these methods to aid in their research and identify new testable hypotheses. We will do this in three aims. First, we will integrate predictions of protein-disease associations with mutation predictions to develop a new quantitative model of genotype and phenotype. Second, we will integrate each of these together to develop a systems level, molecular function genome annotator with functionality to import into the genome databases. Finally, we will continue to build new methods for characterization of mutations using sequence, function and structure and begin testing our published hypotheses. Each of these aims will include collaboration with the maintainers of genetic datasets to better understand their underlying molecular effects.           PrjctNrrative Tis cmetigrnwlR1aims t nerstn owgntic vritindat iscvrdi gnom sqecin  effortsdisrpts mlclr fnctinad te tsts wetertesemlclr fnctindisrptigvrintsar  mreliklytola to umn gneticdisaseusigbiiformtics.",Informatic profiling of clinically relevant mutation,8526549,R01LM009722,"['Affect ', ' Algorithms ', ' Biomedical Research ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Malignant Neoplasms ', ' Systematics ', ' Classification ', ' disease/disorder ', ' Disorder ', ' Disease ', ' Feedback ', ' Focus Groups ', ' Gene Regulation Process ', ' Gene Regulation ', ' Gene Action Regulation ', ' Gene Expression Regulation ', ' Genes ', ' Genome ', ' human whole genome ', ' Human Genome ', ' Genotype ', ' Goals ', ' hereditary disorder ', ' genetic disorder ', ' Molecular Disease ', ' Genetic Diseases ', ' Genetic Condition ', ' Hereditary Disease ', ' Modern Man ', ' Man (Taxonomy) ', ' Human ', ' Laboratories ', ' Leadership ', ' Methods ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' Paper ', ' Pharmacogenetics ', ' Phenotype ', ' polymorphism ', ' Polymorphism (Genetics) ', ' Genetic Polymorphism ', ' gene product ', ' Proteins ', ' Publishing ', ' Research ', ' Researchers ', ' Investigators ', ' Research Personnel ', ' Research Proposals ', ' Research Resources ', ' Resources ', ' social role ', ' Role ', ' Science ', ' computer program/software ', ' Software ', ' Computer software ', ' Testing ', ' Work ', ' Dataset ', ' Data Set ', ' base ', ' career ', ' improved ', ' Left ', ' Area ', ' Variation ', ' Variant ', ' Individual ', ' Funding ', ' world wide web ', ' web ', ' WWW ', ' Internet ', ' Collaborations ', ' Letters ', ' Genetic ', ' Staging ', ' tool ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Scientist ', ' Hereditary ', ' Inherited ', ' Complex ', ' LOINC Axis 4 System ', ' System ', ' Amino Acid Substitution ', ' data management ', ' Performance ', ' protein structure function ', ' Informatics ', ' UTRs ', ' Untranslated Regions ', ' Structure ', ' novel ', ' disorder model ', ' Disease model ', ' Mutation Analysis ', ' Coding System ', ' Code ', ' regulatory gene product ', ' Regulatory Protein ', ' genetic regulatory protein ', ' Modeling ', ' developing computer software ', ' develop software ', ' software development ', ' genome database ', ' Genomics ', ' Meta-Analyses ', ' Data Pooling ', ' Clinical Trial Overviews ', ' Meta-Analysis ', ' Genetic Sequence Databases ', ' Bio-Informatics ', ' Bioinformatics ', ' genome sequencing ', ' Non-Coding RNA ', ' Non-Coding ', ' Functional RNA ', ' Resequencing ', ' DNA Resequencing ', ' Data ', ' Disease Association ', ' Transcript ', ' Molecular ', ' Process ', ' disease phenotype ', ' cancer genome ', ' genetic variant ', ' new approaches ', ' novel strategy ', ' novel approaches ', ' novel strategies ', ' innovative ', ' innovate ', ' innovation ', ' clinical relevance ', ' clinically relevant ', ' multidisciplinary ', ' user-friendly ', ' human disease ', ' disease-causing mutation ', ' exome sequencing ', ' genome annotation ', ' ']",NLM,BUCK INSTITUTE FOR RESEARCH ON AGING,R01,2013,444076,CA-02,0.1954144328615251
"Integrated Genomic Discovery and Functional Validation of Colorectal Cancer Loci    DESCRIPTION (provided by applicant): Colorectal carcinoma (CRC) arises from multiple mutations and genomic aberrations in distinct driver cancer genes that that in concert to spur neoplastic development and phenotype. This inherent genetic complexity greatly complicates both personalized diagnosis and treatment. Previously published studies have confined that large numbers of genes will be mutated or subject to genomic aberrations in CRC. A significant and emerging challenge for the post-genomic era is to identify which of these mutated genes are ""driver"" loci that functionally drive colon cancer development, versus ""passenger"" loci without functional relevance. Finally, it is of the highest priority that one forges these genetic observations with correlations of prognosis and clinical outcome. This can only be done if we better understand the unified biological ramifications of the combined and diverse multigenic driver background which act synergistically to promote CRC tumorigenesis. This proposal details an integrated analysis that will rely on the CRC genomic data generated by the Cancer Genome Atlas Project (TCGA) to discover novel candidate CRC genes and study multigenic CRC driver gene co-mutated / dysregulated modules within the genetic context of other drivers and provide biological validation in a powerful in vitro primary culture CRC model which can be engineered for multiple genetic events.  To accomplish these goals, we will develop and implement novel statistical methodologies for the integrative analysis of multiple TCGA genomic and clinical data sets. The goal is to identify and prioritize novel CRC genes either singly or as co-mutated modules in combination with other known ""driver"" CRC genes. We will use the rich TCGA data set to conduct an integrated CRC genomic analysis of point mutations, gene expression, copy number aberrations and methylation data. We will prioritize the discovery of mutations and other genomic aberrations of these novel CRC genes that are associated with specific clinical stages of disease and other clinical parameters.  These statistical and computational studies will then be directly coupled to rapid and robust functional target validation of candidate loci using our rigorously characterized in vitro primary intestinal culture methodology (Gotani et al, Nature Medicine, 2009), in which we have recently established the transforming activity of established CRC loci such as APC, KRAS and TP53. Genetic deletion and retroviral expression of shRNA, cDNA or mutants thereof will be utilized to evaluate putative individual driver loci, as well as combinatorial oncogene modules. This proposal directly addresses fundamental problems in the exploration and translation of novel colorectal cancer gene discovery in the context of clinical data which is available from TCGA. RELEVANCE (See instructions): Colorectal cancer (CRC) represents the third most commonly diagnosed cancer in the United States. This proposal utilizes a fusion of genomic analysis of a large population of patients, mathematical modeling and culture of intestinal fragments to functionally identify genes that are critical for colon cancer development. These studies have implications for generation of novel diagnostic and therapeutic strategies for colon cancer.           ",Integrated Genomic Discovery and Functional Validation of Colorectal Cancer Loci,8534039,U01CA151920,"['Algorithms ', ' Atlases ', ' Biology ', ' cDNA ', ' Complementary DNA ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Malignant Neoplasms ', ' Large Bowel Carcinoma ', ' Colorectal Carcinomas ', ' Large Intestine Carcinoma ', ' Diagnosis ', ' disease/disorder ', ' Disorder ', ' Disease ', ' Engineering ', ' Future ', ' Gene Expression ', ' Genes ', ' Genome ', ' Goals ', ' In Vitro ', ' bowel ', ' Intestinal ', ' Intestines ', ' Literature ', ' Medicine ', ' Methods ', ' Method LOINC Axis 6 ', ' Methodology ', ' Protein Methylation ', ' Methylation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' Transforming Genes ', ' Cancer-Promoting Gene ', ' Cancer Genes ', ' Oncogenes ', ' Phenotype ', ' Prognosis ', ' outcome forecast ', ' Scientific Publication ', ' Publications ', ' Publishing ', ' Research ', ' Statistical Study ', ' statistics ', ' Survey Instrument ', ' Surveys ', ' Technology ', ' Translations ', ' United States ', ' Generations ', ' p53 Genes ', ' Tumor Protein p53 Gene ', ' TRP53 ', ' TP53 ', ' P53 ', ' TP53 gene ', ' Racial Segregation ', ' segregation ', ' Dataset ', ' Data Set ', ' Point Mutation ', ' Clinical ', ' Variation ', ' Variant ', ' Biological ', ' Evaluation ', ' intestinal epithelium ', ' Individual ', ' Bayesian Analysis ', ' Measurement ', ' Oncologist ', ' Genetic ', ' Staging ', ' Diagnostic ', ' Nature ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Event ', ' Somatic Mutation ', ' experience ', ' Sequence Alteration ', ' Genetic mutation ', ' Gene Alteration ', ' DNA mutation ', ' DNA Alteration ', ' Gene Mutation ', ' mutant ', ' authority ', ' novel ', ' Colonic Carcinoma ', ' Colon Cancer ', ' Colon Carcinoma ', ' Modeling ', ' mathematical modeling ', ' Math Models ', ' mathematical model ', ' Genomics ', ' cancer diagnosis ', ' Oncogenesis ', ' tumorigenesis ', ' v-Ki-RAS2 Kirsten Rat Sarcoma 2 Viral Oncogene Homolog ', ' RASK2 ', ' Oncogene K-Ras ', ' Ki-RAS ', ' KRAS2 ', ' KRAS ', ' K-Ras-2 Oncogene ', ' K-Ras 2A ', ' K-RAS2B ', ' K-RAS2A ', ' C-K-RAS ', ' KRAS2 gene ', ' Address ', ' Systems Biology ', ' copy number variation ', ' Copy Number Polymorphism ', ' Data ', ' Mutate ', ' Clinical Data ', ' Validation ', ' Principal Investigator ', ' developmental ', ' Development ', ' Colorectal Cancer ', ' neoplastic ', ' Instruction ', ' clinical phenotype ', ' oncogenomics ', ' cancer genomics ', ' forging ', ' cancer genome ', ' computational studies ', ' computer studies ', ' designing ', ' design ', ' new approaches ', ' novel strategy ', ' novel approaches ', ' novel strategies ', ' Outcome ', ' Coupled ', ' short hairpin RNA ', ' shRNA ', ' small hairpin RNA ', ' combinatorial ', ' next generation therapeutics ', ' new therapeutics ', ' novel therapeutics ', ' next generation diagnostics ', ' new diagnostics ', ' novel diagnostics ', ' discover genes ', ' gene discovery ', ' patient population ', ' candidate validation ', ' exomes ', ' exome ', ' TCGA ', ' The Cancer Genome Atlas ', ' exome sequencing ', ' ']",NCI,STANFORD UNIVERSITY,U01,2013,507962,CA-18,0.09622183646985695
"Informatics Tools for High-throughput Analysis of Cancer Mutations  PROJECT SUMMARY  Large tumor exome sequencing projects have identified a very large number of mutations whose cancer relevance is not yet understood. To begin to address this need, our team has produced two web applications for high-throughput computational analysis of cancer mutations: the Cancer-Related Analysis of VAriants Toolkit (CRAVAT) and the Mutation Position Imaging Toolbox (MuPIT). CRAVAT accepts millions of mutations in a single batch upload and maps mutations from genomic coordinates to annotated transcripts and proteins. MuPIT currently accepts batch uploads of up to 2500 SNVs and maps from genomic coordinates onto X-ray crystal structures of proteins from Protein Data Bank (PDB). We propose to combine and harden CRAVAT and MuPIT into a single web application, in which we will substantially improve the tools, user interface, software infrastructure, integration with external data resources and tools used by the community, and support for protected data. The scope of all tools in the web application will be broadened to handle analysis of the full range of small-scale mutation consequence types found in cancer exomes.  CRAVAT analysis identifies mutations most likely to have deleterious impact on protein function and those that are most likely to confer a selective advantage to cancer cells (drivers), using classifiers developed by our team. Classifier scores are supplemented with annotations, including population allele frequencies, previous occurrence in tumor tissue types, and gene functional categories, enabling filtering (e.g. removing polymorphisms) and prioritization. Gene-level annotation and scoring, by aggregation of classifier scores from mutations in a cohort is also provided.  MuPIT maps mutations from genomic positions onto to protein structures and provides interactive viewing of mutations in the context of protein structure, and in relation to a variety of annotations. To enable prioritization of interesting mutations and genes, the application provides a preview describing each structure and all available annotations (e.g., binding sites, experimental mutagenesis results, polymorphic and disease- associated variants that have been previously documented). After selecting a PDB of interest, the user is led to an interactive visualization page. An enhanced Jmol applet displays all SNVs mapped onto the structure. Frequently, many SNVs in the input list can be mapped onto a single structure, revealing clustering patterns around key functional sites.  Based only on word-of-mouth, since the debut of the two applications in August 2012, CRAVAT has been utilized by 129 unique users from 39 countries, and it has analyzed 1,136 submitted jobs, totaling 27.9 million mutations. MuPIT has been utilized by 242 unique users from 25 countries, with 720 submitted jobs. (Source: Google Analytics). PUBLIC HEALTH RELEVANCE: The proposed work will harden and develop web applications for the cancer genomics community to interpret small-scale mutations in cancer exomes. They are designed to handle very large number of mutations and to provide analysis targeted at researchers who are not bioinformatics experts. The work will contribute to understanding of the genetic complexity and heterogeneity of tumors and assist in discovery of new approaches for cancer prognosis and treatments.            ",Informatics Tools for High-throughput Analysis of Cancer Mutations,8606625,U01CA180956,"['Reactive Site ', ' Combining Site ', ' Binding Sites ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Malignant Neoplasms ', ' Systematics ', ' Classification ', ' Communities ', ' disease/disorder ', ' Disorder ', ' Disease ', ' drug/agent ', ' Pharmaceutic Preparations ', ' Medication ', ' Drugs ', ' Pharmaceutical Preparations ', ' allelic frequency ', ' Allele Frequency ', ' Gene Frequency ', ' Genes ', ' Heterogeneity ', ' histocompatibility typing ', ' Tissue Typing ', ' Tissue Crossmatching ', ' Histocompatibility Testing ', ' Housing ', ' Maps ', ' Methods ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' Professional Postions ', ' Jobs ', ' Occupations ', ' polymorphism ', ' Polymorphism (Genetics) ', ' Genetic Polymorphism ', ' Production ', ' gene product ', ' Proteins ', ' Scientific Publication ', ' Publications ', ' Researchers ', ' Investigators ', ' Research Personnel ', ' Research Resources ', ' Resources ', ' Splicing ', ' RNA Splicing ', ' computer program/software ', ' Software ', ' Computer software ', ' Technology ', ' Translations ', ' Work ', ' Xrays ', ' X-Rays Radiation ', ' X-Rays ', ' X-Radiation ', ' Radiation, X-Rays, Gamma-Rays ', ' Roentgen Rays ', ' alkaline protease inhibitor ', ' MAPI ', ' API ', ' microbial alkaline proteinase inhibitor ', ' Mutagenesis Molecular Biology ', ' Genetics-Mutagenesis ', ' Mutagenesis ', ' Privacy ', ' Visualization ', ' Imagery ', ' base ', ' improved ', ' Site ', ' Variation ', ' Variant ', ' Biological ', ' Ensure ', ' prognostic ', ' insight ', ' data repository ', ' clinical data repository ', ' Electronic Database ', ' Electronic Databank ', ' Databanks ', ' Data Bases ', ' Data Banks ', ' Databases ', ' world wide web ', ' web ', ' WWW ', ' Internet ', ' Collaborations ', ' Letters ', ' Genetic ', ' Malignant Cell ', ' cancer cell ', ' tool ', ' Diagnostic ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Scientist ', ' Source ', ' Pattern ', ' Country ', ' Tumor Tissue ', ' interest ', ' experience ', ' Sequence Alteration ', ' Genetic mutation ', ' Gene Alteration ', ' DNA mutation ', ' DNA Alteration ', ' Gene Mutation ', ' Missense Mutation ', ' cohort ', ' Informatics ', ' UTRs ', ' Untranslated Regions ', ' Structure ', ' Categories ', ' Position ', ' Positioning Attribute ', ' Mutation Analysis ', ' Network Analysis ', ' Pathway Analysis ', ' high throughput analysis ', ' developing computer software ', ' develop software ', ' software development ', ' Genomics ', ' cancer classification ', ' anticancer therapy ', ' Malignant Neoplasm Treatment ', ' Malignant Neoplasm Therapy ', ' Cancer Treatment ', ' cancer therapy ', ' Bio-Informatics ', ' Bioinformatics ', ' Address ', ' protein structure ', ' Data ', ' M.D. ', ' Doctor of Medicine ', ' Mutate ', ' Qualifying ', ' Infrastructure ', ' Research Infrastructure ', ' Cancer Center ', ' Cancer Prognosis ', ' computational analysis ', ' Computer Analysis ', ' Transcript ', ' Update ', ' Molecular ', ' protein function ', ' developmental ', ' Development ', ' imaging ', ' Image ', ' web services ', ' oncogenomics ', ' cancer genomics ', ' cancer genome ', ' insertion/deletion ', ' insertion-deletion mutation ', ' insertion-deletion ', ' insertion/deletion mutation ', ' cancer research ', ' anticancer research ', ' designing ', ' design ', ' new approaches ', ' novel strategy ', ' novel approaches ', ' novel strategies ', ' Population ', ' user-friendly ', ' web interface ', ' tumor ', ' public health relevance ', ' data transmission ', ' data exchange ', ' exomes ', ' exome ', ' Secure ', ' TCGA ', ' The Cancer Genome Atlas ', ' next generation sequencing ', ' exome sequencing ', ' ']",NCI,JOHNS HOPKINS UNIVERSITY,U01,2013,289971,MD-07,0.24274529083540825
"Informatics Tools for High-throughput Analysis of Cancer Mutations     DESCRIPTION (provided by applicant): Large tumor exome sequencing projects have identified a very large number of mutations whose cancer relevance is not yet understood. To begin to address this need, our team has produced two web applications for high-throughput computational analysis of cancer mutations: the Cancer-Related Analysis of VAriants Toolkit (CRAVAT) and the Mutation Position Imaging Toolbox (MuPIT). CRAVAT accepts millions of mutations in a single batch upload and maps mutations from genomic coordinates to annotated transcripts and proteins. MuPIT currently accepts batch uploads of up to 2500 SNVs and maps from genomic coordinates onto X-ray crystal structures of proteins from Protein Data Bank (PDB). We propose to combine and harden CRAVAT and MuPIT into a single web application, in which we will substantially improve the tools, user interface, software infrastructure, integration with external data resources and tools used by the community, and support for protected data. The scope of all tools in the web application will be broadened to handle analysis of the full range of small-scale mutation consequence types found in cancer exomes.  CRAVAT analysis identifies mutations most likely to have deleterious impact on protein function and those that are most likely to confer a selective advantage to cancer cells (drivers), using classifiers developed by our team. Classifier scores are supplemented with annotations, including population allele frequencies, previous occurrence in tumor tissue types, and gene functional categories, enabling filtering (e.g. removing polymorphisms) and prioritization. Gene-level annotation and scoring, by aggregation of classifier scores from mutations in a cohort is also provided.  MuPIT maps mutations from genomic positions onto to protein structures and provides interactive viewing of mutations in the context of protein structure, and in relation to a variety of annotations. To enable prioritization of interesting mutations and genes, the application provides a preview describing each structure and all available annotations (e.g., binding sites, experimental mutagenesis results, polymorphic and disease- associated variants that have been previously documented). After selecting a PDB of interest, the user is led to an interactive visualization page. An enhanced Jmol applet displays all SNVs mapped onto the structure. Frequently, many SNVs in the input list can be mapped onto a single structure, revealing clustering patterns around key functional sites.  Based only on word-of-mouth, since the debut of the two applications in August 2012, CRAVAT has been utilized by 129 unique users from 39 countries, and it has analyzed 1,136 submitted jobs, totaling 27.9 million mutations. MuPIT has been utilized by 242 unique users from 25 countries, with 720 submitted jobs. (Source: Google Analytics).         PUBLIC HEALTH RELEVANCE: The proposed work will harden and develop web applications for the cancer genomics community to interpret small-scale mutations in cancer exomes. They are designed to handle very large number of mutations and to provide analysis targeted at researchers who are not bioinformatics experts. The work will contribute to understanding of the genetic complexity and heterogeneity of tumors and assist in discovery of new approaches for cancer prognosis and treatments.            ",Informatics Tools for High-throughput Analysis of Cancer Mutations,8735910,U01CA180956,"['Reactive Site ', ' Combining Site ', ' Binding Sites ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Malignant Neoplasms ', ' Systematics ', ' Classification ', ' Communities ', ' disease/disorder ', ' Disorder ', ' Disease ', ' drug/agent ', ' Pharmaceutic Preparations ', ' Medication ', ' Drugs ', ' Pharmaceutical Preparations ', ' allelic frequency ', ' Allele Frequency ', ' Gene Frequency ', ' Genes ', ' Heterogeneity ', ' histocompatibility typing ', ' Tissue Typing ', ' Tissue Crossmatching ', ' Histocompatibility Testing ', ' Housing ', ' Maps ', ' Methods ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' Professional Positions ', ' Jobs ', ' Occupations ', ' polymorphism ', ' Polymorphism (Genetics) ', ' Genetic Polymorphism ', ' Production ', ' gene product ', ' Proteins ', ' Scientific Publication ', ' Publications ', ' Researchers ', ' Investigators ', ' Research Personnel ', ' Research Resources ', ' Resources ', ' Splicing ', ' RNA Splicing ', ' computer program/software ', ' Software ', ' Computer software ', ' Technology ', ' Translations ', ' Work ', ' Xrays ', ' X-Rays Radiation ', ' X-Rays ', ' X-Radiation ', ' Radiation, X-Rays, Gamma-Rays ', ' Roentgen Rays ', ' alkaline protease inhibitor ', ' MAPI ', ' API ', ' microbial alkaline proteinase inhibitor ', ' Mutagenesis Molecular Biology ', ' Genetics-Mutagenesis ', ' Mutagenesis ', ' Privacy ', ' Visualization ', ' Imagery ', ' base ', ' improved ', ' Site ', ' Variation ', ' Variant ', ' Biological ', ' Ensure ', ' prognostic ', ' insight ', ' data repository ', ' clinical data repository ', ' Electronic Database ', ' Electronic Databank ', ' Databanks ', ' Data Bases ', ' Data Banks ', ' Databases ', ' world wide web ', ' web ', ' WWW ', ' Internet ', ' Collaborations ', ' Letters ', ' Genetic ', ' Malignant Cell ', ' cancer cell ', ' tool ', ' Diagnostic ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Scientist ', ' Source ', ' Pattern ', ' Country ', ' Tumor Tissue ', ' interest ', ' experience ', ' Sequence Alteration ', ' Genetic mutation ', ' Gene Alteration ', ' DNA mutation ', ' DNA Alteration ', ' Gene Mutation ', ' Missense Mutation ', ' cohort ', ' Informatics ', ' UTRs ', ' Untranslated Regions ', ' Structure ', ' Categories ', ' Position ', ' Positioning Attribute ', ' Mutation Analysis ', ' Network Analysis ', ' Pathway Analysis ', ' high throughput analysis ', ' developing computer software ', ' develop software ', ' software development ', ' Genomics ', ' cancer classification ', ' anticancer therapy ', ' Malignant Neoplasm Treatment ', ' Malignant Neoplasm Therapy ', ' Cancer Treatment ', ' cancer therapy ', ' Bio-Informatics ', ' Bioinformatics ', ' Address ', ' protein structure ', ' Data ', ' M.D. ', ' Doctor of Medicine ', ' Mutate ', ' Qualifying ', ' Infrastructure ', ' Research Infrastructure ', ' Cancer Center ', ' Cancer Prognosis ', ' computational analysis ', ' Computer Analysis ', ' Transcript ', ' Update ', ' Molecular ', ' protein function ', ' developmental ', ' Development ', ' imaging ', ' Image ', ' web services ', ' oncogenomics ', ' cancer genomics ', ' cancer genome ', ' insertion/deletion ', ' insertion-deletion mutation ', ' insertion-deletion ', ' insertion/deletion mutation ', ' cancer research ', ' anticancer research ', ' designing ', ' design ', ' novel strategy ', ' novel approaches ', ' new approaches ', ' novel strategies ', ' Population ', ' user-friendly ', ' web interface ', ' tumor ', ' public health relevance ', ' data transmission ', ' data exchange ', ' exomes ', ' exome ', ' Secure ', ' TCGA ', ' The Cancer Genome Atlas ', ' next generation sequencing ', ' exome sequencing ', ' cloud based ', ' ']",NCI,JOHNS HOPKINS UNIVERSITY,U01,2014,317146,MD-07,0.24274529083540825
"Integrated Genomic Discovery and Functional Validation of Colorectal Cancer Loci    DESCRIPTION (provided by applicant): Colorectal carcinoma (CRC) arises from multiple mutations and genomic aberrations in distinct driver cancer genes that that in concert to spur neoplastic development and phenotype. This inherent genetic complexity greatly complicates both personalized diagnosis and treatment. Previously published studies have confined that large numbers of genes will be mutated or subject to genomic aberrations in CRC. A significant and emerging challenge for the post-genomic era is to identify which of these mutated genes are ""driver"" loci that functionally drive colon cancer development, versus ""passenger"" loci without functional relevance. Finally, it is of the highest priority that one forges these genetic observations with correlations of prognosis and clinical outcome. This can only be done if we better understand the unified biological ramifications of the combined and diverse multigenic driver background which act synergistically to promote CRC tumorigenesis. This proposal details an integrated analysis that will rely on the CRC genomic data generated by the Cancer Genome Atlas Project (TCGA) to discover novel candidate CRC genes and study multigenic CRC driver gene co-mutated / dysregulated modules within the genetic context of other drivers and provide biological validation in a powerful in vitro primary culture CRC model which can be engineered for multiple genetic events.  To accomplish these goals, we will develop and implement novel statistical methodologies for the integrative analysis of multiple TCGA genomic and clinical data sets. The goal is to identify and prioritize novel CRC genes either singly or as co-mutated modules in combination with other known ""driver"" CRC genes. We will use the rich TCGA data set to conduct an integrated CRC genomic analysis of point mutations, gene expression, copy number aberrations and methylation data. We will prioritize the discovery of mutations and other genomic aberrations of these novel CRC genes that are associated with specific clinical stages of disease and other clinical parameters.  These statistical and computational studies will then be directly coupled to rapid and robust functional target validation of candidate loci using our rigorously characterized in vitro primary intestinal culture methodology (Gotani et al, Nature Medicine, 2009), in which we have recently established the transforming activity of established CRC loci such as APC, KRAS and TP53. Genetic deletion and retroviral expression of shRNA, cDNA or mutants thereof will be utilized to evaluate putative individual driver loci, as well as combinatorial oncogene modules. This proposal directly addresses fundamental problems in the exploration and translation of novel colorectal cancer gene discovery in the context of clinical data which is available from TCGA. RELEVANCE (See instructions): Colorectal cancer (CRC) represents the third most commonly diagnosed cancer in the United States. This proposal utilizes a fusion of genomic analysis of a large population of patients, mathematical modeling and culture of intestinal fragments to functionally identify genes that are critical for colon cancer development. These studies have implications for generation of novel diagnostic and therapeutic strategies for colon cancer.           ",Integrated Genomic Discovery and Functional Validation of Colorectal Cancer Loci,8727268,U01CA151920,"['Algorithms ', ' Atlases ', ' Biology ', ' cDNA ', ' Complementary DNA ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Malignant Neoplasms ', ' Large Bowel Carcinoma ', ' Colorectal Carcinomas ', ' Large Intestine Carcinoma ', ' Diagnosis ', ' disease/disorder ', ' Disorder ', ' Disease ', ' Engineering ', ' Future ', ' Gene Expression ', ' Genes ', ' Genome ', ' Goals ', ' In Vitro ', ' bowel ', ' Intestinal ', ' Intestines ', ' Literature ', ' Medicine ', ' Methods ', ' Method LOINC Axis 6 ', ' Methodology ', ' Protein Methylation ', ' Methylation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' Transforming Genes ', ' Cancer-Promoting Gene ', ' Cancer Genes ', ' Oncogenes ', ' Phenotype ', ' Prognosis ', ' outcome forecast ', ' Scientific Publication ', ' Publications ', ' Publishing ', ' Research ', ' Statistical Study ', ' statistics ', ' Survey Instrument ', ' Surveys ', ' Technology ', ' Translations ', ' United States ', ' Generations ', ' p53 Genes ', ' Tumor Protein p53 Gene ', ' TRP53 ', ' TP53 ', ' P53 ', ' TP53 gene ', ' Racial Segregation ', ' segregation ', ' Dataset ', ' Data Set ', ' Point Mutation ', ' Clinical ', ' Variation ', ' Variant ', ' Biological ', ' Evaluation ', ' intestinal epithelium ', ' Individual ', ' Bayesian statistics ', ' Bayesian statistical inference ', ' Bayesian statistical analysis ', ' Bayesian spatial analysis ', ' Bayesian network analysis ', ' Bayesian inference ', ' Bayesian Analysis ', ' Measurement ', ' Oncologist ', ' Genetic ', ' Staging ', ' Diagnostic ', ' Nature ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Event ', ' Somatic Mutation ', ' experience ', ' Sequence Alteration ', ' Genetic mutation ', ' Gene Alteration ', ' DNA mutation ', ' DNA Alteration ', ' Gene Mutation ', ' mutant ', ' authority ', ' novel ', ' Colonic Carcinoma ', ' Colon Cancer ', ' Colon Carcinoma ', ' Modeling ', ' mathematical modeling ', ' mathematic model ', ' Math Models ', ' mathematical model ', ' Genomics ', ' cancer diagnosis ', ' Oncogenesis ', ' tumorigenesis ', ' v-Ki-RAS2 Kirsten Rat Sarcoma 2 Viral Oncogene Homolog ', ' RASK2 ', ' Oncogene K-Ras ', ' Ki-RAS ', ' KRAS2 ', ' KRAS ', ' K-Ras-2 Oncogene ', ' K-Ras 2A ', ' K-RAS2B ', ' K-RAS2A ', ' C-K-RAS ', ' KRAS2 gene ', ' Address ', ' Systems Biology ', ' copy number variation ', ' Copy Number Polymorphism ', ' Data ', ' Mutate ', ' Clinical Data ', ' Validation ', ' Principal Investigator ', ' developmental ', ' Development ', ' Colorectal Cancer ', ' neoplastic ', ' Instruction ', ' clinical phenotype ', ' oncogenomics ', ' cancer genomics ', ' forging ', ' cancer genome ', ' computational studies ', ' computer studies ', ' novel strategy ', ' novel approaches ', ' new approaches ', ' novel strategies ', ' Outcome ', ' Coupled ', ' short hairpin RNA ', ' shRNA ', ' small hairpin RNA ', ' combinatorial ', ' next generation therapeutics ', ' new therapeutics ', ' novel therapeutics ', ' next generation diagnostics ', ' new diagnostics ', ' novel diagnostics ', ' discover genes ', ' gene discovery ', ' patient population ', ' candidate validation ', ' exomes ', ' exome ', ' TCGA ', ' The Cancer Genome Atlas ', ' exome sequencing ', ' algorithmic composition ', ' algorithm engineering ', ' Algorithmic Engineering ', ' Algorithmic Design ', ' Algorithm Design ', ' ']",NCI,STANFORD UNIVERSITY,U01,2014,523201,CA-18,0.09622183646985695
"Identification, Characterization, and Prediction of Cancer Driver Mutations in Regulatory Regions     DESCRIPTION (provided by applicant): The goal of the proposed research training program is to provide me (Dr. Collin Melton) with additional training in areas that will accelerate my career development as I transition from a post-doctoral fellow in Dr. Michael Snyder's lab to an independent tenure track professor. The key elements of this plan are: Candidate: I have extensive training in experimental and computational approaches to studying biomedicine. Areas of additional focus for career development during the K99 mentored post-doctoral research phase include the acquisition of additional experimental skills and supplemental training in cancer biology, human genetics, human genomics, applied statistics, and parallel computing. Additionally, I will receive training in laboratory management, mentorship, and responsible conduct of research. This well-rounded plan will provide me with a skill set that will enable a facile transition from postdoctoral fellow to tenure track faculty. Environment: I have a valuable advisory committee with experts in the areas of genomics, genetics, and cancer biology to ensure my success in this training program and to guide me through the successful acquisition of a faculty job. These include my mentor Dr. Michael Snyder, my co-mentor Dr. James Ford and two advisors, Dr. Hanlee Ji and Dr. Anshul Kundaje. The environment at Stanford University in the Snyder lab and department of Genetics fosters productivity and collaboration with word class facilities, resources, and researchers. Research: My proposed research plan in cancer genomics is timely, relevant, and innovative. The majority of current research in cancer genomics has made groundbreaking progress in understanding the relevant DNA variation that occurs in coding regions of the genome; however, 97-98% of the human genome does not code for protein. This proposal focuses specifically on studying the regulatory regions of the human genome to identify, characterize, and interpret the impact of point mutations in these regulatory regions. The central hypothesis of this proposal is that point mutations in regulatory regions of the human genome drive cancer formation and the functional consequences of these mutations can be predicted using machine learning algorithms. Aim 1 proposes the statistical identification of regulatory regions which are mutated across cancer samples, Aim 2 proposes functional characterization of the prevalent mutations identified in Aim 1, and Aim 3 extends the analysis of characterizing the effects of mutations genome-wide through use of genomics approaches and proposes the use of machine learning to classify novel mutations as either disrupting, activating, or having no effect on regulatory element activity. Through its use of experimental datasets combined with predictive models for functional consequences of individual cancer variation, this research will further the goal of personalized genome interpretation for cancer therapy.         PUBLIC HEALTH RELEVANCE: Every cancer patient's disease is caused by unique set of abnormal variation in the human genome. Advancing our understanding this variation aids in the development of new treatments and the proper application of existing treatments. This proposal focuses on understanding a particular type of cancer variation that occurs in regulatory regions of the human genome.        The written critiques of individual reviewers are provided in essentially unedited form in this section. Please note that these critiques and criteria scores were prepared prior to the meeting and may not have been revised subsequent to any discussions at the review meeting. The ""Resume and Summary of Discussion"" section above summarizes the final opinions of the committee.                ","Identification, Characterization, and Prediction of Cancer Driver Mutations in Regulatory Regions",8805723,K99CA191093,"['Algorithms ', ' Allelomorphs ', ' Alleles ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Malignant Neoplasms ', ' Cause of Death ', ' cultured cell line ', ' Strains Cell Lines ', ' CellLine ', ' Cell Line ', ' Critiques ', ' disease/disorder ', ' Disorder ', ' Disease ', ' Deoxyribonucleic Acid ', ' DNA ', ' Elements ', ' Environment ', ' Faculty ', ' Future ', ' Genes ', ' Genome ', ' human whole genome ', ' Human Genome ', ' Goals ', ' HeLa ', ' Hela Cells ', ' Modern Man ', ' Man (Taxonomy) ', ' Human ', ' Human Genetics ', ' Laboratories ', ' Mentors ', ' Mentorship ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' Professional Positions ', ' Jobs ', ' Occupations ', ' Productivity ', ' gene product ', ' Proteins ', ' genetic regulatory element ', ' Regulatory Regions, Nucleic Acid (Genetics) ', ' Regulatory Regions ', ' Nucleic Acid Regulator Regions ', ' Nucleic Acid Regulatory Sequences ', ' Research ', ' Researchers ', ' Investigators ', ' Research Personnel ', ' Research Resources ', ' Resources ', ' social role ', ' Role ', ' statistics ', ' Training Programs ', ' United States ', ' Universities ', ' visual function ', ' Sight ', ' Vision ', ' Writing ', ' Dataset ', ' Data Set ', ' Task Forces ', ' Advisory Committees ', ' Programmed Cell Death ', ' Apoptosis Pathway ', ' Apoptosis ', ' Point Mutation ', ' base ', ' neoplastic progression ', ' neoplasm progression ', ' cancer progression ', ' tumor progression ', ' Distal ', ' Site ', ' Area ', ' Phase ', ' Variation ', ' Variant ', ' Ensure ', ' Evaluation ', ' Training ', ' Individual ', ' Fostering ', ' Gene Targeting ', ' Sample Size ', ' Collaborations ', ' Therapeutic ', ' Genetic ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' interest ', ' meetings ', ' post-doctoral ', ' post-doc ', ' Research Associate ', ' Postdoc ', ' Postdoctoral Fellow ', ' American ', ' Cancer Induction ', ' carcinogenesis ', ' mutant ', ' success ', ' professor ', ' skills ', ' novel ', ' Coding System ', ' Code ', ' Sampling ', ' career development ', ' Genomics ', ' anticancer therapy ', ' Malignant Neoplasm Treatment ', ' Malignant Neoplasm Therapy ', ' Cancer Treatment ', ' cancer therapy ', ' Normal Cell ', ' genome sequencing ', ' Non-Coding RNA ', ' Non-Coding ', ' Functional RNA ', ' Address ', ' Data ', ' Mutate ', ' Regulatory Element ', ' Research Training ', ' Cancer Biology ', ' Cancer Patient ', ' trend ', ' developmental ', ' Development ', ' epigenomics ', ' oncogenomics ', ' cancer genomics ', ' cancer genome ', ' computer based prediction ', ' predictive modeling ', ' Cancer cell line ', ' cancer type ', ' migration ', ' innovative ', ' innovate ', ' innovation ', ' parallel computing ', ' parallel computation ', ' parallel computer ', ' public health relevance ', ' genomewide ', ' genome-wide ', ' responsible research conduct ', ' Regimen ', ' TCGA ', ' The Cancer Genome Atlas ', ' Chip sequencing ', ' Chip seq ', ' Encyclopedia of DNA Elements ', ' Cas nuclease technology ', ' CRISPR/Cas system ', ' CRISPR ', ' Clustered Regularly Interspaced Short Palindromic Repeats ', ' ']",NCI,STANFORD UNIVERSITY,K99,2014,116122,CA-18,0.06476744691593285
"Informatic Profiling of Clinically Relevant Mutation    DESCRIPTION (provided by applicant): Our group focuses on genetic variants that disrupt molecular functions that cause human disease. In this renewal R01 application, we propose to begin the process of realizing our long-term goals, and to expand our original scope of research to include the challenge of understanding genetic disease mutations and polymorphisms that affect gene expression regulation in noncoding regions. Additionally, we have formed collaborations with genetic data managers and will apply these methods to aid in their research and identify new testable hypotheses. We will do this in three aims. First, we will integrate predictions of protein-disease associations with mutation predictions to develop a new quantitative model of genotype and phenotype. Second, we will integrate each of these together to develop a systems level, molecular function genome annotator with functionality to import into the genome databases. Finally, we will continue to build new methods for characterization of mutations using sequence, function and structure and begin testing our published hypotheses. Each of these aims will include collaboration with the maintainers of genetic datasets to better understand their underlying molecular effects.           PrjctNrrative Tis cmetigrnwlR1aims t nerstn owgntic vritindat iscvrdi gnom sqecin  effortsdisrpts mlclr fnctinad te tsts wetertesemlclr fnctindisrptigvrintsar  mreliklytola to umn gneticdisaseusigbiiformtics.",Informatic Profiling of Clinically Relevant Mutation,8722025,R01LM009722,"['Affect ', ' Algorithms ', ' Biomedical Research ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Malignant Neoplasms ', ' Systematics ', ' Classification ', ' disease/disorder ', ' Disorder ', ' Disease ', ' Feedback ', ' Focus Groups ', ' Gene Regulation Process ', ' Gene Regulation ', ' Gene Action Regulation ', ' Gene Expression Regulation ', ' Genes ', ' Genome ', ' human whole genome ', ' Human Genome ', ' Genotype ', ' Goals ', ' hereditary disorder ', ' genetic disorder ', ' Molecular Disease ', ' Genetic Diseases ', ' Genetic Condition ', ' Hereditary Disease ', ' Modern Man ', ' Man (Taxonomy) ', ' Human ', ' Laboratories ', ' Leadership ', ' Methods ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' Paper ', ' Pharmacogenetics ', ' Phenotype ', ' polymorphism ', ' Polymorphism (Genetics) ', ' Genetic Polymorphism ', ' gene product ', ' Proteins ', ' Publishing ', ' Research ', ' Researchers ', ' Investigators ', ' Research Personnel ', ' Research Proposals ', ' Research Resources ', ' Resources ', ' social role ', ' Role ', ' Science ', ' computer program/software ', ' Software ', ' Computer software ', ' Testing ', ' Work ', ' Dataset ', ' Data Set ', ' base ', ' career ', ' improved ', ' Left ', ' Area ', ' Variation ', ' Variant ', ' Individual ', ' Funding ', ' world wide web ', ' web ', ' WWW ', ' Internet ', ' Collaborations ', ' Letters ', ' Genetic ', ' Staging ', ' tool ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Scientist ', ' Hereditary ', ' Inherited ', ' Complex ', ' LOINC Axis 4 System ', ' System ', ' Amino Acid Substitution ', ' data management ', ' Performance ', ' protein structure function ', ' Informatics ', ' UTRs ', ' Untranslated Regions ', ' Structure ', ' novel ', ' disorder model ', ' Disease model ', ' Mutation Analysis ', ' Coding System ', ' Code ', ' regulatory gene product ', ' Regulatory Protein ', ' genetic regulatory protein ', ' Modeling ', ' developing computer software ', ' develop software ', ' software development ', ' genome database ', ' Genomics ', ' Meta-Analyses ', ' Data Pooling ', ' Clinical Trial Overviews ', ' Meta-Analysis ', ' Genetic Sequence Databases ', ' Bio-Informatics ', ' Bioinformatics ', ' genome sequencing ', ' Non-Coding RNA ', ' Non-Coding ', ' Functional RNA ', ' Resequencing ', ' DNA Resequencing ', ' Data ', ' Disease Association ', ' Transcript ', ' Molecular ', ' Process ', ' disease phenotype ', ' cancer genome ', ' allelic variant ', ' Gene variant ', ' genetic variant ', ' novel strategy ', ' novel approaches ', ' new approaches ', ' novel strategies ', ' innovative ', ' innovate ', ' innovation ', ' clinical relevance ', ' clinically relevant ', ' multidisciplinary ', ' user-friendly ', ' human disease ', ' disease-causing mutation ', ' exome sequencing ', ' genome annotation ', ' ']",NLM,BUCK INSTITUTE FOR RESEARCH ON AGING,R01,2014,114720,CA-02,0.1954144328615251
"Tracing the evolution of the human mutation rate DESCRIPTION (provided by applicant): All genetic variation is created by mutations, changes that arise due to DNA damage or copying mistakes during DNA replication. Mutations are frequent enough that, on average, a child's 3-billion base pair genome contains 74 new genetic variants that are not present in the genome of either parent. Such new mutations confer a higher disease risk than older mutations because they have not passed the test of surviving through several generations of parents and offspring. We aim to pinpoint how the human mutation rate has evolved as humans left Africa and adapted to diverse new environments across the globe.  One specific aim will follow up on my preliminary research which showed that Europeans experienced a mutation rate change after diverging from Africans and Asians. The primary evidence for this change is that European genomes have a higher burden than African or Asian genomes of the mutation type TCCTTC, where the trinucleotide ""TCC"" has experienced a mutation from ""C"" to ""T"" at its central site. We wish to and the genetic basis of this mutation rate change by looking at rare variants in mixed- ancestry Latino and African-American individuals. Specially, we will isolate young genetic variants that probably arose via mutation within the past 10-15 generations, after gene ow from Europe into the Americas had already begun. We will infer the genetic background (European, African, or Native American) upon which each new mutation arose and look for genomic regions where European ances- try correlates strongly with an excess of TCCTTC mutations. These will be the regions most likely to harbor a causal allele that changed the process of mutation accumulation in Europeans. This work has the potential to yield valuable insights into melanoma, a cancer that predominantly affects individuals of European ancestry and whose somatic mutational signature is dominated by TCCTTC.  A second specific aim is to look for other signatures of mutation rate change that have occurred within the human species or, more broadly, within the great apes. We will use a natural language processing technique called Latent Dirichlet Allocation (LDA) to identify collections of mutation types whose rates appear to be under common genetic control. A few mutation types besides TCCTTC show weak signals of rate differentiation between populations, and we will attempt to infer how many separate mutation rate change events are necessary to explain these signals. The admixture mapping technique from Specific Aim I can also be adapted to interrogate the genetic basis of other mutation rate changes that might have occurred in the recent past. These efforts should improve our understanding of the human mutation rate's genetic architecture and how mutation rates differ between populations. PUBLIC HEALTH RELEVANCE: All genetic variation is created by mutations, the copying mistakes that occasionally happen during DNA replication. There is evidence that children born with a higher burden of new mutations are at increased risk for autism, schizophrenia, and serious congenital diseases [1, 2, 3], but it is not well understood how much the human mutation rate varies and what genetic risk factors affect the mutation rate [4]. We aim to follow up on preliminary evidence that the Europeans have a higher mutation rate than Asians or Africans [5], looking for the genetic basis of this rate difference and investigating how often the mutation rate has changed during human evolution.",Tracing the evolution of the human mutation rate,8982093,F32GM116381,"['Acceleration ', ' Affect ', ' Africa ', ' Allelomorphs ', ' Alleles ', ' Americas ', ' Engineering / Architecture ', ' Architecture ', "" Kanner's Syndrome "", ' Infantile Autism ', ' Early Infantile Autism ', ' Autism ', ' Autistic Disorder ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Malignant Neoplasms ', ' youngster ', "" childrens' "", ' children ', ' Children (0-21) ', ' Child Youth ', ' Child Human ', ' 0-11 years old ', ' Child ', ' genetic mapping ', ' Total Human and Non-Human Gene Mapping ', ' Linkage Mapping ', ' Gene Mapping Genetics ', ' Gene Mapping ', ' Gene Localization ', ' Chromosome Mapping ', ' disease/disorder ', ' Disorder ', ' Disease ', ' DNA Injury ', ' DNA Damage ', ' Environment ', ' Europe ', ' Evolution ', ' Exhibits ', ' Genes ', ' Genome ', ' Health ', ' hereditary disorder ', ' genetic disorder ', ' Molecular Disease ', ' Genetic Diseases ', ' Genetic Condition ', ' Hereditary Disease ', ' History ', ' Recording of previous events ', ' Modern Man ', ' Man (Taxonomy) ', ' Human ', ' Maps ', ' Malignant Melanoma ', ' melanoma ', ' Methods ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' natural language understanding ', ' Natural Language Processing ', ' Parents ', ' great ape ', ' Apes ', ' Pongidae ', ' Research ', ' Risk ', ' Risk Factors ', ' schizophrenic ', ' dementia praecox ', ' Schizophrenic Disorders ', ' Schizophrenia ', ' biological signal transduction ', ' Signaling ', ' Signal Transduction Systems ', ' Intracellular Communication and Signaling ', ' Cell Signaling ', ' Cell Communication and Signaling ', ' Signal Transduction ', ' Strikes ', ' Employee Strikes ', ' Testing ', ' Time ', ' Genetic Variation ', ' Genetic Diversity ', ' Variation (Genetics) ', ' Work ', ' oriental ', ' Asians ', ' Generations ', ' black American ', ' Black or African American ', ' Black Populations ', ' Afroamerican ', ' Afro American ', ' African American ', ' Latino ', ' base ', ' improved ', ' Left ', ' Site ', ' Variation ', ' Variant ', ' Hereditary Mutation ', ' Germline Mutation ', ' Germ-Line Mutation ', ' insight ', ' Individual ', ' African ', ' European ', ' Bayesian statistics ', ' Bayesian statistical inference ', ' Bayesian statistical analysis ', ' Bayesian spatial analysis ', ' Bayesian network analysis ', ' Bayesian inference ', ' Bayesian Analysis ', ' Native Americans ', ' Genetic ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Event ', ' Techniques ', ' Somatic Mutation ', ' American ', ' experience ', ' success ', ' DNA Synthesis ', ' DNA Replication ', ' DNA biosynthesis ', ' transition mutation ', ' trait ', ' Base Pairing ', ' offspring ', ' disease risk ', ' disorder risk ', ' inherited factor ', ' genetic risk factor ', ' developmental disorder ', ' developmental disease/disorder ', ' Admixture ', ' PhD ', ' Ph.D. ', ' Doctor of Philosophy ', ' Mutation Spectra ', ' Cancer Biology ', ' Collection ', ' Genomic Segment ', ' Process ', ' followed up ', ' follow up ', ' Active Follow-up ', ' follow-up ', ' genomic variant ', ' allelic variant ', ' Gene variant ', ' genetic variant ', ' designing ', ' design ', ' Population ', ' rare allele ', ' rare variant ', ' ']",NIGMS,STANFORD UNIVERSITY,F32,2015,50690,CA-18,0.3048368049063037
"Identification, Characterization, and Prediction of Cancer Driver Mutations in Regulatory Regions DESCRIPTION (provided by applicant): The goal of the proposed research training program is to provide me (Dr. Collin Melton) with additional training in areas that will accelerate my career development as I transition from a post-doctoral fellow in Dr. Michael Snyder's lab to an independent tenure track professor. The key elements of this plan are: Candidate: I have extensive training in experimental and computational approaches to studying biomedicine. Areas of additional focus for career development during the K99 mentored post-doctoral research phase include the acquisition of additional experimental skills and supplemental training in cancer biology, human genetics, human genomics, applied statistics, and parallel computing. Additionally, I will receive training in laboratory management, mentorship, and responsible conduct of research. This well-rounded plan will provide me with a skill set that will enable a facile transition from postdoctoral fellow to tenure track faculty. Environment: I have a valuable advisory committee with experts in the areas of genomics, genetics, and cancer biology to ensure my success in this training program and to guide me through the successful acquisition of a faculty job. These include my mentor Dr. Michael Snyder, my co-mentor Dr. James Ford and two advisors, Dr. Hanlee Ji and Dr. Anshul Kundaje. The environment at Stanford University in the Snyder lab and department of Genetics fosters productivity and collaboration with word class facilities, resources, and researchers. Research: My proposed research plan in cancer genomics is timely, relevant, and innovative. The majority of current research in cancer genomics has made groundbreaking progress in understanding the relevant DNA variation that occurs in coding regions of the genome; however, 97-98% of the human genome does not code for protein. This proposal focuses specifically on studying the regulatory regions of the human genome to identify, characterize, and interpret the impact of point mutations in these regulatory regions. The central hypothesis of this proposal is that point mutations in regulatory regions of the human genome drive cancer formation and the functional consequences of these mutations can be predicted using machine learning algorithms. Aim 1 proposes the statistical identification of regulatory regions which are mutated across cancer samples, Aim 2 proposes functional characterization of the prevalent mutations identified in Aim 1, and Aim 3 extends the analysis of characterizing the effects of mutations genome-wide through use of genomics approaches and proposes the use of machine learning to classify novel mutations as either disrupting, activating, or having no effect on regulatory element activity. Through its use of experimental datasets combined with predictive models for functional consequences of individual cancer variation, this research will further the goal of personalized genome interpretation for cancer therapy. PUBLIC HEALTH RELEVANCE: Every cancer patient's disease is caused by unique set of abnormal variation in the human genome. Advancing our understanding this variation aids in the development of new treatments and the proper application of existing treatments. This proposal focuses on understanding a particular type of cancer variation that occurs in regulatory regions of the human genome.","Identification, Characterization, and Prediction of Cancer Driver Mutations in Regulatory Regions",8931936,K99CA191093,"['Algorithms ', ' Allelomorphs ', ' Alleles ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Malignant Neoplasms ', ' Cause of Death ', ' cultured cell line ', ' Strains Cell Lines ', ' CellLine ', ' Cell Line ', ' disease/disorder ', ' Disorder ', ' Disease ', ' Deoxyribonucleic Acid ', ' DNA ', ' Elements ', ' Environment ', ' Faculty ', ' Future ', ' Genes ', ' Genome ', ' Human Genome ', ' human whole genome ', ' Goals ', ' Health ', ' HeLa ', ' Hela Cells ', ' Modern Man ', ' Man (Taxonomy) ', ' Human ', ' Human Genetics ', ' Laboratories ', ' Mentors ', ' Mentorship ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' Professional Positions ', ' Jobs ', ' Occupations ', ' Productivity ', ' gene product ', ' Proteins ', ' genetic regulatory element ', ' Regulatory Regions, Nucleic Acid (Genetics) ', ' Regulatory Regions ', ' Nucleic Acid Regulator Regions ', ' Nucleic Acid Regulatory Sequences ', ' Research ', ' Researchers ', ' Investigators ', ' Research Personnel ', ' Research Resources ', ' Resources ', ' social role ', ' Role ', ' statistics ', ' Training Programs ', ' United States ', ' Universities ', ' visual function ', ' Sight ', ' Vision ', ' Dataset ', ' Data Set ', ' Task Forces ', ' Advisory Committees ', ' Programmed Cell Death ', ' Apoptosis Pathway ', ' Apoptosis ', ' Point Mutation ', ' base ', ' neoplastic progression ', ' neoplasm progression ', ' cancer progression ', ' tumor progression ', ' Distal ', ' Site ', ' Area ', ' Phase ', ' Variation ', ' Variant ', ' Ensure ', ' Evaluation ', ' Training ', ' Individual ', ' Fostering ', ' Gene Targeting ', ' Sample Size ', ' Collaborations ', ' Therapeutic ', ' Genetic ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' interest ', ' post-doctoral ', ' post-doc ', ' Research Associate ', ' Postdoc ', ' Postdoctoral Fellow ', ' American ', ' Cancer Induction ', ' carcinogenesis ', ' mutant ', ' success ', ' professor ', ' skills ', ' novel ', ' Coding System ', ' Code ', ' Sampling ', ' career development ', ' Nontranslated RNA ', ' Noncoding RNA ', ' Untranslated RNA ', ' Genomics ', ' anticancer therapy ', ' Malignant Neoplasm Treatment ', ' Malignant Neoplasm Therapy ', ' Cancer Treatment ', ' cancer therapy ', ' Normal Cell ', ' genome sequencing ', ' Address ', ' Data ', ' Mutate ', ' Regulatory Element ', ' Research Training ', ' Cancer Biology ', ' Cancer Patient ', ' trend ', ' developmental ', ' Development ', ' epigenomics ', ' oncogenomics ', ' cancer genomics ', ' cancer genome ', ' risk prediction model ', ' prognostic model ', ' computer based prediction ', ' predictive modeling ', ' Cancer cell line ', ' cancer type ', ' migration ', ' innovative ', ' innovate ', ' innovation ', ' parallel computing ', ' parallel computation ', ' parallel computer ', ' genomewide ', ' genome-wide ', ' responsible research conduct ', ' Regimen ', ' TCGA ', ' The Cancer Genome Atlas ', ' ChIP Sequencing ', ' ChIP-seq ', ' Encyclopedia of DNA Elements ', ' Cas nuclease technology ', ' CRISPR/Cas system ', ' CRISPR ', ' Clustered Regularly Interspaced Short Palindromic Repeats ', ' ']",NCI,STANFORD UNIVERSITY,K99,2015,116122,CA-18,0.06615646355143433
"Functional Annotation of Natural and Disease Variants in Tryosine Kinases     DESCRIPTION (provided by applicant): Protein tyrosine kinases are dynamic molecular switches that toggle between a catalytically ""on"" and ""off"" state to turn on and off signals responsible for cell growth and survival. While the tyrosine kinase switch is tightly regulated by  diverse array of structural mechanisms in normal states, in many disease states, the switch is permanently turned on or off due, in part, to mutations in the tyrosine kinase domain. Although genome sequencing studies have revealed the mutational patterns of tyrosine kinases from many different disease types, understanding the structural and functional impact of these mutations is a challenge because many recurrent mutations occur far from the active site (distal mutations) and the residue networks that contribute to the complex modes of tyrosine kinase allosteric regulation are not fully understood. Our long term goal is to understand the relationships connecting sequence, structure, function, regulation and disease in protein kinases using a combination of computational and experimental approaches. Our objective in this proposal, which is the next logical step toward attainment of our long-term goal, is to delineate the residue interaction networks that contribute to the unique modes of allosteric regulation in tyrosine kinases, and to develop a computational framework for predicting mutation impact using the evolutionary and allosteric properties encoded in three dimensional structures. The central hypothesis is that distal mutations alter evolutionarily conserved allosteric networks in tyrosine kinases, and delineating the allosteric networks unique to tyrosine kinases will provide context for predicting and testing disease mutation impact. The specific aims are: * To identify and characterize natural sequence and structural variants associated with tight  allosteric control of tyrosine kinase activity * To develop a computational framework for predicting mutation impact on kinase activation and to  experimentally validate computational predictions using selected receptor tyrosine kinases as  model systems Successful completion of these aims is expected to reveal novel activating mutations in putative allosteric sites in the tyrosine kinase domain, and pinpoint key residues and interactions for functional studies. These outcomes, in turn, are expected to have major biomedical impact by accelerating the functional characterization of the mutated tyrosine kinome, which is emerging as a major target for personalized medicine. Finally, by providing detailed mechanistic annotation of mutations identified in genome sequencing studies, this proposal will address a fundamental NIH roadmap problem in translational medicine of converting genomic discoveries into therapeutic strategies.         PUBLIC HEALTH RELEVANCE: Protein tyrosine kinases are a biomedically important class of proteins that are abnormally regulated in many human diseases including cancer, diabetes, and inflammatory disorders, to name but a few. They have been the focus of many drug discovery efforts and genome sequencing studies because of the therapeutic potential of targeting mutated tyrosine kinases for personalized therapy. By providing functional annotation of natural and disease mutations in tyrosine kinases, the proposed studies will accelerate the targeting of mutated tyrosine kinases for drug discovery and personalized therapy.            ",Functional Annotation of Natural and Disease Variants in Tryosine Kinases,8984471,R01GM114409,"['Allosteric Regulation ', ' Allosteric Site ', ' anticancer drug ', ' anticancer agent ', ' Tumor-Specific Treatment Agents ', ' Neoplastic Disease Chemotherapeutic Agents ', ' Cancer Drug ', ' Antineoplastics ', ' Antineoplastic Drugs ', ' Anti-Cancer Agents ', ' Antineoplastic Agents ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' Biological Assay ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Malignant Neoplasms ', ' Cellular Growth ', ' Cellular Expansion ', ' cell growth ', ' Cell Viability ', ' Cell Survival ', ' Communities ', ' diabetes ', ' Diabetes Mellitus ', ' disease/disorder ', ' Disorder ', ' Disease ', ' Drug Regulations ', ' resistant to Drug ', ' resistance to Drug ', ' drug resistant ', ' Drug resistance ', ' drug/agent ', ' Pharmaceutic Preparations ', ' Medication ', ' Drugs ', ' Pharmaceutical Preparations ', ' Family ', ' Foundations ', ' Genes ', ' Human Genome ', ' human whole genome ', ' Goals ', ' In Vitro ', ' Model System ', ' Biologic Models ', ' Biological Models ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' Names ', ' National Institutes of Health ', ' NIH ', ' United States National Institutes of Health ', ' living system ', ' Organism ', ' Peptides ', ' Transphosphorylases ', ' Kinases ', ' EC 2.7 ', ' Phosphotransferases ', ' phosphorylase b kinase kinase ', ' hydroxyalkyl protein kinase ', ' glycogen synthase a kinase ', ' ATP-protein phosphotransferase ', ' Protein Kinase ', ' tyrosyl protein kinase ', ' hydroxyaryl protein kinase ', ' Tyrosylprotein Kinase ', ' Tyrosine-Specific Protein Kinase ', ' Tyrosine-Protein Kinase Receptor EEK ', ' Tyrosine Kinase ', ' Protein Tyrosine Kinase EEK ', ' Ephrin Type-A Receptor 8 Precursor ', ' Ephrin Type-A Receptor 8 ', ' EPH-and ELK-Related Kinase ', ' EPH- and ELK-Related Tyrosine Kinase ', ' Protein Tyrosine Kinase ', ' gene product ', ' Proteins ', ' Publishing ', ' Recurrent ', ' Recurrence ', ' biological signal transduction ', ' Signaling ', ' Signal Transduction Systems ', ' Intracellular Communication and Signaling ', ' Cell Signaling ', ' Cell Communication and Signaling ', ' Signal Transduction ', ' Testing ', ' para-Tyrosine ', ' L-isomer Tyrosine ', ' L-Tyrosine ', ' Tyrosine ', ' Work ', ' Threonine Kinase ', ' Serine-Threonine Kinases ', ' Serine Kinase ', ' Protein-Threonine Kinase ', ' Protein-Serine Kinase ', ' Protein-Serine-Threonine Kinases ', ' base ', ' improved ', ' Distal ', ' Site ', ' Variation ', ' Variant ', ' Active Sites ', ' Tyrosine Kinase Receptors ', ' Tyrosine Kinase Linked Receptors ', ' Tyrosine Kinase Growth Factor Receptor ', ' Transmembrane Receptor Protein Tyrosine Kinase ', ' PTK Receptors ', ' Receptor Protein-Tyrosine Kinases ', ' insight ', ' Therapeutic ', ' Inflammatory ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Complex ', ' Pattern ', ' LOINC Axis 4 System ', ' System ', ' Molecular Dynamics Simulation ', ' molecular dynamics ', ' mutant ', ' Structure ', ' novel ', ' Regulation ', ' Modeling ', ' LOINC Axis 2 Property ', ' Property ', ' Genomics ', ' drug discovery ', ' Molecular Interaction ', ' Binding ', ' Binding (Molecular Function) ', ' genome sequencing ', ' Address ', ' Drug Binding Site ', ' Mutate ', ' Ontology ', ' Tyrosine Kinase Domain ', ' computational framework ', ' computer framework ', ' Outcome ', ' 3D structure ', ' 3-dimensional structure ', ' 3-D structure ', ' three dimensional structure ', ' translational medicine ', ' human disease ', ' public health relevance ', ' personalized treatment ', ' personalized therapy ', ' personalized medicine ', ' ']",NIGMS,UNIVERSITY OF GEORGIA,R01,2015,300000,GA-10,0.253183175078445
"Developing integrative approaches for identifying disease-causing genes and dysfunctional networks     DESCRIPTION: Cancer is a consequence of the accumulation of genetic alterations. Large whole-genome scale resequencing projects such as The Cancer Genome Atlas (TCGA) have been launched in an effort to comprehensively catalog the genomic mutations and epigenetic modifications that are associated with cancer. It is essential to identify cancer-causing genes and pathways to gain insight into the disease mechanisms and hence facilitate early diagnosis and optimal treatment. However, identifying cancer-causing genes and their functional pathways remains challenging due to the complex biological interactions and the heterogeneity of diseases. Genetic mutations in disease-causing genes can disturb signaling pathways that impact the expression of a set of genes performing certain biological functions. We refer to a set of such genes as a functional module. We hypothesize that driver mutations, that is, mutations that lead to cancer progression, are likely to affect common disease-associated functional modules, and the causal relationship between the mutations and the perturbed signals of the modules can be reconstructed from gene expression data and protein interaction data. In this project, we will develop a novel approach to infer disease-causing genes and networks by integrating information from multiple types of data including genomic variations, gene expression and protein interactions. We first dynamically identify disease-associated modules that consist of a set of interacting genes, then develop a Bayesian-based approach to infer causative genes from the disease-associated modules. Then, by developing a stochastic search based method, we can determine the paths connecting causative genes and gene modules. As a result, disease- related pathways are inferred from the paths. Furthermore, we will integrate those pathways with the human interactome to discover higher-level disease-associated networks. In addition, we will develop machine learning based classifiers to predict disease types and clinical outcomes utilizing the molecular signatures identified in this project, such as differentially expressed gene modules and causative genes. Our computational framework and classifiers will be made available to the research community via a webserver. The PI serves as the university bioinformatics program director and has extensive teaching and research experience. A goal of this project is also to provide scientific research training to students and o help students to gain biological insight through their involvement with the project. Students will learn practical scientific computing skills from the PI and develop their own computational approaches to solving specific biomedical problems under the guidance of the PI. Thus the project will serve as an effective learning-research model in bioinformatics.         PUBLIC HEALTH RELEVANCE: In this project, we will develop and implement a novel framework to identify causative mutations and pathways and study cancer disease mechanisms by reconstructing signaling pathways. This will help to advance personalized medicine and lead to a greater understanding of cancer mechanisms, which can lay the foundation for improving early diagnosis and treatment planning, as well as the discovery of new therapeutic targets.            ",Developing integrative approaches for identifying disease-causing genes and dysfunctional networks,8880075,R15GM114739,"['Affect ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Malignant Neoplasms ', ' Cataloging ', ' Communities ', ' disease/disorder ', ' Disorder ', ' Disease ', ' Deoxyribonucleic Acid ', ' DNA ', ' Foundations ', ' Gene Cluster ', ' Gene Expression ', ' Genes ', ' Genome ', ' Goals ', ' Heterogeneity ', ' Modern Man ', ' Man (Taxonomy) ', ' Human ', ' heavy metal lead ', ' heavy metal Pb ', ' Pb element ', ' Lead ', ' Learning ', ' Methods ', ' statistical linear models ', ' statistical linear mixed models ', ' Probability Models ', ' Probabilistic Models ', ' Statistical Models ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' Protein Phosphorylation ', ' Phosphorylation ', ' gene product ', ' Proteins ', ' Research ', ' Research Resources ', ' Resources ', ' social role ', ' Role ', ' Signal Pathway ', ' biological signal transduction ', ' Signaling ', ' Signal Transduction Systems ', ' Intracellular Communication and Signaling ', ' Cell Signaling ', ' Cell Communication and Signaling ', ' Signal Transduction ', ' Students ', ' Teaching ', ' Educational process of instructing ', ' Technology ', ' Universities ', ' Promotor ', ' Promoters (Genetics) ', ' Promoter ', ' Promotor (Genetics) ', ' base ', ' neoplastic progression ', ' neoplasm progression ', ' cancer progression ', ' tumor progression ', ' improved ', ' Clinical ', ' Biological ', ' insight ', ' Relapsed Disease ', ' Recurrent disease ', ' Biological Function ', ' Biological Process ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Catalogs ', ' programs ', ' Investigation ', ' Complex ', ' LOINC Axis 4 System ', ' System ', ' early detection ', ' Early Diagnosis ', ' experience ', ' Sequence Alteration ', ' Genetic mutation ', ' Gene Alteration ', ' DNA mutation ', ' DNA Alteration ', ' Gene Mutation ', ' Performance ', ' heuristics ', ' knowledgebase ', ' knowledge base ', ' treatment planning ', ' skills ', ' novel ', ' disease risk ', ' disorder risk ', ' Protein Gene Products ', ' Gene Proteins ', ' Single Base Polymorphism ', ' Single Nucleotide Polymorphism ', ' Modeling ', ' Sampling ', ' protein protein interaction ', ' Genomics ', ' ovarian cancer ', ' Ovary Cancer ', ' Malignant Tumor of the Ovary ', ' Malignant Ovarian Tumor ', ' Malignant Ovarian Neoplasm ', ' Malignant neoplasm of ovary ', ' Bio-Informatics ', ' Bioinformatics ', ' DNA-Protein Interaction ', ' Resequencing ', ' DNA Resequencing ', ' DNA Sequence Alteration ', ' Data ', ' molecular signature ', ' molecular profile ', ' Molecular Fingerprinting ', ' Expression Signature ', ' Expression Profiling ', ' Molecular Profiling ', ' Research Training ', ' Cancer Cause ', ' Cancer Etiology ', ' Clinical Data ', ' Epigenetic Mechanism ', ' Epigenetic Change ', ' Epigenetic ', ' Epigenetic Process ', ' Molecular ', ' Modification ', ' pathway ', ' Pathway interactions ', ' whole-genome scan ', ' whole genome association study ', ' whole genome association studies ', ' whole genome association analysis ', ' genomewide scan ', ' genomewide association study ', ' genomewide association studies ', ' genomewide association scan ', ' genome-wide scan ', ' genome-wide identification ', ' genome wide studies ', ' genome wide screen ', ' genome wide association studies ', ' genome wide association scan ', ' genome wide association ', ' genome wide analysis ', ' GWAS ', ' genome wide association study ', ' computational framework ', ' computer framework ', ' Bayesian computation ', ' Bayesian Networks ', ' computer based statistical methods ', ' risk prediction model ', ' prognostic model ', ' computer based prediction ', ' predictive modeling ', ' novel strategy ', ' novel approaches ', ' new approaches ', ' novel strategies ', ' Outcome ', ' Population ', ' prospective ', ' innovative ', ' innovate ', ' innovation ', ' early therapy ', ' Early treatment ', ' scientific computing ', ' novel therapeutic target ', ' new therapeutic target ', ' public health relevance ', ' genomewide ', ' genome-wide ', ' disease diagnosis ', ' TCGA ', ' The Cancer Genome Atlas ', ' nextgen sequencing ', ' next gen sequencing ', ' NGS system ', ' NGS Method ', ' next generation sequencing ', ' Drug Targeting ', ' personalized treatment ', ' personalized therapy ', ' personalized medicine ', ' ']",NIGMS,UNIVERSITY OF ARKANSAS AT LITTLE ROCK,R15,2015,373520,AR-02,0.11873792093891983
"Informatics Tools for High-throughput Analysis of Cancer Mutations DESCRIPTION (provided by applicant): Large tumor exome sequencing projects have identified a very large number of mutations whose cancer relevance is not yet understood. To begin to address this need, our team has produced two web applications for high-throughput computational analysis of cancer mutations: the Cancer-Related Analysis of VAriants Toolkit (CRAVAT) and the Mutation Position Imaging Toolbox (MuPIT). CRAVAT accepts millions of mutations in a single batch upload and maps mutations from genomic coordinates to annotated transcripts and proteins. MuPIT currently accepts batch uploads of up to 2500 SNVs and maps from genomic coordinates onto X-ray crystal structures of proteins from Protein Data Bank (PDB). We propose to combine and harden CRAVAT and MuPIT into a single web application, in which we will substantially improve the tools, user interface, software infrastructure, integration with external data resources and tools used by the community, and support for protected data. The scope of all tools in the web application will be broadened to handle analysis of the full range of small-scale mutation consequence types found in cancer exomes.  CRAVAT analysis identifies mutations most likely to have deleterious impact on protein function and those that are most likely to confer a selective advantage to cancer cells (drivers), using classifiers developed by our team. Classifier scores are supplemented with annotations, including population allele frequencies, previous occurrence in tumor tissue types, and gene functional categories, enabling filtering (e.g. removing polymorphisms) and prioritization. Gene-level annotation and scoring, by aggregation of classifier scores from mutations in a cohort is also provided.  MuPIT maps mutations from genomic positions onto to protein structures and provides interactive viewing of mutations in the context of protein structure, and in relation to a variety of annotations. To enable prioritization of interesting mutations and genes, the application provides a preview describing each structure and all available annotations (e.g., binding sites, experimental mutagenesis results, polymorphic and disease- associated variants that have been previously documented). After selecting a PDB of interest, the user is led to an interactive visualization page. An enhanced Jmol applet displays all SNVs mapped onto the structure. Frequently, many SNVs in the input list can be mapped onto a single structure, revealing clustering patterns around key functional sites.  Based only on word-of-mouth, since the debut of the two applications in August 2012, CRAVAT has been utilized by 129 unique users from 39 countries, and it has analyzed 1,136 submitted jobs, totaling 27.9 million mutations. MuPIT has been utilized by 242 unique users from 25 countries, with 720 submitted jobs. (Source: Google Analytics). PUBLIC HEALTH RELEVANCE: The proposed work will harden and develop web applications for the cancer genomics community to interpret small-scale mutations in cancer exomes. They are designed to handle very large number of mutations and to provide analysis targeted at researchers who are not bioinformatics experts. The work will contribute to understanding of the genetic complexity and heterogeneity of tumors and assist in discovery of new approaches for cancer prognosis and treatments.",Informatics Tools for High-throughput Analysis of Cancer Mutations,8910262,U01CA180956,"['Reactive Site ', ' Combining Site ', ' Binding Sites ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Malignant Neoplasms ', ' Systematics ', ' Classification ', ' Communities ', ' disease/disorder ', ' Disorder ', ' Disease ', ' drug/agent ', ' Pharmaceutic Preparations ', ' Medication ', ' Drugs ', ' Pharmaceutical Preparations ', ' Gene Frequency ', ' allelic frequency ', ' Allele Frequency ', ' Genes ', ' Health ', ' Heterogeneity ', ' histocompatibility typing ', ' Tissue Typing ', ' Tissue Crossmatching ', ' Histocompatibility Testing ', ' Housing ', ' Maps ', ' Methods ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' Professional Positions ', ' Jobs ', ' Occupations ', ' polymorphism ', ' Polymorphism (Genetics) ', ' Genetic Polymorphism ', ' Production ', ' gene product ', ' Proteins ', ' Scientific Publication ', ' Publications ', ' Researchers ', ' Investigators ', ' Research Personnel ', ' Research Resources ', ' Resources ', ' Splicing ', ' RNA Splicing ', ' computer program/software ', ' Software ', ' Computer software ', ' Technology ', ' Translations ', ' Work ', ' Xrays ', ' X-Rays Radiation ', ' X-Rays ', ' X-Radiation ', ' Radiation, X-Rays, Gamma-Rays ', ' Roentgen Rays ', ' Mutagenesis Molecular Biology ', ' Genetics-Mutagenesis ', ' Mutagenesis ', ' Privacy ', ' Visualization ', ' Imagery ', ' base ', ' improved ', ' Site ', ' Variation ', ' Variant ', ' Biological ', ' Ensure ', ' prognostic ', ' insight ', ' data repository ', ' clinical data repository ', ' Electronic Database ', ' Electronic Databank ', ' Databanks ', ' Data Bases ', ' Data Banks ', ' Databases ', ' world wide web ', ' web ', ' WWW ', ' Internet ', ' Collaborations ', ' Letters ', ' Genetic ', ' Malignant Cell ', ' cancer cell ', ' tool ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Scientist ', ' Source ', ' Pattern ', ' Country ', ' Tumor Tissue ', ' interest ', ' experience ', ' Sequence Alteration ', ' Genetic mutation ', ' Gene Alteration ', ' DNA mutation ', ' DNA Alteration ', ' Gene Mutation ', ' Missense Mutation ', ' cohort ', ' Informatics ', ' UTRs ', ' Untranslated Regions ', ' Structure ', ' Categories ', ' Position ', ' Positioning Attribute ', ' Mutation Analysis ', ' Network Analysis ', ' Pathway Analysis ', ' high throughput analysis ', ' developing computer software ', ' develop software ', ' software development ', ' Genomics ', ' cancer classification ', ' anticancer therapy ', ' Malignant Neoplasm Treatment ', ' Malignant Neoplasm Therapy ', ' Cancer Treatment ', ' cancer therapy ', ' Bio-Informatics ', ' Bioinformatics ', ' Address ', ' protein structure ', ' Data ', ' M.D. ', ' Doctor of Medicine ', ' Mutate ', ' Qualifying ', ' Infrastructure ', ' Research Infrastructure ', ' Cancer Center ', ' Cancer Prognosis ', ' computational analysis ', ' Computer Analysis ', ' Transcript ', ' Update ', ' Molecular ', ' protein function ', ' developmental ', ' Development ', ' imaging ', ' Image ', ' web services ', ' oncogenomics ', ' cancer genomics ', ' cancer genome ', ' insertion/deletion ', ' insertion-deletion mutation ', ' insertion-deletion ', ' insertion/deletion mutation ', ' cancer research ', ' anticancer research ', ' designing ', ' design ', ' novel strategy ', ' novel approaches ', ' new approaches ', ' novel strategies ', ' Population ', ' user-friendly ', ' web interface ', ' tumor ', ' data transmission ', ' data exchange ', ' exomes ', ' exome ', ' Secure ', ' TCGA ', ' The Cancer Genome Atlas ', ' nextgen sequencing ', ' next gen sequencing ', ' NGS system ', ' NGS Method ', ' next generation sequencing ', ' exome sequencing ', ' cloud based ', ' ']",NCI,JOHNS HOPKINS UNIVERSITY,U01,2015,315948,MD-07,0.24274529083540825
"Integrated Genomic Discovery and Functional Validation of Colorectal Cancer Loci DESCRIPTION (provided by applicant): Colorectal carcinoma (CRC) arises from multiple mutations and genomic aberrations in distinct driver cancer genes that that in concert to spur neoplastic development and phenotype. This inherent genetic complexity greatly complicates both personalized diagnosis and treatment. Previously published studies have confined that large numbers of genes will be mutated or subject to genomic aberrations in CRC. A significant and emerging challenge for the post-genomic era is to identify which of these mutated genes are ""driver"" loci that functionally drive colon cancer development, versus ""passenger"" loci without functional relevance. Finally, it is of the highest priority that one forges these genetic observations with correlations of prognosis and clinical outcome. This can only be done if we better understand the unified biological ramifications of the combined and diverse multigenic driver background which act synergistically to promote CRC tumorigenesis. This proposal details an integrated analysis that will rely on the CRC genomic data generated by the Cancer Genome Atlas Project (TCGA) to discover novel candidate CRC genes and study multigenic CRC driver gene co-mutated / dysregulated modules within the genetic context of other drivers and provide biological validation in a powerful in vitro primary culture CRC model which can be engineered for multiple genetic events.  To accomplish these goals, we will develop and implement novel statistical methodologies for the integrative analysis of multiple TCGA genomic and clinical data sets. The goal is to identify and prioritize novel CRC genes either singly or as co-mutated modules in combination with other known ""driver"" CRC genes. We will use the rich TCGA data set to conduct an integrated CRC genomic analysis of point mutations, gene expression, copy number aberrations and methylation data. We will prioritize the discovery of mutations and other genomic aberrations of these novel CRC genes that are associated with specific clinical stages of disease and other clinical parameters.  These statistical and computational studies will then be directly coupled to rapid and robust functional target validation of candidate loci using our rigorously characterized in vitro primary intestinal culture methodology (Gotani et al, Nature Medicine, 2009), in which we have recently established the transforming activity of established CRC loci such as APC, KRAS and TP53. Genetic deletion and retroviral expression of shRNA, cDNA or mutants thereof will be utilized to evaluate putative individual driver loci, as well as combinatorial oncogene modules. This proposal directly addresses fundamental problems in the exploration and translation of novel colorectal cancer gene discovery in the context of clinical data which is available from TCGA. RELEVANCE (See instructions): Colorectal cancer (CRC) represents the third most commonly diagnosed cancer in the United States. This proposal utilizes a fusion of genomic analysis of a large population of patients, mathematical modeling and culture of intestinal fragments to functionally identify genes that are critical for colon cancer development. These studies have implications for generation of novel diagnostic and therapeutic strategies for colon cancer. ",Integrated Genomic Discovery and Functional Validation of Colorectal Cancer Loci,8916038,U01CA151920,"['Algorithms ', ' Atlases ', ' Biology ', ' cDNA ', ' Complementary DNA ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Malignant Neoplasms ', ' Large Bowel Carcinoma ', ' Colorectal Carcinomas ', ' Large Intestine Carcinoma ', ' Diagnosis ', ' disease/disorder ', ' Disorder ', ' Disease ', ' Engineering ', ' Future ', ' Gene Expression ', ' Genes ', ' Goals ', ' In Vitro ', ' bowel ', ' Intestinal ', ' Intestines ', ' Literature ', ' Medicine ', ' Methods ', ' Method LOINC Axis 6 ', ' Methodology ', ' Protein Methylation ', ' Methylation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' Transforming Genes ', ' Cancer-Promoting Gene ', ' Cancer Genes ', ' Oncogenes ', ' Phenotype ', ' Prognosis ', ' outcome forecast ', ' Scientific Publication ', ' Publications ', ' Publishing ', ' Research ', ' Statistical Study ', ' statistics ', ' Survey Instrument ', ' Surveys ', ' Technology ', ' Translations ', ' United States ', ' Generations ', ' p53 Genes ', ' Tumor Protein p53 Gene ', ' TRP53 ', ' TP53 ', ' P53 ', ' TP53 gene ', ' Racial Segregation ', ' segregation ', ' Dataset ', ' Data Set ', ' Point Mutation ', ' Clinical ', ' Variation ', ' Variant ', ' Biological ', ' Evaluation ', ' intestinal epithelium ', ' Individual ', ' Bayesian statistics ', ' Bayesian statistical inference ', ' Bayesian statistical analysis ', ' Bayesian spatial analysis ', ' Bayesian network analysis ', ' Bayesian inference ', ' Bayesian Analysis ', ' Measurement ', ' Oncologist ', ' Genetic ', ' Staging ', ' Diagnostic ', ' Nature ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Event ', ' Somatic Mutation ', ' experience ', ' Sequence Alteration ', ' Genetic mutation ', ' Gene Alteration ', ' DNA mutation ', ' DNA Alteration ', ' Gene Mutation ', ' mutant ', ' authority ', ' novel ', ' Colonic Carcinoma ', ' Colon Cancer ', ' Colon Carcinoma ', ' Modeling ', ' mathematical modeling ', ' mathematic model ', ' Math Models ', ' mathematical model ', ' Genomics ', ' cancer diagnosis ', ' Oncogenesis ', ' tumorigenesis ', ' v-Ki-RAS2 Kirsten Rat Sarcoma 2 Viral Oncogene Homolog ', ' RASK2 ', ' Oncogene K-Ras ', ' Ki-RAS ', ' KRAS2 ', ' KRAS ', ' K-Ras-2 Oncogene ', ' K-Ras 2A ', ' K-RAS2B ', ' K-RAS2A ', ' C-K-RAS ', ' KRAS2 gene ', ' Address ', ' Systems Biology ', ' copy number variation ', ' Copy Number Polymorphism ', ' Data ', ' Mutate ', ' Clinical Data ', ' Validation ', ' Principal Investigator ', ' developmental ', ' Development ', ' Colorectal Cancer ', ' neoplastic ', ' Instruction ', ' clinical phenotype ', ' oncogenomics ', ' cancer genomics ', ' forging ', ' cancer genome ', ' computational studies ', ' computer studies ', ' novel strategy ', ' novel approaches ', ' new approaches ', ' novel strategies ', ' Outcome ', ' Coupled ', ' short hairpin RNA ', ' shRNA ', ' small hairpin RNA ', ' combinatorial ', ' next generation therapeutics ', ' new therapeutics ', ' novel therapeutics ', ' next generation diagnostics ', ' new diagnostics ', ' novel diagnostics ', ' discover genes ', ' gene discovery ', ' patient population ', ' genomewide ', ' genome-wide ', ' candidate validation ', ' exomes ', ' exome ', ' TCGA ', ' The Cancer Genome Atlas ', ' exome sequencing ', ' algorithmic composition ', ' algorithm engineering ', ' Algorithmic Engineering ', ' Algorithmic Design ', ' Algorithm Design ', ' ']",NCI,STANFORD UNIVERSITY,U01,2015,538250,CA-18,0.09622183646985695
"Integrative approach for predicting cancer driver genes     DESCRIPTION (provided by applicant): Carcinogenesis, progression of normal cells to malignant cancer, derives from hallmark capabilities of cancer driven by acquiring (somatic) mutations in ""driver genes"" with a selective advantage for cellular proliferation and potentially metastasis. A major motivation for modern cancer genomics studies is to decipher the genetic architecture of cancer by discovering new driver genes. The most widely-used approaches to predict and prioritize driver genes are based on statistics of mutation frequencies. Several methods have been proposed to identify genes with an excessive number of somatic mutations [9-11], known as significantly mutated genes. I propose to address two major limitations of this approach. First, these methods are insufficiently statistically powered given the amount of sequencing data currently available [15]. I will improve statistical power by leveraging diverse information in cancer genomics currently available into a developed machine learning method. Second, there is little objective clarity about the true effectiveness of these methods [11, 14], since there is no agreed-upon gold standard of driver genes, with the exception of a few well-known drivers. I will develop a framework to compare the effectiveness of driver gene prediction methods, in the absence of a gold standard. Both effectively and efficiently identifying cancer driver genes is a matter of great importance to science funding policy towards cancer genomics.         PUBLIC HEALTH RELEVANCE: Large sequencing studies have revolutionized our capability to identify the genetic architecture of cancer. However, effectively integrating this stream of big data to identify specific driver genes has remained troublesome. My proposed research project aims to develop an integrative machine learning method that leverages diverse features in cancer genomics to improve predictions of cancer driver genes, and to utilize a principled approach for evaluating the performance of any such method.            ",Integrative approach for predicting cancer driver genes,8982803,F31CA200266,"['Cell Multiplication ', ' Cell Growth in Number ', ' Cell Proliferation ', ' Performance ', ' Statistical Bias ', ' novel ', ' Sampling ', ' LOINC Axis 2 Property ', ' Property ', ' Normal Cell ', ' Effectiveness ', ' Address ', ' Data ', ' Mutate ', ' Scheme ', ' Tumor Biology ', ' Characteristics ', ' transcriptome ', ' gene expression signature ', ' gene expression pattern ', ' Gene Expression Profile ', ' oncogenomics ', ' cancer genomics ', ' compare effectiveness ', ' public health relevance ', ' Big Data ', ' Algorithms ', ' Engineering / Architecture ', ' Architecture ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Malignant Neoplasms ', ' Genes ', ' Au element ', ' Gold ', ' Methods ', ' Motivation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' tumor cell metastasis ', ' cancer metastasis ', ' Tumor Cell Migration ', ' Secondary Tumor ', ' Secondary Neoplasm ', ' Metastatic Tumor ', ' Metastatic Neoplasm ', ' Metastasize ', ' Metastasis ', ' Neoplasm Metastasis ', ' Play ', ' Science ', ' statistics ', ' oncosuppressor gene ', ' Tumor Suppressing Genes ', ' Recessive Oncogenes ', ' Oncogenes-Tumor Suppressors ', ' Onco-Suppressor Genes ', ' Emerogenes ', ' Cancer Suppressor Genes ', ' Antioncogenes ', ' Anti-Oncogenes ', ' Tumor Suppressor Genes ', ' base ', ' improved ', ' Malignant ', ' Malignant - descriptor ', ' Evaluation ', ' Policies ', ' Funding ', ' Research Projects ', ' Research Grants ', ' R01 Program ', ' R01 Mechanism ', ' R-Series Research Projects ', ' Research Project Grants ', ' Genetic ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Frequency ', ' Frequencies (time pattern) ', ' Stream ', ' Pattern ', ' Somatic Mutation ', ' Cancer Induction ', ' carcinogenesis ', ' Cellular Proliferation ', ' ']",NCI,JOHNS HOPKINS UNIVERSITY,F31,2015,43120,MD-07,0.08419461590946394
"Molecular impact of mutations in monogenic disease and cancer ABSTRACT Nextgenerationgenomescalesequencingofpatientsisnowbecomingroutinefortwoclassesofdisease:rare Mendeliantraitsandcancer.Infavorablecases,thesedataallowidentificationofrelevantmutationsandthus aiddiagnosisandtherapy.Inbothclassesofdisease,themostcommontypeofmutationismissense-single base changes that result in an amino acid substitution in a protein. Uncertainty as to the impact of these mutationsoninvivoproteinactivityhasresultedinaveryconservativeapproachtotheirinterpretationinthe clinic, so causing many missed opportunities for targeted treatment. The goal of this project is to use a combinationofthreestrategiestomaketheinterpretationofthesemutationsmuchmoreapplicableintheclinic. Therearealreadyalargenumberofcomputationalmethodsthatattempttodeterminetheimpactofmissense mutationsonfunction,andthereissubstantialevidencethatthesehaveusefulaccuracy.Theprimarydifficulty isthattheaccuracyinanyparticularcaseisnotreliablycalibrated.Therefore,ourfirstaimistouseacombination ofthesemethodstodevelopanapproachfocusedonmorereliableestimatesfortheprobabilityofhighimpact on protein function (i.e. more confident P values). The second aim is to maximize the utilization of three- dimensionalstructuralinformation,largelyignoredbymostcomputationalmethods.Alargefractionofmissense mutationsintheseclassesofdiseaseactbydestabilizingproteinstructureandknowledgeofstructureallows thesetobeidentifiedwithmuchhigherreliability.Also,structureprovidesaframeworkfordetailedannotation andcomprehensionoffunction.Tofacilitatetheutilizationofstructure,wewillimplementamodelingplatform thatleveragesavailableexperimentalinformationtomaximizethestructuraldataavailableforanalyzingmutation impact. An important aspect of the platform is incorporation of methods for evaluating the reliability of the structuralfeaturesrelevanttoanalysisofeachmutation.Inthethirdaimwewillbuildspecificfunctionalmodels foreachproteinofinterest,integratinginformationfromcurrentdatabases,theliterature,andcommunityinput, soastoprovidetherichestpossiblebackgroundagainstwhichtojudgetheimpactofmutations.Proteopedia,a wellestablishedmediawikiforproteins,willbeusedtoprovideanintegratedviewoftext,data,andstructure.A keycomponentoftheinformationresourcewillbecontributionsfromcurators,whowillprovideannotationand alsosolicitinputfromotherexperts.Thisaspectoftheprojectbuildsonexperiencewithothercrowdsourcing endeavors, including CASP, CAGI and Proteopedia.  There will be three primary outcomes from the project: First,improvedreliabilityfortheinterpretationofmissensemutations.Second,aprototypemutationannotation proceduresuitableforuseinaclinicalsetting.Third,theresourcewillprovideinformationofbenefittoarange ofotherscientists,thusfacilitatingtheanalysisofdiseaserelatedmutations.  NARRATIVE Genome scale DNA sequencing is now contributing to diagnosis and therapy in cases of rare human diseaseandcancer.Fullexploitationofthesedataiscurrentlyhamperedbyinadequateunderstanding ofwhichDNAchangesaffectproteinfunctionsoastocontributetodisease.Thisprojectaimstodevelop themethodsandtoolsneededtoremovethatobstacle.",Molecular impact of mutations in monogenic disease and cancer,9156099,R01GM120364,"['Affect ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Malignant Neoplasms ', ' Communities ', ' computing method ', ' computer methods ', ' computational methods ', ' computational methodology ', ' Computing Methodologies ', ' Diagnosis ', ' Disorder ', ' Disease ', ' Deoxyribonucleic Acid ', ' DNA ', ' Goals ', ' Modern Man ', ' Human ', ' Literature ', ' Methods ', ' Structural Models ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' Patients ', ' Play ', ' Probability ', ' Proteins ', ' Research Resources ', ' Resources ', ' social role ', ' Role ', ' Software ', ' Computer software ', ' Uncertainty ', ' doubt ', ' DNA Sequence ', ' Comprehension ', ' Protein Domains ', ' Peptide Domain ', ' Tertiary Protein Structure ', ' base ', ' improved ', ' Procedures ', ' Clinical ', ' data repository ', ' clinical data repository ', ' Databanks ', ' Data Bases ', ' Data Banks ', ' Databases ', ' tool ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Consensus ', ' Knowledge ', ' Scientist ', ' Clinic ', ' Amino Acid Substitution ', ' interest ', ' experience ', ' Missense Mutation ', ' trait ', ' orphan disorder ', ' Rare Disorder ', ' Orphan Disease ', ' Rare Diseases ', ' Structure ', ' Reporting ', ' Mutation Analysis ', ' Modeling ', ' protein protein interaction ', ' Address ', ' protein structure ', ' Data ', ' knowledge resources ', ' knowledge resource ', ' information resource ', ' Information Resources ', ' in vivo ', ' computer analyses ', ' computational analysis ', ' computational analyses ', ' Computer Analysis ', ' Molecular ', ' Process ', ' Text ', ' protein function ', ' next generation ', ' clinically relevant ', ' clinical relevance ', ' wiki ', ' data structure ', ' human disease ', ' prototype ', ' primary outcome ', ' genome-wide ', ' genomewide ', ' genome scale ', ' targeted treatment ', ' targeted therapy ', ' targeted therapeutic agents ', ' targeted therapeutic ', ' targeted drug treatments ', ' targeted drug therapy ', ' Mendelian disorder ', ' single-gene disorder ', ' single-gene disease ', ' monogenic disorder ', ' monogenic disease ', ' Mendelian genetic disorder ', ' Mendelian disease ', ' crowdsourcing ', ' crowdsource ', ' crowd-sourcing ', ' crowd source ', ' learning strategy ', ' learning method ', ' learning activity ', ' ']",NIGMS,"UNIV OF MARYLAND, COLLEGE PARK",R01,2016,372928,MD-05,0.258328104292124
"Functional Annotation of Natural and Disease Variants in Tryosine Kinases     DESCRIPTION (provided by applicant): Protein tyrosine kinases are dynamic molecular switches that toggle between a catalytically ""on"" and ""off"" state to turn on and off signals responsible for cell growth and survival. While the tyrosine kinase switch is tightly regulated by  diverse array of structural mechanisms in normal states, in many disease states, the switch is permanently turned on or off due, in part, to mutations in the tyrosine kinase domain. Although genome sequencing studies have revealed the mutational patterns of tyrosine kinases from many different disease types, understanding the structural and functional impact of these mutations is a challenge because many recurrent mutations occur far from the active site (distal mutations) and the residue networks that contribute to the complex modes of tyrosine kinase allosteric regulation are not fully understood. Our long term goal is to understand the relationships connecting sequence, structure, function, regulation and disease in protein kinases using a combination of computational and experimental approaches. Our objective in this proposal, which is the next logical step toward attainment of our long-term goal, is to delineate the residue interaction networks that contribute to the unique modes of allosteric regulation in tyrosine kinases, and to develop a computational framework for predicting mutation impact using the evolutionary and allosteric properties encoded in three dimensional structures. The central hypothesis is that distal mutations alter evolutionarily conserved allosteric networks in tyrosine kinases, and delineating the allosteric networks unique to tyrosine kinases will provide context for predicting and testing disease mutation impact. The specific aims are: * To identify and characterize natural sequence and structural variants associated with tight  allosteric control of tyrosine kinase activity * To develop a computational framework for predicting mutation impact on kinase activation and to  experimentally validate computational predictions using selected receptor tyrosine kinases as  model systems Successful completion of these aims is expected to reveal novel activating mutations in putative allosteric sites in the tyrosine kinase domain, and pinpoint key residues and interactions for functional studies. These outcomes, in turn, are expected to have major biomedical impact by accelerating the functional characterization of the mutated tyrosine kinome, which is emerging as a major target for personalized medicine. Finally, by providing detailed mechanistic annotation of mutations identified in genome sequencing studies, this proposal will address a fundamental NIH roadmap problem in translational medicine of converting genomic discoveries into therapeutic strategies. PUBLIC HEALTH RELEVANCE: Protein tyrosine kinases are a biomedically important class of proteins that are abnormally regulated in many human diseases including cancer, diabetes, and inflammatory disorders, to name but a few. They have been the focus of many drug discovery efforts and genome sequencing studies because of the therapeutic potential of targeting mutated tyrosine kinases for personalized therapy. By providing functional annotation of natural and disease mutations in tyrosine kinases, the proposed studies will accelerate the targeting of mutated tyrosine kinases for drug discovery and personalized therapy.",Functional Annotation of Natural and Disease Variants in Tryosine Kinases,9116916,R01GM114409,"['Allosteric Regulation ', ' Allosteric Site ', ' anticancer drug ', ' anticancer agent ', ' Tumor-Specific Treatment Agents ', ' Neoplastic Disease Chemotherapeutic Agents ', ' Cancer Drug ', ' Antineoplastics ', ' Antineoplastic Drugs ', ' Anti-Cancer Agents ', ' Antineoplastic Agents ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' Biological Assay ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Malignant Neoplasms ', ' Cellular Growth ', ' Cellular Expansion ', ' cell growth ', ' Cell Viability ', ' Cell Survival ', ' Communities ', ' diabetes ', ' Diabetes Mellitus ', ' Disorder ', ' Disease ', ' Drug Regulations ', ' resistant to Drug ', ' resistance to Drug ', ' drug resistant ', ' Drug resistance ', ' drug/agent ', ' Pharmaceutic Preparations ', ' Medication ', ' Drugs ', ' Pharmaceutical Preparations ', ' Family ', ' Foundations ', ' Genes ', ' human whole genome ', ' Human Genome ', ' Goals ', ' Health ', ' In Vitro ', ' Model System ', ' Biologic Models ', ' Biological Models ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' Names ', ' National Institutes of Health ', ' NIH ', ' United States National Institutes of Health ', ' living system ', ' Organism ', ' Peptides ', ' Transphosphorylases ', ' Phosphotransferase Gene ', ' Kinases ', ' Phosphotransferases ', ' phosphorylase b kinase kinase ', ' hydroxyalkyl protein kinase ', ' glycogen synthase a kinase ', ' Kinase Family Gene ', ' ATP-protein phosphotransferase ', ' Protein Kinase ', ' tyrosyl protein kinase ', ' hydroxyaryl protein kinase ', ' Tyrosylprotein Kinase ', ' Tyrosine-Specific Protein Kinase ', ' Tyrosine-Protein Kinase Receptor EEK ', ' Tyrosine Kinase ', ' Protein Tyrosine Kinase EEK ', ' Ephrin Type-A Receptor 8 Precursor ', ' Ephrin Type-A Receptor 8 ', ' EPH-and ELK-Related Kinase ', ' EPH- and ELK-Related Tyrosine Kinase ', ' Protein Tyrosine Kinase ', ' Proteins ', ' Publishing ', ' Recurrent ', ' Recurrence ', ' biological signal transduction ', ' Signaling ', ' Signal Transduction Systems ', ' Intracellular Communication and Signaling ', ' Cell Signaling ', ' Cell Communication and Signaling ', ' Signal Transduction ', ' Testing ', ' Tyrosine ', ' Work ', ' Protein-Serine-Threonine Kinases ', ' Threonine Kinase ', ' Serine/Threonine Protein Kinase Gene ', ' Serine-Threonine Kinases ', ' Serine Kinase ', ' Protein-Threonine Kinase ', ' Protein-Serine Kinase ', ' base ', ' improved ', ' Distal ', ' Site ', ' Variation ', ' Variant ', ' Active Sites ', ' Tyrosine Kinase Receptors ', ' Tyrosine Kinase Linked Receptors ', ' Transmembrane Receptor Protein Tyrosine Kinase ', ' Receptor Tyrosine Kinase Gene ', ' PTK Receptors ', ' Receptor Protein-Tyrosine Kinases ', ' insight ', ' Therapeutic ', ' Inflammatory ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Complex ', ' Pattern ', ' System ', ' Molecular Dynamics Simulation ', ' molecular dynamics ', ' mutant ', ' Structure ', ' novel ', ' Regulation ', ' Modeling ', ' Property ', ' Genomics ', ' drug discovery ', ' Molecular Interaction ', ' Binding ', ' genome sequencing ', ' Address ', ' Drug Binding Site ', ' Mutate ', ' Ontology ', ' Tyrosine Kinase Domain ', ' computational framework ', ' computer framework ', ' Outcome ', ' three dimensional structure ', ' 3D structure ', ' 3-dimensional structure ', ' 3-D structure ', ' translational medicine ', ' human disease ', ' personalized medicine ', ' personalized treatment ', ' personalized therapy ', ' personalization of treatment ', ' ']",NIGMS,UNIVERSITY OF GEORGIA,R01,2016,300000,GA-10,0.253183175078445
"Molecular Characterization of Joubert Syndrome Project Summary Congenital ataxia presents in early childhood with non-progressive hypotonia, gross motor, fine motor and cognitive delays. These disorders are distinct from the progressive ataxias because of the presence of congenital cerebellar malformations and because they are typically inherited recessively. Joubert Syndrome and Related Disorders (JSRD) constitute a major subset of these conditions, consisting of a cerebellar midline (vermis) malformation, a nearly pathognomonic Molar Tooth sign on brain Imaging (MTI) and co-existent oculomotor apraxia and episodic breathing dysrhythmias. In our published data, we have: 1] Identified ten unique genetic causes of JSRD (nearly half of the published causes), 2] Generated genotype-phenotype correlations involving cerebellar, retinal, renal, hepatic, digit, and cerebral manifestations. 3] Identified common founder mutations that allow for population-based screening. 4] Discovered that JSRD encoded proteins frequently localize to the cilium. 5] Identified ciliary transition zone (TZ) defects in cells with JSRD mutations. 6] Performed siRNA cell-based screens for defective ciliogenesis to prioritize candidate JSRD genes. 7] Generated and characterized multiple zebrafish, mouse and human cell culture models for JSRD. 8] Defined the concept of Ciliary localization model, in which one JSRD gene is required for ciliary localization of other JSRD proteins. In our unpublished data we have: 1] Recruited an additional 200 JSRD patients without molecular diagnosis. 2] Performed whole exome (WES) and whole genome sequencing (WGS) on an additional 100 JSRD families. 3] Identified an additional 12 novel likely JSRD candidate genes. 4] Generated IPSCs and cerebellar organoids from mutation-positive and negative families to aid in functional analysis and gene discovery using RNAseq. 5] Begun functional validation of the putative mutations. 6] Developed methods to interrogate ciliary structure in a high-throughput fashion with electron microscopy (EM). The goal of this competing renewal is to identify the remaining discoverable genes that lead to JSRD when lost, functionally validate mutations within the pathogenetic framework, and test the hypothesis that mutations in JSRD genes lead to collapse of the ciliary TZ. Because the majority of patients still have unknown cause of disease, this renewal aims to advance knowledge through molecular characterization of new genes, using newly evolving high-throughput techniques, integrated bioinformatics, and a unique resource of consanguineous families recruited world-wide. We further aim to validate these mutations in patient cells, within a mechanistic framework that JSRD genes are required for essential ciliary structural components during cerebellar development. Project Narrative Joubert syndrome is a genetically and phenotypically heterogeneous neurodevelopmental disorder unified by defects of the cellular primary cilium. This work will identify new genetic causes and dissect ciliary defects associated with genetic mutations.",Molecular Characterization of Joubert Syndrome,9239923,R01NS048453,"['Termination of pregnancy ', ' apraxia ', ' Dyspraxia ', ' Apraxias ', ' inspiration ', ' Respiratory Inspiration ', ' Respiratory Aspiration ', ' Inhaling ', ' Inhalation ', ' Breathing ', ' Dyssynergia ', ' Coordination Impairment ', ' Ataxy ', ' Ataxia ', ' cell culture ', ' Cell Culture Techniques ', ' Cell Body ', ' Cells ', ' Cultured Cells ', ' Cilia ', ' granule ', ' Cytoplasmic Granules ', ' Disorder ', ' Disease ', ' Negatrons ', ' Negative Beta Particle ', ' Electrons ', ' Embryonic ', ' Embryo ', ' facial ', ' faces ', ' Face ', ' Family ', ' Genes ', ' Genotype ', ' Goals ', ' Au element ', ' Gold ', ' Modern Man ', ' Human ', ' renal ', ' Kidney Urinary System ', ' Kidney ', ' heavy metal lead ', ' heavy metal Pb ', ' Pb element ', ' Lead ', ' Methods ', ' Electron Microscopy ', ' Scanning Electron Microscopy ', ' Middle East ', ' Molar tooth ', ' Morphogenesis ', ' Murine ', ' Mice Mammals ', ' Mice ', ' Mus ', ' Muscular Hypotonia ', ' Muscle Tone Poor ', ' Muscle Hypotony ', ' Hypotonia ', ' Hypomyotonia ', ' Decreased Muscle Tone ', ' Muscle hypotonia ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' Organoids ', ' Patients ', ' Phenotype ', ' Probability ', ' Proteins ', ' Publishing ', ' recruit ', ' active recruitment ', ' Recruitment Activity ', ' Research Resources ', ' Resources ', ' Risk ', ' biological signal transduction ', ' Signaling ', ' Signal Transduction Systems ', ' Intracellular Communication and Signaling ', ' Cell Signaling ', ' Cell Communication and Signaling ', ' Signal Transduction ', ' Mass Spectrum Analyses ', ' Mass Spectrum ', ' Mass Spectroscopy ', ' Mass Spectrometry ', ' Mass Photometry/Spectrum Analysis ', ' Mass Spectrum Analysis ', ' Syndrome ', ' Testing ', ' Work ', ' Zebrafish ', ' Zebra Fish ', ' Zebra Danio ', ' Danio rerio ', ' Brachydanio rerio ', ' base ', ' brain visualization ', ' Brain imaging ', ' Hepatic ', ' Clinical ', ' Microscopic ', ' Variation ', ' Variant ', ' Series ', ' Training ', ' vermis ', ' Cerebellar vermis structure ', ' insight ', ' Individual ', ' cerebral ', ' Cerebrum ', ' data repository ', ' clinical data repository ', ' Databanks ', ' Data Bases ', ' Data Banks ', ' Databases ', ' Cerebellar hypoplasia ', ' Congenital cerebellar hypoplasia ', ' Genetic ', ' Morphology ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Knowledge ', ' cerebelloparenchymal disorder IV ', ' cerebellar vermis agenesis ', ' Joubert-Boltshauser syndrome ', ' Joubert syndrome ', ' Hereditary ', ' Inherited ', ' Severities ', ' cell type ', ' Techniques ', ' fetal ', ' Digit ', ' Digit structure ', ' Gene Alteration ', ' Gene Mutation ', ' mutant ', ' early childhood ', ' cohort ', ' Transmission Electron Microscopy ', ' Structure ', ' genetic testing ', ' gene-based testing ', ' gene testing ', ' Genetic screening method ', ' novel ', ' Modeling ', ' affection ', ' ocularmotor ', ' ocular motor ', ' oculomotor ', ' disease subtype ', ' disorder subtype ', ' siRNA ', ' Short interfering RNA ', ' Small Interfering RNA ', ' Pathogenicity ', ' Bio-Informatics ', ' Bioinformatics ', ' ciliogenesis ', ' cilium biogenesis ', ' genome sequencing ', ' Candidate Gene ', ' Candidate Disease Gene ', ' Length ', ' Defect ', ' genomic alteration ', ' Sequence Alteration ', ' Genetic mutation ', ' DNA mutation ', ' DNA Alteration ', ' DNA Sequence Alteration ', ' Data ', ' Molecular Diagnosis ', ' Motor ', ' Protein Analysis ', ' Cognitive ', ' enroll ', ' Enrollment ', ' Validation ', ' Molecular ', ' Knockout ', ' Knock-out ', ' developmental ', ' Development ', ' Neurological Development Disorder ', ' Neurodevelopmental Disorder ', ' Cerebellum malformation ', ' Cerebellar malformation ', ' reconstruction ', ' knockdown ', ' knock-down ', ' Three-dimensional analysis ', ' 3D analysis ', ' 3-dimensional analysis ', ' 3-D analysis ', ' Retinal ', ' loss of function mutation ', ' founder mutation ', ' malformation ', ' induced pluripotent stem cell ', ' iPSCs ', ' iPSC ', ' iPS ', ' gene discovery ', ' discover genes ', ' population based ', ' stem cell biology ', ' genome-wide ', ' genomewide ', ' genome scale ', ' exome ', ' exomes ', ' transcriptome sequencing ', ' RNAseq ', ' RNA sequencing ', ' RNA Seq ', ' exome sequencing ', ' screening ', ' Clustered Regularly Interspaced Short Palindromic Repeats ', ' CRISPR/Cas system ', ' CRISPR ', ' accurate diagnosis ', ' consanguineous family ', ' consanguineous\xa0kindreds ', ' consanguineous pedigree ', ' whole genome ', ' entire genome ', ' ']",NINDS,ROCKEFELLER UNIVERSITY,R01,2016,557723,NY-12,0.20843462185098818
"Tracing the evolution of the human mutation rate DESCRIPTION (provided by applicant): All genetic variation is created by mutations, changes that arise due to DNA damage or copying mistakes during DNA replication. Mutations are frequent enough that, on average, a child's 3-billion base pair genome contains 74 new genetic variants that are not present in the genome of either parent. Such new mutations confer a higher disease risk than older mutations because they have not passed the test of surviving through several generations of parents and offspring. We aim to pinpoint how the human mutation rate has evolved as humans left Africa and adapted to diverse new environments across the globe.  One specific aim will follow up on my preliminary research which showed that Europeans experienced a mutation rate change after diverging from Africans and Asians. The primary evidence for this change is that European genomes have a higher burden than African or Asian genomes of the mutation type TCCTTC, where the trinucleotide ""TCC"" has experienced a mutation from ""C"" to ""T"" at its central site. We wish to and the genetic basis of this mutation rate change by looking at rare variants in mixed- ancestry Latino and African-American individuals. Specially, we will isolate young genetic variants that probably arose via mutation within the past 10-15 generations, after gene ow from Europe into the Americas had already begun. We will infer the genetic background (European, African, or Native American) upon which each new mutation arose and look for genomic regions where European ances- try correlates strongly with an excess of TCCTTC mutations. These will be the regions most likely to harbor a causal allele that changed the process of mutation accumulation in Europeans. This work has the potential to yield valuable insights into melanoma, a cancer that predominantly affects individuals of European ancestry and whose somatic mutational signature is dominated by TCCTTC.  A second specific aim is to look for other signatures of mutation rate change that have occurred within the human species or, more broadly, within the great apes. We will use a natural language processing technique called Latent Dirichlet Allocation (LDA) to identify collections of mutation types whose rates appear to be under common genetic control. A few mutation types besides TCCTTC show weak signals of rate differentiation between populations, and we will attempt to infer how many separate mutation rate change events are necessary to explain these signals. The admixture mapping technique from Specific Aim I can also be adapted to interrogate the genetic basis of other mutation rate changes that might have occurred in the recent past. These efforts should improve our understanding of the human mutation rate's genetic architecture and how mutation rates differ between populations. PUBLIC HEALTH RELEVANCE: All genetic variation is created by mutations, the copying mistakes that occasionally happen during DNA replication. There is evidence that children born with a higher burden of new mutations are at increased risk for autism, schizophrenia, and serious congenital diseases [1, 2, 3], but it is not well understood how much the human mutation rate varies and what genetic risk factors affect the mutation rate [4]. We aim to follow up on preliminary evidence that the Europeans have a higher mutation rate than Asians or Africans [5], looking for the genetic basis of this rate difference and investigating how often the mutation rate has changed during human evolution.",Tracing the evolution of the human mutation rate,9117987,F32GM116381,"['Acceleration ', ' Affect ', ' Africa ', ' Allelomorphs ', ' Alleles ', ' Americas ', ' Engineering / Architecture ', ' Architecture ', "" Kanner's Syndrome "", ' Infantile Autism ', ' Early Infantile Autism ', ' Autism ', ' Autistic Disorder ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Malignant Neoplasms ', ' youngster ', "" childrens' "", ' children ', ' Children (0-21) ', ' Child Youth ', ' 0-11 years old ', ' Child ', ' genetic mapping ', ' Total Human and Non-Human Gene Mapping ', ' Linkage Mapping ', ' Gene Mapping Genetics ', ' Gene Mapping ', ' Gene Localization ', ' Chromosome Mapping ', ' Disorder ', ' Disease ', ' DNA Injury ', ' DNA Damage ', ' Environment ', ' Europe ', ' Evolution ', ' Exhibits ', ' Genes ', ' Genome ', ' Health ', ' hereditary disorder ', ' genetic disorder ', ' Molecular Disease ', ' Genetic Diseases ', ' Genetic Condition ', ' Hereditary Disease ', ' History ', ' Recording of previous events ', ' Modern Man ', ' Human ', ' Maps ', ' Malignant Melanoma ', ' melanoma ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' natural language understanding ', ' Natural Language Processing ', ' Parents ', ' great ape ', ' Apes ', ' Pongidae ', ' Research ', ' Risk ', ' Risk Factors ', ' schizophrenic ', ' dementia praecox ', ' Schizophrenic Disorders ', ' Schizophrenia ', ' biological signal transduction ', ' Signaling ', ' Signal Transduction Systems ', ' Intracellular Communication and Signaling ', ' Cell Signaling ', ' Cell Communication and Signaling ', ' Signal Transduction ', ' Strikes ', ' Employee Strikes ', ' Testing ', ' Time ', ' Variation (Genetics) ', ' Genetic Variation ', ' Genetic Diversity ', ' Work ', ' Asians ', ' oriental ', ' Generations ', ' African American ', ' black American ', ' Black Populations ', ' Afroamerican ', ' Afro American ', ' Latino ', ' base ', ' improved ', ' Left ', ' Site ', ' Variation ', ' Variant ', ' Hereditary Mutation ', ' Germline Mutation ', ' Germ-Line Mutation ', ' insight ', ' Individual ', ' African ', ' European ', ' Bayesian statistics ', ' Bayesian statistical inference ', ' Bayesian statistical analysis ', ' Bayesian spatial analysis ', ' Bayesian network analysis ', ' Bayesian inference ', ' Bayesian Analysis ', ' Native Americans ', ' Genetic ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Event ', ' Techniques ', ' Somatic Mutation ', ' American ', ' experience ', ' success ', ' DNA Synthesis ', ' DNA Replication ', ' DNA biosynthesis ', ' transition mutation ', ' trait ', ' Base Pairing ', ' offspring ', ' disease risk ', ' disorder risk ', ' inherited factor ', ' genetic risk factor ', ' developmental disorder ', ' developmental disease/disorder ', ' PhD ', ' Ph.D. ', ' Doctor of Philosophy ', ' Mutation Spectra ', ' Cancer Biology ', ' Collection ', ' genomic region ', ' Genomic Segment ', ' Process ', ' followed up ', ' follow up ', ' Active Follow-up ', ' follow-up ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' genetic variant ', ' designing ', ' design ', ' Population ', ' rare variant ', ' rare allele ', ' learning strategy ', ' learning method ', ' learning activity ', ' rate of change ', ' admixture mapping ', ' ']",NIGMS,STANFORD UNIVERSITY,F32,2016,56118,CA-18,0.3048368049063037
"Integrative approach for predicting cancer driver genes     DESCRIPTION (provided by applicant): Carcinogenesis, progression of normal cells to malignant cancer, derives from hallmark capabilities of cancer driven by acquiring (somatic) mutations in ""driver genes"" with a selective advantage for cellular proliferation and potentially metastasis. A major motivation for modern cancer genomics studies is to decipher the genetic architecture of cancer by discovering new driver genes. The most widely-used approaches to predict and prioritize driver genes are based on statistics of mutation frequencies. Several methods have been proposed to identify genes with an excessive number of somatic mutations [9-11], known as significantly mutated genes. I propose to address two major limitations of this approach. First, these methods are insufficiently statistically powered given the amount of sequencing data currently available [15]. I will improve statistical power by leveraging diverse information in cancer genomics currently available into a developed machine learning method. Second, there is little objective clarity about the true effectiveness of these methods [11, 14], since there is no agreed-upon gold standard of driver genes, with the exception of a few well-known drivers. I will develop a framework to compare the effectiveness of driver gene prediction methods, in the absence of a gold standard. Both effectively and efficiently identifying cancer driver genes is a matter of great importance to science funding policy towards cancer genomics.         PUBLIC HEALTH RELEVANCE: Large sequencing studies have revolutionized our capability to identify the genetic architecture of cancer. However, effectively integrating this stream of big data to identify specific driver genes has remained troublesome. My proposed research project aims to develop an integrative machine learning method that leverages diverse features in cancer genomics to improve predictions of cancer driver genes, and to utilize a principled approach for evaluating the performance of any such method.            ",Integrative approach for predicting cancer driver genes,9152184,F31CA200266,"['Algorithms ', ' Engineering / Architecture ', ' Architecture ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Malignant Neoplasms ', ' Genes ', ' Au element ', ' Gold ', ' Methods ', ' Motivation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' tumor cell metastasis ', ' cancer metastasis ', ' Secondary Tumor ', ' Secondary Neoplasm ', ' Metastatic Tumor ', ' Metastatic Neoplasm ', ' Metastatic Mass ', ' Metastatic Lesion ', ' Metastasize ', ' Metastasis ', ' Neoplasm Metastasis ', ' Play ', ' Science ', ' statistics ', ' Tumor Suppressor Genes ', ' oncosuppressor gene ', ' Tumor Suppressing Genes ', ' Recessive Oncogenes ', ' Oncogenes-Tumor Suppressors ', ' Onco-Suppressor Genes ', ' Emerogenes ', ' Cancer Suppressor Genes ', ' Antioncogenes ', ' Anti-Oncogenes ', ' base ', ' improved ', ' Malignant ', ' Malignant - descriptor ', ' Evaluation ', ' Policies ', ' Funding ', ' Research Projects ', ' Research Grants ', ' R01 Program ', ' R01 Mechanism ', ' R-Series Research Projects ', ' Research Project Grants ', ' Genetic ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Frequencies ', ' Stream ', ' Pattern ', ' Somatic Mutation ', ' Cancer Induction ', ' carcinogenesis ', ' Cellular Proliferation ', ' Cell Multiplication ', ' Cell Growth in Number ', ' Cell Proliferation ', ' Performance ', ' Statistical Bias ', ' novel ', ' Sampling ', ' Property ', ' Normal Cell ', ' Effectiveness ', ' Address ', ' Data ', ' Mutate ', ' Scheme ', ' Tumor Biology ', ' Characteristics ', ' oncogenomics ', ' cancer genomics ', ' compare effectiveness ', ' public health relevance ', ' Big Data ', ' BigData ', ' learning strategy ', ' learning method ', ' learning activity ', ' transcriptome ', ' ']",NCI,JOHNS HOPKINS UNIVERSITY,F31,2016,43576,MD-07,0.08419461590946394
"High-resolution map of human germline mutation patterns and inference of mutagenic mechanisms     DESCRIPTION (provided by applicant): Mutations are the ultimate source of genetic variation and one of the driving forces of evolution. Both the absolute mutation rate and the relative rate among mutation subtypes fluctuate along the genome, affected by adjacent nucleotide motifs and local features such as GC content and replication timing. Characterizing regional variation of mutation patterns is critical for understanding genome evolution and to identify variants causing genetic diseases. However, mutation rate and molecular spectrum are difficult to measure at high resolution, genomewide, and in an unbiased fashion. Estimates based on common variants and between- species substitutions are confounded by natural selection, population demographic history, and biased gene conversion (BGC). Methods relying on incidence rates of monogenic diseases or finding de novo variants by trio sequencing can inform global trends, but do not provide sufficient data to assess fine-scale local parameters. This study will overcome these limitations by using the extremely rare variants (ERVs) as a new data source to characterize patterns of recent germline variation in humans. ERVs, defined in this study as singletons in 30,000 samples, are becoming available via large-scale whole-genome sequencing (WGS) of population samples. Unlike common variants or substitutions, ERVs arose very recently and are largely unaffected by selection, BGC, etc. We will analyze 200-300 million singleton variants observed in 30,000 subjects at 20-30X coverage. The regional distribution of ERV subtypes will establish a quantitative atlas of the rate and spectrum of human germline mutations mostly unaltered by selection. We will share this resource with the research community and apply it to determine the impact of local genomic features and epigenomic attributes. We will use the systematic departures between ERVs and variants of higher frequencies (polymorphisms and substitutions) to infer local effects of selection, and this may uncover hitherto unknown functional regions of the genome. By comparing mutation signatures in ERVs with those in somatic variations observed in diverse cancers we will attribute distinct mutational signatures to known biochemical processes and thus infer the major contributors to new germline mutations in the human genome. This subtype-specific atlas will also be used to predict the probability of observing every possible single-base mutation in the genome, thus facilitating the interpretation of candidate causal variants of human diseases. We will assess mutation pattern differences among European Americans, African Americans and Latinos, and seek to discover genetic modifiers of germline mutation rate by finding functionally damaging mutations that show increased ERV counts in the surrounding genomic region, potentially identifying both known and previous unknown ""mutator"" genes that play a role in transmission fidelity in humans. This research will provide an essential resource to study the genesis and maintenance of germline mutations in humans. Understanding such a fundamental process will be the basis for a deeper understanding of human evolution and diseases.         PUBLIC HEALTH RELEVANCE: We will study the patterns of inherited mutations in humans using approximately 250 million extremely rare DNA variants in human populations. Our results will allow the prediction of the rate of new mutations at every site in the genome based on features of the surrounding DNA sequence, thus providing a common resource to study the arrival and maintenance of mutations in humans. Understanding such a basic process is important for answering fundamental questions in human evolution, the cause of inherited diseases, and the role of DNA abnormality in cancer and aging.            ",High-resolution map of human germline mutation patterns and inference of mutagenic mechanisms,9083570,R01GM118928,"['Affect ', ' Aging ', ' Algorithms ', ' Allelomorphs ', ' Alleles ', ' Atlases ', ' Biologic Factor ', ' Biological Factors ', ' Biology ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Malignant Neoplasms ', ' youngster ', "" childrens' "", ' children ', ' Children (0-21) ', ' Child Youth ', ' 0-11 years old ', ' Child ', ' Chromatin ', ' Communities ', ' data interpretation ', ' Data Analysis ', ' Data Analyses ', ' Data Sources ', ' Demographic Factors ', ' Disorder ', ' Disease ', ' Deoxyribonucleic Acid ', ' DNA ', ' Evolution ', ' Family ', ' Foundations ', ' Future ', ' Gene Conversion ', ' Genes ', ' Genome ', ' human whole genome ', ' Human Genome ', ' hereditary disorder ', ' genetic disorder ', ' Molecular Disease ', ' Genetic Diseases ', ' Genetic Condition ', ' Hereditary Disease ', ' History ', ' Recording of previous events ', ' Modern Man ', ' Human ', ' Human Genetics ', ' Incidence ', ' Maintenance ', ' Maps ', ' Methods ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' Nucleotides ', ' Parents ', ' Play ', ' polymorphism ', ' Genetic Polymorphism ', ' Probability ', ' Recombination ', ' DNA Recombination ', ' Genetic Recombination ', ' Research ', ' Research Resources ', ' Resources ', ' Rest ', ' social role ', ' Role ', ' Selection Bias ', ' Technology ', ' Time ', ' Body Tissues ', ' Tissues ', ' Variation (Genetics) ', ' Genetic Variation ', ' Genetic Diversity ', ' Weight ', ' Generations ', ' Measures ', ' Mutagenesis ', ' Mutagenesis Molecular Biology ', ' Genetics-Mutagenesis ', ' African American ', ' black American ', ' Black Populations ', ' Afroamerican ', ' Afro American ', ' Latino ', ' Natural Selections ', ' Data Set ', ' Dataset ', ' DNA Sequence ', ' base ', ' density ', ' improved ', ' Site ', ' Variation ', ' Variant ', ' Hereditary Mutation ', ' Germline Mutation ', ' Germ-Line Mutation ', ' Individual ', ' European ', ' Biological Function ', ' Biological Process ', ' world wide web ', ' web ', ' WWW ', ' Internet ', ' Genetic ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Frequencies ', ' Hereditary ', ' Inherited ', ' Complex ', ' Dependence ', ' Source ', ' Pattern ', ' Techniques ', ' Somatic Mutation ', ' American ', ' environmental risk ', ' Environmental Factor ', ' Environmental Risk Factor ', ' Position ', ' Positioning Attribute ', ' Modeling ', ' Sampling ', ' repository ', ' Genomics ', ' Guanine + Cytosine Content ', ' GC Content ', ' GC Composition ', ' G+C Content ', ' G+C Compositions ', ' Guanine + Cytosine Composition ', ' Pathogenicity ', ' Post-Replication Mismatch Repair ', ' Mismatch Repair ', ' genetic evolution ', ' genome sequencing ', ' Address ', ' Biochemical Process ', ' Data ', ' Resolution ', ' Resource Sharing ', ' genomic region ', ' Genomic Segment ', ' Transmission ', ' transmission process ', ' trend ', ' Molecular ', ' Process ', ' epigenomics ', ' Population ', ' driving force ', ' human disease ', ' prototype ', ' public health relevance ', ' genome-wide ', ' genomewide ', ' genome scale ', ' sharing data ', ' next generation sequencing ', ' nextgen sequencing ', ' next gen sequencing ', ' NGS system ', ' NGS Method ', ' rare variant ', ' rare allele ', ' High-Throughput Nucleotide Sequencing ', ' High-Throughput Sequencing ', ' Mendelian disorder ', ' single-gene disorder ', ' single-gene disease ', ' monogenic disorder ', ' monogenic disease ', ' Mendelian genetic disorder ', ' Mendelian disease ', ' actionable mutation ', ' driver mutation ', ' whole genome ', ' entire genome ', ' ']",NIGMS,UNIVERSITY OF MICHIGAN AT ANN ARBOR,R01,2016,300999,MI-12,0.19527015365396436
"Functional Annotation of Natural and Disease Variants in Tryosine Kinases     DESCRIPTION (provided by applicant): Protein tyrosine kinases are dynamic molecular switches that toggle between a catalytically ""on"" and ""off"" state to turn on and off signals responsible for cell growth and survival. While the tyrosine kinase switch is tightly regulated by  diverse array of structural mechanisms in normal states, in many disease states, the switch is permanently turned on or off due, in part, to mutations in the tyrosine kinase domain. Although genome sequencing studies have revealed the mutational patterns of tyrosine kinases from many different disease types, understanding the structural and functional impact of these mutations is a challenge because many recurrent mutations occur far from the active site (distal mutations) and the residue networks that contribute to the complex modes of tyrosine kinase allosteric regulation are not fully understood. Our long term goal is to understand the relationships connecting sequence, structure, function, regulation and disease in protein kinases using a combination of computational and experimental approaches. Our objective in this proposal, which is the next logical step toward attainment of our long-term goal, is to delineate the residue interaction networks that contribute to the unique modes of allosteric regulation in tyrosine kinases, and to develop a computational framework for predicting mutation impact using the evolutionary and allosteric properties encoded in three dimensional structures. The central hypothesis is that distal mutations alter evolutionarily conserved allosteric networks in tyrosine kinases, and delineating the allosteric networks unique to tyrosine kinases will provide context for predicting and testing disease mutation impact. The specific aims are: * To identify and characterize natural sequence and structural variants associated with tight  allosteric control of tyrosine kinase activity * To develop a computational framework for predicting mutation impact on kinase activation and to  experimentally validate computational predictions using selected receptor tyrosine kinases as  model systems Successful completion of these aims is expected to reveal novel activating mutations in putative allosteric sites in the tyrosine kinase domain, and pinpoint key residues and interactions for functional studies. These outcomes, in turn, are expected to have major biomedical impact by accelerating the functional characterization of the mutated tyrosine kinome, which is emerging as a major target for personalized medicine. Finally, by providing detailed mechanistic annotation of mutations identified in genome sequencing studies, this proposal will address a fundamental NIH roadmap problem in translational medicine of converting genomic discoveries into therapeutic strategies. PUBLIC HEALTH RELEVANCE: Protein tyrosine kinases are a biomedically important class of proteins that are abnormally regulated in many human diseases including cancer, diabetes, and inflammatory disorders, to name but a few. They have been the focus of many drug discovery efforts and genome sequencing studies because of the therapeutic potential of targeting mutated tyrosine kinases for personalized therapy. By providing functional annotation of natural and disease mutations in tyrosine kinases, the proposed studies will accelerate the targeting of mutated tyrosine kinases for drug discovery and personalized therapy.",Functional Annotation of Natural and Disease Variants in Tryosine Kinases,9301599,R01GM114409,"['Allosteric Regulation ', ' Allosteric Site ', ' anticancer drug ', ' anticancer agent ', ' Tumor-Specific Treatment Agents ', ' Neoplastic Disease Chemotherapeutic Agents ', ' Cancer Drug ', ' Antineoplastics ', ' Antineoplastic Drugs ', ' Anti-Cancer Agents ', ' Antineoplastic Agents ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' Biological Assay ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Malignant Neoplasms ', ' Cellular Growth ', ' Cellular Expansion ', ' cell growth ', ' Cell Viability ', ' Cell Survival ', ' Communities ', ' diabetes ', ' Diabetes Mellitus ', ' Disorder ', ' Disease ', ' resistant to Drug ', ' resistance to Drug ', ' drug resistant ', ' Drug resistance ', ' drug/agent ', ' Pharmaceutic Preparations ', ' Medication ', ' Drugs ', ' Pharmaceutical Preparations ', ' Foundations ', ' Genes ', ' human whole genome ', ' Human Genome ', ' Goals ', ' In Vitro ', ' Biological Models ', ' Model System ', ' Biologic Models ', ' Mutation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Names ', ' United States National Institutes of Health ', ' National Institutes of Health ', ' NIH ', ' Organism ', ' living system ', ' Peptides ', ' Phosphotransferases ', ' Transphosphorylases ', ' Phosphotransferase Gene ', ' Kinases ', ' Protein Kinase ', ' phosphorylase b kinase kinase ', ' hydroxyalkyl protein kinase ', ' glycogen synthase a kinase ', ' Kinase Family Gene ', ' ATP-protein phosphotransferase ', ' Protein Tyrosine Kinase ', ' tyrosyl protein kinase ', ' hydroxyaryl protein kinase ', ' Tyrosylprotein Kinase ', ' Tyrosine-Specific Protein Kinase ', ' Tyrosine-Protein Kinase Receptor EEK ', ' Tyrosine Kinase ', ' Protein Tyrosine Kinase EEK ', ' Ephrin Type-A Receptor 8 Precursor ', ' Ephrin Type-A Receptor 8 ', ' EPH-and ELK-Related Kinase ', ' EPH- and ELK-Related Tyrosine Kinase ', ' Proteins ', ' Publishing ', ' Recurrence ', ' Recurrent ', ' Signal Transduction ', ' biological signal transduction ', ' Signaling ', ' Signal Transduction Systems ', ' Intracellular Communication and Signaling ', ' Cell Signaling ', ' Cell Communication and Signaling ', ' Testing ', ' Tyrosine ', ' Threonine Kinase ', ' Serine/Threonine Protein Kinase Gene ', ' Serine-Threonine Kinases ', ' Serine Kinase ', ' Protein-Threonine Kinase ', ' Protein-Serine Kinase ', ' Protein-Serine-Threonine Kinases ', ' base ', ' improved ', ' Distal ', ' Site ', ' Variation ', ' Variant ', ' Active Sites ', ' Tyrosine Kinase Receptors ', ' Tyrosine Kinase Linked Receptors ', ' Transmembrane Receptor Protein Tyrosine Kinase ', ' Receptor Tyrosine Kinase Gene ', ' PTK Receptors ', ' Receptor Protein-Tyrosine Kinases ', ' insight ', ' Therapeutic ', ' Inflammatory ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Complex ', ' Pattern ', ' System ', ' molecular dynamics ', ' Molecular Dynamics Simulation ', ' mutant ', ' Structure ', ' novel ', ' Regulation ', ' Modeling ', ' Property ', ' Genomics ', ' drug discovery ', ' Pathogenicity ', ' Binding ', ' Molecular Interaction ', ' genome sequencing ', ' Address ', ' Drug Binding Site ', ' Mutate ', ' Ontology ', ' Tyrosine Kinase Domain ', ' Molecular ', ' computational framework ', ' computer framework ', ' Outcome ', ' three dimensional structure ', ' 3D structure ', ' 3-dimensional structure ', ' 3-D structure ', ' translational medicine ', ' human disease ', ' public health relevance ', ' personalized medicine ', ' personalized treatment ', ' personalized therapy ', ' personalization of treatment ', ' ']",NIGMS,UNIVERSITY OF GEORGIA,R01,2017,300000,GA-10,0.253183175078445
"High-resolution map of human germline mutation patterns and inference of mutagenic mechanisms     DESCRIPTION (provided by applicant): Mutations are the ultimate source of genetic variation and one of the driving forces of evolution. Both the absolute mutation rate and the relative rate among mutation subtypes fluctuate along the genome, affected by adjacent nucleotide motifs and local features such as GC content and replication timing. Characterizing regional variation of mutation patterns is critical for understanding genome evolution and to identify variants causing genetic diseases. However, mutation rate and molecular spectrum are difficult to measure at high resolution, genomewide, and in an unbiased fashion. Estimates based on common variants and between- species substitutions are confounded by natural selection, population demographic history, and biased gene conversion (BGC). Methods relying on incidence rates of monogenic diseases or finding de novo variants by trio sequencing can inform global trends, but do not provide sufficient data to assess fine-scale local parameters. This study will overcome these limitations by using the extremely rare variants (ERVs) as a new data source to characterize patterns of recent germline variation in humans. ERVs, defined in this study as singletons in 30,000 samples, are becoming available via large-scale whole-genome sequencing (WGS) of population samples. Unlike common variants or substitutions, ERVs arose very recently and are largely unaffected by selection, BGC, etc. We will analyze 200-300 million singleton variants observed in 30,000 subjects at 20-30X coverage. The regional distribution of ERV subtypes will establish a quantitative atlas of the rate and spectrum of human germline mutations mostly unaltered by selection. We will share this resource with the research community and apply it to determine the impact of local genomic features and epigenomic attributes. We will use the systematic departures between ERVs and variants of higher frequencies (polymorphisms and substitutions) to infer local effects of selection, and this may uncover hitherto unknown functional regions of the genome. By comparing mutation signatures in ERVs with those in somatic variations observed in diverse cancers we will attribute distinct mutational signatures to known biochemical processes and thus infer the major contributors to new germline mutations in the human genome. This subtype-specific atlas will also be used to predict the probability of observing every possible single-base mutation in the genome, thus facilitating the interpretation of candidate causal variants of human diseases. We will assess mutation pattern differences among European Americans, African Americans and Latinos, and seek to discover genetic modifiers of germline mutation rate by finding functionally damaging mutations that show increased ERV counts in the surrounding genomic region, potentially identifying both known and previous unknown ""mutator"" genes that play a role in transmission fidelity in humans. This research will provide an essential resource to study the genesis and maintenance of germline mutations in humans. Understanding such a fundamental process will be the basis for a deeper understanding of human evolution and diseases. PUBLIC HEALTH RELEVANCE: We will study the patterns of inherited mutations in humans using approximately 250 million extremely rare DNA variants in human populations. Our results will allow the prediction of the rate of new mutations at every site in the genome based on features of the surrounding DNA sequence, thus providing a common resource to study the arrival and maintenance of mutations in humans. Understanding such a basic process is important for answering fundamental questions in human evolution, the cause of inherited diseases, and the role of DNA abnormality in cancer and aging.",High-resolution map of human germline mutation patterns and inference of mutagenic mechanisms,9275505,R01GM118928,"['Affect ', ' Aging ', ' Algorithms ', ' Allelomorphs ', ' Alleles ', ' Atlases ', ' Biologic Factor ', ' Biological Factors ', ' Biology ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Malignant Neoplasms ', ' youngster ', "" childrens' "", ' children ', ' Children (0-21) ', ' Child Youth ', ' 0-11 years old ', ' Child ', ' Chromatin ', ' Communities ', ' data interpretation ', ' Data Analysis ', ' Data Analyses ', ' Data Sources ', ' Demographic Factors ', ' Disorder ', ' Disease ', ' Deoxyribonucleic Acid ', ' DNA ', ' Evolution ', ' Family ', ' Foundations ', ' Future ', ' Gene Conversion ', ' Genes ', ' Genome ', ' human whole genome ', ' Human Genome ', ' hereditary disorder ', ' genetic disorder ', ' Molecular Disease ', ' Genetic Diseases ', ' Genetic Condition ', ' Hereditary Disease ', ' History ', ' Recording of previous events ', ' Modern Man ', ' Human ', ' Human Genetics ', ' Incidence ', ' Maintenance ', ' Maps ', ' Methods ', ' Mutation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Nucleotides ', ' Parents ', ' Play ', ' Genetic Polymorphism ', ' polymorphism ', ' Probability ', ' Genetic Recombination ', ' Recombination ', ' DNA Recombination ', ' Research ', ' Resources ', ' Research Resources ', ' Rest ', ' Role ', ' social role ', ' Selection Bias ', ' Technology ', ' Tissues ', ' Body Tissues ', ' Genetic Diversity ', ' Genetic Variation ', ' Weight ', ' Generations ', ' Measures ', ' Mutagenesis Molecular Biology ', ' Genetics-Mutagenesis ', ' Mutagenesis ', ' black American ', ' Black Populations ', ' Afroamerican ', ' Afro American ', ' African American ', ' Latino ', ' Natural Selections ', ' Dataset ', ' Data Set ', ' DNA Sequence ', ' base ', ' density ', ' improved ', ' Site ', ' Variation ', ' Variant ', ' Hereditary Mutation ', ' Germline Mutation ', ' Germ-Line Mutation ', ' Individual ', ' European ', ' Biological Function ', ' Biological Process ', ' world wide web ', ' web ', ' WWW ', ' Internet ', ' Genetic ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Frequencies ', ' Inherited ', ' Hereditary ', ' Complex ', ' Dependence ', ' Source ', ' Pattern ', ' Techniques ', ' Somatic Mutation ', ' American ', ' Environmental Risk Factor ', ' environmental risk ', ' Environmental Factor ', ' Positioning Attribute ', ' Position ', ' genetic analysis ', ' Genetic analyses ', ' Modeling ', ' Sampling ', ' repository ', ' Genomics ', ' Guanine + Cytosine Composition ', ' Guanine + Cytosine Content ', ' GC Content ', ' GC Composition ', ' G+C Content ', ' G+C Compositions ', ' Pathogenicity ', ' Mismatch Repair ', ' Post-Replication Mismatch Repair ', ' genome sequencing ', ' Address ', ' Biochemical Process ', ' Data ', ' Resolution ', ' Resource Sharing ', ' genomic region ', ' Genomic Segment ', ' Transmission ', ' transmission process ', ' trend ', ' Molecular ', ' Process ', ' epigenomics ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' genetic variant ', ' Population ', ' driving force ', ' human disease ', ' prototype ', ' public health relevance ', ' genome-wide ', ' genomewide ', ' genome scale ', ' sharing data ', ' next generation sequencing ', ' nextgen sequencing ', ' next gen sequencing ', ' NGS system ', ' NGS Method ', ' rare variant ', ' rare allele ', ' High-Throughput Nucleotide Sequencing ', ' High-Throughput Sequencing ', ' Mendelian disorder ', ' single-gene disorder ', ' single-gene disease ', ' monogenic disorder ', ' monogenic disease ', ' Mendelian genetic disorder ', ' Mendelian disease ', ' actionable mutation ', ' driver mutation ', ' whole genome ', ' entire genome ', ' ']",NIGMS,UNIVERSITY OF MICHIGAN AT ANN ARBOR,R01,2017,300742,MI-12,0.19527015365396436
"Molecular impact of mutations in monogenic disease and cancer ABSTRACT Nextgenerationgenomescalesequencingofpatientsisnowbecomingroutinefortwoclassesofdisease:rare Mendeliantraitsandcancer.Infavorablecases,thesedataallowidentificationofrelevantmutationsandthus aiddiagnosisandtherapy.Inbothclassesofdisease,themostcommontypeofmutationismissense-single base changes that result in an amino acid substitution in a protein. Uncertainty as to the impact of these mutationsoninvivoproteinactivityhasresultedinaveryconservativeapproachtotheirinterpretationinthe clinic, so causing many missed opportunities for targeted treatment. The goal of this project is to use a combinationofthreestrategiestomaketheinterpretationofthesemutationsmuchmoreapplicableintheclinic. Therearealreadyalargenumberofcomputationalmethodsthatattempttodeterminetheimpactofmissense mutationsonfunction,andthereissubstantialevidencethatthesehaveusefulaccuracy.Theprimarydifficulty isthattheaccuracyinanyparticularcaseisnotreliablycalibrated.Therefore,ourfirstaimistouseacombination ofthesemethodstodevelopanapproachfocusedonmorereliableestimatesfortheprobabilityofhighimpact on protein function (i.e. more confident P values). The second aim is to maximize the utilization of three- dimensionalstructuralinformation,largelyignoredbymostcomputationalmethods.Alargefractionofmissense mutationsintheseclassesofdiseaseactbydestabilizingproteinstructureandknowledgeofstructureallows thesetobeidentifiedwithmuchhigherreliability.Also,structureprovidesaframeworkfordetailedannotation andcomprehensionoffunction.Tofacilitatetheutilizationofstructure,wewillimplementamodelingplatform thatleveragesavailableexperimentalinformationtomaximizethestructuraldataavailableforanalyzingmutation impact. An important aspect of the platform is incorporation of methods for evaluating the reliability of the structuralfeaturesrelevanttoanalysisofeachmutation.Inthethirdaimwewillbuildspecificfunctionalmodels foreachproteinofinterest,integratinginformationfromcurrentdatabases,theliterature,andcommunityinput, soastoprovidetherichestpossiblebackgroundagainstwhichtojudgetheimpactofmutations.Proteopedia,a wellestablishedmediawikiforproteins,willbeusedtoprovideanintegratedviewoftext,data,andstructure.A keycomponentoftheinformationresourcewillbecontributionsfromcurators,whowillprovideannotationand alsosolicitinputfromotherexperts.Thisaspectoftheprojectbuildsonexperiencewithothercrowdsourcing endeavors, including CASP, CAGI and Proteopedia.  There will be three primary outcomes from the project: First,improvedreliabilityfortheinterpretationofmissensemutations.Second,aprototypemutationannotation proceduresuitableforuseinaclinicalsetting.Third,theresourcewillprovideinformationofbenefittoarange ofotherscientists,thusfacilitatingtheanalysisofdiseaserelatedmutations.  NARRATIVE Genome scale DNA sequencing is now contributing to diagnosis and therapy in cases of rare human diseaseandcancer.Fullexploitationofthesedataiscurrentlyhamperedbyinadequateunderstanding ofwhichDNAchangesaffectproteinfunctionsoastocontributetodisease.Thisprojectaimstodevelop themethodsandtoolsneededtoremovethatobstacle.",Molecular impact of mutations in monogenic disease and cancer,9356560,R01GM120364,"['Affect ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Malignant Neoplasms ', ' Communities ', ' computing method ', ' computer methods ', ' computational methods ', ' computational methodology ', ' Computing Methodologies ', ' Diagnosis ', ' Disorder ', ' Disease ', ' Deoxyribonucleic Acid ', ' DNA ', ' Goals ', ' Modern Man ', ' Human ', ' Literature ', ' Methods ', ' Structural Models ', ' Mutation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Patients ', ' Play ', ' Probability ', ' Proteins ', ' Resources ', ' Research Resources ', ' Role ', ' social role ', ' Computer software ', ' Software ', ' doubt ', ' Uncertainty ', ' Comprehension ', ' Protein Domains ', ' Peptide Domain ', ' Tertiary Protein Structure ', ' base ', ' improved ', ' Procedures ', ' Clinical ', ' data repository ', ' Databanks ', ' Data Bases ', ' Data Banks ', ' Databases ', ' tool ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Consensus ', ' Knowledge ', ' Scientist ', ' Dimensions ', ' Clinic ', ' Amino Acid Substitution ', ' interest ', ' experience ', ' AIDS diagnosis ', ' Missense Mutation ', ' trait ', ' Rare Diseases ', ' orphan disorder ', ' Rare Disorder ', ' Orphan Disease ', ' Structure ', ' Reporting ', ' Mutation Analysis ', ' Modeling ', ' protein protein interaction ', ' Address ', ' protein structure ', ' Data ', ' Information Resources ', ' knowledge resources ', ' knowledge resource ', ' information resource ', ' in vivo ', ' computer analyses ', ' computational analysis ', ' computational analyses ', ' Computer Analysis ', ' Molecular ', ' Process ', ' Text ', ' next generation ', ' clinically relevant ', ' clinical relevance ', ' wiki ', ' human disease ', ' prototype ', ' primary outcome ', ' genome-wide ', ' genomewide ', ' genome scale ', ' targeted treatment ', ' targeted therapy ', ' targeted therapeutic agents ', ' targeted therapeutic ', ' targeted drug treatments ', ' targeted drug therapy ', ' Mendelian disorder ', ' single-gene disorder ', ' single-gene disease ', ' monogenic disorder ', ' monogenic disease ', ' Mendelian genetic disorder ', ' Mendelian disease ', ' crowdsourcing ', ' crowdsource ', ' crowd-sourcing ', ' crowd source ', ' learning strategy ', ' learning method ', ' learning activity ', ' DNA sequencing ', ' DNAseq ', ' DNA seq ', ' ']",NIGMS,"UNIV OF MARYLAND, COLLEGE PARK",R01,2017,343120,MD-05,0.258328104292124
"Unraveling molecular and system-level mechanisms of human disease-associated protein mutations Project Summary Although a quickly expanding catalogue of protein mutations have been discovered, including those that cause human diseases or confer drug resistance, mechanistic understanding and prediction of functional consequences of these mutations remain rather limited. There is a critical need to develop novel, multiscale computational frameworks that are rigorous and generalizable to help close the ever-increasing gap between phenotypic data and mechanistic knowledge about the mutations and to develop effective therapeutic strategies.  My long-term research goals are two folds: (1) to unravel how a change in protein sequence ripples through various aspects of molecular and system-levels to a change in cellular function and cause human diseases or confer drug resistance; and (2) to translate learned mechanistic knowledge to effective drug-design strategies for human diseases and drug resistance. Toward these goals I propose to advance and combine the strengths of computational molecular biology (structural modeling and design for proteins or protein interactions) and computational systems biology (pathway/network-level topology and dynamics) and follow a novel, formal paradigm to develop methods that systematically identify mechanisms underlying various stages of consequence propagation (from conformation, molecular and system-level variables, to cellular functions, where intermediates can be skipped if necessary). In the forward direction of propagating consequences, I will determine, explain and understand mutational consequences at various levels with machine learning, causal analysis, and combinatorial optimization, starting with known or modelled changes at various levels. In the inverse direction of designing consequences, I will follow known or learned mechanistic hypotheses and develop efficient combinatorial optimization methods to design mutagenesis experiments or screen / design ligands for desired perturbations at various levels, which would test and refine corresponding hypotheses directly and translate mechanistic hypotheses to therapeutic strategies. Mechanisms underlying distal (potentially allosteric) mutations, multiple mutations within a protein or across proteins as well as systems pharmacology strategies will also be rigorously determined in the process.  The expected outcomes from the innovative project will include two main components. The first will be both biophysical principles of proteins and integrative understanding of biomedical systems, which will be organized in a database for public access. The second will be translating mechanistic insights into therapeutic intervention strategies to treat diseases. In particular, targeted experiments (mutagenesis or ligand-binding) will be designed following known or discovered mechanistic hypotheses. This project will involve close collaboration with structural biologists and clinician-scientists who are active collaborators of the PI. Project Narrative Genetic mutations, many of which lead to protein mutations, are often associated with human diseases: they often directly cause diseases or contribute to their progressions. Understanding mechanisms by which these mutations lead to significant functional consequences is of extreme importance to developing effective therapeutics to cure diseases and ameliorate drug resistance.",Unraveling molecular and system-level mechanisms of human disease-associated protein mutations,9382414,R35GM124952,"['protein sequence ', ' Primary Protein Structure ', ' Amino Acid Sequence ', ' biophysical sciences ', ' biophysical principles ', ' biophysical foundation ', ' Biophysics ', ' Subcellular Process ', ' Cellular Process ', ' Cellular Physiology ', ' Cellular Function ', ' Cell Process ', ' Cell Function ', ' Cell physiology ', ' Disorder ', ' Disease ', ' Drug Design ', ' resistant to Drug ', ' resistance to Drug ', ' drug resistant ', ' Drug resistance ', ' Goals ', ' Lead ', ' heavy metal lead ', ' heavy metal Pb ', ' Pb element ', ' Ligands ', ' Methods ', ' Structural Models ', ' Molecular Conformation ', ' conformational state ', ' conformation ', ' Molecular Stereochemistry ', ' Molecular Configuration ', ' Mutation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Pharmacology ', ' Protein Engineering ', ' protein design ', ' genetic protein engineering ', ' Proteins ', ' Research ', ' Testing ', ' Translating ', ' Mutagenesis Molecular Biology ', ' Genetics-Mutagenesis ', ' Mutagenesis ', ' Distal ', ' insight ', ' data repository ', ' Databanks ', ' Data Bases ', ' Data Banks ', ' Databases ', ' Collaborations ', ' Therapeutic ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Knowledge ', ' Catalogs ', ' Scientist ', ' System ', ' novel ', ' Therapeutic Intervention ', ' intervention therapy ', ' Modeling ', ' Intervention ', ' interventional strategy ', ' Intervention Strategies ', ' Disease Resistance ', ' resistant to disease ', ' resistant disease ', ' resistance to disease ', ' Computational Molecular Biology ', ' Systems Biology ', ' DNA Sequence Alteration ', ' genomic alteration ', ' Sequence Alteration ', ' Genetic mutation ', ' DNA mutation ', ' DNA Alteration ', ' Structural Biologist ', ' Ligand Binding ', ' Molecular ', ' Process ', ' pathway ', ' Pathway interactions ', ' computational framework ', ' computer framework ', ' designing ', ' design ', ' therapy efficacy ', ' therapeutically effective ', ' therapeutic efficacy ', ' intervention efficacy ', ' Treatment Efficacy ', ' Outcome ', ' innovation ', ' innovative ', ' innovate ', ' human disease ', ' Combinatorial Optimization ', ' phenotypic data ', ' experimental study ', ' experimental research ', ' experiment ', ' ']",NIGMS,TEXAS ENGINEERING EXPERIMENT STATION,R35,2017,335245,TX-17,0.18895753745202024
"Molecular Characterization of Joubert Syndrome     DESCRIPTION (provided by applicant): Congenital ataxia presents in early childhood with non-progressive hypotonia, gross and fine motor delay and cognitive delays. These disorders are distinct from the progressive ataxias because of the presence of congenital cerebellar malformations and because they are typically inherited recessively. Joubert Syndrome and Related Disorders (JSRD) constitute a major subset of these conditions, consisting of a cerebellar midline (vermis) malformation, a nearly pathognomonic Molar Tooth sign on brain Imaging (MTI) and co-existent oculomotor apraxia and episodic breathing dysrhythmias. In our published data, we have: 1] Identified ten unique genetic causes of JSRD (nearly half of the published causes), 2] Generated genotype-phenotype correlations involving cerebellar, retinal, renal, hepatic, digit, and cerebral manifestations. 3] Identified common founder mutations that allow for population-based screening. 4] Discovered that JSRD encoded proteins localize to the cilium. 5] Identified ciliary defects in cells with JSRD mutations. 6] Performed siRNA cell-based screens for defective ciliogenesis to prioritize candidate JSRD genes. 7] Generated and characterized multiple zebrafish, mouse and human cell culture models for JSRD. 8] Defined the concept of `Ciliary localization' model, in which one JSRD gene is required for ciliary localization of other JSRD proteins. In our unpublished work we have: 1] Recruited an additional 200 JSRD patients without molecular diagnosis. 2] Performed whole exome sequencing (WES) and genetic mapping on an additional 100 JSRD families. 3] Identified an additional 12 novel likely JSRD candidate genes. 4] Begun functional validation of the putative mutations. 5] Developed methods to ultrastructurally interrogate ciliary structure in a high-throughput fashion. The goal of this competing renewal is to identify the remaining `discoverable' genes that when mutated lead to JSRD, functionally validate mutations within the pathogenetic framework, and test the hypothesis that mutations in any proven JSRD gene lead to collapse of the ciliary transition zone by correlating genetic mutations with ultrastructural ciliary defects. Because the majority of patients still have unknown cause of disease, this renewal aims to advance knowledge through molecular characterization of new genes, using newly evolving high-throughput techniques, integrated bioinformatics, and a unique resource of consanguineous families recruited world-wide. We further aim to validate these mutations within a mechanistic framework, and a model that JSRD genes are required for essential ciliary structural components during cerebellar development. PUBLIC HEALTH RELEVANCE: Joubert syndrome is a genetically and phenotypically heterogeneous neurodevelopmental disorder unified by defects of the cellular primary cilium. This work will identify new genetic causes and dissect ciliary defects associated with genetic mutations",Molecular Characterization of Joubert Syndrome,9450748,R01NS048453,"['Termination of pregnancy ', ' apraxia ', ' Dyspraxia ', ' Apraxias ', ' inspiration ', ' Respiratory Inspiration ', ' Respiratory Aspiration ', ' Inhaling ', ' Inhalation ', ' Breathing ', ' Dyssynergia ', ' Coordination Impairment ', ' Ataxy ', ' Ataxia ', ' Attention ', "" Kanner's Syndrome "", ' Infantile Autism ', ' Early Infantile Autism ', ' Autism ', ' Autistic Disorder ', ' Intracranial Central Nervous System Disorders ', ' Intracranial CNS Disorders ', ' Encephalon Diseases ', ' Brain Disorders ', ' Brain Diseases ', ' cell culture ', ' Cell Culture Techniques ', ' Cell Body ', ' Cells ', ' Cultured Cells ', ' genetic mapping ', ' Total Human and Non-Human Gene Mapping ', ' Linkage Mapping ', ' Gene Mapping Genetics ', ' Gene Mapping ', ' Gene Localization ', ' Chromosome Mapping ', ' Cilia ', ' Diagnosis ', ' Disorder ', ' Disease ', ' Negatrons ', ' Negative Beta Particle ', ' Electrons ', ' Embryonic ', ' Embryo ', ' facial ', ' faces ', ' Face ', ' Family ', ' Genes ', ' Genotype ', ' Goals ', ' Gold ', ' Modern Man ', ' Human ', ' Kidney ', ' renal ', ' Kidney Urinary System ', ' Lead ', ' heavy metal lead ', ' heavy metal Pb ', ' Pb element ', ' Learning ', ' Mental Retardation ', ' Methods ', ' Scanning Electron Microscopy ', ' Middle East ', ' Molar tooth ', ' Morphogenesis ', ' Mus ', ' Murine ', ' Mice Mammals ', ' Mice ', ' Muscle hypotonia ', ' Muscular Hypotonia ', ' Muscle Tone Poor ', ' Muscle Hypotony ', ' Hypotonia ', ' Hypomyotonia ', ' Decreased Muscle Tone ', ' Mutation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Patients ', ' Phenotype ', ' Pregnancy Tests ', ' Probability ', ' Proteins ', ' Publishing ', ' Recruitment Activity ', ' recruit ', ' active recruitment ', ' Resources ', ' Research Resources ', ' Risk ', ' Sonication ', ' Syndrome ', ' Testing ', ' Work ', ' X-Ray Medical Imaging ', ' X-Ray Imaging ', ' Roentgenography ', ' Radiography ', ' Diagnostic X-Ray Radiology ', ' Diagnostic X-Ray ', ' Diagnostic Radiology ', ' Conventional X-Ray ', ' Diagnostic radiologic examination ', ' Zebra Fish ', ' Zebra Danio ', ' Danio rerio ', ' Brachydanio rerio ', ' Zebrafish ', ' base ', ' brain visualization ', ' Brain imaging ', ' Hepatic ', ' Clinical ', ' Microscopic ', ' Variation ', ' Variant ', ' Series ', ' Training ', ' vermis ', ' Cerebellar vermis structure ', ' pediatric ', ' Childhood ', ' Individual ', ' cerebral ', ' Cerebrum ', ' data repository ', ' Databanks ', ' Data Bases ', ' Data Banks ', ' Databases ', ' Cerebellar hypoplasia ', ' Congenital cerebellar hypoplasia ', ' Genetic ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Knowledge ', ' Joubert syndrome ', ' cerebelloparenchymal disorder IV ', ' cerebellar vermis agenesis ', ' Joubert-Boltshauser syndrome ', ' Inherited ', ' Hereditary ', ' Complex ', ' Techniques ', ' Digit structure ', ' Digit ', ' Gene Mutation ', ' Gene Alteration ', ' mutant ', ' early childhood ', ' cohort ', ' Transmission Electron Microscopy ', ' Structure ', ' Genetic screening method ', ' genetic testing ', ' gene-based testing ', ' gene testing ', ' novel ', ' Modeling ', ' affection ', ' oculomotor ', ' ocularmotor ', ' ocular motor ', ' disorder subtype ', ' disease subtype ', ' unpublished works ', ' Small Interfering RNA ', ' siRNA ', ' Short interfering RNA ', ' Pathogenicity ', ' Bioinformatics ', ' Bio-Informatics ', ' cilium biogenesis ', ' ciliogenesis ', ' genome sequencing ', ' Candidate Disease Gene ', ' Candidate Gene ', ' Length ', ' Defect ', ' DNA Sequence Alteration ', ' genomic alteration ', ' Sequence Alteration ', ' Genetic mutation ', ' DNA mutation ', ' DNA Alteration ', ' Data ', ' Molecular Diagnosis ', ' Motor ', ' Mutate ', ' Protein Analysis ', ' Cognitive ', ' enroll ', ' Enrollment ', ' Validation ', ' WNT signaling ', ' WNT Signaling Pathway ', ' Molecular ', ' Knockout ', ' Knock-out ', ' developmental ', ' Development ', ' Neurological Development Disorder ', ' Neurodevelopmental Disorder ', ' Cerebellum malformation ', ' Cerebellar malformation ', ' reconstruction ', ' knockdown ', ' knock-down ', ' Retinal ', ' loss of function mutation ', ' founder mutation ', ' malformation ', ' gene discovery ', ' discover genes ', ' public health relevance ', ' population based ', ' genome-wide ', ' genomewide ', ' genome scale ', ' exome sequencing ', ' screening ', ' Clustered Regularly Interspaced Short Palindromic Repeats ', ' CRISPR/Cas system ', ' CRISPR ', ' consanguineous family ', ' consanguineous\xa0kindreds ', ' consanguineous pedigree ', ' ']",NINDS,"UNIVERSITY OF CALIFORNIA, SAN DIEGO",R01,2017,510012,CA-52,0.22529626114203766
"Tracing the evolution of the human mutation rate DESCRIPTION (provided by applicant): All genetic variation is created by mutations, changes that arise due to DNA damage or copying mistakes during DNA replication. Mutations are frequent enough that, on average, a child's 3-billion base pair genome contains 74 new genetic variants that are not present in the genome of either parent. Such new mutations confer a higher disease risk than older mutations because they have not passed the test of surviving through several generations of parents and offspring. We aim to pinpoint how the human mutation rate has evolved as humans left Africa and adapted to diverse new environments across the globe.  One specific aim will follow up on my preliminary research which showed that Europeans experienced a mutation rate change after diverging from Africans and Asians. The primary evidence for this change is that European genomes have a higher burden than African or Asian genomes of the mutation type TCCTTC, where the trinucleotide ""TCC"" has experienced a mutation from ""C"" to ""T"" at its central site. We wish to and the genetic basis of this mutation rate change by looking at rare variants in mixed- ancestry Latino and African-American individuals. Specially, we will isolate young genetic variants that probably arose via mutation within the past 10-15 generations, after gene ow from Europe into the Americas had already begun. We will infer the genetic background (European, African, or Native American) upon which each new mutation arose and look for genomic regions where European ances- try correlates strongly with an excess of TCCTTC mutations. These will be the regions most likely to harbor a causal allele that changed the process of mutation accumulation in Europeans. This work has the potential to yield valuable insights into melanoma, a cancer that predominantly affects individuals of European ancestry and whose somatic mutational signature is dominated by TCCTTC.  A second specific aim is to look for other signatures of mutation rate change that have occurred within the human species or, more broadly, within the great apes. We will use a natural language processing technique called Latent Dirichlet Allocation (LDA) to identify collections of mutation types whose rates appear to be under common genetic control. A few mutation types besides TCCTTC show weak signals of rate differentiation between populations, and we will attempt to infer how many separate mutation rate change events are necessary to explain these signals. The admixture mapping technique from Specific Aim I can also be adapted to interrogate the genetic basis of other mutation rate changes that might have occurred in the recent past. These efforts should improve our understanding of the human mutation rate's genetic architecture and how mutation rates differ between populations. PUBLIC HEALTH RELEVANCE: All genetic variation is created by mutations, the copying mistakes that occasionally happen during DNA replication. There is evidence that children born with a higher burden of new mutations are at increased risk for autism, schizophrenia, and serious congenital diseases [1, 2, 3], but it is not well understood how much the human mutation rate varies and what genetic risk factors affect the mutation rate [4]. We aim to follow up on preliminary evidence that the Europeans have a higher mutation rate than Asians or Africans [5], looking for the genetic basis of this rate difference and investigating how often the mutation rate has changed during human evolution.",Tracing the evolution of the human mutation rate,9397848,F32GM116381,"['Acceleration ', ' Affect ', ' Africa ', ' Allelomorphs ', ' Alleles ', ' Americas ', ' Engineering / Architecture ', ' Architecture ', "" Kanner's Syndrome "", ' Infantile Autism ', ' Early Infantile Autism ', ' Autism ', ' Autistic Disorder ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Malignant Neoplasms ', ' youngster ', "" childrens' "", ' children ', ' Children (0-21) ', ' Child Youth ', ' 0-11 years old ', ' Child ', ' Disorder ', ' Disease ', ' DNA Injury ', ' DNA Damage ', ' Environment ', ' Europe ', ' Evolution ', ' Exhibits ', ' Genes ', ' Genome ', ' hereditary disorder ', ' genetic disorder ', ' Molecular Disease ', ' Genetic Diseases ', ' Genetic Condition ', ' Hereditary Disease ', ' History ', ' Recording of previous events ', ' Modern Man ', ' Human ', ' Maps ', ' melanoma ', ' Malignant Melanoma ', ' Mutation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Natural Language Processing ', ' natural language understanding ', ' Parents ', ' Pongidae ', ' great ape ', ' Apes ', ' Research ', ' Risk ', ' Risk Factors ', ' Schizophrenia ', ' schizophrenic ', ' dementia praecox ', ' Schizophrenic Disorders ', ' Signal Transduction ', ' biological signal transduction ', ' Signaling ', ' Signal Transduction Systems ', ' Intracellular Communication and Signaling ', ' Cell Signaling ', ' Cell Communication and Signaling ', ' Employee Strikes ', ' Strikes ', ' Testing ', ' Time ', ' Genetic Diversity ', ' Genetic Variation ', ' Work ', ' oriental ', ' Asians ', ' Generations ', ' black American ', ' Black Populations ', ' Afroamerican ', ' Afro American ', ' African American ', ' Latino ', ' base ', ' improved ', ' Left ', ' Site ', ' Variation ', ' Variant ', ' Hereditary Mutation ', ' Germline Mutation ', ' Germ-Line Mutation ', ' insight ', ' Individual ', ' African ', ' European ', ' Bayesian statistics ', ' Bayesian statistical inference ', ' Bayesian statistical analysis ', ' Bayesian spatial analysis ', ' Bayesian network analysis ', ' Bayesian inference ', ' Bayesian Analysis ', ' Native Americans ', ' Genetic ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Event ', ' Techniques ', ' Somatic Mutation ', ' American ', ' experience ', ' success ', ' DNA biosynthesis ', ' DNA Synthesis ', ' DNA Replication ', ' transition mutation ', ' trait ', ' Base Pairing ', ' offspring ', ' disorder risk ', ' disease risk ', ' genetic risk factor ', ' inherited factor ', ' developmental disease/disorder ', ' developmental disorder ', ' Doctor of Philosophy ', ' PhD ', ' Ph.D. ', ' Cancer Biology ', ' Collection ', ' genomic region ', ' Genomic Segment ', ' Process ', ' followed up ', ' follow up ', ' Active Follow-up ', ' follow-up ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' genetic variant ', ' designing ', ' design ', ' Population ', ' public health relevance ', ' rare variant ', ' rare allele ', ' learning strategy ', ' learning method ', ' learning activity ', ' rate of change ', ' admixture mapping ', ' ']",NIGMS,STANFORD UNIVERSITY,F32,2017,510,CA-18,0.3048368049063037
"Integrative approach for predicting cancer driver genes     DESCRIPTION (provided by applicant): Carcinogenesis, progression of normal cells to malignant cancer, derives from hallmark capabilities of cancer driven by acquiring (somatic) mutations in ""driver genes"" with a selective advantage for cellular proliferation and potentially metastasis. A major motivation for modern cancer genomics studies is to decipher the genetic architecture of cancer by discovering new driver genes. The most widely-used approaches to predict and prioritize driver genes are based on statistics of mutation frequencies. Several methods have been proposed to identify genes with an excessive number of somatic mutations [9-11], known as significantly mutated genes. I propose to address two major limitations of this approach. First, these methods are insufficiently statistically powered given the amount of sequencing data currently available [15]. I will improve statistical power by leveraging diverse information in cancer genomics currently available into a developed machine learning method. Second, there is little objective clarity about the true effectiveness of these methods [11, 14], since there is no agreed-upon gold standard of driver genes, with the exception of a few well-known drivers. I will develop a framework to compare the effectiveness of driver gene prediction methods, in the absence of a gold standard. Both effectively and efficiently identifying cancer driver genes is a matter of great importance to science funding policy towards cancer genomics. PUBLIC HEALTH RELEVANCE: Large sequencing studies have revolutionized our capability to identify the genetic architecture of cancer. However, effectively integrating this stream of big data to identify specific driver genes has remained troublesome. My proposed research project aims to develop an integrative machine learning method that leverages diverse features in cancer genomics to improve predictions of cancer driver genes, and to utilize a principled approach for evaluating the performance of any such method.",Integrative approach for predicting cancer driver genes,9322626,F31CA200266,"['Algorithms ', ' Engineering / Architecture ', ' Architecture ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Malignant Neoplasms ', ' Genes ', ' Gold ', ' Methods ', ' Modernization ', ' Motivation ', ' Mutation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Neoplasm Metastasis ', ' tumor cell metastasis ', ' cancer metastasis ', ' Secondary Tumor ', ' Secondary Neoplasm ', ' Metastatic Tumor ', ' Metastatic Neoplasm ', ' Metastatic Mass ', ' Metastatic Lesion ', ' Metastasize ', ' Metastasis ', ' Play ', ' Science ', ' statistics ', ' Supervision ', ' oncosuppressor gene ', ' Tumor Suppressing Genes ', ' Recessive Oncogenes ', ' Oncogenes-Tumor Suppressors ', ' Onco-Suppressor Genes ', ' Emerogenes ', ' Cancer Suppressor Genes ', ' Antioncogenes ', ' Anti-Oncogenes ', ' Tumor Suppressor Genes ', ' base ', ' improved ', ' Malignant ', ' Malignant - descriptor ', ' Evaluation ', ' Policies ', ' Funding ', ' Research Projects ', ' Research Grants ', ' R01 Program ', ' R01 Mechanism ', ' R-Series Research Projects ', ' Research Project Grants ', ' Genetic ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Frequencies ', ' Stream ', ' Pattern ', ' Somatic Mutation ', ' carcinogenesis ', ' Cancer Induction ', ' Cell Proliferation ', ' Cellular Proliferation ', ' Cell Multiplication ', ' Cell Growth in Number ', ' Gene Mutation ', ' Gene Alteration ', ' Performance ', ' novel ', ' Sampling ', ' Property ', ' Normal Cell ', ' Effectiveness ', ' Address ', ' Data ', ' Mutate ', ' Scheme ', ' Tumor Biology ', ' Characteristics ', ' oncogenomics ', ' cancer genomics ', ' compare effectiveness ', ' public health relevance ', ' Big Data ', ' BigData ', ' learning strategy ', ' learning method ', ' learning activity ', ' transcriptome ', ' ']",NCI,JOHNS HOPKINS UNIVERSITY,F31,2017,44044,MD-07,0.08419461590946394
"Tracing the evolution of the human mutation rate DESCRIPTION (provided by applicant): All genetic variation is created by mutations, changes that arise due to DNA damage or copying mistakes during DNA replication. Mutations are frequent enough that, on average, a child's 3-billion base pair genome contains 74 new genetic variants that are not present in the genome of either parent. Such new mutations confer a higher disease risk than older mutations because they have not passed the test of surviving through several generations of parents and offspring. We aim to pinpoint how the human mutation rate has evolved as humans left Africa and adapted to diverse new environments across the globe.  One specific aim will follow up on my preliminary research which showed that Europeans experienced a mutation rate change after diverging from Africans and Asians. The primary evidence for this change is that European genomes have a higher burden than African or Asian genomes of the mutation type TCCTTC, where the trinucleotide ""TCC"" has experienced a mutation from ""C"" to ""T"" at its central site. We wish to and the genetic basis of this mutation rate change by looking at rare variants in mixed- ancestry Latino and African-American individuals. Specially, we will isolate young genetic variants that probably arose via mutation within the past 10-15 generations, after gene ow from Europe into the Americas had already begun. We will infer the genetic background (European, African, or Native American) upon which each new mutation arose and look for genomic regions where European ances- try correlates strongly with an excess of TCCTTC mutations. These will be the regions most likely to harbor a causal allele that changed the process of mutation accumulation in Europeans. This work has the potential to yield valuable insights into melanoma, a cancer that predominantly affects individuals of European ancestry and whose somatic mutational signature is dominated by TCCTTC.  A second specific aim is to look for other signatures of mutation rate change that have occurred within the human species or, more broadly, within the great apes. We will use a natural language processing technique called Latent Dirichlet Allocation (LDA) to identify collections of mutation types whose rates appear to be under common genetic control. A few mutation types besides TCCTTC show weak signals of rate differentiation between populations, and we will attempt to infer how many separate mutation rate change events are necessary to explain these signals. The admixture mapping technique from Specific Aim I can also be adapted to interrogate the genetic basis of other mutation rate changes that might have occurred in the recent past. These efforts should improve our understanding of the human mutation rate's genetic architecture and how mutation rates differ between populations. PUBLIC HEALTH RELEVANCE: All genetic variation is created by mutations, the copying mistakes that occasionally happen during DNA replication. There is evidence that children born with a higher burden of new mutations are at increased risk for autism, schizophrenia, and serious congenital diseases [1, 2, 3], but it is not well understood how much the human mutation rate varies and what genetic risk factors affect the mutation rate [4]. We aim to follow up on preliminary evidence that the Europeans have a higher mutation rate than Asians or Africans [5], looking for the genetic basis of this rate difference and investigating how often the mutation rate has changed during human evolution.",Tracing the evolution of the human mutation rate,9278228,F32GM116381,"['Acceleration ', ' Affect ', ' Africa ', ' Allelomorphs ', ' Alleles ', ' Americas ', ' Engineering / Architecture ', ' Architecture ', "" Kanner's Syndrome "", ' Infantile Autism ', ' Early Infantile Autism ', ' Autism ', ' Autistic Disorder ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Malignant Neoplasms ', ' youngster ', "" childrens' "", ' children ', ' Children (0-21) ', ' Child Youth ', ' 0-11 years old ', ' Child ', ' Disorder ', ' Disease ', ' DNA Injury ', ' DNA Damage ', ' Environment ', ' Europe ', ' Evolution ', ' Exhibits ', ' Genes ', ' Genome ', ' hereditary disorder ', ' genetic disorder ', ' Molecular Disease ', ' Genetic Diseases ', ' Genetic Condition ', ' Hereditary Disease ', ' History ', ' Recording of previous events ', ' Modern Man ', ' Human ', ' Maps ', ' melanoma ', ' Malignant Melanoma ', ' Mutation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Natural Language Processing ', ' natural language understanding ', ' Parents ', ' Pongidae ', ' great ape ', ' Apes ', ' Research ', ' Risk ', ' Risk Factors ', ' Schizophrenia ', ' schizophrenic ', ' dementia praecox ', ' Schizophrenic Disorders ', ' Signal Transduction ', ' biological signal transduction ', ' Signaling ', ' Signal Transduction Systems ', ' Intracellular Communication and Signaling ', ' Cell Signaling ', ' Cell Communication and Signaling ', ' Employee Strikes ', ' Strikes ', ' Testing ', ' Time ', ' Genetic Diversity ', ' Genetic Variation ', ' Work ', ' oriental ', ' Asians ', ' Generations ', ' black American ', ' Black Populations ', ' Afroamerican ', ' Afro American ', ' African American ', ' Latino ', ' base ', ' improved ', ' Left ', ' Site ', ' Variation ', ' Variant ', ' Hereditary Mutation ', ' Germline Mutation ', ' Germ-Line Mutation ', ' insight ', ' Individual ', ' African ', ' European ', ' Bayesian statistics ', ' Bayesian statistical inference ', ' Bayesian statistical analysis ', ' Bayesian spatial analysis ', ' Bayesian network analysis ', ' Bayesian inference ', ' Bayesian Analysis ', ' Native Americans ', ' Genetic ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Event ', ' Techniques ', ' Somatic Mutation ', ' American ', ' experience ', ' success ', ' DNA biosynthesis ', ' DNA Synthesis ', ' DNA Replication ', ' transition mutation ', ' trait ', ' Base Pairing ', ' offspring ', ' disorder risk ', ' disease risk ', ' genetic risk factor ', ' inherited factor ', ' developmental disease/disorder ', ' developmental disorder ', ' Doctor of Philosophy ', ' PhD ', ' Ph.D. ', ' Cancer Biology ', ' Collection ', ' genomic region ', ' Genomic Segment ', ' Process ', ' followed up ', ' follow up ', ' Active Follow-up ', ' follow-up ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' genetic variant ', ' designing ', ' design ', ' Population ', ' public health relevance ', ' rare variant ', ' rare allele ', ' learning strategy ', ' learning method ', ' learning activity ', ' rate of change ', ' admixture mapping ', ' ']",NIGMS,STANFORD UNIVERSITY,F32,2017,36307,CA-18,0.3048368049063037
"APPLYING ERROR-CORRECTED SEQUENCING TO DETECT MINIMAL RESIDUAL IN THE AAML 1031 STUDY Abstract  Acute myeloid leukemia (AML) accounts for half of all pediatric leukemia deaths and is the leading cause of leukemia-related death in adulthood. One reason for worse outcomes is the inability to properly assess for minimal residual disease (MRD) following therapy. Unlike ALL, AML presents with multiple subclonal populations without a singular clonal surface marker, and surface markers can change during therapy. The current gold standard for AML MRD is multi-parameter flow cytometry (MPFC), which is predictive of outcomes to frequencies of 0.001, yet 30% of MPFC-MRD-negative patients still relapse. Alternatively, every AML case harbors leukemia-specific mutations that could be markers of disease, except that next-generation sequencing has high error rate of ~1%. In this proposal, we will implement a novel, validated error-corrected sequencing (ECS) strategy, developed by the Druley lab in collaboration with Illumina, to improve MRD assessment of AML subclonal heterogeneity in 990 pediatric de novo AML cases from the Children's Oncology Group AAML1031 study. We hypothesize that using a highly sensitive sequencing method will improve identification of residual AML, provide important insights on subclonal heterogeneity in pediatric AML, improve understanding of the role of germline variability and gene function on relapses or refractory disease and facilitate personalized medicine. To interrogate this hypothesis, we propose the following aims: 1. Define subclonal heterogeneity at diagnosis and end of Induction 1 (EOI1) in 990 pediatric de novo  AML patients (n=1890). By using the largest prospective study of pediatric AML that has ever been  performed, we will perform ECS on 94 genes that are the most frequently mutated genes in pediatric and  adult AML at diagnosis and EOI1 to identify patterns of mutation associated with relapsed disease, FAB  subtypes or other cytogenetic features. 2. Correlate ECS-MRD with existing EOI1 MPFC-MRD for all participants in the COG AAML1031 study.  A major question is whether the different from normal cell population identified as residual disease by  MPFC is actually the same population(s) identified by ECS. We will define residual disease by ECS and  compare results to MPFC status (positive/negative), actual MPFC percentages (<0.001) and the clinical  outcomes (relapse risk, disease-free survival and overall survival) of study participants. 3. Integrate germline variation and all subclonal mutations into mechanistic groups that are frequently  mutated in pediatric AML and correlate with outcomes using unbiased machine learning  algorithms. Preliminary data tells us that every patient will have multiple subclones at diagnosis and EOI1  as well as germline variants in AML-associated genes, which may be important for outcome. In this aim, we  will take these mutations into account as well as MPFC, clinical features and cytogenetics for probabilistic  risk assessment using unsupervised machine learning algorithms for improved outcome prognostication. Narrative We have developed Error-Corrected Sequencing (ECS) that enables the highly accurate detection of leukemia- specific mutations in heterogeneous DNA samples to a limit of 0.0001. We will perform ECS with a panel of 94 frequently mutated genes in adult and pediatric AML in matched diagnostic and end of Induction 1 bone marrow samples from 990 pediatric de novo AML patients enrolled on the Children's Oncology Group AAML1031 protocol, which is the largest pediatric AML trial ever performed in North America. With these data, we can truly understand subclonal heterogeneity in pediatric AML, significantly improve minimal residual disease testing in pediatric AML, and integrate these data into an unbiased multivariate probability platform taking into account individual sequencing, flow cytometry, cytogenetic and clinical features to provide truly personalized cancer care.",APPLYING ERROR-CORRECTED SEQUENCING TO DETECT MINIMAL RESIDUAL IN THE AAML 1031 STUDY,9216965,R01CA211711,"['adulthood ', ' Adult Human ', ' 21+ years old ', ' Adult ', ' Algorithms ', ' Allelomorphs ', ' Alleles ', ' Bone Marrow Reticuloendothelial System ', ' Bone Marrow ', ' Cytogenetics ', ' Death ', ' Cessation of life ', ' Diagnosis ', ' Disorder ', ' Disease ', ' Deoxyribonucleic Acid ', ' DNA ', ' Exons ', ' Family ', ' flow cytophotometry ', ' Flow Microfluorometry ', ' Flow Microfluorimetry ', ' Flow Cytofluorometry ', ' Flow Cytofluorometries ', ' Flow Cytometry ', ' Future ', ' Genes ', ' Goals ', ' Gold ', ' leukemia ', ' Acute Myelocytic Leukemia ', ' acute myeloid leukemia ', ' acute granulocytic leukemia ', ' Acute Myelogenous Leukemia ', ' Acute Myeloblastic Leukemia ', ' AML - Acute Myeloid Leukemia ', ' Methods ', ' Methodology ', ' Mutation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' United States National Institutes of Health ', ' National Institutes of Health ', ' NIH ', ' North America ', ' Oncogenes ', ' Transforming Genes ', ' Cancer-Promoting Gene ', ' Cancer Genes ', ' Patients ', ' Protein phosphatase ', ' Protein Phosphatase-2A ', ' Protein Phosphatase-1 ', ' Protein Phosphatase Gene ', ' Protein Phosphatase C ', ' Phosphoprotein Phosphohydrolase ', ' Phosphoprotein Phosphatase-2C ', ' Phosphoprotein Phosphatase ', ' Probability ', ' Prospective Studies ', ' Protein Tyrosine Kinase ', ' tyrosyl protein kinase ', ' hydroxyaryl protein kinase ', ' Tyrosylprotein Kinase ', ' Tyrosine-Specific Protein Kinase ', ' Tyrosine-Protein Kinase Receptor EEK ', ' Tyrosine Kinase ', ' Protein Tyrosine Kinase EEK ', ' Ephrin Type-A Receptor 8 Precursor ', ' Ephrin Type-A Receptor 8 ', ' EPH-and ELK-Related Kinase ', ' EPH- and ELK-Related Tyrosine Kinase ', ' Reagent ', ' Relapse ', ' Risk ', ' Role ', ' social role ', ' Testing ', ' Time ', ' Transcription factor genes ', ' Transcription Factor Proto-Oncogene ', ' General Transcription Factors ', ' General Transcription Factor Gene ', ' Basal transcription factor genes ', ' Basal Transcription Factor ', ' transcription factor ', ' immunophenotype ', ' Immunologic Subtyping ', ' Immunophenotyping ', ' Measures ', ' falls ', ' Risk Assessment ', ' Point Mutation ', ' Spliceosomes ', ' analytical method ', ' base ', ' improved ', ' Site ', ' Surface ', ' Clinical ', ' Residual ', ' Residual state ', ' Phase ', ' Variation ', ' Variant ', ' Adult Acute NonLymphocytic Leukemia ', ' Adult Acute NonLymphoblastic Leukemia ', ' Adult Acute Non-Lymphocytic Leukemia ', ' Adult Acute Non-Lymphoblastic Leukemia ', ' Adult Acute Myeloid Leukemia ', ' Adult Acute Myelogenous Leukemia ', ' Adult Acute Myelocytic Leukemia ', ' Adult Acute Granulocytic Leukemia ', ' Adult ANLL ', ' Adult AML ', ' Adult AGL ', ' Adult Acute Myeloblastic Leukemia ', ' Pediatric Acute Myeloid Leukemia ', ' Pediatric Acute Myelogenous Leukemia ', ' Pediatric Acute Myelocytic Leukemia ', ' Pediatric Acute Myeloblastic Leukemia ', ' Pediatric AML ', ' Childhood Acute Myelogenous Leukemia ', ' Childhood Acute Myelocytic Leukemia ', ' Childhood Acute Myeloblastic Leukemia ', ' Childhood Acute Granulocytic Leukemia ', ' Childhood AML ', ' Childhood Acute Myeloid Leukemia ', ' prognostic ', ' pediatric ', ' Childhood ', ' insight ', ' Individual ', ' Minimal Residual Disease ', ' Detectable Residual Disease ', ' Residual Neoplasm ', ' Gene Targeting ', ' Event-Free Survival ', ' Disease-Free Survival ', ' Relapsed Disease ', ' Recurrent disease ', ' Collaborations ', ' Genetic ', ' gene function ', ' Diagnostic ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Investigation ', ' Frequencies ', ' Complex ', ' Protocols documentation ', ' Protocol ', ' Pattern ', ' Residual Tumors ', ' residual disease ', ' Tumor Suppressor Proteins ', ' tumor suppressor ', ' cohesion ', ' functional group ', ' novel ', ' Participant ', ' Categories ', ' Sampling ', ' response ', ' nucleocytoplasmic transport ', ' Nucleocytoplasmic Shuttling ', ' Nuclear Transport ', ' Cell Nucleus Active Transport ', ' Bortezomib ', ' Normal Cell ', ' Childhood Leukemia ', ' leukemia in children ', ' children with leukemia ', ' Pediatric Leukemia ', ' FLT3 gene ', ' Stem Cell Tyrosine Kinase 1 ', ' STK1 ', ' Fms-Related Tyrosine Kinase 3 ', ' FLT3 ', ' FLK2 ', ' DNA Sequence Alteration ', ' genomic alteration ', ' Sequence Alteration ', ' Genetic mutation ', ' DNA mutation ', ' DNA Alteration ', ' Data ', ' Detection ', ' Disease Marker ', ' Mutate ', ' Refractory Disease ', ' Resolution ', ' Sorafenib ', ' BAY 54-9085 ', ' Clinical Data ', ' enroll ', ' Enrollment ', ' Epigenetic Mechanism ', ' Epigenetic Change ', ' Epigenetic ', ' Epigenetic Process ', "" Children's Oncology Group "", ' Pediatric Oncology Group ', ' Monitor ', ' insertion/deletion ', ' insertion-deletion mutation ', ' insertion-deletion ', ' indel ', ' insertion/deletion mutation ', ' digital ', ' designing ', ' design ', ' next generation ', ' therapy efficacy ', ' therapeutically effective ', ' therapeutic efficacy ', ' intervention efficacy ', ' Treatment Efficacy ', ' Outcome ', ' Population ', ' prospective ', ' chemotherapy ', ' Biological Markers ', ' biomarker ', ' biologic marker ', ' bio-markers ', ' randomized trial ', ' Randomization trial ', ' next generation sequencing ', ' nextgen sequencing ', ' next gen sequencing ', ' NGS system ', ' NGS Method ', ' personalized medicine ', ' personalized treatment ', ' personalized therapy ', ' personalization of treatment ', ' pediatric patients ', ' child patients ', ' leukemia treatment ', ' personalized cancer care ', ' outcome prediction ', ' predictors of outcomes ', ' predictive outcomes ', ' specific biomarkers ', ' improved outcome ', ' relapse risk ', ' subclonal heterogeneity ', ' sub-clonal heterogeneity ', ' Risk stratification ', ' DNA sequencing ', ' DNAseq ', ' DNA seq ', ' ']",NCI,WASHINGTON UNIVERSITY,R01,2017,388615,MO-01,0.07065056628137568
"Molecular impact of mutations in monogenic disease and cancer ABSTRACT Nextgenerationgenomescalesequencingofpatientsisnowbecomingroutinefortwoclassesofdisease:rare Mendeliantraitsandcancer.Infavorablecases,thesedataallowidentificationofrelevantmutationsandthus aiddiagnosisandtherapy.Inbothclassesofdisease,themostcommontypeofmutationismissense-single base changes that result in an amino acid substitution in a protein. Uncertainty as to the impact of these mutationsoninvivoproteinactivityhasresultedinaveryconservativeapproachtotheirinterpretationinthe clinic, so causing many missed opportunities for targeted treatment. The goal of this project is to use a combinationofthreestrategiestomaketheinterpretationofthesemutationsmuchmoreapplicableintheclinic. Therearealreadyalargenumberofcomputationalmethodsthatattempttodeterminetheimpactofmissense mutationsonfunction,andthereissubstantialevidencethatthesehaveusefulaccuracy.Theprimarydifficulty isthattheaccuracyinanyparticularcaseisnotreliablycalibrated.Therefore,ourfirstaimistouseacombination ofthesemethodstodevelopanapproachfocusedonmorereliableestimatesfortheprobabilityofhighimpact on protein function (i.e. more confident P values). The second aim is to maximize the utilization of three- dimensionalstructuralinformation,largelyignoredbymostcomputationalmethods.Alargefractionofmissense mutationsintheseclassesofdiseaseactbydestabilizingproteinstructureandknowledgeofstructureallows thesetobeidentifiedwithmuchhigherreliability.Also,structureprovidesaframeworkfordetailedannotation andcomprehensionoffunction.Tofacilitatetheutilizationofstructure,wewillimplementamodelingplatform thatleveragesavailableexperimentalinformationtomaximizethestructuraldataavailableforanalyzingmutation impact. An important aspect of the platform is incorporation of methods for evaluating the reliability of the structuralfeaturesrelevanttoanalysisofeachmutation.Inthethirdaimwewillbuildspecificfunctionalmodels foreachproteinofinterest,integratinginformationfromcurrentdatabases,theliterature,andcommunityinput, soastoprovidetherichestpossiblebackgroundagainstwhichtojudgetheimpactofmutations.Proteopedia,a wellestablishedmediawikiforproteins,willbeusedtoprovideanintegratedviewoftext,data,andstructure.A keycomponentoftheinformationresourcewillbecontributionsfromcurators,whowillprovideannotationand alsosolicitinputfromotherexperts.Thisaspectoftheprojectbuildsonexperiencewithothercrowdsourcing endeavors, including CASP, CAGI and Proteopedia.  There will be three primary outcomes from the project: First,improvedreliabilityfortheinterpretationofmissensemutations.Second,aprototypemutationannotation proceduresuitableforuseinaclinicalsetting.Third,theresourcewillprovideinformationofbenefittoarange ofotherscientists,thusfacilitatingtheanalysisofdiseaserelatedmutations.  NARRATIVE Genome scale DNA sequencing is now contributing to diagnosis and therapy in cases of rare human diseaseandcancer.Fullexploitationofthesedataiscurrentlyhamperedbyinadequateunderstanding ofwhichDNAchangesaffectproteinfunctionsoastocontributetodisease.Thisprojectaimstodevelop themethodsandtoolsneededtoremovethatobstacle.",Molecular impact of mutations in monogenic disease and cancer,9504498,R01GM120364,"['Affect ', ' Malignant Neoplasms ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Communities ', ' Computing Methodologies ', ' computing method ', ' computer methods ', ' computational methods ', ' computational methodology ', ' Diagnosis ', ' Disease ', ' Disorder ', ' DNA ', ' Deoxyribonucleic Acid ', ' Goals ', ' Literature ', ' Methods ', ' Structural Models ', ' Mutation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Patients ', ' Play ', ' Probability ', ' Proteins ', ' Resources ', ' Research Resources ', ' Role ', ' social role ', ' Computer software ', ' Software ', ' Uncertainty ', ' doubt ', ' Comprehension ', ' Protein Domains ', ' Peptide Domain ', ' Tertiary Protein Structure ', ' base ', ' improved ', ' Procedures ', ' Clinical ', ' data base ', ' Data Bases ', ' Databases ', ' tool ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Consensus ', ' Knowledge ', ' Scientist ', ' Dimensions ', ' Clinic ', ' Amino Acid Substitution ', ' interest ', ' AIDS therapy ', ' experience ', ' AIDS diagnosis ', ' Missense Mutation ', ' trait ', ' Rare Diseases ', ' orphan disorder ', ' Rare Disorder ', ' Orphan Disease ', ' Structure ', ' Reporting ', ' Mutation Analysis ', ' Modeling ', ' protein protein interaction ', ' Address ', ' protein structure ', ' Data ', ' Information Resources ', ' knowledge resources ', ' knowledge resource ', ' information resource ', ' in vivo ', ' computer analyses ', ' computational analysis ', ' computational analyses ', ' Computer Analysis ', ' Molecular ', ' Process ', ' Text ', ' protein function ', ' next generation ', ' clinical relevance ', ' clinically relevant ', ' wiki ', ' human disease ', ' prototype ', ' primary outcome ', ' genomewide ', ' genome scale ', ' genome-wide ', ' targeted therapy ', ' targeted therapeutic agents ', ' targeted therapeutic ', ' targeted drug treatments ', ' targeted drug therapy ', ' targeted treatment ', ' single-gene disorder ', ' single-gene disease ', ' monogenic disorder ', ' monogenic disease ', ' Mendelian genetic disorder ', ' Mendelian disease ', ' Mendelian disorder ', ' crowdsource ', ' crowd-sourcing ', ' crowd source ', ' crowdsourcing ', ' learning method ', ' learning activity ', ' learning strategy ', ' DNAseq ', ' DNA seq ', ' DNA sequencing ', ' human model ', ' ']",NIGMS,"UNIV OF MARYLAND, COLLEGE PARK",R01,2018,336086,MD-05,0.258328104292124
"Understanding modifiers of mendelian mutation penetrance using familial hypercholesterolemia as a model PROJECT SUMMARY / ABSTRACT Rare monogenic forms of common diseases have provided key fundamental insights about common disease. However, genetic, environmental, and stochastic elements influence risk for disease. Familial hypercholesterolemia (FH), an autosomal dominant disorder afflicting 1 in 250 linked to severe increases in LDL cholesterol and premature coronary heart disease (CHD) risk, is an ideal model to characterize modifiers of disease. Despite the presence of a strong genetic driver of hypercholesterolemia from FH mutations, we recently observed that half do not have the expected severe hypercholesterolemia. In this proposal, we outline several methods to discover and dissect the genetic and non-genetic factors influencing CHD risk conferred by FH mutations in humans and determine whether knowledge of these factors can improve risk discrimination among those with FH mutations. Our approach harnesses several multi-dimensional datasets: whole genome sequences, metabolomics, and cross-sectional and longitudinal cardiovascular phenotypes. In Aim 1, we will aggregate and curate 75,000 deep (30X) whole genome sequences and cardiovascular phenotypes. In Aim 2, we will discover genetic and non-genetic modifiers of LDL cholesterol and CHD risk in FH and evaluate their metabolomic consequences. In Aim 3, we will develop a method incorporating genetics and longitudinal non- genetic exposures for CHD risk stratification among ~4,000 with FH mutations in the Million Veteran Program. In addition to the proposed Aims, this five-year proposal outlines a comprehensive strategy for the principal investigator's (PI's) scientific and professional development in academic cardiovascular medicine. The research strategy builds upon the PI's prior research experience and clinical training. In addition to an undergraduate degree in Molecular Biology and master's degree in Biomedical Informatics, he completed post- graduate medical training in Internal Medicine and Cardiovascular Medicine. He recently developed a new preventive/genetic cardiology clinic focusing on the evaluation and management of those with or a family history of premature CHD, including those with FH, at Massachusetts General Hospital (MGH). This proposal now focuses on expanding his scientific skills in human genetics and genomics into new domains: integrative genomics, statistical genetics, clinical informatics, and risk modeling. The career development goals will be at achieved through a multi-faceted approach involving mentorship, collaboration, didactic coursework, conferences, and scientific investigation. This work will take place in a unique training environment comprised of MGH and the Broad Institute. Successful completion of this career development award will result in improved fundamental understanding of the determinants of CHD, result in the PI's transition to an independent physician-scientist, and provide a solid foundation from which he will apply for R01-level funding. PROJECT NARRATIVE / PUBLIC HEALTH RELEVANCE Cardiovascular disease, largely due to coronary heart disease (CHD), remains the leading cause of death in the United States and now worldwide despite current advances. Familial hypercholesterolemia is a relative common genetic disorder characterized by severe hypercholesterolemia and premature CHD but many carrying these mutations do not develop these consequences. This proposal seeks to define and characterize the factors modifying CHD risk among those with FH mutations; success has the potential to broadly identify new mechanisms of CHD and novel strategies for prevention.",Understanding modifiers of mendelian mutation penetrance using familial hypercholesterolemia as a model,9431712,K08HL140203,"['Adult ', ' adulthood ', ' Adult Human ', ' 21+ years old ', ' Affect ', ' Algorithms ', ' Cardiology ', ' Cardiovascular Diseases ', ' cardiovascular disorder ', ' Cardiovascular system ', ' circulatory system ', ' Heart Vascular ', ' Cardiovascular Organ System ', ' Cardiovascular Body System ', ' Cardiovascular ', ' Cause of Death ', ' Clinical Informatics ', ' Computer Simulation ', ' virtual simulation ', ' in silico ', ' computerized simulation ', ' computerized modeling ', ' computer based models ', ' computational simulation ', ' computational models ', ' computational modeling ', ' Mathematical Models and Simulations ', ' Mathematical Model Simulation ', ' Computerized Models ', ' Computer based Simulation ', ' Computer Models ', ' Coronary Arteriosclerosis ', ' coronary arterial disease ', ' atherosclerotic coronary disease ', ' Coronary Atherosclerosis ', ' Coronary Artery Disorder ', ' Coronary Artery Disease ', ' Coronary heart disease ', ' coronary disorder ', ' atherosclerotic heart disease ', ' Coronary Disease ', ' Discrimination ', ' Cognitive Discrimination ', ' Disease ', ' Disorder ', ' Elements ', ' Environment ', ' Foundations ', ' Genetic Counseling ', ' Genotype ', ' Goals ', ' Gold ', ' General Hospitals ', ' Human ', ' Modern Man ', ' Human Genetics ', ' hypercholesterolemia ', ' Hypercholesteremia ', ' Familial Hypercholesterolemia ', ' familial hyperlipoproteinemia type II ', ' familial hyperlipoproteinemia type 2 ', ' familial hypercholesteremia ', ' familial hyperbetalipoproteinemia ', ' Type II Hyperlipidemia ', ' Type 2 Hyperlipidemia ', ' Hyperlipoproteinemia Type II ', ' Hyperlipoproteinemia Type 2 ', ' Hyperbetalipoproteinemia ', ' Essential Hypercholesterolemia ', ' Institutes ', ' Internal Medicine ', ' Lead ', ' heavy metal lead ', ' heavy metal Pb ', ' Pb element ', ' Leadership ', ' Lipids ', ' Low-Density Lipoproteins ', ' beta-Lipoproteins ', ' LDL Lipoproteins ', ' LDL ', ' LDL Cholesterol Lipoproteins ', ' beta-Lipoprotein Cholesterol ', ' Low Density Lipoprotein Cholesterol ', ' LDL Cholesterol ', ' Massachusetts ', ' Medicine ', ' Mentorship ', ' Methods ', ' Statistical Models ', ' statistical linear models ', ' statistical linear mixed models ', ' Probability Models ', ' Probabilistic Models ', ' Molecular Biology ', ' DNA Molecular Biology ', ' Mutation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' United States National Institutes of Health ', ' National Institutes of Health ', ' NIH ', ' Phenotype ', ' Physicians ', ' Quality Control ', ' Research ', ' Risk ', ' Technology ', ' Testing ', ' Time ', ' United States ', ' Veterans ', ' Work ', ' Generations ', ' symposium ', ' symposia ', ' summit ', ' convention ', ' conference ', ' Healthcare ', ' health care ', ' Data Set ', ' Dataset ', ' base ', ' improved ', ' Solid ', ' Clinical ', ' prematurity ', ' premature ', ' Variation ', ' Variant ', ' Physiologic ', ' Physiological ', ' Biochemical ', ' Medical ', ' Link ', ' Evaluation ', ' Training ', ' insight ', ' Individual ', ' African ', ' Amish ', ' European ', ' Family Medical History Epidemiology ', ' Family Medical History ', ' Family history of ', ' Funding ', ' Ethnicity ', ' Ethnic Origin ', ' Collaborations ', ' Genetic ', ' Exposure to ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Knowledge ', ' Catalogs ', ' programs ', ' Scientist ', ' Investigation ', ' Clinic ', ' Penetrance ', ' experience ', ' Gene Mutation ', ' Gene Alteration ', ' success ', ' cohort ', ' trait ', ' skills ', ' novel ', ' Prevention strategy ', ' Preventive strategy ', ' Preventative strategy ', ' disorder risk ', ' disease risk ', ' Environmental Risk Factor ', ' environmental risk ', ' Environmental Factor ', ' Prevention ', ' Positioning Attribute ', ' Position ', ' genetic analysis ', ' Genetic analyses ', ' Pathway Analysis ', ' Network Analysis ', ' Modeling ', ' career development ', ' Genomics ', ' heart disease risk ', ' heart disorder risk ', ' cardiac disorder risk ', ' cardiac disease risk ', ' Pathogenicity ', ' metabolomics ', ' metabonomics ', ' metabolism measurement ', ' genome sequencing ', ' Mediator of activation protein ', ' Mediator of Activation ', ' Mediator ', ' Preventive ', "" Bachelor's Degree "", ' Undergraduate Degree ', ' Baccalaureate Degree ', ' Data ', ' Disease Pathway ', "" Master's Degree "", ' K-Series Research Career Programs ', ' Research Career Program ', ' K-Awards ', ' Career Development Programs K-Series ', ' Career Development Awards and Programs ', ' Career Development Awards ', ' in vivo ', ' lifestyle factors ', ' Principal Investigator ', ' developmental ', ' Development ', ' Electronic Health Record ', ' pathway ', ' Pathway interactions ', ' NHLBI ', ' National Heart, Lung, and Blood Institute ', ' National Center for Human Genome Research ', ' NHGRI ', ' National Human Genome Research Institute ', ' biomed informatics ', ' biomedical informatics ', ' risk prediction model ', ' prognostic model ', ' prediction model ', ' computer based prediction ', ' predictive modeling ', ' next generation ', ' novel strategy ', ' novel approaches ', ' new approaches ', ' novel strategies ', ' Population ', ' Prevalence ', ' Network-based ', ' human disease ', ' high risk ', ' public health relevance ', ' nongenetic ', ' non-genetic ', ' biorepository ', ' biobank ', ' cloud computer ', ' Cloud Infrastructure ', ' Cloud Computing ', ' cloud based ', ' precision-based medicine ', ' precision medicine ', ' genomic variation ', ' single-gene disorder ', ' single-gene disease ', ' monogenic disorder ', ' monogenic disease ', ' Mendelian genetic disorder ', ' Mendelian disease ', ' Mendelian disorder ', ' human genomics ', ' full genome ', ' entire genome ', ' whole genome ', ' Preventative therapy ', ' Preventive therapy ', ' TOPMed ', ' Trans-Omics for Precision Medicine ', ' Risk stratification ', ' DNAseq ', ' DNA seq ', ' DNA sequencing ', ' genetic disorder ', ' genetic condition ', ' Genetic Diseases ', ' ']",NHLBI,MASSACHUSETTS GENERAL HOSPITAL,K08,2018,173296,MA-08,0.12664327181676716
"Molecular Characterization of Joubert Syndrome Project Summary Congenital ataxia presents in early childhood with non-progressive hypotonia, gross motor, fine motor and cognitive delays. These disorders are distinct from the progressive ataxias because of the presence of congenital cerebellar malformations and because they are typically inherited recessively. Joubert Syndrome and Related Disorders (JSRD) constitute a major subset of these conditions, consisting of a cerebellar midline (vermis) malformation, a nearly pathognomonic Molar Tooth sign on brain Imaging (MTI) and co-existent oculomotor apraxia and episodic breathing dysrhythmias. In our published data, we have: 1] Identified ten unique genetic causes of JSRD (nearly half of the published causes), 2] Generated genotype-phenotype correlations involving cerebellar, retinal, renal, hepatic, digit, and cerebral manifestations. 3] Identified common founder mutations that allow for population-based screening. 4] Discovered that JSRD encoded proteins frequently localize to the cilium. 5] Identified ciliary transition zone (TZ) defects in cells with JSRD mutations. 6] Performed siRNA cell-based screens for defective ciliogenesis to prioritize candidate JSRD genes. 7] Generated and characterized multiple zebrafish, mouse and human cell culture models for JSRD. 8] Defined the concept of Ciliary localization model, in which one JSRD gene is required for ciliary localization of other JSRD proteins. In our unpublished data we have: 1] Recruited an additional 200 JSRD patients without molecular diagnosis. 2] Performed whole exome (WES) and whole genome sequencing (WGS) on an additional 100 JSRD families. 3] Identified an additional 12 novel likely JSRD candidate genes. 4] Generated IPSCs and cerebellar organoids from mutation-positive and negative families to aid in functional analysis and gene discovery using RNAseq. 5] Begun functional validation of the putative mutations. 6] Developed methods to interrogate ciliary structure in a high-throughput fashion with electron microscopy (EM). The goal of this competing renewal is to identify the remaining discoverable genes that lead to JSRD when lost, functionally validate mutations within the pathogenetic framework, and test the hypothesis that mutations in JSRD genes lead to collapse of the ciliary TZ. Because the majority of patients still have unknown cause of disease, this renewal aims to advance knowledge through molecular characterization of new genes, using newly evolving high-throughput techniques, integrated bioinformatics, and a unique resource of consanguineous families recruited world-wide. We further aim to validate these mutations in patient cells, within a mechanistic framework that JSRD genes are required for essential ciliary structural components during cerebellar development. Project Narrative Joubert syndrome is a genetically and phenotypically heterogeneous neurodevelopmental disorder unified by defects of the cellular primary cilium. This work will identify new genetic causes and dissect ciliary defects associated with genetic mutations.",Molecular Characterization of Joubert Syndrome,9359994,R01NS048453,"['Termination of pregnancy ', ' Apraxias ', ' apraxia ', ' Dyspraxia ', ' Breathing ', ' inspiration ', ' Respiratory Inspiration ', ' Respiratory Aspiration ', ' Ataxia ', ' Dyssynergia ', ' Coordination Impairment ', ' Ataxy ', ' Cell Culture Techniques ', ' cell culture ', ' Cells ', ' Cell Body ', ' Cultured Cells ', ' Cilia ', ' Cytoplasmic Granules ', ' granule ', ' Disease ', ' Disorder ', ' Electrons ', ' Negatrons ', ' Negative Beta Particle ', ' Embryo ', ' Embryonic ', ' Face ', ' facial ', ' faces ', ' Family ', ' Genes ', ' Genotype ', ' Goals ', ' Gold ', ' Human ', ' Modern Man ', ' Kidney ', ' renal ', ' Kidney Urinary System ', ' Lead ', ' heavy metal lead ', ' heavy metal Pb ', ' Pb element ', ' Methods ', ' Electron Microscopy ', ' Scanning Electron Microscopy ', ' Middle East ', ' Molar tooth ', ' Morphogenesis ', ' Mus ', ' Murine ', ' Mice Mammals ', ' Mice ', ' Muscle hypotonia ', ' Muscular Hypotonia ', ' Muscle Tone Poor ', ' Muscle Hypotony ', ' Hypotonia ', ' Hypomyotonia ', ' Decreased Muscle Tone ', ' Mutation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Organoids ', ' Patients ', ' Phenotype ', ' Probability ', ' Proteins ', ' Publishing ', ' Resources ', ' Research Resources ', ' Risk ', ' Signal Transduction ', ' biological signal transduction ', ' Signaling ', ' Signal Transduction Systems ', ' Intracellular Communication and Signaling ', ' Cell Signaling ', ' Cell Communication and Signaling ', ' Sonication ', ' Mass Spectrum Analysis ', ' Mass Spectrum Analyses ', ' Mass Spectrum ', ' Mass Spectroscopy ', ' Mass Spectrometry ', ' Mass Photometry/Spectrum Analysis ', ' Syndrome ', ' Testing ', ' Work ', ' Zebrafish ', ' Zebra Fish ', ' Zebra Danio ', ' Danio rerio ', ' Brachydanio rerio ', ' base ', ' brain visualization ', ' Brain imaging ', ' Hepatic ', ' Clinical ', ' Microscopic ', ' Variation ', ' Variant ', ' Series ', ' Training ', ' vermis ', ' Cerebellar vermis structure ', ' insight ', ' Individual ', ' cerebral ', ' Cerebrum ', ' data base ', ' Data Bases ', ' Databases ', ' Cerebellar hypoplasia ', ' Congenital cerebellar hypoplasia ', ' Genetic ', ' Morphology ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Knowledge ', ' Joubert syndrome ', ' cerebelloparenchymal disorder IV ', ' cerebellar vermis agenesis ', ' Joubert-Boltshauser syndrome ', ' Inherited ', ' Hereditary ', ' Severities ', ' cell type ', ' Techniques ', ' fetal ', ' Digit structure ', ' Digit ', ' Gene Mutation ', ' Gene Alteration ', ' mutant ', ' early childhood ', ' cohort ', ' Transmission Electron Microscopy ', ' Structure ', ' Genetic screening method ', ' genetic testing ', ' gene-based testing ', ' gene testing ', ' novel ', ' Modeling ', ' affection ', ' oculomotor ', ' ocularmotor ', ' ocular motor ', ' disorder subtype ', ' disease subtype ', ' disease subgroups ', ' Small Interfering RNA ', ' siRNA ', ' Short interfering RNA ', ' Pathogenicity ', ' Bioinformatics ', ' Bio-Informatics ', ' cilium biogenesis ', ' ciliogenesis ', ' genome sequencing ', ' Candidate Disease Gene ', ' Candidate Gene ', ' Length ', ' Defect ', ' DNA Sequence Alteration ', ' genomic alteration ', ' Sequence Alteration ', ' Genetic mutation ', ' DNA mutation ', ' DNA Alteration ', ' Data ', ' Molecular Diagnosis ', ' Motor ', ' Protein Analysis ', ' Cognitive ', ' enroll ', ' Enrollment ', ' Validation ', ' WNT signaling ', ' WNT Signaling Pathway ', ' Molecular ', ' Knockout ', ' Knock-out ', ' developmental ', ' Development ', ' Neurological Development Disorder ', ' Neurodevelopmental Disorder ', ' Cerebellum malformation ', ' Cerebellar malformation ', ' reconstruction ', ' knockdown ', ' knock-down ', ' 3D analysis ', ' 3-dimensional analysis ', ' 3-D analysis ', ' Three-dimensional analysis ', ' Retinal ', ' loss of function mutation ', ' founder mutation ', ' malformation ', ' discover genes ', ' gene discovery ', ' population based ', ' stem cell biology ', ' genomewide ', ' genome scale ', ' genome-wide ', ' exomes ', ' exome ', ' RNAseq ', ' RNA sequencing ', ' RNA Seq ', ' transcriptome sequencing ', ' exome-seq ', ' exome sequencing ', ' screening ', ' CRISPR/Cas system ', ' CRISPR ', ' Clustered Regularly Interspaced Short Palindromic Repeats ', ' accurate diagnosis ', ' consanguineous\xa0kindreds ', ' consanguineous pedigree ', ' consanguineous family ', ' full genome ', ' entire genome ', ' whole genome ', ' recruit ', ' ']",NINDS,"UNIVERSITY OF CALIFORNIA, SAN DIEGO",R01,2018,510012,CA-52,0.20843462185098818
"Functional Annotation of Natural and Disease Variants in Tryosine Kinases Project Summary (unchanged) Protein tyrosine kinases are dynamic molecular switches that toggle between a catalytically on and off state to turn on and off signals responsible for cell growth and survival. While the tyrosine kinase switch is tightly regulated by a diverse array of structural mechanisms in normal states, in many disease states, the switch is permanently turned on or off due, in part, to mutations in the tyrosine kinase domain. Although genome sequencing studies have revealed the mutational patterns of tyrosine kinases from many different disease types, understanding the structural and functional impact of these mutations is a challenge because many recurrent mutations occur far from the active site (distal mutations) and the residue networks that contribute to the complex modes of tyrosine kinase allosteric regulation are not fully understood. Our long term goal is to understand the relationships connecting sequence, structure, function, regulation and disease in protein kinases using a combination of computational and experimental approaches. Our objective in this proposal, which is the next logical step toward attainment of our long-term goal, is to delineate the residue interaction networks that contribute to the unique modes of allosteric regulation in tyrosine kinases, and to develop a computational framework for predicting mutation impact using the evolutionary and allosteric properties encoded in three dimensional structures. The central hypothesis is that distal mutations alter evolutionarily conserved allosteric networks in tyrosine kinases, and delineating the allosteric networks unique to tyrosine kinases will provide context for predicting and testing disease mutation impact. The specific aims are:  To identify and characterize natural sequence and structural variants associated with tight  allosteric control of tyrosine kinase activity  To develop a computational framework for predicting mutation impact on kinase activation and to  experimentally validate computational predictions using selected receptor tyrosine kinases as  model systems Successful completion of these aims is expected to reveal novel activating mutations in putative allosteric sites in the tyrosine kinase domain, and pinpoint key residues and interactions for functional studies. These outcomes, in turn, are expected to have major biomedical impact by accelerating the functional characterization of the mutated tyrosine kinome, which is emerging as a major target for personalized medicine. Finally, by providing detailed mechanistic annotation of mutations identified in genome sequencing studies, this proposal will address a fundamental NIH roadmap problem in translational medicine of converting genomic discoveries into therapeutic strategies. Health Narrative (unchanged) Protein tyrosine kinases are a biomedically important class of proteins that are abnormally regulated in many human diseases including cancer, diabetes, and inflammatory disorders, to name but a few. They have been the focus of many drug discovery efforts and genome sequencing studies because of the therapeutic potential of targeting mutated tyrosine kinases for personalized therapy. By providing functional annotation of natural and disease mutations in tyrosine kinases, the proposed studies will accelerate the targeting of mutated tyrosine kinases for drug discovery and personalized therapy.",Functional Annotation of Natural and Disease Variants in Tryosine Kinases,9700377,R01GM114409,"['Allosteric Regulation ', ' Allosteric Site ', ' inhibitor/antagonist ', ' inhibitor ', ' Antineoplastic Agents ', ' anticancer drug ', ' anticancer agent ', ' anti-cancer drug ', ' Tumor-Specific Treatment Agents ', ' Neoplastic Disease Chemotherapeutic Agents ', ' Cancer Drug ', ' Antineoplastics ', ' Antineoplastic Drugs ', ' Anti-Cancer Agents ', ' Biological Assay ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' Malignant Neoplasms ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' cell growth ', ' Cellular Growth ', ' Cellular Expansion ', ' Cell Survival ', ' Cell Viability ', ' Communities ', ' Diabetes Mellitus ', ' diabetes ', ' Disease ', ' Disorder ', ' Drug resistance ', ' resistant to Drug ', ' resistance to Drug ', ' drug resistant ', ' Pharmaceutical Preparations ', ' drug/agent ', ' Pharmaceutic Preparations ', ' Medication ', ' Drugs ', ' Genes ', ' Human Genome ', ' human whole genome ', ' Goals ', ' Health ', ' In Vitro ', ' Biological Models ', ' Model System ', ' Biologic Models ', ' Mutation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Names ', ' United States National Institutes of Health ', ' National Institutes of Health ', ' NIH ', ' Organism ', ' living system ', ' Peptides ', ' Phosphotransferases ', ' Transphosphorylases ', ' Phosphotransferase Gene ', ' Kinases ', ' Protein Kinase ', ' phosphorylase b kinase kinase ', ' hydroxyalkyl protein kinase ', ' glycogen synthase a kinase ', ' Kinase Family Gene ', ' ATP-protein phosphotransferase ', ' Protein Tyrosine Kinase ', ' tyrosyl protein kinase ', ' hydroxyaryl protein kinase ', ' Tyrosylprotein Kinase ', ' Tyrosine-Specific Protein Kinase ', ' Tyrosine-Protein Kinase Receptor EEK ', ' Tyrosine Kinase ', ' Protein Tyrosine Kinase EEK ', ' Ephrin Type-A Receptor 8 Precursor ', ' Ephrin Type-A Receptor 8 ', ' EPH-and ELK-Related Kinase ', ' EPH- and ELK-Related Tyrosine Kinase ', ' Proteins ', ' Recurrence ', ' Recurrent ', ' Research ', ' Research Personnel ', ' Researchers ', ' Investigators ', ' Signal Transduction ', ' biological signal transduction ', ' Signaling ', ' Signal Transduction Systems ', ' Intracellular Communication and Signaling ', ' Cell Signaling ', ' Cell Communication and Signaling ', ' Testing ', ' Time ', ' Tyrosine ', ' Protein-Serine-Threonine Kinases ', ' Threonine Kinase ', ' Serine/Threonine Protein Kinase Gene ', ' Serine-Threonine Kinases ', ' Serine Kinase ', ' Protein-Threonine Kinase ', ' Protein-Serine Kinase ', ' improved ', ' Distal ', ' Site ', ' Variation ', ' Variant ', ' Active Sites ', ' Tyrosine Kinase Receptors ', ' Tyrosine Kinase Linked Receptors ', ' Transmembrane Receptor Protein Tyrosine Kinase ', ' Receptor Tyrosine Kinase Gene ', ' PTK Receptors ', ' Receptor Protein-Tyrosine Kinases ', ' Therapeutic ', ' Inflammatory ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Complex ', ' Pattern ', ' molecular dynamics ', ' Molecular Dynamics Simulation ', ' mutant ', ' Structure ', ' novel ', ' Regulation ', ' Modeling ', ' Property ', ' Genomics ', ' drug discovery ', ' Pathogenicity ', ' Binding ', ' Molecular Interaction ', ' genome sequencing ', ' Address ', ' Drug Binding Site ', ' Mutate ', ' Ontology ', ' Tyrosine Kinase Domain ', ' Molecular ', ' developmental ', ' Development ', ' computational framework ', ' computer framework ', ' Outcome ', ' 3D structure ', ' 3-dimensional structure ', ' 3-D structure ', ' three dimensional structure ', ' translational medicine ', ' human disease ', ' personalized treatment ', ' personalized therapy ', ' personalization of treatment ', ' personalized medicine ', ' predictive assay ', ' predictive test ', ' ']",NIGMS,UNIVERSITY OF GEORGIA,R01,2018,74718,GA-10,0.253183175078445
"A combined computational and experimental approach to the evolution and role of the DNA sequence environment in targeting mutations to antibody V regions Project summary There is a fundamental gap in our understanding of how mutations are preferentially targeted to the variable (V) regions of the Immunoglobulin (Ig) loci during somatic hypermutation (SHM). The persistence of this gap has limited our understanding of the mutagenic mechanisms involving activation-induced deaminase (AID) in the immune response and in the role of AID in mis-targeting mutations leading to B-cell lymphomas and other cancers. The long-term goal of the proposed research is to understand the global targeting of mutations in immunity that are required to protect us from infections. As high-throughput data from human antibody immune responses became available, it provided us with new opportunities to generate hypotheses to explain the underlying mechanisms of SHM. We now propose to generate further hypotheses using computational models applied to additional databases and to validate these hypotheses using cellular and animal experiments. Our objective is to understand what directs SHM across the many human Ig heavy chain V-regions. Our central hypothesis is that the V-region SHM process is highly dependent on a DNA sequence signature(s) that drives mutations in a largely deterministic fashion. This hypothesis is supported by our preliminary results using human in vivo data from a few human V region genes and has begun to be validated using independent databases and experiments in human B cell lines. The rationale is that evaluations of computational data based upon biological mechanisms, together with appropriate biological experiments, will reveal the key differences between IGHV regions (IGHV 3-23, 4-34, 1-18, 1-02, etc.) that lead to the dominance of each of those V regions in the responses to medically important antigens. Our hypothesis will be tested by pursuing two specific aims: 1) identify the extent to which a DNA signature determines the mutation process in four individual human IGHV genes that are important in disease responses; 2) examine the relationship between AID hotspots and Pol hotspots across all the other human V region genes, thus rigorously defining a mutation targeting signature. Both aims will also entail studying human V region genes and modifications of them in human cell lines and in mice expressing a human V region to further confirm the signature and identify molecular mechanisms in vivo. Our approach is innovative because the computational models we are proposing will be mechanistically motivated focusing on the interaction between AID and Pol hotspots, thus testing molecular mechanisms as opposed to classic statistical models using whole V region sequences that ignore the underlying biology. In addition, to focus on mechanisms we will leverage new high-throughput data from human V regions that have not undergone antigen selection. Our results will be highly relevant to human IgV repertoire analyses from immune responses that are currently hard to interpret and will help future vaccine and therapeutic antibody development, as well as help to understand mutations in human malignancies where AID plays a key role. Project narrative The proposed research is relevant to public health because understanding the targeting of AID-mediated mutations across many human heavy chain V-regions will make it possible to develop vaccines that will lead more rapidly to better and more broadly protective antibodies to infectious agents and reveal the risk factors in the development of B-cell malignancies and gastric and other solid tumors where AID is implicated.",A combined computational and experimental approach to the evolution and role of the DNA sequence environment in targeting mutations to antibody V regions,9518337,R01AI132507,"['Affect ', ' Alleles ', ' Allelomorphs ', ' Antibodies ', ' Antibody Affinity ', ' antigen antibody affinity ', ' Antigens ', ' immunogen ', ' ATGN ', ' Autoimmunity ', ' Autoimmune Status ', ' B-Lymphocytes ', ' Bursa-Equivalent Lymphocyte ', ' Bursa-Dependent Lymphocytes ', ' B-cell ', ' B-Cells ', ' B cells ', ' B cell ', ' B blood cells ', ' Biology ', ' Malignant Neoplasms ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Cell Line ', ' cultured cell line ', ' Strains Cell Lines ', ' CellLine ', ' Chromatin ', ' Computer Simulation ', ' virtual simulation ', ' in silico ', ' computerized simulation ', ' computerized modeling ', ' computer based models ', ' computational simulation ', ' computational models ', ' computational modeling ', ' Mathematical Models and Simulations ', ' Mathematical Model Simulation ', ' Computerized Models ', ' Computer based Simulation ', ' Computer Models ', ' Disease ', ' Disorder ', ' DNA ', ' Deoxyribonucleic Acid ', ' Environment ', ' Enzyme Activation ', ' Evolution ', ' Family ', ' Feedback ', ' Future ', ' Genes ', ' Goals ', ' HIV ', ' Virus-HIV ', ' Lymphadenopathy-Associated Virus ', ' LAV-HTLV-III ', ' Human Immunodeficiency Viruses ', ' Acquired Immunodeficiency Syndrome Virus ', ' Acquired Immune Deficiency Syndrome Virus ', ' AIDS Virus ', ' Human ', ' Modern Man ', ' Immunity ', ' Complementarity Determining Regions ', ' Immunoglobulin Hypervariable Region ', ' Hypervariable Regions ', ' Hypervariable Loop ', ' Complimentarity Determining Region ', ' Immunoglobulins ', ' Immune Globulins ', ' Heavy-Chain Immunoglobulins ', ' Infection ', ' Influenza ', ' influenza infection ', ' flu infection ', ' Grippe ', ' Lead ', ' heavy metal lead ', ' heavy metal Pb ', ' Pb element ', ' Transgenic Mice ', ' Statistical Models ', ' statistical linear models ', ' statistical linear mixed models ', ' Probability Models ', ' Probabilistic Models ', ' Mus ', ' Murine ', ' Mice Mammals ', ' Mice ', ' Mutation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Play ', ' Public Health ', ' Research ', ' Risk Factors ', ' Role ', ' social role ', ' Stomach ', ' gastric ', ' Testing ', ' Time ', ' Vaccines ', ' B-Cell Lymphomas ', ' B lymphoma ', ' Mediating ', ' GTP-Binding Protein alpha Subunits, Gs ', ' -Gs ', ' alpha-Gs ', ' alpha Subunit Stimulatory GTP-Binding Protein ', ' Stimulatory Gs G-Protein ', ' Regulatory Ns Protein ', ' Gs ', ' Gs ', ' Gs alpha Family G-Protein ', ' GTP-Binding Protein  Subunits, Gs ', ' G(s) ', ' G(s)alpha ', ' G(s),  Subunit ', ' G(s), alpha Subunit ', ' DNA Sequence ', ' base ', ' density ', ' Site ', ' Variation ', ' Variant ', ' Biological ', ' Medical ', ' Animal Experiments ', ' Evaluation ', ' Individual ', ' data base ', ' Data Bases ', ' Databases ', ' Solid Tumor ', ' Solid Neoplasm ', ' Germinal Center ', ' Structure of germinal center of lymph node ', ' Immune response ', ' immunoresponse ', ' host response ', ' Immunological response ', ' Infectious Agent ', ' infectious organism ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Frequencies ', ' Event ', ' Pattern ', ' Techniques ', ' Location ', ' neutralizing antibody ', ' human data ', ' repair enzyme ', ' repair endonuclease ', ' Human Cell Line ', ' response ', ' Immunoglobulin Somatic Hypermutation ', ' somatic hypermutation ', ' Ig Somatic Hypermutation ', ' activation-induced cytidine deaminase ', ' activation-induced deaminase ', ' CDA2 protein ', ' AID protein ', ' AID gene ', ' AICDA protein ', ' AICDA ', ' Mismatch Repair ', ' Post-Replication Mismatch Repair ', ' chromatin modification ', ' Polymerase ', ' B-Cell Development ', ' Data ', ' Mutate ', ' in vivo ', ' in vivo Model ', ' computer analyses ', ' computational analysis ', ' computational analyses ', ' Computer Analysis ', ' gene modification ', ' Gene-Modified ', ' Validation ', ' Molecular ', ' Process ', ' developmental ', ' Development ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' genetic variant ', ' B cell malignancy ', ' B lymphoid malignancy ', ' Outcome ', ' innovative ', ' innovate ', ' innovation ', ' Influenza HA ', ' Influenza Hemagglutinin ', ' Therapeutic antibodies ', ' spatial relationship ', ' vaccine response ', ' knockin ', ' Knock-in ', ' experimental research ', ' experiment ', ' experimental study ', ' recruit ', ' ']",NIAID,"ALBERT EINSTEIN COLLEGE OF MEDICINE, INC",R01,2018,537909,NY-14,0.15887011747240132
"Evolutionary Human Genomics: Demography, Natural Selection, and Transcriptional Regulation To be fully understood, the human genome must be considered in the context of evolution. The activities that have dominated human genomics for three decades  such as genome sequencing and annotation, interrogation with high-throughput biochemical assays, and the identification of associations between genetic variants and diseases  have been enormously informative, but these descriptive studies must eventually be understood within the theoretical framework of evolutionary genetics. We must continue to press forward from the what? to the why? and how? of human genetics.  The goal of my laboratory is to interpret high-throughput genomic data from an evolutionary perspective. Drawing from ideas and techniques in molecular evolution, population genetics, statistics, and computer science, we aim both to understand the evolutionary forces that have shaped human genomes, and to use evolution to shed light on the phenotypic importance of particular sequences. Our recent activities have focused in three major areas: (1)  reconstruction  of  features  of  human  evolution  based  on  genome  sequences;  (2)  prediction  of  the  fitness consequences  of  human  mutations;  and  (3)  the  study  of  transcriptional  regulation  and  its  evolution  in primates.   We have reported major findings in each of these areas, including the existence of gene flow from early modern humans to Eastern Neandertals, a map of fitness consequences for mutations across the human genome, and an analysis showing that the architecture of transcription initiation is highly similar at enhancers and promoters in the human genome.  Here we propose to extend our research substantially in each of these areas, working together with a broad range  of  experimental  and  theoretical  collaborators.    Our  new  goals  include  the  development  of  improved methods for reconstructing human demography, with a focus on ancient gene flow; extensions of our ancestral recombination graph (ARG) sampling methods to accommodate much larger samples sizes, with applications in association mapping and the detection of natural selection; two complementary machine-learning approaches for  improving  the  prediction  of  fitness  consequences  from  sequence  data;  an  experimental  collaboration  to leverage CRISPR-Cas9 screens in characterizing noncoding mutations; a multi-pronged study of the sequence determinants of RNA stability and their implications for the evolution of transcription units; and development of a new probabilistic model for turnover of regulatory elements.  Together, these projects will address a wide variety of fundamental questions about the function and evolution of sequences in the human genome. Vast quantities of genomic data are now available to describe patterns of genetic variation within  human populations and across species, and various measures of biochemical activity along the human  genome. These data need to be interpreted in light of the fundamental forces of mutation,  recombination, natural selection, and genetic drift that have shaped genetic variation. This  proposal describes a series of projects that make use of new computational, statistical, and  theoretical methods to address fundamental questions in human evolutionary genetics, including how  humans arose   from our archaic hominin and ape cousins, how human populations diverged from one  another, how new mutations influence human health and fitness, and how regulatory sequences  contribute to unique aspects of human biology.","Evolutionary Human Genomics: Demography, Natural Selection, and Transcriptional Regulation",9486266,R35GM127070,"['Architecture ', ' Engineering / Architecture ', ' Biological Assay ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' Demography ', ' Evolution ', ' Genes ', ' Population Genetics ', ' Genome ', ' Human Genome ', ' human whole genome ', ' Goals ', ' Health ', ' Human ', ' Modern Man ', ' Human Genetics ', ' Laboratories ', ' Light ', ' Photoradiation ', ' Maps ', ' Methods ', ' Statistical Models ', ' statistical linear models ', ' statistical linear mixed models ', ' Probability Models ', ' Probabilistic Models ', ' Modernization ', ' Mutation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Phenotype ', ' Pongidae ', ' great ape ', ' Apes ', ' Primates ', ' Primates Mammals ', ' Genetic Recombination ', ' Recombination ', ' DNA Recombination ', ' Research ', ' statistics ', ' Genetic Transcription ', ' Transcription ', ' RNA Expression ', ' Gene Transcription ', ' Genetic Variation ', ' Genetic Diversity ', ' Measures ', ' Enhancers ', ' Natural Selections ', ' promoter ', ' promotor ', ' base ', ' improved ', ' Area ', ' Biochemical ', ' Series ', ' Sample Size ', ' Collaborations ', ' Molecular Evolution ', ' Genetic ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Pattern ', ' Techniques ', ' computer science ', ' Human Biology ', ' Graph ', ' Reporting ', ' RNA Stability ', ' Sampling ', ' Untranslated RNA ', ' noncoding ', ' Nontranslated RNA ', ' Noncoding RNA ', ' Non-Coding RNA ', ' Non-Coding ', ' Functional RNA ', ' Genetic Drift ', ' Genetic Divergence ', ' Genetic Differentiation ', ' Transcriptional Regulation ', ' Transcriptional Control ', ' Transcription Regulation ', ' Transcription Initiation ', ' genome sequencing ', ' Address ', ' fitness ', ' Data ', ' Detection ', ' Regulatory Element ', ' developmental ', ' Development ', ' reconstruction ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' genetic variant ', ' Population ', ' genome annotation ', ' genome analysis ', ' human genomics ', ' clustered regularly interspaced short palindromic repeats screen ', ' CRISPR/Cas9 screen ', ' CRISPR-based screen ', ' CRISPR editing screen ', ' CRISPR screen ', ' genomic data ', ' genetic disorder ', ' genetic condition ', ' Genetic Diseases ', ' ']",NIGMS,COLD SPRING HARBOR LABORATORY,R35,2018,479215,NY-03,0.07480630374161072
"Massively parallel functional analyses of human PTEN variants Project Summary  We are now able to routinely sequence human genomes at single-base resolution. However, our ability to interpret the functional consequences of detected mutations has lagged behind. Computational approaches scale well but have poor accuracy, whereas retrospective analysis of detected variants has high accuracy but does not scale well. In order to solve this problem, a new experimental paradigm has emerged to empirically characterize the effects of mutations with high accuracy at scale. This approach takes advantage of recent and ongoing improvements in DNA synthesis and sequencing, and has the potential to offer unprecedented insight into protein biochemistry and human disease. We believe these insights will prove to be critical for unlocking the potential of genomic medicine.  In this project we seek to comprehensively assess multiple molecular effects of PTEN mutations on protein function, and assess the utility of this data as a predictor for human clinical phenotype. The PTEN protein is a tumor suppressor that is frequently mutated in diverse human cancers and in the germline of some individuals with overgrowth disorders, cancer predisposition syndromes, or autism. Currently, it is impossible to predict the effects of the vast majority of PTEN germline mutations. Since the phenotypic spectrum of PTEN mutation carriers is broad, it would be highly valuable to understand the ways in which phenotypic outcomes arise from PTEN mutation genotypes.  In Aim 1, we will first employ a yeast-based screen to assess the effects all PTEN single amino acid mutations on lipid phosphatase activity, the primary biochemical function of PTEN protein. It is known that several pathogenic variants are destabilized. Therefore, in Aim 2, we will perform a second, independent screen to assess the steady state protein stability of all PTEN single amino acid mutations. In Aim 3, we will use the data derived from this study as well as publically available biochemical information to train a classifier model to predict the relationship between the mutation genotypes and clinical phenotypes observed in humans. These data will increase our fundamental understanding of PTEN function and the role of mutations in diverse disorders, and could provide a valuable clinical tool that would increase the quality of life for PTEN mutation carriers. Project Narrative  Mutations in the gene PTEN are causal for a diverse set of clinical disorders ranging from cancer to autism spectrum disorder. Here, we seek to gain new fundamental insights into the functional relationships between PTEN mutations and clinical presentations by prospectively characterizing the effects of all single amino acid PTEN mutations in parallel. These data will allow the creation of new models that can predict risk of specific PTEN mutations for different clinical outcomes and potentially lead to personalized therapies, early interventions, and optimal outcomes for PTEN mutation carriers.",Massively parallel functional analyses of human PTEN variants,9539482,F31HD095571,"['Affect ', ' Amino Acids ', ' aminoacid ', ' Autistic Disorder ', "" Kanner's Syndrome "", ' Infantile Autism ', ' Early Infantile Autism ', ' Autism ', ' Biochemistry ', ' Biological Chemistry ', ' Biological Assay ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' Biology ', ' Biophysics ', ' biophysical sciences ', ' biophysical principles ', ' biophysical foundation ', ' Malignant Neoplasms ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Cataloging ', ' Cell Separation ', ' cell sorting ', ' Cell Separation Technology ', ' Cell Segregation ', ' Cell Isolation ', ' Cell Survival ', ' Cell Viability ', ' Cells ', ' Cell Body ', ' Disease ', ' Disorder ', ' Fluorescence ', ' Genes ', ' Genome ', ' Human Genome ', ' human whole genome ', ' Genotype ', ' Goals ', ' Growth ', ' ontogeny ', ' Tissue Growth ', ' Generalized Growth ', ' Human ', ' Modern Man ', ' Human Genetics ', ' Lead ', ' heavy metal lead ', ' heavy metal Pb ', ' Pb element ', ' Light ', ' Photoradiation ', ' Lipids ', ' Metabolism ', ' Metabolic Processes ', ' Intermediary Metabolism ', ' Mutation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Patients ', ' Phenotype ', ' Phosphatidylinositols ', ' PtdIns ', ' Phosphoinositides ', ' Phosphatidyl Inositol ', ' Inositol Phospholipids ', ' Inositol Phosphoglycerides ', ' Inositide Phospholipids ', ' Phosphoric Monoester Hydrolases ', ' Phosphomonoesterases ', ' Phosphohydrolases ', ' Phosphatases ', ' Play ', ' Problem Solving ', ' Proteins ', ' Quality of life ', ' QOL ', ' Risk ', ' Role ', ' social role ', ' Signal Pathway ', ' Signal Transduction ', ' biological signal transduction ', ' Signaling ', ' Signal Transduction Systems ', ' Intracellular Communication and Signaling ', ' Cell Signaling ', ' Cell Communication and Signaling ', ' Syndrome ', ' Temperature ', ' Testing ', ' Time ', ' Yeasts ', ' Measures ', ' Data Set ', ' Dataset ', ' base ', ' improved ', ' Site ', ' Clinical ', ' Variation ', ' Variant ', ' Biochemical ', ' Pythons ', ' Hereditary Mutation ', ' Germline Mutation ', ' Germ-Line Mutation ', ' Susceptibility ', ' Predisposition ', ' Training ', ' insight ', ' Individual ', ' Early Intervention ', ' tool ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Catalogs ', ' Complex ', ' Clinic ', ' Reaction ', ' Techniques ', ' Tumor Suppressor Proteins ', ' tumor suppressor ', ' DNA biosynthesis ', ' DNA Synthesis ', ' DNA Replication ', ' novel ', ' PTEN gene ', ' Phosphatase and Tensin Homolog Deleted on Chromosome 10 ', ' Phosphatase and Tensin Homolog ', ' PTEN1 ', ' PTEN Hamartoma Tumor Syndrome With Granular Cell Tumor ', ' PTEN Hamartoma Tumor Syndrome ', ' PTEN ', ' PHTS protein ', ' PHTS gene ', ' Mutated in Multiple Advanced Cancers 1 ', ' MMAC1 ', ' Therapeutic Intervention ', ' intervention therapy ', ' Modeling ', ' high throughput technology ', ' Genomics ', ' Pathogenicity ', ' FRAP1 gene ', ' mammalian target of rapamycin ', ' mTOR ', ' RAFT1 ', ' Mechanistic Target of Rapamycin ', ' FRAP2 ', ' FRAP1 ', ' FKBP12 Rapamycin Complex Associated Protein 1 ', ' FK506 Binding Protein 12-Rapamycin Associated Protein 1 ', ' fitness ', ' autism spectrum disorder ', ' autistic spectrum disorder ', ' Data ', ' Deletion Mutation ', ' Mutate ', ' Protein Biochemistry ', ' Protein/Amino Acid Biochemistry ', ' Resolution ', ' ubiquitin conjugation ', ' ubiquination ', ' Ubiquitinoylation ', ' Ubiquitilation ', ' Ubiquitination ', ' yeast model ', ' Yeast Model System ', ' Characteristics ', ' Molecular ', ' Process ', ' protein function ', ' developmental ', ' Development ', ' phosphatase and tensin homologue on chromosome ten ', ' mutated in multiple advanced cancers 1 protein ', ' MMAC1 protein ', ' PTEN protein ', ' pathway ', ' Pathway interactions ', ' clinical phenotype ', ' risk prediction model ', ' prognostic model ', ' prediction model ', ' computer based prediction ', ' predictive modeling ', ' next generation ', ' Outcome ', ' tumorigenic ', ' prospective ', ' Coupled ', ' Coupling ', ' synthetic biology ', ' open source ', ' human disease ', ' mutation carrier ', ' screening ', ' personalized treatment ', ' personalized therapy ', ' personalization of treatment ', ' personalized medicine ', ' accurate diagnosis ', ' genomic variation ', ' Genomic medicine ', ' predictor algorithm ', ' predictive algorithm ', ' prediction algorithm ', ' genomic classifier ', ' genomic signature ', ' experimental research ', ' experiment ', ' experimental study ', ' DNAseq ', ' DNA seq ', ' DNA sequencing ', ' ']",NICHD,OREGON HEALTH & SCIENCE UNIVERSITY,F31,2018,44524,OR-03,0.26862667958260855
"Functional Annotation of Natural and Disease Variants in Tryosine Kinases     DESCRIPTION (provided by applicant): Protein tyrosine kinases are dynamic molecular switches that toggle between a catalytically ""on"" and ""off"" state to turn on and off signals responsible for cell growth and survival. While the tyrosine kinase switch is tightly regulated by  diverse array of structural mechanisms in normal states, in many disease states, the switch is permanently turned on or off due, in part, to mutations in the tyrosine kinase domain. Although genome sequencing studies have revealed the mutational patterns of tyrosine kinases from many different disease types, understanding the structural and functional impact of these mutations is a challenge because many recurrent mutations occur far from the active site (distal mutations) and the residue networks that contribute to the complex modes of tyrosine kinase allosteric regulation are not fully understood. Our long term goal is to understand the relationships connecting sequence, structure, function, regulation and disease in protein kinases using a combination of computational and experimental approaches. Our objective in this proposal, which is the next logical step toward attainment of our long-term goal, is to delineate the residue interaction networks that contribute to the unique modes of allosteric regulation in tyrosine kinases, and to develop a computational framework for predicting mutation impact using the evolutionary and allosteric properties encoded in three dimensional structures. The central hypothesis is that distal mutations alter evolutionarily conserved allosteric networks in tyrosine kinases, and delineating the allosteric networks unique to tyrosine kinases will provide context for predicting and testing disease mutation impact. The specific aims are: * To identify and characterize natural sequence and structural variants associated with tight  allosteric control of tyrosine kinase activity * To develop a computational framework for predicting mutation impact on kinase activation and to  experimentally validate computational predictions using selected receptor tyrosine kinases as  model systems Successful completion of these aims is expected to reveal novel activating mutations in putative allosteric sites in the tyrosine kinase domain, and pinpoint key residues and interactions for functional studies. These outcomes, in turn, are expected to have major biomedical impact by accelerating the functional characterization of the mutated tyrosine kinome, which is emerging as a major target for personalized medicine. Finally, by providing detailed mechanistic annotation of mutations identified in genome sequencing studies, this proposal will address a fundamental NIH roadmap problem in translational medicine of converting genomic discoveries into therapeutic strategies. PUBLIC HEALTH RELEVANCE: Protein tyrosine kinases are a biomedically important class of proteins that are abnormally regulated in many human diseases including cancer, diabetes, and inflammatory disorders, to name but a few. They have been the focus of many drug discovery efforts and genome sequencing studies because of the therapeutic potential of targeting mutated tyrosine kinases for personalized therapy. By providing functional annotation of natural and disease mutations in tyrosine kinases, the proposed studies will accelerate the targeting of mutated tyrosine kinases for drug discovery and personalized therapy.",Functional Annotation of Natural and Disease Variants in Tryosine Kinases,9509468,R01GM114409,"['Allosteric Regulation ', ' Allosteric Site ', ' Antineoplastic Agents ', ' anticancer drug ', ' anticancer agent ', ' anti-cancer drug ', ' Tumor-Specific Treatment Agents ', ' Neoplastic Disease Chemotherapeutic Agents ', ' Cancer Drug ', ' Antineoplastics ', ' Antineoplastic Drugs ', ' Anti-Cancer Agents ', ' Biological Assay ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' Malignant Neoplasms ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' cell growth ', ' Cellular Growth ', ' Cellular Expansion ', ' Cell Survival ', ' Cell Viability ', ' Communities ', ' Diabetes Mellitus ', ' diabetes ', ' Disease ', ' Disorder ', ' Drug resistance ', ' resistant to Drug ', ' resistance to Drug ', ' drug resistant ', ' Pharmaceutical Preparations ', ' drug/agent ', ' Pharmaceutic Preparations ', ' Medication ', ' Drugs ', ' Foundations ', ' Genes ', ' Human Genome ', ' human whole genome ', ' Goals ', ' In Vitro ', ' Biological Models ', ' Model System ', ' Biologic Models ', ' Mutation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Names ', ' United States National Institutes of Health ', ' National Institutes of Health ', ' NIH ', ' Organism ', ' living system ', ' Peptides ', ' Phosphotransferases ', ' Transphosphorylases ', ' Phosphotransferase Gene ', ' Kinases ', ' Protein Kinase ', ' phosphorylase b kinase kinase ', ' hydroxyalkyl protein kinase ', ' glycogen synthase a kinase ', ' Kinase Family Gene ', ' ATP-protein phosphotransferase ', ' Protein Tyrosine Kinase ', ' tyrosyl protein kinase ', ' hydroxyaryl protein kinase ', ' Tyrosylprotein Kinase ', ' Tyrosine-Specific Protein Kinase ', ' Tyrosine-Protein Kinase Receptor EEK ', ' Tyrosine Kinase ', ' Protein Tyrosine Kinase EEK ', ' Ephrin Type-A Receptor 8 Precursor ', ' Ephrin Type-A Receptor 8 ', ' EPH-and ELK-Related Kinase ', ' EPH- and ELK-Related Tyrosine Kinase ', ' Proteins ', ' Publishing ', ' Recurrence ', ' Recurrent ', ' Signal Transduction ', ' biological signal transduction ', ' Signaling ', ' Signal Transduction Systems ', ' Intracellular Communication and Signaling ', ' Cell Signaling ', ' Cell Communication and Signaling ', ' Testing ', ' Tyrosine ', ' Protein-Serine-Threonine Kinases ', ' Threonine Kinase ', ' Serine/Threonine Protein Kinase Gene ', ' Serine-Threonine Kinases ', ' Serine Kinase ', ' Protein-Threonine Kinase ', ' Protein-Serine Kinase ', ' base ', ' improved ', ' Distal ', ' Site ', ' Variation ', ' Variant ', ' Active Sites ', ' Tyrosine Kinase Receptors ', ' Tyrosine Kinase Linked Receptors ', ' Transmembrane Receptor Protein Tyrosine Kinase ', ' Receptor Tyrosine Kinase Gene ', ' PTK Receptors ', ' Receptor Protein-Tyrosine Kinases ', ' insight ', ' Therapeutic ', ' Inflammatory ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Complex ', ' Pattern ', ' System ', ' molecular dynamics ', ' Molecular Dynamics Simulation ', ' mutant ', ' Structure ', ' novel ', ' Regulation ', ' Modeling ', ' Property ', ' Genomics ', ' drug discovery ', ' Pathogenicity ', ' Binding ', ' Molecular Interaction ', ' genome sequencing ', ' Address ', ' Drug Binding Site ', ' Mutate ', ' Ontology ', ' Tyrosine Kinase Domain ', ' Molecular ', ' computational framework ', ' computer framework ', ' Outcome ', ' 3D structure ', ' 3-dimensional structure ', ' 3-D structure ', ' three dimensional structure ', ' translational medicine ', ' human disease ', ' public health relevance ', ' personalized treatment ', ' personalized therapy ', ' personalization of treatment ', ' personalized medicine ', ' predictive assay ', ' predictive test ', ' ']",NIGMS,UNIVERSITY OF GEORGIA,R01,2018,300000,GA-10,0.253183175078445
"ADPKD: Disease Spectrum & Genotype-Phenotype Correlations Autosomal dominant polycystic kidney disease (ADPKD) is a common monoallelic disorder associated with progressive cyst development and resulting in end stage renal failure (ESRD) in 50% of patients by 60y. However, there is considerable phenotypic variability, extending from in utero onset to patients with adequate renal function into old age. Autosomal dominant polycystic liver disease (ADPLD), as traditionally defined, results in PLD with minimal renal cysts. Classically there have been considered two ADPKD genes, PKD1 and PKD2, encoding PC1 and PC2, and two ADPLD genes, PRKCSH and SEC63, but in the past few years greater genetic heterogeneity has been described, with nine genes now implicated overall. Recent data also indicates an overlap in etiology and pathogenesis associated with ADPKD and ADPLD, with the efficient biogenesis and localization of the PC-complex central to both disorders. During the last funding period we identified a novel gene, GANAB, which is associated with both disorders, where the encoded protein, GII is involved in the maturation and trafficking of PC1.  In this proposal we will take advantage of advances in next generation sequencing (NGS) methodologies, and large populations of ADPKD and ADPLD patients that have been assembled and screened for the classic genes, to hunt for novel genes for these disorders (Aim 1). The phenotype associated with these genes will be characterized (Aim 3) along with their mechanism of action (Aim 2). NGS methods will be perfected to screen the segmentally duplicated locus, PKD1, and to identify missed mutations at the known loci, including those present in just some cells due to mosaicism (Aim 1). The significance of many PKD1 nontruncating variants has been difficult to evaluate (classed as variants of unknown significance; VUS), but recently evidence that some are incompletely penetrant alleles partially explains phenotypic variability in PKD1 populations. In Aim 2 improved in silico predictions, in combination with machine learning, will improve the understanding of the pathogenicity and penetrance of VUS. A cellular assay of the biogenesis and trafficking of this PC-complex will also be employed to quantify the penetrance of VUS. The mechanism of pathogenesis will be explored in animal models with ultralow penetrant (ULP) Pkd1 or Pkd2 alleles. Employing the large clinically, imaging, and genetically well-defined populations phenotypic groupings of patients will be defined that will then be compared to the genic and PKD1 allelic groups (Aim 3). This iterative process will allow the Variant Score (VS) associated with each PKD1 VUS to be refined. In a separate population the revised VS, alone and in combination with clinical, functional, and imaging data, will be employed to generate a comprehensive, predictive algorithm for ADPKD (Aim 3). Disease modifiers to severe disease, via biallelic ADPKD, and due to alleles at other loci will also be identified and characterized in the cellular assay and in vivo in combination with the Pkd1 hypomorphic, RC model. The final aim will exploit the newly identified information that some PKD1 and PKD2 VUS are rescuable, folding mutations that in a maturation-fostering environment can traffic and function appropriately. A screening scheme based on the level of cell surface PC1 will be improved and new chaperone drugs specific for the PC complex will be sought in collaboration with Sanford Burnham Prebys. A second mutation group that will be explored therapeutically are nonsense mutations. A cellular assay for readthrough efficiency is being developed and will be used for screening. Identified chaperone or readthrough drugs will be tested in available mouse models. Overall this proposal will better explain the etiology and the genetic causes of phenotypic variability in ADPKD/ADPLD, develop better prognostic tools for individual selection of patients for treatment that are now becoming available, and explore allele based treatments for ADPKD. ADPKD and ADPLD are genetic diseases associated with cyst development and loss of function in the kidney and liver cysts, where the disease severity varies greatly between patients. Here we will identify new genes that cause these disorders and evaluate mutations in silico, in a cellular assay, and in whole animals to better predict the disease course in each patient. Treatment options associated with the type of individual patient mutations will also be explored, bringing individualized medicine to these diseases.",ADPKD: Disease Spectrum & Genotype-Phenotype Correlations,9522439,R01DK058816,"['Age ', ' ages ', ' Alleles ', ' Allelomorphs ', ' Animals ', ' Biogenesis ', ' Origin of Life ', ' Budgets ', ' Cells ', ' Cell Body ', ' Computer Simulation ', ' virtual simulation ', ' in silico ', ' computerized simulation ', ' computerized modeling ', ' computer based models ', ' computational simulation ', ' computational models ', ' computational modeling ', ' Mathematical Models and Simulations ', ' Mathematical Model Simulation ', ' Computerized Models ', ' Computer based Simulation ', ' Computer Models ', ' Cyst ', ' Disease ', ' Disorder ', ' Pharmaceutical Preparations ', ' drug/agent ', ' Pharmaceutic Preparations ', ' Medication ', ' Drugs ', ' Environment ', ' Family ', ' Genes ', ' Genotype ', ' Goals ', ' Kidney ', ' renal ', ' Kidney Urinary System ', ' Cystic kidney ', ' Renal Cyst ', ' Kidney Cyst ', ' Methods ', ' Methodology ', ' Mosaicism ', ' mosaic disorders ', ' Mutation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Patients ', ' Phenotype ', ' Proteins ', ' Role ', ' social role ', ' Signal Transduction ', ' biological signal transduction ', ' Signaling ', ' Signal Transduction Systems ', ' Intracellular Communication and Signaling ', ' Cell Signaling ', ' Cell Communication and Signaling ', ' Testing ', ' Proprotein Convertase 2 ', ' Proinsulin Convertase 2 ', ' Prohormone Convertase 2 ', ' PC2 Protein ', ' PC2 Prohormone Convertase ', ' PC2 Endoprotease ', ' PC2 ', ' Neuroendocrine Convertase PC2 ', ' Endopeptidase PC2 ', ' Autosomal Dominant Polycystic Kidney ', ' Dominant Polycystic Kidney Disease ', ' Autosomal Dominant Polycystic Kidney Disease ', ' Adult Polycystic Kidney Disease ', ' ADPKD ', ' Proprotein Convertase 1 ', ' Proprotein Convertase SPC3 ', ' Proinsulin Convertase 1 ', ' Prohormone Convertase 3 ', ' Prohormone Convertase 1 ', ' PC3 Prohormone Convertase ', ' PC3 Endoprotease ', ' PC1 Prohormone Convertase ', ' PC1 Endoprotease ', ' PC1 ', ' Neuroendocrine Convertase PC1 ', ' Data Set ', ' Dataset ', ' Fibrocystic liver disease ', ' Cystic disease of liver ', ' Congenital cystic liver disease ', ' polycystic liver disease ', ' protein folding ', ' base ', ' dosage ', ' improved ', ' Hepatic ', ' Clinical ', ' Variation ', ' Variant ', ' Biological ', ' Biochemical ', ' Hereditary Mutation ', ' Germline Mutation ', ' Germ-Line Mutation ', ' prognostic ', ' kidney function ', ' Renal function ', ' insight ', ' Individual ', ' Fostering ', ' Patient Selection ', ' Genetic Heterogeneity ', ' Chaperone ', ' Molecular Chaperones ', ' Funding ', ' Liver Cyst ', ' Hepatic Cyst ', ' Collaborations ', ' Therapeutic ', ' Genetic ', ' Diagnostic ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Knowledge ', ' Severities ', ' Complex ', ' Event ', ' Severity of illness ', ' disease severity ', ' Penetrance ', ' PRKCSH protein ', ' protein kinase substrate 80KD protein, heavy chain ', ' protein kinase substrate 80K-H ', ' PRKCSH ', ' G19P1 protein ', ' FGF-stimulated p90 ', ' 80K-H protein ', ' Nonsense Mutation ', ' non-sense mutation ', ' mutant ', ' Animal Model ', ' model organism ', ' model of animal ', ' Animal Models and Related Studies ', ' trafficking ', ' novel ', ' Cell surface ', ' Pathogenesis ', ' Modeling ', ' Pathogenicity ', ' End stage renal failure ', ' End-Stage Renal Disease ', ' End-Stage Kidney Disease ', ' ESRD ', ' Etiology ', ' disease causation ', ' causation ', ' Causality ', ' Defect ', ' Data ', ' in vitro Assay ', ' in vivo ', ' cell assay ', ' Cellular Assay ', ' physiological imaging ', ' Physiologic Imaging ', ' Functional Imaging ', ' Other Genetics ', ' Scheme ', ' Process ', ' groupings ', ' Grouping ', ' developmental ', ' Development ', ' imaging ', ' Image ', ' in utero ', ' early onset ', ' disease phenotype ', ' Population ', ' murine model ', ' mouse model ', ' loss of function ', ' treatment development ', ' intervention development ', ' develop therapy ', ' therapy development ', ' nextgen sequencing ', ' next gen sequencing ', ' NGS system ', ' NGS Method ', ' next generation sequencing ', ' exome-seq ', ' exome sequencing ', ' screening ', ' unique treatment ', ' tailored treatment ', ' tailored therapy ', ' tailored medical treatment ', ' individualized treatment ', ' individualized therapy ', ' individualized patient treatment ', ' customized treatment ', ' customized therapy ', ' individualized medicine ', ' variant of undetermined significance ', ' variant of uncertain significance ', ' variant of uncertain clinical significance ', ' unclassified variant ', ' variant of unknown significance ', ' prognostic tool ', ' mutation scanning ', ' mutation screening ', ' individual patient ', ' molecular diagnostics ', ' predictor algorithm ', ' predictive algorithm ', ' prediction algorithm ', ' genetic disorder ', ' genetic condition ', ' Genetic Diseases ', ' ']",NIDDK,MAYO CLINIC ROCHESTER,R01,2018,510292,MN-01,0.10158678176448475
"High-resolution map of human germline mutation patterns and inference of mutagenic mechanisms     DESCRIPTION (provided by applicant): Mutations are the ultimate source of genetic variation and one of the driving forces of evolution. Both the absolute mutation rate and the relative rate among mutation subtypes fluctuate along the genome, affected by adjacent nucleotide motifs and local features such as GC content and replication timing. Characterizing regional variation of mutation patterns is critical for understanding genome evolution and to identify variants causing genetic diseases. However, mutation rate and molecular spectrum are difficult to measure at high resolution, genomewide, and in an unbiased fashion. Estimates based on common variants and between- species substitutions are confounded by natural selection, population demographic history, and biased gene conversion (BGC). Methods relying on incidence rates of monogenic diseases or finding de novo variants by trio sequencing can inform global trends, but do not provide sufficient data to assess fine-scale local parameters. This study will overcome these limitations by using the extremely rare variants (ERVs) as a new data source to characterize patterns of recent germline variation in humans. ERVs, defined in this study as singletons in 30,000 samples, are becoming available via large-scale whole-genome sequencing (WGS) of population samples. Unlike common variants or substitutions, ERVs arose very recently and are largely unaffected by selection, BGC, etc. We will analyze 200-300 million singleton variants observed in 30,000 subjects at 20-30X coverage. The regional distribution of ERV subtypes will establish a quantitative atlas of the rate and spectrum of human germline mutations mostly unaltered by selection. We will share this resource with the research community and apply it to determine the impact of local genomic features and epigenomic attributes. We will use the systematic departures between ERVs and variants of higher frequencies (polymorphisms and substitutions) to infer local effects of selection, and this may uncover hitherto unknown functional regions of the genome. By comparing mutation signatures in ERVs with those in somatic variations observed in diverse cancers we will attribute distinct mutational signatures to known biochemical processes and thus infer the major contributors to new germline mutations in the human genome. This subtype-specific atlas will also be used to predict the probability of observing every possible single-base mutation in the genome, thus facilitating the interpretation of candidate causal variants of human diseases. We will assess mutation pattern differences among European Americans, African Americans and Latinos, and seek to discover genetic modifiers of germline mutation rate by finding functionally damaging mutations that show increased ERV counts in the surrounding genomic region, potentially identifying both known and previous unknown ""mutator"" genes that play a role in transmission fidelity in humans. This research will provide an essential resource to study the genesis and maintenance of germline mutations in humans. Understanding such a fundamental process will be the basis for a deeper understanding of human evolution and diseases. PUBLIC HEALTH RELEVANCE: We will study the patterns of inherited mutations in humans using approximately 250 million extremely rare DNA variants in human populations. Our results will allow the prediction of the rate of new mutations at every site in the genome based on features of the surrounding DNA sequence, thus providing a common resource to study the arrival and maintenance of mutations in humans. Understanding such a basic process is important for answering fundamental questions in human evolution, the cause of inherited diseases, and the role of DNA abnormality in cancer and aging.",High-resolution map of human germline mutation patterns and inference of mutagenic mechanisms,9494629,R01GM118928,"['Affect ', ' Aging ', ' Algorithms ', ' Alleles ', ' Allelomorphs ', ' Atlases ', ' Biological Factors ', ' Biologic Factor ', ' Biology ', ' Malignant Neoplasms ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Child ', ' youngster ', "" childrens' "", ' children ', ' Children (0-21) ', ' Child Youth ', ' 0-11 years old ', ' Chromatin ', ' Communities ', ' Data Analyses ', ' data interpretation ', ' Data Analysis ', ' Data Sources ', ' Demographic Factors ', ' Disease ', ' Disorder ', ' DNA ', ' Deoxyribonucleic Acid ', ' Evolution ', ' Family ', ' Foundations ', ' Future ', ' Gene Conversion ', ' Genes ', ' Genome ', ' Human Genome ', ' human whole genome ', ' Hereditary Disease ', ' inherited genetic disorder ', ' inherited genetic disease ', ' inherited diseases ', ' inborn error ', ' hereditary disorder ', ' Inherited disorder ', ' Inborn Genetic Diseases ', ' Recording of previous events ', ' History ', ' Human ', ' Modern Man ', ' Human Genetics ', ' Incidence ', ' Maintenance ', ' Maps ', ' Methods ', ' Mutation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Nucleotides ', ' Parents ', ' Play ', ' Genetic Polymorphism ', ' polymorphism ', ' Probability ', ' Genetic Recombination ', ' Recombination ', ' DNA Recombination ', ' Research ', ' Resources ', ' Research Resources ', ' Rest ', ' Role ', ' social role ', ' Selection Bias ', ' Technology ', ' Tissues ', ' Body Tissues ', ' Genetic Variation ', ' Genetic Diversity ', ' Weight ', ' Generations ', ' Measures ', ' Mutagenesis ', ' Mutagenesis Molecular Biology ', ' Genetics-Mutagenesis ', ' African American ', ' black American ', ' Black Populations ', ' Afroamerican ', ' Afro American ', ' Latino ', ' Natural Selections ', ' Data Set ', ' Dataset ', ' DNA Sequence ', ' base ', ' density ', ' improved ', ' Site ', ' Variation ', ' Variant ', ' Hereditary Mutation ', ' Germline Mutation ', ' Germ-Line Mutation ', ' Individual ', ' European ', ' Biological Function ', ' Biological Process ', ' world wide web ', ' web ', ' WWW ', ' Internet ', ' Genetic ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Frequencies ', ' Inherited ', ' Hereditary ', ' Complex ', ' Dependence ', ' Source ', ' Pattern ', ' Techniques ', ' Somatic Mutation ', ' American ', ' Environmental Risk Factor ', ' environmental risk ', ' Environmental Factor ', ' Positioning Attribute ', ' Position ', ' genetic analysis ', ' Genetic analyses ', ' Modeling ', ' Sampling ', ' repository ', ' Genomics ', ' Guanine + Cytosine Composition ', ' Guanine + Cytosine Content ', ' GC Content ', ' GC Composition ', ' G+C Content ', ' G+C Compositions ', ' Pathogenicity ', ' Mismatch Repair ', ' Post-Replication Mismatch Repair ', ' genome sequencing ', ' Address ', ' Biochemical Process ', ' Data ', ' Resolution ', ' Resource Sharing ', ' genomic region ', ' Genomic Segment ', ' Transmission ', ' transmission process ', ' trend ', ' Molecular ', ' Process ', ' epigenomics ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' genetic variant ', ' Population ', ' driving force ', ' human disease ', ' prototype ', ' public health relevance ', ' genomewide ', ' genome scale ', ' genome-wide ', ' sharing data ', ' nextgen sequencing ', ' next gen sequencing ', ' NGS system ', ' NGS Method ', ' next generation sequencing ', ' rare allele ', ' rare variant ', ' High-Throughput Sequencing ', ' High-Throughput Nucleotide Sequencing ', ' single-gene disorder ', ' single-gene disease ', ' monogenic disorder ', ' monogenic disease ', ' Mendelian genetic disorder ', ' Mendelian disease ', ' Mendelian disorder ', ' driver mutation ', ' actionable variants ', ' actionable mutation ', ' full genome ', ' entire genome ', ' whole genome ', ' genetic disorder ', ' genetic condition ', ' Genetic Diseases ', ' human model ', ' ']",NIGMS,UNIVERSITY OF MICHIGAN AT ANN ARBOR,R01,2018,300473,MI-12,0.19527015365396436
"Predicting Transcriptional and Epigenetic Networks in Cancer from Sequencing Data Limitless replicative potential is a key hallmark of cancer and critically depends on telomere maintenance. Many cancers thus aberrantly reactivate the telomerase reverse transcriptase (TERT), a catalytic subunit of the telomerase complex that elongates telomere. It has been recently discovered that this common path to immortality in multiple cancers is through two activating point mutations in the TERT promoter (TERTp), found in more than 50 different cancer types, often at strikingly high frequencies, e.g. roughly 83% in glioblastomas (GBM) and 71% in melanomas. In the previous funding period, the PI has identified the molecular function of these highly recurrent mutations, demonstrating that the transcription factor (TF) GABP binds the mutant TERTp with exquisite specificity, but not the wild-type TERTp. The high prevalence of TERTp mutations across multiple cancer types and the selectivity of GABP recruitment to mutant TERTp thus provide an unprecedented opportunity for treating a large number of cancer patients with minimal toxicity to healthy cells. Despite the clear significance of this opportunity, however, several important questions surrounding the molecular functions and modulators of TERTp mutations remain poorly understood, hindering the development of effective and safe therapeutic strategies.  Our long-term goal is to establish a rigorous computational framework for understanding the aberrant transcriptional and epigenetic networks in cancers and to apply the resulting knowledge to devise novel therapeutic strategies that account for the genetic background of individual patients and that can a priori predict and avoid potential resistance mechanisms. The objective of our current renewal proposal is to develop powerful computational methods for transforming our knowledge about the non-coding TERTp mutations into an effective and safe molecular target. At the same time, the resulting methods will help resolve several outstanding challenges in the field of transcriptional gene regulation and have broad applications in cancer genomics. We will accomplish our objective my pursuing the following Aims: (1) Develop and test a computational framework for inferring sequence features that determine the distinct and shared binding patterns of paralogous TFs; (2) Develop and validate integrative tools for discovering the molecular basis of genetic interactions between germline variations and oncogenic mutations; (3) Develop and apply computational methods for studying the role of DNA helical phase between adjacent binding motifs in recruiting ETS factors to chromatin; (4) Perform a systematic genomic characterization of the effects of knocking out GABPB1L in TERTp-mutant cancer cells and healthy cells. The results of this proposal will have a broad impact on cancer research by providing powerful tools for studying paralogous oncogenic TFs and revealing novel insights into a highly promising therapeutic strategy. The proposed research will provide computational and bioinformatic resources for studying the binding pattern of paralogous oncogenic transcription factors. It will provide a computational framework for inferring the function of non-coding regulatory mutations and studying their interaction with common genetic variants. As an important application, we will systematically analyze a novel therapeutic strategy that has the potential to treat effectively a large number of patients across multiple cancer types harboring the recently discovered TERT promoter mutations.",Predicting Transcriptional and Epigenetic Networks in Cancer from Sequencing Data,9472091,R01CA163336,"['Binding Sites ', ' Reactive Site ', ' Combining Site ', ' Malignant Neoplasms ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Cells ', ' Cell Body ', ' Chromatin ', ' Computing Methodologies ', ' computing method ', ' computer methods ', ' computational methods ', ' computational methodology ', ' DNA ', ' Deoxyribonucleic Acid ', ' Drug resistance ', ' resistant to Drug ', ' resistance to Drug ', ' drug resistant ', ' Family ', ' Gene Expression Regulation ', ' Gene Regulation Process ', ' Gene Regulation ', ' Gene Action Regulation ', ' Genome ', ' Glioblastoma ', ' spongioblastoma multiforme ', ' glioblastoma multiforme ', ' Grade IV Astrocytoma ', ' Grade IV Astrocytic Tumor ', ' Grade IV Astrocytic Neoplasm ', ' Goals ', ' knowledge of results ', ' melanoma ', ' Malignant Melanoma ', ' Methods ', ' Mutation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Patients ', ' Recurrence ', ' Recurrent ', ' Research ', ' RNA-Directed DNA Polymerase ', ' Revertase ', ' Reverse Transcriptase ', ' RNA-Dependent DNA Polymerase ', ' RNA Transcriptase ', ' EC 2.7.7.49 ', ' Role ', ' social role ', ' Specificity ', ' Testing ', ' Time ', ' transcription factor ', ' Transcription factor genes ', ' Transcription Factor Proto-Oncogene ', ' General Transcription Factors ', ' General Transcription Factor Gene ', ' Basal transcription factor genes ', ' Basal Transcription Factor ', ' Genetic Transcription ', ' Transcription ', ' RNA Expression ', ' Gene Transcription ', ' Work ', ' c-myc Genes ', ' v-myc Avian Myelocytomatosis Viral Oncogene Cellular Homolog ', ' cmyc ', ' c myc ', ' telomere ', ' Family member ', ' Mediating ', ' promoter ', ' promotor ', ' Telomerase ', ' Point Mutation ', ' base ', ' Phase ', ' Variation ', ' Variant ', ' Link ', ' insight ', ' Individual ', ' Funding ', ' Therapeutic ', ' Genetic ', ' cancer cell ', ' Malignant Cell ', ' tool ', ' Nature ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Knowledge ', ' Frequencies ', ' Complex ', ' Pattern ', ' Techniques ', ' Somatic Mutation ', ' dimer ', ' mutant ', ' Protein Isoforms ', ' Isoforms ', ' Toxic effect ', ' Toxicities ', ' novel ', ' member ', ' Untranslated RNA ', ' noncoding ', ' Nontranslated RNA ', ' Noncoding RNA ', ' Non-Coding RNA ', ' Non-Coding ', ' Functional RNA ', ' Genomics ', ' Telomere Maintenance ', ' Transcriptional Regulation ', ' Transcriptional Control ', ' Transcription Regulation ', ' Binding ', ' Molecular Interaction ', ' TERT gene ', ' telomerase catalytic subunit ', ' Telomere Reverse Transcriptase ', ' TCS1 ', ' EST2 ', ' Address ', ' DNA Sequence Alteration ', ' genomic alteration ', ' Sequence Alteration ', ' Genetic mutation ', ' DNA mutation ', ' DNA Alteration ', ' Data ', ' High Prevalence ', ' Molecular Target ', ' Cancer Patient ', ' Epigenetic Mechanism ', ' Epigenetic Change ', ' Epigenetic ', ' Epigenetic Process ', ' Validation ', ' Molecular ', ' Knockout ', ' Knock-out ', ' resistant mechanism ', ' resistance mechanism ', ' developmental ', ' Development ', ' oncogenomics ', ' cancer genomics ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' genetic variant ', ' cancer research ', ' anti-cancer research ', ' anticancer research ', ' computational framework ', ' computer framework ', ' cancer type ', ' Oncogenic ', ' computational resources ', ' computing resources ', ' novel therapy ', ' novel drugs ', ' novel drug treatments ', ' next generation therapeutics ', ' new therapy ', ' new therapeutics ', ' new drugs ', ' new drug treatments ', ' novel therapeutics ', ' therapeutic target ', ' therapeutic response ', ' response to treatment ', ' treatment response ', ' genomewide ', ' genome scale ', ' genome-wide ', ' individual patient ', ' recruit ', ' bioinformatics resource ', ' deep learning ', ' ']",NCI,UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN,R01,2018,327546,IL-13,0.14913333291555572
"Computational evaluation of the causal role of somatic mutations in human aging Project Abstract Although genome instability has long been considered as one of the major causal factors of aging, little is known about the actual number of genome alterations per cell and their effects on aging organisms, most notably humans. In the research proposed here I will take a single cell approach to identify the most common types of somatic mutations, i.e., base substitutions, small INDELS, copy number variation, genome structural variation and retrotranspositions, in human B lymphocytes as a function of age. The overarching goal is then to estimate functional effects of these DNA mutations accumulated during human aging in this particular cell type, which will also serve as a model for studying somatic mutations and their consequences in other cell types. This could never be tested before, because it was never possible to analyze random somatic mutations in a tissue by sequencing bulk DNA from that tissue (mutations are low- abundant), I will achieve this goal by utilizing a new, single-cell, whole genome sequencing (SCWGS) protocol that we developed. In this project I will focus on human B lymphocytes from individuals varying in age from about 30 to over 100 years and determine the genome-wide frequency and location of the different types of mutations in multiple cells from each individual (Aim 1). Preliminary results already show a significant increase of both base substitution mutations and CNVs with age, with a substantial number of these mutations in B cell genomic regions that are potentially functional. Hence, in Aim 2 I will predict the actual functional effects of these potentially functional, age-related mutations using machine learning approaches and integrative network analysis. Finally, in Aim 3 I will empirically test these predictions as to whether the mutation loads observed affect B cell's ability of response to stimulus. Hence, to test the long-standing hypothesis of genome instability as a causal factor in aging ,I will determine age-related mutations in single cells at four levels: (1) number of mutations, mutation spectra and genome distribution in individual cells; (2) potential functional effects of individual mutations, i.e., non-synonymous mutations in exons and mutations in gene regulatory regions; (3) mutations collectively affecting the gene regulatory network; and (4) relationship between mutation load and B cell activation status. In summary, the results of the proposed project will, for the first time uncover possible direct functional effects of somatic mutations on cellular function. Project Narrative Genome instability is considered as one of the major factors of aging and age-related diseases. This research aims to study somatic DNA mutations in normal blood cells (B lymphocytes) of humans of different ages and evaluate the functional effect of these mutations. It will dramatically improve the knowledge of DNA mutations in aging and deepen the understanding of genome instability as a basic aging mechanism in human.",Computational evaluation of the causal role of somatic mutations in human aging,9527264,K99AG056656,"['Affect ', ' Age ', ' ages ', ' Elderly ', ' senior citizen ', ' older person ', ' older adult ', ' later life ', ' late life ', ' geriatric ', ' elders ', ' advanced age ', ' Aging ', ' B-Lymphocytes ', ' Bursa-Equivalent Lymphocyte ', ' Bursa-Dependent Lymphocytes ', ' B-cell ', ' B-Cells ', ' B cells ', ' B cell ', ' B blood cells ', ' Binding Sites ', ' Reactive Site ', ' Combining Site ', ' Blood Cells ', ' Peripheral Blood Cell ', ' Cell Count ', ' Cell Number ', ' Cell physiology ', ' Subcellular Process ', ' Cellular Process ', ' Cellular Physiology ', ' Cellular Function ', ' Cell Process ', ' Cell Function ', ' Cells ', ' Cell Body ', ' Centenarian ', ' centenarian human (100+) ', ' 100+ years old ', ' Deoxyribonuclease I ', ' Thymonuclease ', ' Pancreatic DNase ', ' DNase I ', ' DNA Endonuclease ', ' Disease ', ' Disorder ', ' DNA ', ' Deoxyribonucleic Acid ', ' DNA Damage ', ' DNA Injury ', ' DNA Transposable Elements ', ' Transposable Elements ', ' DNA Repair ', ' Unscheduled DNA Synthesis ', ' DNA Damage Repair ', ' Exons ', ' Genes ', ' Regulator Genes ', ' trans acting element ', ' regulatory gene ', ' Transcriptional Regulatory Elements ', ' Genome ', ' Goals ', ' Human ', ' Modern Man ', ' Hypersensitivity ', ' Allergy ', ' Immunization ', ' Immunostimulation ', ' Immunological Stimulation ', ' Immunological Sensitization ', ' Immunologic Stimulation ', ' Immunologic Sensitization ', ' Laboratories ', ' Lead ', ' heavy metal lead ', ' heavy metal Pb ', ' Pb element ', ' Learning ', ' Mentors ', ' Methods ', ' Study models ', ' Mutation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Nucleotides ', ' Organism ', ' living system ', ' Proteins ', ' Nucleic Acid Regulatory Sequences ', ' genetic regulatory element ', ' Regulatory Regions ', ' Nucleic Acid Regulator Regions ', ' Research ', ' RNA ', ' Ribonucleic Acid ', ' RNA Gene Products ', ' Non-Polyadenylated RNA ', ' Role ', ' social role ', ' Software Tools ', ' Computer Software Tools ', ' Testing ', ' Time ', ' Tissues ', ' Body Tissues ', ' transcription factor ', ' Transcription factor genes ', ' Transcription Factor Proto-Oncogene ', ' General Transcription Factors ', ' General Transcription Factor Gene ', ' Basal transcription factor genes ', ' Basal Transcription Factor ', ' Enhancers ', ' promoter ', ' promotor ', ' base ', ' cross-link ', ' crosslink ', ' improved ', ' Site ', ' repair ', ' repaired ', ' Variation ', ' Variant ', ' Evaluation ', ' Stimulus ', ' Individual ', ' pathophysiology ', ' Physiopathology ', ' Dysfunction ', ' Functional disorder ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Knowledge ', ' dietary restriction ', ' restricted diet ', ' diet restriction ', ' Frequencies ', ' Protocols documentation ', ' Protocol ', ' Source ', ' cell type ', ' Location ', ' Locus Control Region ', ' Somatic Mutation ', ' repair enzyme ', ' repair endonuclease ', "" 5' Untranslated Regions "", ' mRNA Leader Sequences ', "" 5'UTR "", "" 3' Untranslated Regions "", "" 3'UTR "", ' DNA amplification ', ' Somatic Cell ', ' Mutation Analysis ', ' Code ', ' Coding System ', ' Pathway Analysis ', ' Network Analysis ', ' response ', ' theories ', ' Genomic Instability ', ' Genome Instability ', ' RNA amplification ', ' B-Cell Activation ', ' genome sequencing ', ' Defect ', ' Copy Number Polymorphism ', ' copy number variation ', ' copy number variant ', ' DNA Replication Damage ', ' DNA Replicating Damage ', ' DNA Sequence Alteration ', ' genomic alteration ', ' Sequence Alteration ', ' Genetic mutation ', ' DNA mutation ', ' DNA Alteration ', ' Data ', ' Mutation Spectra ', ' Retrotransposition ', ' Cancer Cause ', ' Cancer Etiology ', ' Collecting Cell ', ' genomic region ', ' Genomic Segment ', ' Process ', ' age dependent ', ' age related ', ' insertion/deletion ', ' insertion-deletion mutation ', ' insertion-deletion ', ' indel ', ' insertion/deletion mutation ', ' genomewide ', ' genome scale ', ' genome-wide ', ' single cell sequencing ', ' Cas nuclease technology ', ' CRISPR/Cas9 technology ', ' CRISPR/Cas9 ', ' CRISPR/Cas method ', ' CRISPR-based tool ', ' CRISPR-based technology ', ' CRISPR-based technique ', ' CRISPR-based method ', ' CRISPR-CAS-9 ', ' CRISPR technology ', ' CRISPR technique ', ' CRISPR methodology ', ' CRISPR method ', ' CRISPR/Cas technology ', ' full genome ', ' entire genome ', ' whole genome ', ' single cell technology ', ' ']",NIA,"ALBERT EINSTEIN COLLEGE OF MEDICINE, INC",K99,2018,40760,NY-14,0.2879436696139564
"A novel human T-cell platform to define biological effects of genome editing PROJECT SUMMARY Genome editing technologies have extraordinary potential as new genomic medicines that address underlying genetic causes of human disease; however, it remains challenging to predict their long-term safety, because we do not know the consequences of potential side effects of genome editing such as off-target mutations or immunogenicity. Our long-term goal is to understand and predict such unintended biological effects to advance the development of safe and effective therapies. T-cells are an ideal cellular model because: 1) they are highly relevant as the most widely used cells for development of therapeutic genome editing strategies (such as cell- based treatments for HIV and cancer) and 2) mature T-cells encode a diverse T-cell receptor repertoire that can be exploited as built-in cellular barcodes for quantifying clonal expansion or depletion in response to specific treatments. We, therefore, propose the following specific aims: 1) to predict which unintended editing sites have biological effects on human T-cells by integrating large-scale genome-wide activity and epigenomic profiles with state-of-the-art deep learning models and 2) to develop a human primary T-cell platform to detect functional effects of genome editing by measuring clonal representation, off-target mutation frequencies, immunogenicity, or gene expression. If successful, our experimental and predictive framework will profoundly increase confidence in the safety of the next generation of promising genome editing therapies. PROJECT NARRATIVE Genome editing technologies have extraordinary potential as the basis of new genomic medicines that address the underlying genetic causes of human disease; however, it is challenging to predict their long-term safety, because we do not know the consequences of potential unintended side effects of genome editing such as off- target mutations or immunogenicity. To define the biological effects of genome editing strategies, we will develop a human primary T-cell platform to sensitively detect functional effects coupled with an empirically-trained artificial intelligence models to predict them. Together, our platform will significantly improve confidence in safety assessments of promising genome editing therapeutics.",A novel human T-cell platform to define biological effects of genome editing,9678132,U01HL145793,"['Affect ', ' Epitopes ', ' Binding Determinants ', ' Antigenic Determinants ', ' Artificial Intelligence ', ' Machine Intelligence ', ' Computer Reasoning ', ' Biological Assay ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' Malignant Neoplasms ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Cell physiology ', ' Subcellular Process ', ' Cellular Process ', ' Cellular Physiology ', ' Cellular Function ', ' Cell Process ', ' Cell Function ', ' Cells ', ' Cell Body ', ' Chromatin ', ' Engineering ', ' Gene Expression ', ' gene therapy ', ' genetic therapy ', ' gene-based therapy ', ' Genetic Intervention ', ' Gene Transfer Clinical ', ' DNA Therapy ', ' Genes ', ' Human Genome ', ' human whole genome ', ' Goals ', ' HIV ', ' Virus-HIV ', ' Lymphadenopathy-Associated Virus ', ' LAV-HTLV-III ', ' Human Immunodeficiency Viruses ', ' Acquired Immunodeficiency Syndrome Virus ', ' Acquired Immune Deficiency Syndrome Virus ', ' AIDS Virus ', ' Human ', ' Modern Man ', ' Human Genetics ', ' Immunologic Deficiency Syndromes ', ' immunodeficiency ', ' immune deficiency disorder ', ' hypoimmunity ', ' Immunological Deficiency Syndromes ', ' Immunodeficiency Syndrome ', ' Immunodeficiency Disorder ', ' In Vitro ', ' Maps ', ' Methods ', ' Mutation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Phenotype ', ' Proto-Oncogenes ', ' protooncogene ', ' c-ONC ', ' Cellular Oncogene ', ' T-Cell Receptor ', ' Receptors, Antigen, T-Cell ', ' Major Histocompatibility Complex Receptor ', ' MHC Receptor ', ' Ribonucleoproteins ', ' Safety ', ' Standardization ', ' Streptococcus pyogenes ', ' Streptococcus Group A ', ' S.pyogenes ', ' S. pyogenes ', ' S pyogenes ', ' T-Lymphocyte ', ' thymus derived lymphocyte ', ' Thymus-Dependent Lymphocytes ', ' T-Cells ', ' Technology ', ' Testing ', ' Genetic Transcription ', ' Transcription ', ' RNA Expression ', ' Gene Transcription ', ' Genetic Variation ', ' Genetic Diversity ', ' cytokine ', ' Measures ', ' Site-Directed Mutagenesis ', ' Targeted Modification ', ' Targeted DNA Modification ', ' Site-Specific Mutagenesis ', ' Organizational Change ', ' base ', ' improved ', ' Site ', ' Benign ', ' Variation ', ' Variant ', ' Biological ', ' Biochemical ', ' Training ', ' Therapeutic ', ' Genetic ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Peptide Library ', ' DNA Methylation ', ' Frequencies ', ' Inherited ', ' Hereditary ', ' Complex ', ' genotoxicity ', ' Peripheral Blood Mononuclear Cell ', ' PBMC ', ' novel ', ' Modeling ', ' response ', ' immunogenic ', ' functional genomics ', ' Adverse effects ', ' treatment adverse effect ', ' therapy adverse effect ', ' side effect ', ' Treatment Side Effects ', ' Genomics ', ' Bioinformatics ', ' Bio-Informatics ', ' histone modification ', ' Address ', ' Detection ', ' Mature T-Lymphocyte ', ' Mature T-Cell ', ' Regulatory Element ', ' Retroviral Vector ', ' Retrovirus Vector ', ' in vivo ', ' Clonal Expansion ', ' epigenomics ', ' Advanced Development ', ' immunogenicity ', ' next generation ', ' Outcome ', ' Population ', ' Coupled ', ' therapeutic gene ', ' Oncogenic ', ' Cellular model ', ' Cell model ', ' human disease ', ' novel therapy ', ' novel drugs ', ' novel drug treatments ', ' next generation therapeutics ', ' new therapy ', ' new therapeutics ', ' new drugs ', ' new drug treatments ', ' novel therapeutics ', ' therapeutic agent development ', ' therapeutic development ', ' effective treatment ', ' effective therapy ', ' genomewide ', ' genome scale ', ' genome-wide ', ' safety testing ', ' comparative genomics ', ' T cell response ', ' adverse consequence ', ' adverse outcome ', ' RNAseq ', ' RNA sequencing ', ' RNA Seq ', ' transcriptome sequencing ', ' genomic editing ', ' genome editing ', ' learning method ', ' learning activity ', ' learning strategy ', ' Genomic medicine ', ' adaptive immune response ', ' genetic disorder ', ' genetic condition ', ' Genetic Diseases ', ' TCR repertoire ', ' T-cell receptor repertoire ', ' therapeutic genome editing ', ' deep learning ', ' ']",NHLBI,ST. JUDE CHILDREN'S RESEARCH HOSPITAL,U01,2018,651251,TN-09,0.09653223666615235
"The Evolution of Gene Regulation and Human Disease PROJECT SUMMARY Genetic variants that disrupt the functionality of regulatory sequences, and thereby alter gene expression levels, are major contributors to both evolutionary divergence between species and differences in risk for complex disease among humans. However, due to the complexity of the gene regulatory programs encoded in mammalian genomes and their rapid turnover between species, evaluating the function of non-protein-coding mutations is challenging. This is a major roadblock to tracing the evolution of human-specific biology. In addition, since the majority of disease-associated variants are non-coding, it impairs our ability to map the genetics of complex disease.  The long-term mission of my lab is to interpret the complex gene regulatory programs encoded in the human genome and accurately model the effects of genetic mutations to these elements on phenotypes relevant to disease and human evolution. We work toward these goals by integrating cutting-edge machine learning, statistical modeling of evolution, and the analysis of genotypes and phenotypes from large-scale clinical biobanks. In particular, my lab is uniquely well positioned to build on our previous work to address the following fundamental questions:  1. How have evolutionary transitions on the human-lineage modified the genomein particular gene  regulatory programsto produce human-specific biology? And how do these modifications relate to  human-specific disease risk?  2. What are the combinatorial rules underlying how TF binding patterns specify precise control of gene  regulation? And how do these gene regulatory programs evolve between species?  3. How do genetic and epigenetic mechanisms interact to specify the dynamic gene regulatory programs  that drive cellular development? And how are these programs perturbed in disease?  4. How can we interpret non-protein-coding mutations identified in patient genomes to inform treatment  and preventative care? Our work will produce much-needed methods for understanding the effects of mutations to gene regulatory regions and identify mutations responsible for differences in disease risk between human populations. PROJECT NARRATIVE The genetic mutations that distinguish humans from other great apes and that influence risk for complex disease are mostly found outside of genes. Many of these mutations influence when and where genes are expressed. However, we do not know how to interpret the effects of most such mutations on gene regulation, disease risk, or human evolution, we will develop computational models that leverage machine learning, evolutionary patterns, and large-scale clinical biobanks to identify mutations that disrupt proper control of genes and lead to disease.",The Evolution of Gene Regulation and Human Disease,9486376,R35GM127087,"['Biology ', ' Computer Simulation ', ' virtual simulation ', ' in silico ', ' computerized simulation ', ' computerized modeling ', ' computer based models ', ' computational simulation ', ' computational models ', ' computational modeling ', ' Mathematical Models and Simulations ', ' Mathematical Model Simulation ', ' Computerized Models ', ' Computer based Simulation ', ' Computer Models ', ' Disease ', ' Disorder ', ' Elements ', ' Evolution ', ' Gene Expression ', ' Gene Expression Regulation ', ' Gene Regulation Process ', ' Gene Regulation ', ' Gene Action Regulation ', ' Genes ', ' Regulator Genes ', ' trans acting element ', ' regulatory gene ', ' Transcriptional Regulatory Elements ', ' Genome ', ' Human Genome ', ' human whole genome ', ' Genotype ', ' Goals ', ' Human ', ' Modern Man ', ' Lead ', ' heavy metal lead ', ' heavy metal Pb ', ' Pb element ', ' Maps ', ' Methods ', ' Mission ', ' Statistical Models ', ' statistical linear models ', ' statistical linear mixed models ', ' Probability Models ', ' Probabilistic Models ', ' Mutation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Patients ', ' Phenotype ', ' Pongidae ', ' great ape ', ' Apes ', ' Nucleic Acid Regulatory Sequences ', ' genetic regulatory element ', ' Regulatory Regions ', ' Nucleic Acid Regulator Regions ', ' Risk ', ' Work ', ' species difference ', ' Clinical ', ' Specified ', ' Specific qualifier value ', ' Variation ', ' Variant ', ' Genetic ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' programs ', ' Complex ', ' Pattern ', ' disorder risk ', ' disease risk ', ' Positioning Attribute ', ' Position ', ' Code ', ' Coding System ', ' Modeling ', ' Untranslated RNA ', ' noncoding ', ' Nontranslated RNA ', ' Noncoding RNA ', ' Non-Coding RNA ', ' Non-Coding ', ' Functional RNA ', ' Binding ', ' Molecular Interaction ', ' Address ', ' DNA Sequence Alteration ', ' genomic alteration ', ' Sequence Alteration ', ' Genetic mutation ', ' DNA mutation ', ' DNA Alteration ', ' Epigenetic Mechanism ', ' Epigenetic Change ', ' Epigenetic ', ' Epigenetic Process ', ' To specify ', ' Modification ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' genetic variant ', ' Population ', ' Impairment ', ' combinatorial ', ' mammalian genome ', ' human disease ', ' cellular development ', ' biorepository ', ' biobank ', ' Preventative care ', ' Preventive care ', ' ']",NIGMS,VANDERBILT UNIVERSITY,R35,2018,226333,TN-05,0.11439979874233072
"Unraveling molecular and system-level mechanisms of human disease-associated protein mutations Project Summary Although a quickly expanding catalogue of protein mutations have been discovered, including those that cause human diseases or confer drug resistance, mechanistic understanding and prediction of functional consequences of these mutations remain rather limited. There is a critical need to develop novel, multiscale computational frameworks that are rigorous and generalizable to help close the ever-increasing gap between phenotypic data and mechanistic knowledge about the mutations and to develop effective therapeutic strategies.  My long-term research goals are two folds: (1) to unravel how a change in protein sequence ripples through various aspects of molecular and system-levels to a change in cellular function and cause human diseases or confer drug resistance; and (2) to translate learned mechanistic knowledge to effective drug-design strategies for human diseases and drug resistance. Toward these goals I propose to advance and combine the strengths of computational molecular biology (structural modeling and design for proteins or protein interactions) and computational systems biology (pathway/network-level topology and dynamics) and follow a novel, formal paradigm to develop methods that systematically identify mechanisms underlying various stages of consequence propagation (from conformation, molecular and system-level variables, to cellular functions, where intermediates can be skipped if necessary). In the forward direction of propagating consequences, I will determine, explain and understand mutational consequences at various levels with machine learning, causal analysis, and combinatorial optimization, starting with known or modelled changes at various levels. In the inverse direction of designing consequences, I will follow known or learned mechanistic hypotheses and develop efficient combinatorial optimization methods to design mutagenesis experiments or screen / design ligands for desired perturbations at various levels, which would test and refine corresponding hypotheses directly and translate mechanistic hypotheses to therapeutic strategies. Mechanisms underlying distal (potentially allosteric) mutations, multiple mutations within a protein or across proteins as well as systems pharmacology strategies will also be rigorously determined in the process.  The expected outcomes from the innovative project will include two main components. The first will be both biophysical principles of proteins and integrative understanding of biomedical systems, which will be organized in a database for public access. The second will be translating mechanistic insights into therapeutic intervention strategies to treat diseases. In particular, targeted experiments (mutagenesis or ligand-binding) will be designed following known or discovered mechanistic hypotheses. This project will involve close collaboration with structural biologists and clinician-scientists who are active collaborators of the PI. Project Narrative Genetic mutations, many of which lead to protein mutations, are often associated with human diseases: they often directly cause diseases or contribute to their progressions. Understanding mechanisms by which these mutations lead to significant functional consequences is of extreme importance to developing effective therapeutics to cure diseases and ameliorate drug resistance.",Unraveling molecular and system-level mechanisms of human disease-associated protein mutations,9564155,R35GM124952,"['Amino Acid Sequence ', ' protein sequence ', ' Primary Protein Structure ', ' Biophysics ', ' biophysical sciences ', ' biophysical principles ', ' biophysical foundation ', ' Cell physiology ', ' Subcellular Process ', ' Cellular Process ', ' Cellular Physiology ', ' Cellular Function ', ' Cell Process ', ' Cell Function ', ' Disease ', ' Disorder ', ' Drug Design ', ' Drug resistance ', ' resistant to Drug ', ' resistance to Drug ', ' drug resistant ', ' Goals ', ' Lead ', ' heavy metal lead ', ' heavy metal Pb ', ' Pb element ', ' Ligands ', ' Methods ', ' Structural Models ', ' Molecular Conformation ', ' conformational state ', ' conformation ', ' Molecular Stereochemistry ', ' Molecular Configuration ', ' Mutation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Pharmacology ', ' Protein Engineering ', ' protein design ', ' genetic protein engineering ', ' Proteins ', ' Research ', ' Testing ', ' Translating ', ' Mutagenesis ', ' Mutagenesis Molecular Biology ', ' Genetics-Mutagenesis ', ' Distal ', ' insight ', ' data base ', ' Data Bases ', ' Databases ', ' Collaborations ', ' Therapeutic ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Knowledge ', ' Catalogs ', ' Scientist ', ' System ', ' novel ', ' Therapeutic Intervention ', ' intervention therapy ', ' Modeling ', ' Intervention ', ' interventional strategy ', ' Intervention Strategies ', ' Disease Resistance ', ' resistant to disease ', ' resistant disease ', ' resistance to disease ', ' Computational Molecular Biology ', ' Systems Biology ', ' DNA Sequence Alteration ', ' genomic alteration ', ' Sequence Alteration ', ' Genetic mutation ', ' DNA mutation ', ' DNA Alteration ', ' Structural Biologist ', ' Ligand Binding ', ' Molecular ', ' Process ', ' pathway ', ' Pathway interactions ', ' computational framework ', ' computer framework ', ' designing ', ' design ', ' therapy efficacy ', ' therapeutically effective ', ' therapeutic efficacy ', ' intervention efficacy ', ' Treatment Efficacy ', ' Outcome ', ' innovative ', ' innovate ', ' innovation ', ' human disease ', ' Combinatorial Optimization ', ' phenotypic data ', ' experimental research ', ' experiment ', ' experimental study ', ' ']",NIGMS,TEXAS ENGINEERING EXPERIMENT STATION,R35,2018,335245,TX-17,0.18895753745202024
"APPLYING ERROR-CORRECTED SEQUENCING TO DETECT MINIMAL RESIDUAL IN THE AAML 1031 STUDY Abstract  Acute myeloid leukemia (AML) accounts for half of all pediatric leukemia deaths and is the leading cause of leukemia-related death in adulthood. One reason for worse outcomes is the inability to properly assess for minimal residual disease (MRD) following therapy. Unlike ALL, AML presents with multiple subclonal populations without a singular clonal surface marker, and surface markers can change during therapy. The current gold standard for AML MRD is multi-parameter flow cytometry (MPFC), which is predictive of outcomes to frequencies of 0.001, yet 30% of MPFC-MRD-negative patients still relapse. Alternatively, every AML case harbors leukemia-specific mutations that could be markers of disease, except that next-generation sequencing has high error rate of ~1%. In this proposal, we will implement a novel, validated error-corrected sequencing (ECS) strategy, developed by the Druley lab in collaboration with Illumina, to improve MRD assessment of AML subclonal heterogeneity in 990 pediatric de novo AML cases from the Children's Oncology Group AAML1031 study. We hypothesize that using a highly sensitive sequencing method will improve identification of residual AML, provide important insights on subclonal heterogeneity in pediatric AML, improve understanding of the role of germline variability and gene function on relapses or refractory disease and facilitate personalized medicine. To interrogate this hypothesis, we propose the following aims: 1. Define subclonal heterogeneity at diagnosis and end of Induction 1 (EOI1) in 990 pediatric de novo  AML patients (n=1890). By using the largest prospective study of pediatric AML that has ever been  performed, we will perform ECS on 94 genes that are the most frequently mutated genes in pediatric and  adult AML at diagnosis and EOI1 to identify patterns of mutation associated with relapsed disease, FAB  subtypes or other cytogenetic features. 2. Correlate ECS-MRD with existing EOI1 MPFC-MRD for all participants in the COG AAML1031 study.  A major question is whether the different from normal cell population identified as residual disease by  MPFC is actually the same population(s) identified by ECS. We will define residual disease by ECS and  compare results to MPFC status (positive/negative), actual MPFC percentages (<0.001) and the clinical  outcomes (relapse risk, disease-free survival and overall survival) of study participants. 3. Integrate germline variation and all subclonal mutations into mechanistic groups that are frequently  mutated in pediatric AML and correlate with outcomes using unbiased machine learning  algorithms. Preliminary data tells us that every patient will have multiple subclones at diagnosis and EOI1  as well as germline variants in AML-associated genes, which may be important for outcome. In this aim, we  will take these mutations into account as well as MPFC, clinical features and cytogenetics for probabilistic  risk assessment using unsupervised machine learning algorithms for improved outcome prognostication. Narrative We have developed Error-Corrected Sequencing (ECS) that enables the highly accurate detection of leukemia- specific mutations in heterogeneous DNA samples to a limit of 0.0001. We will perform ECS with a panel of 94 frequently mutated genes in adult and pediatric AML in matched diagnostic and end of Induction 1 bone marrow samples from 990 pediatric de novo AML patients enrolled on the Children's Oncology Group AAML1031 protocol, which is the largest pediatric AML trial ever performed in North America. With these data, we can truly understand subclonal heterogeneity in pediatric AML, significantly improve minimal residual disease testing in pediatric AML, and integrate these data into an unbiased multivariate probability platform taking into account individual sequencing, flow cytometry, cytogenetic and clinical features to provide truly personalized cancer care.",APPLYING ERROR-CORRECTED SEQUENCING TO DETECT MINIMAL RESIDUAL IN THE AAML 1031 STUDY,9395904,R01CA211711,"['Adult ', ' adulthood ', ' Adult Human ', ' 21+ years old ', ' Algorithms ', ' Alleles ', ' Allelomorphs ', ' Bone Marrow ', ' Bone Marrow Reticuloendothelial System ', ' Cytogenetics ', ' Cessation of life ', ' Death ', ' Diagnosis ', ' Disease ', ' Disorder ', ' DNA ', ' Deoxyribonucleic Acid ', ' Exons ', ' Family ', ' Flow Cytometry ', ' flow cytophotometry ', ' Flow Microfluorometry ', ' Flow Microfluorimetry ', ' Flow Cytofluorometry ', ' Flow Cytofluorometries ', ' Future ', ' Genes ', ' Goals ', ' Gold ', ' leukemia ', ' Acute Myelocytic Leukemia ', ' acute myeloid leukemia ', ' acute granulocytic leukemia ', ' Acute Myelogenous Leukemia ', ' Acute Myeloblastic Leukemia ', ' AML - Acute Myeloid Leukemia ', ' Methods ', ' Methodology ', ' Mutation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' United States National Institutes of Health ', ' National Institutes of Health ', ' NIH ', ' North America ', ' Oncogenes ', ' Transforming Genes ', ' Cancer-Promoting Gene ', ' Cancer Genes ', ' Patients ', ' Protein phosphatase ', ' Protein Phosphatase-2A ', ' Protein Phosphatase-1 ', ' Protein Phosphatase Gene ', ' Protein Phosphatase C ', ' Phosphoprotein Phosphohydrolase ', ' Phosphoprotein Phosphatase-2C ', ' Phosphoprotein Phosphatase ', ' Probability ', ' Prospective Studies ', ' Protein Tyrosine Kinase ', ' tyrosyl protein kinase ', ' hydroxyaryl protein kinase ', ' Tyrosylprotein Kinase ', ' Tyrosine-Specific Protein Kinase ', ' Tyrosine-Protein Kinase Receptor EEK ', ' Tyrosine Kinase ', ' Protein Tyrosine Kinase EEK ', ' Ephrin Type-A Receptor 8 Precursor ', ' Ephrin Type-A Receptor 8 ', ' EPH-and ELK-Related Kinase ', ' EPH- and ELK-Related Tyrosine Kinase ', ' Reagent ', ' Relapse ', ' Risk ', ' Role ', ' social role ', ' Testing ', ' Time ', ' transcription factor ', ' Transcription factor genes ', ' Transcription Factor Proto-Oncogene ', ' General Transcription Factors ', ' General Transcription Factor Gene ', ' Basal transcription factor genes ', ' Basal Transcription Factor ', ' Immunophenotyping ', ' immunophenotype ', ' Immunologic Subtyping ', ' Measures ', ' falls ', ' Risk Assessment ', ' Point Mutation ', ' Spliceosomes ', ' analytical method ', ' base ', ' improved ', ' Site ', ' Surface ', ' Clinical ', ' Residual ', ' Residual state ', ' Phase ', ' Variation ', ' Variant ', ' Adult Acute NonLymphocytic Leukemia ', ' Adult Acute NonLymphoblastic Leukemia ', ' Adult Acute Non-Lymphocytic Leukemia ', ' Adult Acute Non-Lymphoblastic Leukemia ', ' Adult Acute Myeloid Leukemia ', ' Adult Acute Myelogenous Leukemia ', ' Adult Acute Myelocytic Leukemia ', ' Adult Acute Granulocytic Leukemia ', ' Adult ANLL ', ' Adult AML ', ' Adult AGL ', ' Adult Acute Myeloblastic Leukemia ', ' Pediatric Acute Myeloid Leukemia ', ' Pediatric Acute Myelogenous Leukemia ', ' Pediatric Acute Myelocytic Leukemia ', ' Pediatric Acute Myeloblastic Leukemia ', ' Pediatric AML ', ' Childhood Acute Myelogenous Leukemia ', ' Childhood Acute Myelocytic Leukemia ', ' Childhood Acute Myeloblastic Leukemia ', ' Childhood Acute Granulocytic Leukemia ', ' Childhood AML ', ' Childhood Acute Myeloid Leukemia ', ' prognostic ', ' pediatric ', ' Childhood ', ' insight ', ' Individual ', ' Minimal Residual Disease ', ' Detectable Residual Disease ', ' Residual Neoplasm ', ' Gene Targeting ', ' Event-Free Survival ', ' Disease-Free Survival ', ' Relapsed Disease ', ' Recurrent disease ', ' Collaborations ', ' Genetic ', ' gene function ', ' Diagnostic ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Investigation ', ' Frequencies ', ' Complex ', ' Protocols documentation ', ' Protocol ', ' Pattern ', ' Residual Tumors ', ' residual disease ', ' Tumor Suppressor Proteins ', ' tumor suppressor ', ' cohesion ', ' functional group ', ' novel ', ' Participant ', ' Categories ', ' Sampling ', ' response ', ' nucleocytoplasmic transport ', ' Nucleocytoplasmic Shuttling ', ' Nuclear Transport ', ' Cell Nucleus Active Transport ', ' Bortezomib ', ' Normal Cell ', ' Childhood Leukemia ', ' leukemia in children ', ' children with leukemia ', ' Pediatric Leukemia ', ' FLT3 gene ', ' Stem Cell Tyrosine Kinase 1 ', ' STK1 ', ' Fms-Related Tyrosine Kinase 3 ', ' FLT3 ', ' FLK2 ', ' DNA Sequence Alteration ', ' genomic alteration ', ' Sequence Alteration ', ' Genetic mutation ', ' DNA mutation ', ' DNA Alteration ', ' Data ', ' Detection ', ' Disease Marker ', ' Mutate ', ' Refractory Disease ', ' Resolution ', ' Sorafenib ', ' BAY 54-9085 ', ' Clinical Data ', ' enroll ', ' Enrollment ', ' Epigenetic Mechanism ', ' Epigenetic Change ', ' Epigenetic ', ' Epigenetic Process ', "" Children's Oncology Group "", ' Pediatric Oncology Group ', ' Monitor ', ' digital ', ' designing ', ' design ', ' next generation ', ' therapy efficacy ', ' therapeutically effective ', ' therapeutic efficacy ', ' intervention efficacy ', ' Treatment Efficacy ', ' Outcome ', ' Population ', ' prospective ', ' chemotherapy ', ' biomarker ', ' biologic marker ', ' bio-markers ', ' Biological Markers ', ' Randomization trial ', ' randomized trial ', ' nextgen sequencing ', ' next gen sequencing ', ' NGS system ', ' NGS Method ', ' next generation sequencing ', ' personalized treatment ', ' personalized therapy ', ' personalization of treatment ', ' personalized medicine ', ' child patients ', ' pediatric patients ', ' leukemia treatment ', ' personalized cancer care ', ' predictors of outcomes ', ' predictive outcomes ', ' outcome prediction ', ' specific biomarkers ', ' improved outcome ', ' relapse risk ', ' sub-clonal heterogeneity ', ' subclonal heterogeneity ', ' Risk stratification ', ' DNAseq ', ' DNA seq ', ' DNA sequencing ', ' unsupervised machine learning ', ' unsupervised learning ', ' ']",NCI,WASHINGTON UNIVERSITY,R01,2018,352587,MO-01,0.07065056628137568
"Massively parallel functional analyses of human PTEN variants Project Summary  We are now able to routinely sequence human genomes at single-base resolution. However, our ability to interpret the functional consequences of detected mutations has lagged behind. Computational approaches scale well but have poor accuracy, whereas retrospective analysis of detected variants has high accuracy but does not scale well. In order to solve this problem, a new experimental paradigm has emerged to empirically characterize the effects of mutations with high accuracy at scale. This approach takes advantage of recent and ongoing improvements in DNA synthesis and sequencing, and has the potential to offer unprecedented insight into protein biochemistry and human disease. We believe these insights will prove to be critical for unlocking the potential of genomic medicine.  In this project we seek to comprehensively assess multiple molecular effects of PTEN mutations on protein function, and assess the utility of this data as a predictor for human clinical phenotype. The PTEN protein is a tumor suppressor that is frequently mutated in diverse human cancers and in the germline of some individuals with overgrowth disorders, cancer predisposition syndromes, or autism. Currently, it is impossible to predict the effects of the vast majority of PTEN germline mutations. Since the phenotypic spectrum of PTEN mutation carriers is broad, it would be highly valuable to understand the ways in which phenotypic outcomes arise from PTEN mutation genotypes.  In Aim 1, we will first employ a yeast-based screen to assess the effects all PTEN single amino acid mutations on lipid phosphatase activity, the primary biochemical function of PTEN protein. It is known that several pathogenic variants are destabilized. Therefore, in Aim 2, we will perform a second, independent screen to assess the steady state protein stability of all PTEN single amino acid mutations. In Aim 3, we will use the data derived from this study as well as publically available biochemical information to train a classifier model to predict the relationship between the mutation genotypes and clinical phenotypes observed in humans. These data will increase our fundamental understanding of PTEN function and the role of mutations in diverse disorders, and could provide a valuable clinical tool that would increase the quality of life for PTEN mutation carriers. Project Narrative  Mutations in the gene PTEN are causal for a diverse set of clinical disorders ranging from cancer to autism spectrum disorder. Here, we seek to gain new fundamental insights into the functional relationships between PTEN mutations and clinical presentations by prospectively characterizing the effects of all single amino acid PTEN mutations in parallel. These data will allow the creation of new models that can predict risk of specific PTEN mutations for different clinical outcomes and potentially lead to personalized therapies, early interventions, and optimal outcomes for PTEN mutation carriers.",Massively parallel functional analyses of human PTEN variants,9794010,F31HD095571,"['Affect ', ' Amino Acids ', ' aminoacid ', ' Biochemistry ', ' Biological Chemistry ', ' Biological Assay ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' Biology ', ' Biophysics ', ' biophysical sciences ', ' biophysical principles ', ' biophysical foundation ', ' Malignant Neoplasms ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Cataloging ', ' cell sorting ', ' Cell Separation Technology ', ' Cell Segregation ', ' Cell Isolation ', ' Cell Separation ', ' Cell Viability ', ' Cell Survival ', ' Cell Body ', ' Cells ', ' Disorder ', ' Disease ', ' Fluorescence ', ' Genes ', ' Genome ', ' human whole genome ', ' Human Genome ', ' Genotype ', ' Goals ', ' ontogeny ', ' Tissue Growth ', ' Generalized Growth ', ' Growth ', ' Modern Man ', ' Human ', ' Human Genetics ', ' heavy metal lead ', ' heavy metal Pb ', ' Pb element ', ' Lead ', ' Photoradiation ', ' Light ', ' Lipids ', ' Metabolic Processes ', ' Intermediary Metabolism ', ' Metabolism ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' Patients ', ' Phenotype ', ' PtdIns ', ' Phosphoinositides ', ' Phosphatidyl Inositol ', ' Inositol Phospholipids ', ' Inositol Phosphoglycerides ', ' Inositide Phospholipids ', ' Phosphatidylinositols ', ' Phosphomonoesterases ', ' Phosphohydrolases ', ' Phosphatases ', ' Phosphoric Monoester Hydrolases ', ' Play ', ' Problem Solving ', ' Proteins ', ' QOL ', ' Quality of life ', ' Risk ', ' social role ', ' Role ', ' Signal Pathway ', ' biological signal transduction ', ' Signaling ', ' Signal Transduction Systems ', ' Intracellular Communication and Signaling ', ' Cell Signaling ', ' Cell Communication and Signaling ', ' Signal Transduction ', ' Syndrome ', ' Temperature ', ' Testing ', ' Time ', ' Yeasts ', ' Measures ', ' Dataset ', ' Data Set ', ' base ', ' improved ', ' Site ', ' Clinical ', ' Variant ', ' Variation ', ' Biochemical ', ' Pythons ', ' Germ-Line Mutation ', ' Hereditary Mutation ', ' Germline Mutation ', ' Predisposition ', ' Susceptibility ', ' Training ', ' insight ', ' Individual ', ' Early Intervention ', ' tool ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Catalogs ', ' Complex ', ' Clinic ', ' Reaction ', ' Techniques ', ' Tumor Suppressor Proteins ', ' tumor suppressor ', ' DNA biosynthesis ', ' DNA Synthesis ', ' DNA Replication ', ' novel ', ' PTEN gene ', ' Phosphatase and Tensin Homolog Deleted on Chromosome 10 ', ' Phosphatase and Tensin Homolog ', ' PTEN1 ', ' PTEN Hamartoma Tumor Syndrome With Granular Cell Tumor ', ' PTEN Hamartoma Tumor Syndrome ', ' PTEN ', ' PHTS protein ', ' PHTS gene ', ' Mutated in Multiple Advanced Cancers 1 ', ' MMAC1 ', ' Therapeutic Intervention ', ' intervention therapy ', ' Modeling ', ' high throughput technology ', ' Genomics ', ' Pathogenicity ', ' FRAP1 gene ', ' mammalian target of rapamycin ', ' mTOR ', ' RAFT1 ', ' Mechanistic Target of Rapamycin ', ' FRAP2 ', ' FRAP1 ', ' FKBP12 Rapamycin Complex Associated Protein 1 ', ' FK506 Binding Protein 12-Rapamycin Associated Protein 1 ', ' fitness ', ' autism spectrum disorder ', ' autistic spectrum disorder ', "" Kanner's Syndrome "", ' Infantile Autism ', ' Early Infantile Autism ', ' Autistic Disorder ', ' Autism ', ' Data ', ' Deletion Mutation ', ' Mutate ', ' Protein Biochemistry ', ' Protein/Amino Acid Biochemistry ', ' Resolution ', ' Ubiquitination ', ' ubiquitin conjugation ', ' ubiquination ', ' Ubiquitinoylation ', ' Ubiquitilation ', ' Yeast Model System ', ' yeast model ', ' Characteristics ', ' Molecular ', ' Process ', ' protein function ', ' Development ', ' developmental ', ' PTEN protein ', ' phosphatase and tensin homologue on chromosome ten ', ' mutated in multiple advanced cancers 1 protein ', ' MMAC1 protein ', ' Pathway interactions ', ' pathway ', ' clinical phenotype ', ' predictive modeling ', ' prognostic model ', ' prediction model ', ' computer based prediction ', ' next generation ', ' Outcome ', ' tumorigenic ', ' prospective ', ' Coupled ', ' Coupling ', ' synthetic biology ', ' open source ', ' human disease ', ' mutation carrier ', ' screening ', ' personalized medicine ', ' personalized treatment ', ' personalized therapy ', ' personalization of treatment ', ' accurate diagnosis ', ' genomic variation ', ' Genomic medicine ', ' prediction algorithm ', ' predictor algorithm ', ' predictive algorithm ', ' genomic signature ', ' genomic classifier ', ' experimental study ', ' experimental research ', ' experiment ', ' DNA sequencing ', ' DNAseq ', ' DNA seq ', ' ']",NICHD,OREGON HEALTH & SCIENCE UNIVERSITY,F31,2019,45016,OR-03,0.26862667958260855
"APPLYING ERROR-CORRECTED SEQUENCING TO DETECT MINIMAL RESIDUAL IN THE AAML 1031 STUDY Abstract  Acute myeloid leukemia (AML) accounts for half of all pediatric leukemia deaths and is the leading cause of leukemia-related death in adulthood. One reason for worse outcomes is the inability to properly assess for minimal residual disease (MRD) following therapy. Unlike ALL, AML presents with multiple subclonal populations without a singular clonal surface marker, and surface markers can change during therapy. The current gold standard for AML MRD is multi-parameter flow cytometry (MPFC), which is predictive of outcomes to frequencies of 0.001, yet 30% of MPFC-MRD-negative patients still relapse. Alternatively, every AML case harbors leukemia-specific mutations that could be markers of disease, except that next-generation sequencing has high error rate of ~1%. In this proposal, we will implement a novel, validated error-corrected sequencing (ECS) strategy, developed by the Druley lab in collaboration with Illumina, to improve MRD assessment of AML subclonal heterogeneity in 990 pediatric de novo AML cases from the Children's Oncology Group AAML1031 study. We hypothesize that using a highly sensitive sequencing method will improve identification of residual AML, provide important insights on subclonal heterogeneity in pediatric AML, improve understanding of the role of germline variability and gene function on relapses or refractory disease and facilitate personalized medicine. To interrogate this hypothesis, we propose the following aims: 1. Define subclonal heterogeneity at diagnosis and end of Induction 1 (EOI1) in 990 pediatric de novo  AML patients (n=1890). By using the largest prospective study of pediatric AML that has ever been  performed, we will perform ECS on 94 genes that are the most frequently mutated genes in pediatric and  adult AML at diagnosis and EOI1 to identify patterns of mutation associated with relapsed disease, FAB  subtypes or other cytogenetic features. 2. Correlate ECS-MRD with existing EOI1 MPFC-MRD for all participants in the COG AAML1031 study.  A major question is whether the different from normal cell population identified as residual disease by  MPFC is actually the same population(s) identified by ECS. We will define residual disease by ECS and  compare results to MPFC status (positive/negative), actual MPFC percentages (<0.001) and the clinical  outcomes (relapse risk, disease-free survival and overall survival) of study participants. 3. Integrate germline variation and all subclonal mutations into mechanistic groups that are frequently  mutated in pediatric AML and correlate with outcomes using unbiased machine learning  algorithms. Preliminary data tells us that every patient will have multiple subclones at diagnosis and EOI1  as well as germline variants in AML-associated genes, which may be important for outcome. In this aim, we  will take these mutations into account as well as MPFC, clinical features and cytogenetics for probabilistic  risk assessment using unsupervised machine learning algorithms for improved outcome prognostication. Narrative We have developed Error-Corrected Sequencing (ECS) that enables the highly accurate detection of leukemia- specific mutations in heterogeneous DNA samples to a limit of 0.0001. We will perform ECS with a panel of 94 frequently mutated genes in adult and pediatric AML in matched diagnostic and end of Induction 1 bone marrow samples from 990 pediatric de novo AML patients enrolled on the Children's Oncology Group AAML1031 protocol, which is the largest pediatric AML trial ever performed in North America. With these data, we can truly understand subclonal heterogeneity in pediatric AML, significantly improve minimal residual disease testing in pediatric AML, and integrate these data into an unbiased multivariate probability platform taking into account individual sequencing, flow cytometry, cytogenetic and clinical features to provide truly personalized cancer care.",APPLYING ERROR-CORRECTED SEQUENCING TO DETECT MINIMAL RESIDUAL IN THE AAML 1031 STUDY,9606448,R01CA211711,"['Adult ', ' adulthood ', ' Adult Human ', ' 21+ years old ', ' Alleles ', ' Allelomorphs ', ' Bone Marrow ', ' Bone Marrow Reticuloendothelial System ', ' Cytogenetics ', ' Death ', ' Cessation of life ', ' Diagnosis ', ' Disorder ', ' Disease ', ' Deoxyribonucleic Acid ', ' DNA ', ' Exons ', ' Family ', ' flow cytophotometry ', ' Flow Microfluorometry ', ' Flow Microfluorimetry ', ' Flow Cytofluorometry ', ' Flow Cytofluorometries ', ' Flow Cytometry ', ' Future ', ' Genes ', ' Goals ', ' Gold ', ' Hematology ', ' leukemia ', ' acute myeloid leukemia ', ' acute granulocytic leukemia ', ' Acute Myelogenous Leukemia ', ' Acute Myeloblastic Leukemia ', ' AML - Acute Myeloid Leukemia ', ' Acute Myelocytic Leukemia ', ' Methods ', ' Methodology ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' National Institutes of Health ', ' NIH ', ' United States National Institutes of Health ', ' North America ', ' Transforming Genes ', ' Cancer-Promoting Gene ', ' Cancer Genes ', ' Oncogenes ', ' Patients ', ' Protein Phosphatase-2A ', ' Protein Phosphatase-1 ', ' Protein Phosphatase Gene ', ' Protein Phosphatase C ', ' Phosphoprotein Phosphohydrolase ', ' Phosphoprotein Phosphatase-2C ', ' Phosphoprotein Phosphatase ', ' Protein phosphatase ', ' Probability ', ' Prospective Studies ', ' tyrosyl protein kinase ', ' hydroxyaryl protein kinase ', ' Tyrosylprotein Kinase ', ' Tyrosine-Specific Protein Kinase ', ' Tyrosine-Protein Kinase Receptor EEK ', ' Tyrosine Kinase ', ' Protein Tyrosine Kinase EEK ', ' Ephrin Type-A Receptor 8 Precursor ', ' Ephrin Type-A Receptor 8 ', ' EPH-and ELK-Related Kinase ', ' EPH- and ELK-Related Tyrosine Kinase ', ' Protein Tyrosine Kinase ', ' Reagent ', ' Relapse ', ' Risk ', ' social role ', ' Role ', ' Testing ', ' Time ', ' Transcription factor genes ', ' Transcription Factor Proto-Oncogene ', ' General Transcription Factors ', ' General Transcription Factor Gene ', ' Basal transcription factor genes ', ' Basal Transcription Factor ', ' transcription factor ', ' immunophenotype ', ' Immunologic Subtyping ', ' Immunophenotyping ', ' Measures ', ' falls ', ' Risk Assessment ', ' Point Mutation ', ' Spliceosomes ', ' analytical method ', ' base ', ' improved ', ' Site ', ' Surface ', ' Clinical ', ' Residual state ', ' Residual ', ' Phase ', ' Variant ', ' Variation ', ' Adult Acute Myeloblastic Leukemia ', ' Adult Acute NonLymphocytic Leukemia ', ' Adult Acute NonLymphoblastic Leukemia ', ' Adult Acute Non-Lymphocytic Leukemia ', ' Adult Acute Non-Lymphoblastic Leukemia ', ' Adult Acute Myeloid Leukemia ', ' Adult Acute Myelogenous Leukemia ', ' Adult Acute Myelocytic Leukemia ', ' Adult Acute Granulocytic Leukemia ', ' Adult ANLL ', ' Adult AML ', ' Adult AGL ', ' Childhood Acute Myeloid Leukemia ', ' Pediatric Acute Myeloid Leukemia ', ' Pediatric Acute Myelogenous Leukemia ', ' Pediatric Acute Myelogeneous Leukemia ', ' Pediatric Acute Myelocytic Leukemia ', ' Pediatric Acute Myeloblastic Leukemia ', ' Pediatric AML ', ' Childhood Acute Myelogenous Leukemia ', ' Childhood Acute Myelogeneous Leukemia ', ' Childhood Acute Myelocytic Leukemia ', ' Childhood Acute Myeloblastic Leukemia ', ' Childhood Acute Granulocytic Leukemia ', ' Childhood AML ', ' prognostic ', ' Childhood ', ' pediatric ', ' insight ', ' Individual ', ' Residual Neoplasm ', ' Minimal Residual Disease ', ' Detectable Residual Disease ', ' Disease-Free Survival ', ' Event-Free Survival ', ' Recurrent disease ', ' Relapsed Disease ', ' Collaborations ', ' Genetic ', ' gene function ', ' Diagnostic ', ' Investigation ', ' Frequencies ', ' Complex ', ' Protocols documentation ', ' Protocol ', ' Pattern ', ' Residual Tumors ', ' residual disease ', ' Tumor Suppressor Proteins ', ' tumor suppressor ', ' cohesion ', ' functional group ', ' novel ', ' Participant ', ' Categories ', ' Sampling ', ' response ', ' nucleocytoplasmic transport ', ' Nucleocytoplasmic Shuttling ', ' Nuclear Transport ', ' Cell Nucleus Active Transport ', ' Bortezomib ', ' Normal Cell ', ' Childhood Leukemia ', ' leukemia in children ', ' children with leukemia ', ' Pediatric Leukemia ', ' FLT3 gene ', ' Stem Cell Tyrosine Kinase 1 ', ' STK1 ', ' Fms-Related Tyrosine Kinase 3 ', ' FLT3 ', ' FLK2 ', ' DNA Sequence Alteration ', ' genomic alteration ', ' Sequence Alteration ', ' Genetic mutation ', ' DNA mutation ', ' DNA Alteration ', ' Data ', ' Detection ', ' Disease Marker ', ' Mutate ', ' Refractory Disease ', ' Resolution ', ' BAY 54-9085 ', ' Sorafenib ', ' Clinical Data ', ' Enrollment ', ' enroll ', ' Epigenetic Process ', ' Epigenetic Mechanism ', ' Epigenetic Change ', ' Epigenetic ', ' Pediatric Oncology Group ', "" Children's Oncology Group "", ' Monitor ', ' digital ', ' design ', ' designing ', ' next generation ', ' Treatment Efficacy ', ' therapy efficacy ', ' therapeutically effective ', ' therapeutic efficacy ', ' intervention efficacy ', ' Outcome ', ' Population ', ' prospective ', ' chemotherapy ', ' Biological Markers ', ' biomarker ', ' biologic marker ', ' bio-markers ', ' randomized trial ', ' Randomization trial ', ' next generation sequencing ', ' nextgen sequencing ', ' next gen sequencing ', ' NGS system ', ' NGS Method ', ' personalized medicine ', ' personalized treatment ', ' personalized therapy ', ' personalization of treatment ', ' pediatric patients ', ' child patients ', ' leukemia treatment ', ' personalized cancer care ', ' outcome prediction ', ' predictors of outcomes ', ' predictive outcomes ', ' specific biomarkers ', ' improved outcome ', ' relapse risk ', ' subclonal heterogeneity ', ' sub-clonal heterogeneity ', ' Risk stratification ', ' DNA sequencing ', ' DNAseq ', ' DNA seq ', ' unsupervised learning ', ' unsupervised machine learning ', ' machine learning algorithm ', ' ']",NCI,WASHINGTON UNIVERSITY,R01,2019,342009,MO-01,0.07065056628137568
"Evolutionary Human Genomics: Demography, Natural Selection, and Transcriptional Regulation To be fully understood, the human genome must be considered in the context of evolution. The activities that have dominated human genomics for three decades  such as genome sequencing and annotation, interrogation with high-throughput biochemical assays, and the identification of associations between genetic variants and diseases  have been enormously informative, but these descriptive studies must eventually be understood within the theoretical framework of evolutionary genetics. We must continue to press forward from the what? to the why? and how? of human genetics.  The goal of my laboratory is to interpret high-throughput genomic data from an evolutionary perspective. Drawing from ideas and techniques in molecular evolution, population genetics, statistics, and computer science, we aim both to understand the evolutionary forces that have shaped human genomes, and to use evolution to shed light on the phenotypic importance of particular sequences. Our recent activities have focused in three major areas: (1)  reconstruction  of  features  of  human  evolution  based  on  genome  sequences;  (2)  prediction  of  the  fitness consequences  of  human  mutations;  and  (3)  the  study  of  transcriptional  regulation  and  its  evolution  in primates.   We have reported major findings in each of these areas, including the existence of gene flow from early modern humans to Eastern Neandertals, a map of fitness consequences for mutations across the human genome, and an analysis showing that the architecture of transcription initiation is highly similar at enhancers and promoters in the human genome.  Here we propose to extend our research substantially in each of these areas, working together with a broad range  of  experimental  and  theoretical  collaborators.    Our  new  goals  include  the  development  of  improved methods for reconstructing human demography, with a focus on ancient gene flow; extensions of our ancestral recombination graph (ARG) sampling methods to accommodate much larger samples sizes, with applications in association mapping and the detection of natural selection; two complementary machine-learning approaches for  improving  the  prediction  of  fitness  consequences  from  sequence  data;  an  experimental  collaboration  to leverage CRISPR-Cas9 screens in characterizing noncoding mutations; a multi-pronged study of the sequence determinants of RNA stability and their implications for the evolution of transcription units; and development of a new probabilistic model for turnover of regulatory elements.  Together, these projects will address a wide variety of fundamental questions about the function and evolution of sequences in the human genome. Vast quantities of genomic data are now available to describe patterns of genetic variation within  human populations and across species, and various measures of biochemical activity along the human  genome. These data need to be interpreted in light of the fundamental forces of mutation,  recombination, natural selection, and genetic drift that have shaped genetic variation. This  proposal describes a series of projects that make use of new computational, statistical, and  theoretical methods to address fundamental questions in human evolutionary genetics, including how  humans arose   from our archaic hominin and ape cousins, how human populations diverged from one  another, how new mutations influence human health and fitness, and how regulatory sequences  contribute to unique aspects of human biology.","Evolutionary Human Genomics: Demography, Natural Selection, and Transcriptional Regulation",9658531,R35GM127070,"['Architecture ', ' Engineering / Architecture ', ' Biological Assay ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' Demography ', ' Evolution ', ' Genes ', ' Population Genetics ', ' Genome ', ' human whole genome ', ' Human Genome ', ' Goals ', ' Health ', ' Modern Man ', ' Human ', ' Human Genetics ', ' Laboratories ', ' Photoradiation ', ' Light ', ' Maps ', ' Methods ', ' statistical linear models ', ' statistical linear mixed models ', ' Probability Models ', ' Probabilistic Models ', ' Statistical Models ', ' Modernization ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' Phenotype ', ' great ape ', ' Apes ', ' Pongidae ', ' Primates Mammals ', ' Primates ', ' Recombination ', ' DNA Recombination ', ' Genetic Recombination ', ' Research ', ' statistics ', ' Transcription ', ' RNA Expression ', ' Gene Transcription ', ' Genetic Transcription ', ' Genetic Diversity ', ' Genetic Variation ', ' Measures ', ' Enhancers ', ' Natural Selections ', ' promotor ', ' promoter ', ' base ', ' improved ', ' Area ', ' Biochemical ', ' Series ', ' Sample Size ', ' Collaborations ', ' Molecular Evolution ', ' Genetic ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Pattern ', ' Techniques ', ' computer science ', ' Human Biology ', ' Graph ', ' Reporting ', ' RNA Stability ', ' Sampling ', ' Untranslated RNA ', ' noncoding ', ' Nontranslated RNA ', ' Noncoding RNA ', ' Non-translated RNA ', ' Non-Coding RNA ', ' Non-Coding ', ' Functional RNA ', ' Genetic Drift ', ' Genetic Divergence ', ' Genetic Differentiation ', ' Transcriptional Control ', ' Transcription Regulation ', ' Transcriptional Regulation ', ' Transcription Initiation ', ' genome sequencing ', ' Address ', ' fitness ', ' Data ', ' Detection ', ' Regulatory Element ', ' Development ', ' developmental ', ' reconstruction ', ' genetic variant ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' Population ', ' genome annotation ', ' genome analysis ', ' human genomics ', ' CRISPR screen ', ' clustered regularly interspaced short palindromic repeats screen ', ' CRISPR/Cas9 screen ', ' CRISPR-based screen ', ' CRISPR editing screen ', ' genomic data ', ' genomic dataset ', ' genomic data-set ', ' Genetic Diseases ', ' genetic disorder ', ' genetic condition ', ' ']",NIGMS,COLD SPRING HARBOR LABORATORY,R35,2019,479215,NY-03,0.07480630374161072
"Physics-based precision medicine: computationally phenotyping myosin isoforms and cardiomyopathy mutations PROJECT SUMMARY/ABSTRACT  Myosins are a diverse and ubiquitous class of molecular motors that are responsible for generating much of the macroscopic force in the human body. The human genome encodes 38 different isoforms of myosin, and members of this group act as force sensors or generators for a diverse set of processes throughout the body. To serve this wide array of functions, each myosin isoform has been biophysically tuned for its physiological role. In fact, the tuning is so precise that missense variants in one myosin isoform, !-cardiac myosin, can cause a congenital cardiomyopathy that is the leading cause of sudden cardiac death in people under 30. And yet, it is unknown how particular variants cause disease, or how to infer the pathogenic potential for novel mutations.  Large differences in functional properties between myosin isoforms are not the result of large differences in coding sequence or overall topology. Neither foreknowledge of phylogeny nor crystal structure is sufcient to predict an isoform's biophysical properties. Furthermore, mutations causing disease frequently occur in regions of the protein far from the site of their deleterious effects. Poor understanding of the biophysical regulation of motor function has hampered the development of pharmaceuticals and the interpretation of human genomic data.  My goal is to establish a mechanistic understanding of myosin motors that is capable of predicting if and how sequence variation changes biophysical properties and can cause cardiac disease. Since myosin kinetics are not apparent from sequence or overall structure, they must be determined by other factors. I hypothesize that kinetic differences result from differences in the allosteric networks in these proteins. Allosteric network in this context refers to the coordinated conformational uctuations that give protein regulation the appearance of action at a distance. To test this hypothesis, we will use our unique combination of enormous computational power for molecular simulation and cutting-edge machine learning tools for analyzing protein allostery.  Aim 1 is to identify the biophysical determinants of myosin isoforms' differing speeds. To test our hypothesis that allosteric networks are responsible for modulating dynamics, I will use molecular simulations of different myosin isoforms and compare their allosteric networks with biochemical data about their properties. Aim 1 directly addresses outstanding questions about normal molecular-biological function of the heart, putting it in line with NHLBI overarching objective #1.  Aim 2 is to determine the difference, at atomic resolution, between healthy and diseased !-cardiac myosin. I hypothesize that the pathogenicity of variants with an unknown molecular etiology is a consequence of allosteric disruption, and will use our computational tools to test this hypothesis by simulating a set of known-pathogenic variants. This aim uses techniques from data science to understand the genetic determinants of health, and will apply equally well to rare alleles in under-represented groups as to majority groups. It is directly addresses NHLBI overarching objectives #3, #4, and #7. PROJECT NARRATIVE  Myosins are a closely-related group of molecules that are responsible for generating much of the force in the human body, including the heartbeat, the movement of limbs, and driving food through the stomach and intestines. Small changes to the myosin genes can have large effects: in healthy people, these give rise to different myosins that perform different functions, and mutations in some myosin genes can give rise to diseases that cause of sudden cardiac death. This proposal aims to learn, at the level of atoms and interatomic bonds, why and how these subtle changes to the myosin gene can create such large effects in the protein's function.",Physics-based precision medicine: computationally phenotyping myosin isoforms and cardiomyopathy mutations,9678589,F30HL146052,"['Actins ', ' Automobile Driving ', ' driving ', ' Behavior ', ' Binding Sites ', ' Reactive Site ', ' Combining Site ', ' Biophysics ', ' biophysical sciences ', ' biophysical principles ', ' biophysical foundation ', ' Catalysis ', ' Chemistry ', ' Crystallization ', ' Disorder ', ' Disease ', ' Food or Food Product ', ' Food ', ' Genes ', ' human whole genome ', ' Human Genome ', ' Goals ', ' Health ', ' heart disorder ', ' Cardiac Disorders ', ' Cardiac Diseases ', ' Heart Diseases ', ' Modern Man ', ' Human ', ' bowel ', ' Intestinal ', ' Intestines ', ' Kinetics ', ' Learning ', ' Surface Proteins ', ' Membrane-Associated Proteins ', ' Membrane Protein Gene ', ' Membrane Proteins ', ' Methods ', ' conformational state ', ' conformation ', ' Molecular Stereochemistry ', ' Molecular Configuration ', ' Molecular Conformation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' Myosins ', ' Myosin Adenosinetriphosphatase ', ' Myosin Adenosine Triphosphatase ', ' Actin-Activated ATPase ', ' Myosin ATPase ', ' Phenotype ', ' Phylogeny ', ' Physics ', ' Proteins ', ' Relaxation ', ' social role ', ' Role ', ' biological signal transduction ', ' Signaling ', ' Signal Transduction Systems ', ' Intracellular Communication and Signaling ', ' Cell Signaling ', ' Cell Communication and Signaling ', ' Signal Transduction ', ' Solvents ', ' gastric ', ' Stomach ', ' Testing ', ' Time ', ' Genetic Diversity ', ' Genetic Variation ', ' Measures ', ' sudden cardiac death ', ' base ', ' sensor ', ' improved ', ' Site ', ' Surface ', ' Clinical ', ' Variant ', ' Variation ', ' Physiological ', ' Physiologic ', ' Biochemical ', ' heart function ', ' function of the heart ', ' cardiac function ', ' insight ', ' Human body ', ' Human Figure ', ' Biological Process ', ' Biological Function ', ' tool ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' millisecond ', ' Msec ', ' Techniques ', ' limb movement ', ' molecular dynamics ', ' Molecular Dynamics Simulation ', ' Protein Isoforms ', ' Isoforms ', ' Molecular Motors ', ' rat Ran 2 protein ', ' rat Ran-2 antigen ', ' Ran 2 ', ' Speed ', ' Structure ', ' simulation ', ' novel ', ' member ', ' Appearance ', ' Code ', ' Coding System ', ' Regulation ', ' Modeling ', ' Property ', ' Cardiomyopathies ', ' myocardium disorder ', ' myocardium disease ', ' Myocardiopathies ', ' Myocardial Disorder ', ' Myocardial Diseases ', ' Genetic Determinism ', ' genetic determinant ', ' Cardiac Myosins ', ' Cardiac Muscle Myosins ', ' Pathogenicity ', ' Molecular Interaction ', ' Binding ', ' Pharmacological Substance ', ' Pharmaceuticals ', ' Pharmaceutical Agent ', ' Pharmacologic Substance ', ' disease causation ', ' causation ', ' Causality ', ' Etiology ', ' Address ', ' Affinity ', ' Data ', ' Drug Binding Site ', ' Motor ', ' Protein Analysis ', ' Protein Region ', ' Resolution ', ' Molecular ', ' Process ', ' protein function ', ' Development ', ' developmental ', ' National Heart, Lung, and Blood Institute ', ' NHLBI ', ' computerized tools ', ' computational tools ', ' prototype ', ' disease-causing mutation ', ' rare variant ', ' rare allele ', ' biophysical properties ', ' biophysical parameters ', ' biophysical measurement ', ' biophysical characterization ', ' biophysical characteristics ', ' precision medicine ', ' precision-based medicine ', ' Patient risk ', ' Data Science ', ' Congenital cardiomyopathy ', ' Underrepresented Groups ', ' whole genome ', ' full genome ', ' entire genome ', ' genomic data ', ' genomic dataset ', ' genomic data-set ', ' Risk stratification ', ' ']",NHLBI,WASHINGTON UNIVERSITY,F30,2019,30442,MO-01,0.03642626328894276
"Development of New Genome Editing Agents Using RNA Modifying Enzymes Komor  Project Summary/Abstract - Development of New Genome Editing Agents Using RNA Modifying Enzymes  While targeted genome editing, the introduction of a specific modification in genomic DNA, has the potential to allow researchers to study and better understand mechanisms of human genetic diseases, traditional genome editing methods (including CRISPR-Cas9) that rely on the initial introduction of double stranded DNA breaks (DSB) suffer from modest genome editing efficiencies as well as unwanted gene alterations (indels), particularly when attempting to correct point mutations. Recently, a class of genome editing agents called single base editors was developed that does not involve DSBs, but rather uses a dCas9-tethered single-stranded DNA (ssDNA) modifying enzyme to directly chemically modify target nucleobases within a ~5 nucleotide window determined by the protospacer. Two classes of editors have been developed that use cytosine and adenine deamination chemistries to catalyze the conversion of CG base pairs to TA (CBEs), and AT base pairs to GC (ABEs), respectively. Here we propose the development and characterization of new base editors capable of facilitating new point mutations using methylation chemistry. We have use a bioinformatic approach to identify RNA modifying enzymes that have the potential to be repurposed into new base editors, and have rationally designed mutant libraries to use with directed evolution to convert these enzymes into base editors (Aim 1). Concurrently, we are developing a machine learning program that utilizes existing ssDNA modifying enzymes to identify putative mutations that will expand the substrate scope of the identified methyltransferases to ssDNA (Aim 2). Mutations identified from both strategies will then be tested and characterized for base editing in multiple orthogonal systems (Aim 3). The successful completion of the proposed work will represent a significant addition to existing base editing technologies, and will enable researchers to cleanly and efficiently install two additional types of point mutations into the genome of living cells, allowing researchers to quickly and effectively general model systems for the study of human genetic diseases. Komor  Project Narrative - Development of New Genome Editing Agents Using RNA Modifying Enzymes Base editing enables high efficiency genomic point mutation introduction in a variety of cell types and has the potential to allow researchers to better study human genetic diseases. We propose transformative improvements to current base editing technologies that will expand the types of point mutations that can be introduced by base editors. The tools developed here will enable researchers to cleanly and efficiently install additional types of point mutations into the genome of living cells for the study and potential treatment of human genetic diseases.",Development of New Genome Editing Agents Using RNA Modifying Enzymes,9876634,R21GM135736,"['Methylation ', ' transmethylase ', ' methylase ', ' EC 2.1.1 ', ' Methyltransferase ', ' Model System ', ' Biologic Models ', ' Biological Models ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' Nucleotides ', ' Program Development ', ' Proteins ', ' Purines ', ' Pyrimidine ', ' Researchers ', ' Investigators ', ' Research Personnel ', ' Ribonucleic Acid ', ' RNA Gene Products ', ' Non-Polyadenylated RNA ', ' RNA ', ' transfer Ribonucleic acids ', ' tRNA ', ' Triplet Codon-Amino Acid Adaptor ', ' Transfer RNA ', ' Specificity ', ' Technology ', ' Testing ', ' Uracil ', ' Work ', ' Generations ', ' Measures ', ' case report ', ' Case Study ', ' Mediating ', ' Point Mutation ', ' base ', ' Site ', ' Variant ', ' Variation ', ' Link ', ' Chemicals ', ' Lesion ', ' Individual ', ' Directed Molecular Evolution ', ' directed evolution ', ' tool ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' programs ', ' cell type ', ' System ', ' preference ', ' Gene Mutation ', ' Gene Alteration ', ' molecular dynamics ', ' Molecular Dynamics Simulation ', ' mutant ', ' nucleobase ', ' transition mutation ', ' transversion mutation ', ' Base Pairing ', ' novel ', ' Genomics ', ' Pathogenicity ', ' Bioinformatics ', ' Bio-Informatics ', ' DNA Double Strand Break ', ' Mammalian Cell ', ' Modification ', ' Development ', ' developmental ', ' insertion/deletion mutation ', ' insertion/deletion ', ' insertion-deletion mutation ', ' insertion-deletion ', ' indel ', ' design ', ' designing ', ' combat ', ' Genomic DNA ', ' gDNA ', ' genome editing ', ' genomic editing ', ' CRISPR/Cas technology ', ' Cas nuclease technology ', ' CRISPR/Cas9 technology ', ' CRISPR/Cas9 ', ' CRISPR/Cas method ', ' CRISPR-based tool ', ' CRISPR-based technology ', ' CRISPR-based technique ', ' CRISPR-based method ', ' CRISPR-CAS-9 ', ' CRISPR technology ', ' CRISPR technique ', ' CRISPR methodology ', ' CRISPR method ', ' Genetic Diseases ', ' genetic disorder ', ' genetic condition ', ' machine learning algorithm ', ' Adenine ', ' Vitamin B4 ', ' 1H-Purin-6-amine ', ' adenosine deaminase ', ' Adenosine Aminohydrolase ', ' Adoption ', ' Algorithms ', ' Biological Assay ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' cultured cell line ', ' Strains Cell Lines ', ' CellLine ', ' Cell Line ', ' Cell Body ', ' Cells ', ' Chemistry ', ' Communities ', ' Cytosine ', ' Deamination ', ' Deoxyribonucleic Acid ', ' DNA ', ' DNA Injury ', ' DNA Damage ', ' Single-Stranded DNA ', ' Engineering ', ' Enzyme Gene ', ' Enzymes ', ' E. coli ', ' E coli ', ' Escherichia coli ', ' Evolution ', ' Genome ', ' Modern Man ', ' Human ', ' Human Genetics ', ' In Vitro ', ' Inosine ', ' Libraries ', ' Methods ', ' ']",NIGMS,"UNIVERSITY OF CALIFORNIA, SAN DIEGO",R21,2019,205479,CA-52,0.09832153943009558
"A statistical framework to systematically characterize cancer driver mutations in noncoding genomic regions PROJECT SUMMARY Cancer genomes typically harbor a substantial number of somatic mutations. Relatively few driver mutations actually alter the function of proteins in tumor cells, whereas most mutations are considered to be functionally neutral passenger mutations. Over the past decade, the search for cancer driver mutations has focused on coding regions and several mutational significance algorithms have been developed for coding mutations. The contribution of mutations in noncoding regulatory regions to tumor formation largely remains unknown and current mutational significance algorithms are not designed to detect driver mutations in noncoding regions, due to biological differences between coding and noncoding mutations. The emerging availability of large whole- genome sequencing datasets (e.g. PCAWG and HMF datasets) creates an ample opportunity to develop new mutational significance algorithms that are particularly designed for the interpretation of noncoding regions. Recently, we have developed a new statistical approach that identifies driver mutations in coding regions based on the nucleotide context. Critically, consideration of the nucleotide context around mutations does not require prior knowledge for functional consequences associated with these mutations. Hence, we hypothesize that generalizing our nucleotide context model to noncoding regions will uncover novel noncoding driver mutations that cannot be detected using the mutational significance approaches currently available. For this purpose, we will develop a statistical framework that incorporates the biological differences between coding and noncoding mutations and that is specifically designed to detect driver mutations in noncoding regions. Specifically, we will consider the context-dependent distribution of passenger mutations, modeling of the background mutation rate, accurately partition the background mutation rate, model the sequence composition of the reference genome, and account for coverage fluctuation. We will then combine these statistical components by computing an independent product of their underlying probabilities. We will derive a significance p-value using a Monte-Carlo simulation approach, and use FDR for multiple hypothesis test correction. This strategy will allow us to accurately estimate the significance of somatic mutations in noncoding genomic regions. We will next apply this statistical framework to whole-genome sequencing data of 5,523 tumor patients, thereby deriving a comprehensive list of candidate driver mutations in noncoding regions. Finally, we will investigate whether noncoding mutations are overrepresented in transcription factor binding sites, regulate gene expression levels, induce alternative splicing, or affect epigenomic states. Upon the completion of this project, we will have developed and applied a statistical framework for discovery of significant somatic mutations in noncoding regions, and defined the mutational landscape of the non-coding cancer genome. All aspects of the methods developed and applied in this project will be made open source and developed in an online platform. PROJECT NARRATIVE While coding cancer driver mutations have been characterized in detail over the past decade, the contribution of noncoding mutations to tumor formation remains - apart from few examples (e.g. mutations in TERT promoters) - largely unknown. Recently, large-scale whole-genome sequencing datasets have been made available, but a major bottleneck for the biological and clinical interpretation of these cancer whole-genome cohorts is the lack of statistical models that identify driver mutations in noncoding regions. We developed a new statistical approach that characterizes driver mutations based on their surrounding nucleotide context in coding regions, and herein we propose a concrete plan to generalize our computational model to noncoding regions, apply our model to aggregated whole-genome sequencing data of 5,523 tumor patients (PCAWG, HMF datasets), and define the noncoding driver and passenger mutational landscape for biological discovery and focused clinical application.",A statistical framework to systematically characterize cancer driver mutations in noncoding genomic regions,9825986,R21CA242861,"['Affect ', ' Algorithms ', ' Alternative Splicing ', ' Alternative RNA Splicing ', ' Alternate Splicing ', ' Attention ', ' Binding Sites ', ' Reactive Site ', ' Combining Site ', ' Biology ', ' malignant breast neoplasm ', ' malignant breast tumor ', ' Breast Cancer ', ' Malignant Neoplasms ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Communities ', ' virtual simulation ', ' in silico ', ' computerized simulation ', ' computerized modeling ', ' computer based models ', ' computational simulation ', ' computational models ', ' computational modeling ', ' Mathematical Models and Simulations ', ' Mathematical Model Simulation ', ' Computerized Models ', ' Computer based Simulation ', ' Computer Models ', ' Computer Simulation ', ' Gene Expression ', ' Gene Regulation Process ', ' Gene Regulation ', ' Gene Action Regulation ', ' Gene Expression Regulation ', ' immuno therapy ', ' immune-based treatments ', ' immune-based therapies ', ' immune therapy ', ' immune therapeutic strategy ', ' immune therapeutic regimens ', ' immune therapeutic interventions ', ' immune therapeutic approach ', ' immune drugs ', ' Immunologically Directed Therapy ', ' Immunotherapy ', ' Malignant Melanoma ', ' melanoma ', ' Methods ', ' statistical linear models ', ' statistical linear mixed models ', ' Probability Models ', ' Probabilistic Models ', ' Statistical Models ', ' Monte Carlo simulation ', ' Monte Carlo procedure ', ' Monte Carlo calculation ', ' Monte Carlo algorithm ', ' Monte Carlo Method ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' Nucleotides ', ' Patients ', ' Play ', ' Probability ', ' genetic regulatory element ', ' Regulatory Regions ', ' Nucleic Acid Regulator Regions ', ' Nucleic Acid Regulatory Sequences ', ' social role ', ' Role ', ' Testing ', ' Transcription factor genes ', ' Transcription Factor Proto-Oncogene ', ' General Transcription Factors ', ' General Transcription Factor Gene ', ' Basal transcription factor genes ', ' Basal Transcription Factor ', ' transcription factor ', ' Mediating ', ' promotor ', ' promoter ', ' Dataset ', ' Data Set ', ' base ', ' Clinical ', ' Biological ', ' Biological Process ', ' Biological Function ', ' cancer immunotherapy ', ' immunotherapy of cancer ', ' immunotherapy for cancer ', ' anticancer immunotherapy ', ' anti-cancer immunotherapy ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Computational Biology ', ' computer biology ', ' Knowledge ', ' Pattern ', ' Somatic Mutation ', ' mutant ', ' neoplastic cell ', ' Tumor Cell ', ' cohort ', ' novel ', ' Positioning Attribute ', ' Position ', ' Code ', ' Coding System ', ' Modeling ', ' response ', ' Untranslated RNA ', ' noncoding ', ' Nontranslated RNA ', ' Noncoding RNA ', ' Non-translated RNA ', ' Non-Coding RNA ', ' Non-Coding ', ' Functional RNA ', ' Microsatellite Instability ', ' genome sequencing ', ' Address ', ' Data ', ' Stratification ', ' Genomic Segment ', ' genomic region ', ' Process ', ' protein function ', ' Development ', ' developmental ', ' epigenomics ', ' cancer genome ', ' tumor genome ', ' cancer cell genome ', ' immunogenicity ', ' design ', ' designing ', ' Outcome ', ' clinical effect ', ' clinical application ', ' clinical applicability ', ' open source ', ' tumor ', ' genome-wide ', ' genomewide ', ' genome scale ', ' The Cancer Genome Atlas ', ' TCGA ', ' exome sequencing ', ' exome-seq ', ' targeted treatment ', ' targeted therapy ', ' targeted therapeutic agents ', ' targeted therapeutic ', ' targeted drug treatments ', ' targeted drug therapy ', ' predicting response ', ' response prediction ', ' predictor of response ', ' predictive response ', ' prediction of response ', ' reference genome ', ' reference assembly ', ' actionable mutation ', ' driver mutation ', ' actionable variants ', ' whole genome ', ' full genome ', ' entire genome ', ' checkpoint therapy ', ' immune checkpoint therapy ', ' immune check point therapy ', ' checkpoint inhibitor therapy ', ' checkpoint immunotherapy ', ' check point therapy ', ' check point inhibitor therapy ', ' check point immunotherapy ', ' immune checkpoint blockade ', ' immune check point blockade ', ' checkpoint blockade ', ' check point blockade ', ' neoantigens ', ' neoepitopes ', ' neo-epitopes ', ' neo-antigen ', ' ']",NCI,DANA-FARBER CANCER INST,R21,2019,232291,MA-07,0.2587934284878348
"Computational evaluation of the causal role of somatic mutations in human aging Project Abstract Although genome instability has long been considered as one of the major causal factors of aging, little is known about the actual number of genome alterations per cell and their effects on aging organisms, most notably humans. In the research proposed here I will take a single cell approach to identify the most common types of somatic mutations, i.e., base substitutions, small INDELS, copy number variation, genome structural variation and retrotranspositions, in human B lymphocytes as a function of age. The overarching goal is then to estimate functional effects of these DNA mutations accumulated during human aging in this particular cell type, which will also serve as a model for studying somatic mutations and their consequences in other cell types. This could never be tested before, because it was never possible to analyze random somatic mutations in a tissue by sequencing bulk DNA from that tissue (mutations are low- abundant), I will achieve this goal by utilizing a new, single-cell, whole genome sequencing (SCWGS) protocol that we developed. In this project I will focus on human B lymphocytes from individuals varying in age from about 30 to over 100 years and determine the genome-wide frequency and location of the different types of mutations in multiple cells from each individual (Aim 1). Preliminary results already show a significant increase of both base substitution mutations and CNVs with age, with a substantial number of these mutations in B cell genomic regions that are potentially functional. Hence, in Aim 2 I will predict the actual functional effects of these potentially functional, age-related mutations using machine learning approaches and integrative network analysis. Finally, in Aim 3 I will empirically test these predictions as to whether the mutation loads observed affect B cell's ability of response to stimulus. Hence, to test the long-standing hypothesis of genome instability as a causal factor in aging ,I will determine age-related mutations in single cells at four levels: (1) number of mutations, mutation spectra and genome distribution in individual cells; (2) potential functional effects of individual mutations, i.e., non-synonymous mutations in exons and mutations in gene regulatory regions; (3) mutations collectively affecting the gene regulatory network; and (4) relationship between mutation load and B cell activation status. In summary, the results of the proposed project will, for the first time uncover possible direct functional effects of somatic mutations on cellular function. Project Narrative Genome instability is considered as one of the major factors of aging and age-related diseases. This research aims to study somatic DNA mutations in normal blood cells (B lymphocytes) of humans of different ages and evaluate the functional effect of these mutations. It will dramatically improve the knowledge of DNA mutations in aging and deepen the understanding of genome instability as a basic aging mechanism in human.",Computational evaluation of the causal role of somatic mutations in human aging,9785353,K99AG056656,"['Affect ', ' Age ', ' ages ', ' Elderly ', ' senior citizen ', ' older person ', ' older adult ', ' later life ', ' late life ', ' geriatric ', ' elders ', ' advanced age ', ' Aging ', ' B-Lymphocytes ', ' B-cell ', ' B-Cells ', ' B cells ', ' B cell ', ' B blood cells ', ' Binding Sites ', ' Reactive Site ', ' Combining Site ', ' Blood Cells ', ' Peripheral Blood Cell ', ' Subcellular Process ', ' Cellular Process ', ' Cellular Physiology ', ' Cellular Function ', ' Cell Process ', ' Cell Function ', ' Cell physiology ', ' Cell Body ', ' Cells ', ' centenarian human (100+) ', ' 100+ years old ', ' Centenarian ', ' Thymonuclease ', ' Pancreatic DNase ', ' DNase I ', ' DNA Endonuclease ', ' Deoxyribonuclease I ', ' Disorder ', ' Disease ', ' Deoxyribonucleic Acid ', ' DNA ', ' DNA Injury ', ' DNA Damage ', ' Transposable Elements ', ' DNA Transposable Elements ', ' Unscheduled DNA Synthesis ', ' DNA Damage Repair ', ' DNA Repair ', ' Exons ', ' Genes ', ' trans acting element ', ' regulatory gene ', ' Transcriptional Regulatory Elements ', ' Regulator Genes ', ' Genome ', ' Goals ', ' Modern Man ', ' Human ', ' Allergy ', ' Hypersensitivity ', ' Immunostimulation ', ' Immunological Stimulation ', ' Immunological Sensitization ', ' Immunologic Stimulation ', ' Immunologic Sensitization ', ' Immunization ', ' Laboratories ', ' heavy metal lead ', ' heavy metal Pb ', ' Pb element ', ' Lead ', ' Learning ', ' Mentors ', ' Methods ', ' Study models ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' Nucleotides ', ' living system ', ' Organism ', ' Proteins ', ' genetic regulatory element ', ' Regulatory Regions ', ' Nucleic Acid Regulator Regions ', ' Nucleic Acid Regulatory Sequences ', ' Research ', ' Ribonucleic Acid ', ' RNA Gene Products ', ' Non-Polyadenylated RNA ', ' RNA ', ' social role ', ' Role ', ' Computer Software Tools ', ' Software Tools ', ' Testing ', ' Time ', ' Body Tissues ', ' Tissues ', ' Transcription factor genes ', ' Transcription Factor Proto-Oncogene ', ' General Transcription Factors ', ' General Transcription Factor Gene ', ' Basal transcription factor genes ', ' Basal Transcription Factor ', ' transcription factor ', ' Enhancers ', ' promotor ', ' promoter ', ' base ', ' crosslink ', ' cross-link ', ' improved ', ' Site ', ' repaired ', ' repair ', ' Variant ', ' Variation ', ' Evaluation ', ' Stimulus ', ' Individual ', ' Functional disorder ', ' pathophysiology ', ' Physiopathology ', ' Dysfunction ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Knowledge ', ' dietary restriction ', ' restricted diet ', ' diet restriction ', ' Frequencies ', ' Protocols documentation ', ' Protocol ', ' Source ', ' cell type ', ' Location ', ' Locus Control Region ', ' Somatic Mutation ', ' repair enzyme ', ' repair endonuclease ', "" 5' Untranslated Regions "", ' mRNA Leader Sequences ', "" 5'UTR "", "" 3' Untranslated Regions "", "" 3'UTR "", ' Structure ', ' DNA amplification ', ' Somatic Cell ', ' Mutation Analysis ', ' Code ', ' Coding System ', ' Pathway Analysis ', ' Network Analysis ', ' response ', ' theories ', ' Genomic Instability ', ' Genome Instability ', ' RNA amplification ', ' B-Cell Activation ', ' genome sequencing ', ' Defect ', ' Copy Number Polymorphism ', ' copy number variation ', ' copy number variant ', ' DNA Replication Damage ', ' DNA Replicating Damage ', ' DNA Sequence Alteration ', ' genomic alteration ', ' Sequence Alteration ', ' Genetic mutation ', ' DNA mutation ', ' DNA Alteration ', ' Data ', ' Mutation Spectra ', ' Retrotransposition ', ' Cancer Etiology ', ' Cancer Cause ', ' Collecting Cell ', ' Genomic Segment ', ' genomic region ', ' Process ', ' age related ', ' age dependent ', ' nonsynonymous mutation ', ' non-synonymous mutation ', ' insertion/deletion mutation ', ' insertion/deletion ', ' insertion-deletion mutation ', ' insertion-deletion ', ' indel ', ' genome-wide ', ' genomewide ', ' genome scale ', ' single cell sequencing ', ' CRISPR/Cas technology ', ' Cas nuclease technology ', ' CRISPR/Cas9 technology ', ' CRISPR/Cas9 ', ' CRISPR/Cas method ', ' CRISPR-based tool ', ' CRISPR-based technology ', ' CRISPR-based technique ', ' CRISPR-based method ', ' CRISPR-CAS-9 ', ' CRISPR technology ', ' CRISPR technique ', ' CRISPR methodology ', ' CRISPR method ', ' whole genome ', ' full genome ', ' entire genome ', ' single cell technology ', ' ']",NIA,ALBERT EINSTEIN COLLEGE OF MEDICINE,K99,2019,135945,NY-14,0.2879436696139564
"ADPKD: Disease Spectrum & Genotype-Phenotype Correlations Autosomal dominant polycystic kidney disease (ADPKD) is a common monoallelic disorder associated with progressive cyst development and resulting in end stage renal failure (ESRD) in 50% of patients by 60y. However, there is considerable phenotypic variability, extending from in utero onset to patients with adequate renal function into old age. Autosomal dominant polycystic liver disease (ADPLD), as traditionally defined, results in PLD with minimal renal cysts. Classically there have been considered two ADPKD genes, PKD1 and PKD2, encoding PC1 and PC2, and two ADPLD genes, PRKCSH and SEC63, but in the past few years greater genetic heterogeneity has been described, with nine genes now implicated overall. Recent data also indicates an overlap in etiology and pathogenesis associated with ADPKD and ADPLD, with the efficient biogenesis and localization of the PC-complex central to both disorders. During the last funding period we identified a novel gene, GANAB, which is associated with both disorders, where the encoded protein, GII is involved in the maturation and trafficking of PC1.  In this proposal we will take advantage of advances in next generation sequencing (NGS) methodologies, and large populations of ADPKD and ADPLD patients that have been assembled and screened for the classic genes, to hunt for novel genes for these disorders (Aim 1). The phenotype associated with these genes will be characterized (Aim 3) along with their mechanism of action (Aim 2). NGS methods will be perfected to screen the segmentally duplicated locus, PKD1, and to identify missed mutations at the known loci, including those present in just some cells due to mosaicism (Aim 1). The significance of many PKD1 nontruncating variants has been difficult to evaluate (classed as variants of unknown significance; VUS), but recently evidence that some are incompletely penetrant alleles partially explains phenotypic variability in PKD1 populations. In Aim 2 improved in silico predictions, in combination with machine learning, will improve the understanding of the pathogenicity and penetrance of VUS. A cellular assay of the biogenesis and trafficking of this PC-complex will also be employed to quantify the penetrance of VUS. The mechanism of pathogenesis will be explored in animal models with ultralow penetrant (ULP) Pkd1 or Pkd2 alleles. Employing the large clinically, imaging, and genetically well-defined populations phenotypic groupings of patients will be defined that will then be compared to the genic and PKD1 allelic groups (Aim 3). This iterative process will allow the Variant Score (VS) associated with each PKD1 VUS to be refined. In a separate population the revised VS, alone and in combination with clinical, functional, and imaging data, will be employed to generate a comprehensive, predictive algorithm for ADPKD (Aim 3). Disease modifiers to severe disease, via biallelic ADPKD, and due to alleles at other loci will also be identified and characterized in the cellular assay and in vivo in combination with the Pkd1 hypomorphic, RC model. The final aim will exploit the newly identified information that some PKD1 and PKD2 VUS are rescuable, folding mutations that in a maturation-fostering environment can traffic and function appropriately. A screening scheme based on the level of cell surface PC1 will be improved and new chaperone drugs specific for the PC complex will be sought in collaboration with Sanford Burnham Prebys. A second mutation group that will be explored therapeutically are nonsense mutations. A cellular assay for readthrough efficiency is being developed and will be used for screening. Identified chaperone or readthrough drugs will be tested in available mouse models. Overall this proposal will better explain the etiology and the genetic causes of phenotypic variability in ADPKD/ADPLD, develop better prognostic tools for individual selection of patients for treatment that are now becoming available, and explore allele based treatments for ADPKD. ADPKD and ADPLD are genetic diseases associated with cyst development and loss of function in the kidney and liver cysts, where the disease severity varies greatly between patients. Here we will identify new genes that cause these disorders and evaluate mutations in silico, in a cellular assay, and in whole animals to better predict the disease course in each patient. Treatment options associated with the type of individual patient mutations will also be explored, bringing individualized medicine to these diseases.",ADPKD: Disease Spectrum & Genotype-Phenotype Correlations,9778816,R01DK058816,"['Age ', ' ages ', ' Alleles ', ' Allelomorphs ', ' Animals ', ' Biogenesis ', ' Origin of Life ', ' Budgets ', ' Cell Body ', ' Cells ', ' virtual simulation ', ' in silico ', ' computerized simulation ', ' computerized modeling ', ' computer based models ', ' computational simulation ', ' computational models ', ' computational modeling ', ' Mathematical Models and Simulations ', ' Mathematical Model Simulation ', ' Computerized Models ', ' Computer based Simulation ', ' Computer Models ', ' Computer Simulation ', ' Cyst ', ' Disorder ', ' Disease ', ' drug/agent ', ' Pharmaceutic Preparations ', ' Medication ', ' Drugs ', ' Pharmaceutical Preparations ', ' Environment ', ' Family ', ' Genes ', ' Genotype ', ' Goals ', ' renal ', ' Kidney Urinary System ', ' Kidney ', ' Renal Cyst ', ' Kidney Cyst ', ' Cystic kidney ', ' Methods ', ' Methodology ', ' mosaic disorders ', ' Mosaicism ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' Patients ', ' Phenotype ', ' Proteins ', ' social role ', ' Role ', ' biological signal transduction ', ' Signaling ', ' Signal Transduction Systems ', ' Intracellular Communication and Signaling ', ' Cell Signaling ', ' Cell Communication and Signaling ', ' Signal Transduction ', ' Testing ', ' Proinsulin Convertase 2 ', ' Prohormone Convertase 2 ', ' PC2 Protein ', ' PC2 Prohormone Convertase ', ' PC2 Endoprotease ', ' PC2 ', ' Neuroendocrine Convertase PC2 ', ' Endopeptidase PC2 ', ' Proprotein Convertase 2 ', ' Dominant Polycystic Kidney Disease ', ' Autosomal Dominant Polycystic Kidney Disease ', ' Adult Polycystic Kidney Disease ', ' ADPKD ', ' Autosomal Dominant Polycystic Kidney ', ' Proprotein Convertase SPC3 ', ' Proinsulin Convertase 1 ', ' Prohormone Convertase 3 ', ' Prohormone Convertase 1 ', ' PC3 Prohormone Convertase ', ' PC3 Endoprotease ', ' PC1 Prohormone Convertase ', ' PC1 Endoprotease ', ' PC1 ', ' Neuroendocrine Convertase PC1 ', ' Proprotein Convertase 1 ', ' Dataset ', ' Data Set ', ' polycystic liver disease ', ' Fibrocystic liver disease ', ' Cystic disease of liver ', ' Congenital cystic liver disease ', ' protein folding ', ' base ', ' dosage ', ' improved ', ' Hepatic ', ' Clinical ', ' Variant ', ' Variation ', ' Biological ', ' Biochemical ', ' Germ-Line Mutation ', ' Hereditary Mutation ', ' Germline Mutation ', ' prognostic ', ' Renal function ', ' kidney function ', ' insight ', ' Individual ', ' Fostering ', ' Patient Selection ', ' Genetic Heterogeneity ', ' Molecular Chaperones ', ' Chaperone ', ' Funding ', ' Hepatic Cyst ', ' Liver Cyst ', ' Collaborations ', ' Therapeutic ', ' Genetic ', ' Diagnostic ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Knowledge ', ' Severities ', ' Complex ', ' Event ', ' Severity of illness ', ' disease severity ', ' Penetrance ', ' PRKCSH protein ', ' protein kinase substrate 80KD protein, heavy chain ', ' protein kinase substrate 80K-H ', ' PRKCSH ', ' G19P1 protein ', ' FGF-stimulated p90 ', ' 80K-H protein ', ' Nonsense Mutation ', ' non-sense mutation ', ' mutant ', ' Animal Model ', ' model organism ', ' model of animal ', ' Animal Models and Related Studies ', ' trafficking ', ' novel ', ' Cell surface ', ' Pathogenesis ', ' Modeling ', ' Pathogenicity ', ' End-Stage Renal Disease ', ' End-Stage Kidney Disease ', ' ESRD ', ' End stage renal failure ', ' disease causation ', ' causation ', ' Causality ', ' Etiology ', ' Defect ', ' Data ', ' in vitro Assay ', ' in vivo ', ' Cellular Assay ', ' cell assay ', ' Functional Imaging ', ' physiological imaging ', ' Physiologic Imaging ', ' Other Genetics ', ' Scheme ', ' Process ', ' Grouping ', ' groupings ', ' Development ', ' developmental ', ' Image ', ' imaging ', ' in utero ', ' early onset ', ' disease phenotype ', ' Population ', ' mouse model ', ' murine model ', ' loss of function ', ' therapy development ', ' treatment development ', ' intervention development ', ' develop therapy ', ' next generation sequencing ', ' nextgen sequencing ', ' next gen sequencing ', ' NGS system ', ' NGS Method ', ' exome sequencing ', ' exome-seq ', ' screening ', ' individualized medicine ', ' unique treatment ', ' tailored treatment ', ' tailored therapy ', ' tailored medical treatment ', ' individualized treatment ', ' individualized therapy ', ' individualized patient treatment ', ' customized treatment ', ' customized therapy ', ' variant of unknown significance ', ' variant of undetermined significance ', ' variant of uncertain significance ', ' variant of uncertain clinical significance ', ' unclassified variant ', ' prognostic tool ', ' mutation screening ', ' mutation scanning ', ' individual patient ', ' molecular diagnostics ', ' prediction algorithm ', ' predictor algorithm ', ' predictive algorithm ', ' Genetic Diseases ', ' genetic disorder ', ' genetic condition ', ' ']",NIDDK,MAYO CLINIC ROCHESTER,R01,2019,510292,MN-01,0.10158678176448475
"Functional Annotation of Natural and Disease Variants in Tryosine Kinases     DESCRIPTION (provided by applicant): Protein tyrosine kinases are dynamic molecular switches that toggle between a catalytically ""on"" and ""off"" state to turn on and off signals responsible for cell growth and survival. While the tyrosine kinase switch is tightly regulated by  diverse array of structural mechanisms in normal states, in many disease states, the switch is permanently turned on or off due, in part, to mutations in the tyrosine kinase domain. Although genome sequencing studies have revealed the mutational patterns of tyrosine kinases from many different disease types, understanding the structural and functional impact of these mutations is a challenge because many recurrent mutations occur far from the active site (distal mutations) and the residue networks that contribute to the complex modes of tyrosine kinase allosteric regulation are not fully understood. Our long term goal is to understand the relationships connecting sequence, structure, function, regulation and disease in protein kinases using a combination of computational and experimental approaches. Our objective in this proposal, which is the next logical step toward attainment of our long-term goal, is to delineate the residue interaction networks that contribute to the unique modes of allosteric regulation in tyrosine kinases, and to develop a computational framework for predicting mutation impact using the evolutionary and allosteric properties encoded in three dimensional structures. The central hypothesis is that distal mutations alter evolutionarily conserved allosteric networks in tyrosine kinases, and delineating the allosteric networks unique to tyrosine kinases will provide context for predicting and testing disease mutation impact. The specific aims are: * To identify and characterize natural sequence and structural variants associated with tight  allosteric control of tyrosine kinase activity * To develop a computational framework for predicting mutation impact on kinase activation and to  experimentally validate computational predictions using selected receptor tyrosine kinases as  model systems Successful completion of these aims is expected to reveal novel activating mutations in putative allosteric sites in the tyrosine kinase domain, and pinpoint key residues and interactions for functional studies. These outcomes, in turn, are expected to have major biomedical impact by accelerating the functional characterization of the mutated tyrosine kinome, which is emerging as a major target for personalized medicine. Finally, by providing detailed mechanistic annotation of mutations identified in genome sequencing studies, this proposal will address a fundamental NIH roadmap problem in translational medicine of converting genomic discoveries into therapeutic strategies. PUBLIC HEALTH RELEVANCE: Protein tyrosine kinases are a biomedically important class of proteins that are abnormally regulated in many human diseases including cancer, diabetes, and inflammatory disorders, to name but a few. They have been the focus of many drug discovery efforts and genome sequencing studies because of the therapeutic potential of targeting mutated tyrosine kinases for personalized therapy. By providing functional annotation of natural and disease mutations in tyrosine kinases, the proposed studies will accelerate the targeting of mutated tyrosine kinases for drug discovery and personalized therapy.",Functional Annotation of Natural and Disease Variants in Tryosine Kinases,9731524,R01GM114409,"['Allosteric Regulation ', ' Allosteric Site ', ' Antineoplastic Agents ', ' anticancer drug ', ' anticancer agent ', ' anti-cancer drug ', ' Tumor-Specific Treatment Agents ', ' Neoplastic Disease Chemotherapeutic Agents ', ' Cancer Drug ', ' Antineoplastics ', ' Antineoplastic Drugs ', ' Anti-Cancer Agents ', ' Biological Assay ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' Malignant Neoplasms ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Cellular Growth ', ' Cellular Expansion ', ' cell growth ', ' Cell Viability ', ' Cell Survival ', ' Communities ', ' diabetes ', ' Diabetes Mellitus ', ' Disorder ', ' Disease ', ' resistant to Drug ', ' resistance to Drug ', ' drug resistant ', ' Drug resistance ', ' drug/agent ', ' Pharmaceutic Preparations ', ' Medication ', ' Drugs ', ' Pharmaceutical Preparations ', ' Foundations ', ' Genes ', ' human whole genome ', ' Human Genome ', ' Goals ', ' In Vitro ', ' Model System ', ' Biologic Models ', ' Biological Models ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' Names ', ' National Institutes of Health ', ' NIH ', ' United States National Institutes of Health ', ' living system ', ' Organism ', ' Peptides ', ' Transphosphorylases ', ' Phosphotransferase Gene ', ' Kinases ', ' Phosphotransferases ', ' phosphorylase b kinase kinase ', ' hydroxyalkyl protein kinase ', ' glycogen synthase a kinase ', ' Kinase Family Gene ', ' ATP-protein phosphotransferase ', ' Protein Kinase ', ' tyrosyl protein kinase ', ' hydroxyaryl protein kinase ', ' Tyrosylprotein Kinase ', ' Tyrosine-Specific Protein Kinase ', ' Tyrosine-Protein Kinase Receptor EEK ', ' Tyrosine Kinase ', ' Protein Tyrosine Kinase EEK ', ' Ephrin Type-A Receptor 8 Precursor ', ' Ephrin Type-A Receptor 8 ', ' EPH-and ELK-Related Kinase ', ' EPH- and ELK-Related Tyrosine Kinase ', ' Protein Tyrosine Kinase ', ' Proteins ', ' Publishing ', ' Recurrent ', ' Recurrence ', ' biological signal transduction ', ' Signaling ', ' Signal Transduction Systems ', ' Intracellular Communication and Signaling ', ' Cell Signaling ', ' Cell Communication and Signaling ', ' Signal Transduction ', ' Testing ', ' Tyrosine ', ' Threonine Kinase ', ' Serine/Threonine Protein Kinase Gene ', ' Serine-Threonine Kinases ', ' Serine Kinase ', ' Protein-Threonine Kinase ', ' Protein-Serine Kinase ', ' Protein-Serine-Threonine Kinases ', ' base ', ' improved ', ' Distal ', ' Site ', ' Variant ', ' Variation ', ' Active Sites ', ' Receptor Protein-Tyrosine Kinases ', ' Tyrosine Kinase Receptors ', ' Tyrosine Kinase Linked Receptors ', ' Transmembrane Receptor Protein Tyrosine Kinase ', ' Receptor Tyrosine Kinase Gene ', ' PTK Receptors ', ' insight ', ' Therapeutic ', ' Inflammatory ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Complex ', ' Pattern ', ' System ', ' molecular dynamics ', ' Molecular Dynamics Simulation ', ' mutant ', ' Structure ', ' novel ', ' Regulation ', ' Modeling ', ' Property ', ' Genomics ', ' drug discovery ', ' Pathogenicity ', ' Molecular Interaction ', ' Binding ', ' genome sequencing ', ' Address ', ' Drug Binding Site ', ' Mutate ', ' Ontology ', ' Tyrosine Kinase Domain ', ' Molecular ', ' nonsynonymous mutation ', ' non-synonymous mutation ', ' computer framework ', ' computational framework ', ' Outcome ', ' three dimensional structure ', ' 3D structure ', ' 3-dimensional structure ', ' 3-D structure ', ' translational medicine ', ' human disease ', ' public health relevance ', ' personalized medicine ', ' personalized treatment ', ' personalized therapy ', ' personalization of treatment ', ' predictive test ', ' predictive assay ', ' ']",NIGMS,UNIVERSITY OF GEORGIA,R01,2019,300000,GA-10,0.253183175078445
"Predicting Transcriptional and Epigenetic Networks in Cancer from Sequencing Data Limitless replicative potential is a key hallmark of cancer and critically depends on telomere maintenance. Many cancers thus aberrantly reactivate the telomerase reverse transcriptase (TERT), a catalytic subunit of the telomerase complex that elongates telomere. It has been recently discovered that this common path to immortality in multiple cancers is through two activating point mutations in the TERT promoter (TERTp), found in more than 50 different cancer types, often at strikingly high frequencies, e.g. roughly 83% in glioblastomas (GBM) and 71% in melanomas. In the previous funding period, the PI has identified the molecular function of these highly recurrent mutations, demonstrating that the transcription factor (TF) GABP binds the mutant TERTp with exquisite specificity, but not the wild-type TERTp. The high prevalence of TERTp mutations across multiple cancer types and the selectivity of GABP recruitment to mutant TERTp thus provide an unprecedented opportunity for treating a large number of cancer patients with minimal toxicity to healthy cells. Despite the clear significance of this opportunity, however, several important questions surrounding the molecular functions and modulators of TERTp mutations remain poorly understood, hindering the development of effective and safe therapeutic strategies.  Our long-term goal is to establish a rigorous computational framework for understanding the aberrant transcriptional and epigenetic networks in cancers and to apply the resulting knowledge to devise novel therapeutic strategies that account for the genetic background of individual patients and that can a priori predict and avoid potential resistance mechanisms. The objective of our current renewal proposal is to develop powerful computational methods for transforming our knowledge about the non-coding TERTp mutations into an effective and safe molecular target. At the same time, the resulting methods will help resolve several outstanding challenges in the field of transcriptional gene regulation and have broad applications in cancer genomics. We will accomplish our objective my pursuing the following Aims: (1) Develop and test a computational framework for inferring sequence features that determine the distinct and shared binding patterns of paralogous TFs; (2) Develop and validate integrative tools for discovering the molecular basis of genetic interactions between germline variations and oncogenic mutations; (3) Develop and apply computational methods for studying the role of DNA helical phase between adjacent binding motifs in recruiting ETS factors to chromatin; (4) Perform a systematic genomic characterization of the effects of knocking out GABPB1L in TERTp-mutant cancer cells and healthy cells. The results of this proposal will have a broad impact on cancer research by providing powerful tools for studying paralogous oncogenic TFs and revealing novel insights into a highly promising therapeutic strategy. The proposed research will provide computational and bioinformatic resources for studying the binding pattern of paralogous oncogenic transcription factors. It will provide a computational framework for inferring the function of non-coding regulatory mutations and studying their interaction with common genetic variants. As an important application, we will systematically analyze a novel therapeutic strategy that has the potential to treat effectively a large number of patients across multiple cancer types harboring the recently discovered TERT promoter mutations.",Predicting Transcriptional and Epigenetic Networks in Cancer from Sequencing Data,9609431,R01CA163336,"['Binding Sites ', ' Reactive Site ', ' Combining Site ', ' Malignant Neoplasms ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Cell Body ', ' Cells ', ' Chromatin ', ' computing method ', ' computer methods ', ' computer based method ', ' computational methods ', ' computational methodology ', ' Computing Methodologies ', ' Deoxyribonucleic Acid ', ' DNA ', ' resistant to Drug ', ' resistance to Drug ', ' drug resistant ', ' Drug resistance ', ' Family ', ' Gene Regulation Process ', ' Gene Regulation ', ' Gene Action Regulation ', ' Gene Expression Regulation ', ' Genome ', ' spongioblastoma multiforme ', ' glioblastoma multiforme ', ' Grade IV Astrocytoma ', ' Grade IV Astrocytic Tumor ', ' Grade IV Astrocytic Neoplasm ', ' Glioblastoma ', ' Goals ', ' knowledge of results ', ' Malignant Melanoma ', ' melanoma ', ' Methods ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' Patients ', ' Recurrent ', ' Recurrence ', ' Research ', ' Revertase ', ' Reverse Transcriptase ', ' RNA-Dependent DNA Polymerase ', ' RNA Transcriptase ', ' EC 2.7.7.49 ', ' RNA-Directed DNA Polymerase ', ' social role ', ' Role ', ' Specificity ', ' Testing ', ' Time ', ' Transcription factor genes ', ' Transcription Factor Proto-Oncogene ', ' General Transcription Factors ', ' General Transcription Factor Gene ', ' Basal transcription factor genes ', ' Basal Transcription Factor ', ' transcription factor ', ' Transcription ', ' RNA Expression ', ' Gene Transcription ', ' Genetic Transcription ', ' Work ', ' v-myc Avian Myelocytomatosis Viral Oncogene Cellular Homolog ', ' cmyc ', ' c myc ', ' c-myc Genes ', ' telomere ', ' Family member ', ' Mediating ', ' promotor ', ' promoter ', ' Telomerase ', ' Point Mutation ', ' base ', ' Phase ', ' Variant ', ' Variation ', ' Link ', ' insight ', ' Individual ', ' Funding ', ' Therapeutic ', ' Genetic ', ' cancer cell ', ' Malignant Cell ', ' tool ', ' Nature ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Knowledge ', ' Frequencies ', ' Complex ', ' Pattern ', ' Techniques ', ' Somatic Mutation ', ' dimer ', ' mutant ', ' Protein Isoforms ', ' Isoforms ', ' Toxic effect ', ' Toxicities ', ' novel ', ' member ', ' Untranslated RNA ', ' noncoding ', ' Nontranslated RNA ', ' Noncoding RNA ', ' Non-translated RNA ', ' Non-Coding RNA ', ' Non-Coding ', ' Functional RNA ', ' Genomics ', ' Telomere Maintenance ', ' Transcriptional Control ', ' Transcription Regulation ', ' Transcriptional Regulation ', ' Molecular Interaction ', ' Binding ', ' TERT gene ', ' telomerase catalytic subunit ', ' Telomere Reverse Transcriptase ', ' TCS1 ', ' EST2 ', ' Address ', ' DNA Sequence Alteration ', ' genomic alteration ', ' Sequence Alteration ', ' Genetic mutation ', ' DNA mutation ', ' DNA Alteration ', ' Data ', ' High Prevalence ', ' Molecular Target ', ' Cancer Patient ', ' Epigenetic Process ', ' Epigenetic Mechanism ', ' Epigenetic Change ', ' Epigenetic ', ' Validation ', ' Molecular ', ' Knock-out ', ' Knockout ', ' resistance mechanism ', ' resistant mechanism ', ' Development ', ' developmental ', ' cancer genomics ', ' oncogenomics ', ' genetic variant ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' anticancer research ', ' cancer research ', ' anti-cancer research ', ' computer framework ', ' computational framework ', ' cancer type ', ' Oncogenic ', ' computing resources ', ' computational resources ', ' novel therapeutics ', ' novel therapy ', ' novel drugs ', ' novel drug treatments ', ' next generation therapeutics ', ' new therapy ', ' new therapeutics ', ' new drugs ', ' new drug treatments ', ' therapeutic target ', ' treatment response ', ' therapeutic response ', ' response to treatment ', ' genome-wide ', ' genomewide ', ' genome scale ', ' individual patient ', ' recruit ', ' bioinformatics resource ', ' deep learning ', ' ']",NCI,UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN,R01,2019,317385,IL-13,0.14913333291555572
"Advancing Protein Engineering Using Artificial Intelligence and the ProtaBank Mutation Database PROJECT SUMMARY Therapeutic antibodies, specialized enzymes for drug manufacturing, small molecule drug screening agents, and other proteins have been instrumental in advancing biotechnology and medicine. Protein therapeutics alone represents a rapidly growing $100+ billion market with broad applications in the treatment of cancer, inflammatory and metabolic diseases, and numerous other disorders. Most of the antibodies and other protein therapeutics developed in the last several years have been engineered, leading to improvements in important properties such as efficacy, binding affinity, expression, stability, and immunogenicity. However, improving protein properties through sequence modification remains a challenging task. Artificial intelligence (AI), which has been enormously successful in several fields (e.g., image recognition, self-driving cars, natural language processing), is now being applied to protein engineering and has the potential to transform this field as well. AI and machine learning (ML) can take advantage of large and diverse datasets to identify correlations, predict beneficial mutations, and explore novel protein sequences in ways that are not possible using other techniques. Other advantages include the ability to simultaneously optimize multiple protein properties and explore sequence space more efficiently. In Phases I and II of this project, we developed the ProtaBank database as a central repository to store, organize, and annotate protein mutation data spanning a broad range of properties. ProtaBank is the largest and only database actively collecting such a comprehensive set of sequence mutation data and is growing rapidly due to the wealth of data being generated with advanced automation and next-generation sequencing techniques. ProtaBank's depth and breadth makes it an ideal data source to train ML models. This proposal aims to create the ProtaBank AI Platform to enable the use of AI and ML tools to apply the data in ProtaBank to engineer proteins. The platform will provide fully customizable computational tools and will invoke protein-specific knowledge to properly prepare data for use with ML models. An interface to popular ML frameworks will be provided so that scientists can use these techniques to discover new predictive algorithms and enhance their ability to design proteins with the desired properties. Specific aims include: (1) integrating peer validated ML methods and proprietary technology for protein engineering into the ProtaBank AI Platform, (2) developing dynamic ML dataset creation tools, (3) expanding and improving the ProtaBank database by reaching out to scientists to contribute data, (4) enhancing our data deposition tools, and (5) integrating ProtaBank with the Protein Data Bank structure database and other databases. ! Project Narrative Protein engineering has enabled significant advances in health care by playing a key role in the development of antibodies and other protein therapeutics (e.g., for the treatment of cancer, inflammatory and metabolic diseases, and other disorders), highly selective enzymes for drug manufacturing, and novel proteins for use in diagnostics and the identification of new small molecule drugs. This project will enable the power of artificial intelligence (AI) to be applied to accelerate the engineering of proteins with new and improved properties. AI approaches can capitalize on the large amounts of protein mutation data being generated and stored in our recently developed ProtaBank protein mutation database to transform the way in which protein therapeutics and reagents are discovered and developed.!",Advancing Protein Engineering Using Artificial Intelligence and the ProtaBank Mutation Database,9847841,R44GM117961,"['Amino Acid Sequence ', ' protein sequence ', ' Primary Protein Structure ', ' Antibodies ', ' Artificial Intelligence ', ' Machine Intelligence ', ' Computer Reasoning ', ' Automation ', ' Automobile Driving ', ' driving ', ' Base Sequence ', ' nucleic acid sequence ', ' Nucleotide Sequence ', ' Biological Assay ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' Biotechnology ', ' Biotech ', ' Communities ', ' Data Sources ', ' Disorder ', ' Disease ', ' drug/agent ', ' Pharmaceutic Preparations ', ' Medication ', ' Drugs ', ' Pharmaceutical Preparations ', ' Engineering ', ' Enzyme Gene ', ' Enzymes ', ' Medicine ', ' metabolism disorder ', ' Thesaurismosis ', ' Metabolic Disorder ', ' Metabolic Diseases ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' natural language understanding ', ' Natural Language Processing ', ' Play ', ' protein design ', ' genetic protein engineering ', ' Protein Engineering ', ' Proteins ', ' Reagent ', ' Researchers ', ' Investigators ', ' Research Personnel ', ' Standardization ', ' Technology ', ' Generations ', ' health care ', ' Healthcare ', ' Dataset ', ' Data Set ', ' base ', ' improved ', ' Phase ', ' Link ', ' Training ', ' insight ', ' Databases ', ' data base ', ' Data Bases ', ' Data Quality ', ' Meteor ', ' Inflammatory ', ' Deposition ', ' Deposit ', ' tool ', ' Diagnostic ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Knowledge ', ' Scientist ', ' Protocols documentation ', ' Protocol ', ' Techniques ', ' Structure ', ' novel ', ' peer ', ' Modeling ', ' Sampling ', ' Property ', ' repository ', ' therapeutic protein ', ' protein drug agent ', ' pharmaceutical protein ', ' native protein drug ', ' cancer therapy ', ' anticancer therapy ', ' anti-cancer therapy ', ' Malignant Neoplasm Treatment ', ' Malignant Neoplasm Therapy ', ' Cancer Treatment ', ' Molecular Interaction ', ' Binding ', ' small molecule ', ' protein structure ', ' Affinity ', ' Data ', ' Collection ', ' Preparation ', ' Modification ', ' Development ', ' developmental ', ' Image ', ' imaging ', ' computerized tools ', ' computational tools ', ' immunogenicity ', ' design ', ' designing ', ' Coupled ', ' Therapeutic antibodies ', ' multitask ', ' multi-task ', ' database structure ', ' data base structure ', ' flexibility ', ' flexible ', ' next generation sequencing ', ' nextgen sequencing ', ' next gen sequencing ', ' NGS system ', ' NGS Method ', ' learning strategy ', ' learning method ', ' learning activity ', ' prediction algorithm ', ' predictor algorithm ', ' predictive algorithm ', ' Structural Protein ', ' Drug Screening ', ' data warehouse ', ' data repository ', ' Databanks ', ' Data Banks ', ' data submission ', ' data deposition ', ' deep learning ', ' ']",NIGMS,"PROTABIT, LLC",R44,2019,990318,CA-27,0.0816111822418586
"The Evolution of Gene Regulation and Human Disease PROJECT SUMMARY Genetic variants that disrupt the functionality of regulatory sequences, and thereby alter gene expression levels, are major contributors to both evolutionary divergence between species and differences in risk for complex disease among humans. However, due to the complexity of the gene regulatory programs encoded in mammalian genomes and their rapid turnover between species, evaluating the function of non-protein-coding mutations is challenging. This is a major roadblock to tracing the evolution of human-specific biology. In addition, since the majority of disease-associated variants are non-coding, it impairs our ability to map the genetics of complex disease.  The long-term mission of my lab is to interpret the complex gene regulatory programs encoded in the human genome and accurately model the effects of genetic mutations to these elements on phenotypes relevant to disease and human evolution. We work toward these goals by integrating cutting-edge machine learning, statistical modeling of evolution, and the analysis of genotypes and phenotypes from large-scale clinical biobanks. In particular, my lab is uniquely well positioned to build on our previous work to address the following fundamental questions:  1. How have evolutionary transitions on the human-lineage modified the genomein particular gene  regulatory programsto produce human-specific biology? And how do these modifications relate to  human-specific disease risk?  2. What are the combinatorial rules underlying how TF binding patterns specify precise control of gene  regulation? And how do these gene regulatory programs evolve between species?  3. How do genetic and epigenetic mechanisms interact to specify the dynamic gene regulatory programs  that drive cellular development? And how are these programs perturbed in disease?  4. How can we interpret non-protein-coding mutations identified in patient genomes to inform treatment  and preventative care? Our work will produce much-needed methods for understanding the effects of mutations to gene regulatory regions and identify mutations responsible for differences in disease risk between human populations. PROJECT NARRATIVE The genetic mutations that distinguish humans from other great apes and that influence risk for complex disease are mostly found outside of genes. Many of these mutations influence when and where genes are expressed. However, we do not know how to interpret the effects of most such mutations on gene regulation, disease risk, or human evolution, we will develop computational models that leverage machine learning, evolutionary patterns, and large-scale clinical biobanks to identify mutations that disrupt proper control of genes and lead to disease.",The Evolution of Gene Regulation and Human Disease,9673749,R35GM127087,"['Biology ', ' virtual simulation ', ' in silico ', ' computerized simulation ', ' computerized modeling ', ' computer based models ', ' computational simulation ', ' computational models ', ' computational modeling ', ' Mathematical Models and Simulations ', ' Mathematical Model Simulation ', ' Computerized Models ', ' Computer based Simulation ', ' Computer Models ', ' Computer Simulation ', ' Disorder ', ' Disease ', ' Elements ', ' Evolution ', ' Gene Expression ', ' Gene Regulation Process ', ' Gene Regulation ', ' Gene Action Regulation ', ' Gene Expression Regulation ', ' Genes ', ' trans acting element ', ' regulatory gene ', ' Transcriptional Regulatory Elements ', ' Regulator Genes ', ' Genome ', ' human whole genome ', ' Human Genome ', ' Genotype ', ' Goals ', ' Modern Man ', ' Human ', ' heavy metal lead ', ' heavy metal Pb ', ' Pb element ', ' Lead ', ' Maps ', ' Methods ', ' Mission ', ' statistical linear models ', ' statistical linear mixed models ', ' Probability Models ', ' Probabilistic Models ', ' Statistical Models ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' Patients ', ' Phenotype ', ' great ape ', ' Apes ', ' Pongidae ', ' genetic regulatory element ', ' Regulatory Regions ', ' Nucleic Acid Regulator Regions ', ' Nucleic Acid Regulatory Sequences ', ' Risk ', ' Work ', ' species difference ', ' Clinical ', ' Specific qualifier value ', ' Specified ', ' Variant ', ' Variation ', ' Genetic ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' programs ', ' Complex ', ' Pattern ', ' disorder risk ', ' disease risk ', ' Positioning Attribute ', ' Position ', ' Code ', ' Coding System ', ' Modeling ', ' Untranslated RNA ', ' noncoding ', ' Nontranslated RNA ', ' Noncoding RNA ', ' Non-translated RNA ', ' Non-Coding RNA ', ' Non-Coding ', ' Functional RNA ', ' Molecular Interaction ', ' Binding ', ' Address ', ' DNA Sequence Alteration ', ' genomic alteration ', ' Sequence Alteration ', ' Genetic mutation ', ' DNA mutation ', ' DNA Alteration ', ' Epigenetic Process ', ' Epigenetic Mechanism ', ' Epigenetic Change ', ' Epigenetic ', ' To specify ', ' Modification ', ' genetic variant ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' Population ', ' Impairment ', ' combinatorial ', ' mammalian genome ', ' human disease ', ' cellular development ', ' biobank ', ' biorepository ', ' Preventive care ', ' Preventative care ', ' ']",NIGMS,VANDERBILT UNIVERSITY,R35,2019,392270,TN-05,0.11439979874233072
"A combined computational and experimental approach to the evolution and role of the DNA sequence environment in targeting mutations to antibody V regions Project summary There is a fundamental gap in our understanding of how mutations are preferentially targeted to the variable (V) regions of the Immunoglobulin (Ig) loci during somatic hypermutation (SHM). The persistence of this gap has limited our understanding of the mutagenic mechanisms involving activation-induced deaminase (AID) in the immune response and in the role of AID in mis-targeting mutations leading to B-cell lymphomas and other cancers. The long-term goal of the proposed research is to understand the global targeting of mutations in immunity that are required to protect us from infections. As high-throughput data from human antibody immune responses became available, it provided us with new opportunities to generate hypotheses to explain the underlying mechanisms of SHM. We now propose to generate further hypotheses using computational models applied to additional databases and to validate these hypotheses using cellular and animal experiments. Our objective is to understand what directs SHM across the many human Ig heavy chain V-regions. Our central hypothesis is that the V-region SHM process is highly dependent on a DNA sequence signature(s) that drives mutations in a largely deterministic fashion. This hypothesis is supported by our preliminary results using human in vivo data from a few human V region genes and has begun to be validated using independent databases and experiments in human B cell lines. The rationale is that evaluations of computational data based upon biological mechanisms, together with appropriate biological experiments, will reveal the key differences between IGHV regions (IGHV 3-23, 4-34, 1-18, 1-02, etc.) that lead to the dominance of each of those V regions in the responses to medically important antigens. Our hypothesis will be tested by pursuing two specific aims: 1) identify the extent to which a DNA signature determines the mutation process in four individual human IGHV genes that are important in disease responses; 2) examine the relationship between AID hotspots and Pol hotspots across all the other human V region genes, thus rigorously defining a mutation targeting signature. Both aims will also entail studying human V region genes and modifications of them in human cell lines and in mice expressing a human V region to further confirm the signature and identify molecular mechanisms in vivo. Our approach is innovative because the computational models we are proposing will be mechanistically motivated focusing on the interaction between AID and Pol hotspots, thus testing molecular mechanisms as opposed to classic statistical models using whole V region sequences that ignore the underlying biology. In addition, to focus on mechanisms we will leverage new high-throughput data from human V regions that have not undergone antigen selection. Our results will be highly relevant to human IgV repertoire analyses from immune responses that are currently hard to interpret and will help future vaccine and therapeutic antibody development, as well as help to understand mutations in human malignancies where AID plays a key role. Project narrative The proposed research is relevant to public health because understanding the targeting of AID-mediated mutations across many human heavy chain V-regions will make it possible to develop vaccines that will lead more rapidly to better and more broadly protective antibodies to infectious agents and reveal the risk factors in the development of B-cell malignancies and gastric and other solid tumors where AID is implicated.",A combined computational and experimental approach to the evolution and role of the DNA sequence environment in targeting mutations to antibody V regions,9653955,R01AI132507,"['Affect ', ' Alleles ', ' Allelomorphs ', ' Antibodies ', ' Antibody Affinity ', ' antigen antibody affinity ', ' Antigens ', ' immunogen ', ' ATGN ', ' Autoimmunity ', ' Autoimmune Status ', ' B-Lymphocytes ', ' B-cell ', ' B-Cells ', ' B cells ', ' B cell ', ' B blood cells ', ' Biology ', ' Malignant Neoplasms ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' cultured cell line ', ' Strains Cell Lines ', ' CellLine ', ' Cell Line ', ' Chromatin ', ' virtual simulation ', ' in silico ', ' computerized simulation ', ' computerized modeling ', ' computer based models ', ' computational simulation ', ' computational models ', ' computational modeling ', ' Mathematical Models and Simulations ', ' Mathematical Model Simulation ', ' Computerized Models ', ' Computer based Simulation ', ' Computer Models ', ' Computer Simulation ', ' Disorder ', ' Disease ', ' Deoxyribonucleic Acid ', ' DNA ', ' Environment ', ' Enzyme Activation ', ' Evolution ', ' Family ', ' Feedback ', ' Future ', ' Genes ', ' Goals ', ' Virus-HIV ', ' Lymphadenopathy-Associated Virus ', ' LAV-HTLV-III ', ' Human Immunodeficiency Viruses ', ' Acquired Immunodeficiency Syndrome Virus ', ' Acquired Immune Deficiency Syndrome Virus ', ' AIDS Virus ', ' HIV ', ' Modern Man ', ' Human ', ' Immunity ', ' Immunoglobulin Hypervariable Region ', ' Hypervariable Regions ', ' Hypervariable Loop ', ' Complimentarity Determining Region ', ' Complementarity Determining Regions ', ' Immune Globulins ', ' Immunoglobulins ', ' Heavy-Chain Immunoglobulins ', ' Infection ', ' influenza infection ', ' flu infection ', ' Grippe ', ' Influenza ', ' heavy metal lead ', ' heavy metal Pb ', ' Pb element ', ' Lead ', ' Transgenic Mice ', ' statistical linear models ', ' statistical linear mixed models ', ' Probability Models ', ' Probabilistic Models ', ' Statistical Models ', ' Murine ', ' Mice Mammals ', ' Mice ', ' Mus ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' Play ', ' Public Health ', ' Research ', ' Risk Factors ', ' social role ', ' Role ', ' gastric ', ' Stomach ', ' Testing ', ' Time ', ' Vaccines ', ' B lymphoma ', ' B-Cell Lymphomas ', ' Mediating ', ' -Gs ', ' alpha-Gs ', ' alpha Subunit Stimulatory GTP-Binding Protein ', ' Stimulatory Gs G-Protein ', ' Regulatory Ns Protein ', ' Gs ', ' Gs ', ' Gs alpha Family G-Protein ', ' GTP-Binding Protein  Subunits, Gs ', ' G(s) ', ' G(s)alpha ', ' G(s),  Subunit ', ' G(s), alpha Subunit ', ' GTP-Binding Protein alpha Subunits, Gs ', ' DNA Sequence ', ' base ', ' density ', ' Site ', ' Variant ', ' Variation ', ' Biological ', ' Medical ', ' Animal Experiments ', ' Evaluation ', ' Individual ', ' Databases ', ' data base ', ' Data Bases ', ' Solid Neoplasm ', ' Solid Tumor ', ' Structure of germinal center of lymph node ', ' Germinal Center ', ' Immune response ', ' immunoresponse ', ' host response ', ' Immunological response ', ' Infectious Agent ', ' infectious organism ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Frequencies ', ' Event ', ' Pattern ', ' Techniques ', ' Location ', ' neutralizing antibody ', ' human data ', ' repair enzyme ', ' repair endonuclease ', ' Human Cell Line ', ' response ', ' Immunoglobulin Somatic Hypermutation ', ' somatic hypermutation ', ' Ig Somatic Hypermutation ', ' activation-induced cytidine deaminase ', ' activation-induced deaminase ', ' CDA2 protein ', ' AID protein ', ' AID gene ', ' AICDA protein ', ' AICDA ', ' Mismatch Repair ', ' Post-Replication Mismatch Repair ', ' chromatin modification ', ' Polymerase ', ' B-Cell Development ', ' Data ', ' Mutate ', ' in vivo ', ' in vivo Model ', ' Computer Analysis ', ' computer analyses ', ' computational analysis ', ' computational analyses ', ' Gene-Modified ', ' gene modification ', ' Validation ', ' Molecular ', ' Process ', ' Development ', ' developmental ', ' genetic variant ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' B lymphoid malignancy ', ' B cell malignancy ', ' Outcome ', ' innovation ', ' innovative ', ' innovate ', ' Influenza Hemagglutinin ', ' influenza virus hemagglutinin ', ' influenza virus HA ', ' flu hemagglutinin ', ' flu HA ', ' Influenza HA ', ' Therapeutic antibodies ', ' spatial relationship ', ' vaccine response ', ' Knock-in ', ' knockin ', ' experimental study ', ' experimental research ', ' experiment ', ' recruit ', ' ']",NIAID,ALBERT EINSTEIN COLLEGE OF MEDICINE,R01,2019,587448,NY-14,0.15887011747240132
"A novel human T-cell platform to define biological effects of genome editing PROJECT SUMMARY Genome editing technologies have extraordinary potential as new genomic medicines that address underlying genetic causes of human disease; however, it remains challenging to predict their long-term safety, because we do not know the consequences of potential side effects of genome editing such as off-target mutations or immunogenicity. Our long-term goal is to understand and predict such unintended biological effects to advance the development of safe and effective therapies. T-cells are an ideal cellular model because: 1) they are highly relevant as the most widely used cells for development of therapeutic genome editing strategies (such as cell-based treatments for HIV and cancer) and 2) mature T-cells encode a diverse T-cell receptor repertoire that can be exploited as built-in cellular barcodes for quantifying clonal expansion or depletion in response to specific treatments. We, therefore, propose the following specific aims: 1) to predict which unintended editing sites have biological effects on human T-cells by integrating large-scale genome-wide activity and epigenomic profiles with state-of-the-art deep learning models and 2) to develop a human primary T-cell platform to detect functional effects of genome editing by measuring clonal representation, off-target mutation frequencies, immunogenicity, or gene expression. If successful, our experimental and predictive framework will profoundly increase confidence in the safety of the next generation of promising genome editing therapies. PROJECT NARRATIVE Genome editing technologies have extraordinary potential as the basis of new genomic medicines that address the underlying genetic causes of human disease; however, it is challenging to predict their long-term safety, because we do not know the consequences of potential unintended side effects of genome editing such as off-target mutations or immunogenicity. To define the biological effects of genome editing strategies, we will develop a human primary T-cell platform to sensitively detect functional effects coupled with an empirically-trained artificial intelligence models to predict them. Together, our platform will significantly improve confidence in safety assessments of promising genome editing therapeutics.",A novel human T-cell platform to define biological effects of genome editing,9783881,U01EB029373,"['Affect ', ' Epitopes ', ' Binding Determinants ', ' Antigenic Determinants ', ' Artificial Intelligence ', ' Machine Intelligence ', ' Computer Reasoning ', ' Biological Assay ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' Malignant Neoplasms ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Subcellular Process ', ' Cellular Process ', ' Cellular Physiology ', ' Cellular Function ', ' Cell Process ', ' Cell Function ', ' Cell physiology ', ' Cell Body ', ' Cells ', ' Chromatin ', ' Engineering ', ' Gene Expression ', ' genomic therapy ', ' genetic therapy ', ' gene-based therapy ', ' Genetic Intervention ', ' Gene Transfer Clinical ', ' DNA Therapy ', ' gene therapy ', ' Genes ', ' human whole genome ', ' Human Genome ', ' Goals ', ' Virus-HIV ', ' Lymphadenopathy-Associated Virus ', ' LAV-HTLV-III ', ' Human Immunodeficiency Viruses ', ' Acquired Immunodeficiency Syndrome Virus ', ' Acquired Immune Deficiency Syndrome Virus ', ' AIDS Virus ', ' HIV ', ' Modern Man ', ' Human ', ' Human Genetics ', ' immunodeficiency ', ' immune deficiency disorder ', ' hypoimmunity ', ' Immunological Deficiency Syndromes ', ' Immunodeficiency Syndrome ', ' Immunodeficiency Disorder ', ' Immunologic Deficiency Syndromes ', ' In Vitro ', ' Maps ', ' Methods ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' Phenotype ', ' protooncogene ', ' c-ONC ', ' Cellular Oncogene ', ' Proto-Oncogenes ', ' Receptors, Antigen, T-Cell ', ' Major Histocompatibility Complex Receptor ', ' MHC Receptor ', ' T-Cell Receptor ', ' Ribonucleoproteins ', ' Safety ', ' Standardization ', ' Streptococcus Group A ', ' S.pyogenes ', ' S. pyogenes ', ' S pyogenes ', ' Streptococcus pyogenes ', ' thymus derived lymphocyte ', ' T-Cells ', ' T-Lymphocyte ', ' Technology ', ' Testing ', ' Transcription ', ' RNA Expression ', ' Gene Transcription ', ' Genetic Transcription ', ' Genetic Diversity ', ' Genetic Variation ', ' cytokine ', ' Measures ', ' Targeted Modification ', ' Targeted DNA Modification ', ' Site-Specific Mutagenesis ', ' Site-Directed Mutagenesis ', ' Organizational Change ', ' base ', ' improved ', ' Site ', ' Benign ', ' Variant ', ' Variation ', ' Biological ', ' Biochemical ', ' Training ', ' Therapeutic ', ' Genetic ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Peptide Library ', ' DNA Methylation ', ' Frequencies ', ' Inherited ', ' Hereditary ', ' Complex ', ' genotoxicity ', ' Peripheral Blood Mononuclear Cell ', ' PBMC ', ' novel ', ' Modeling ', ' response ', ' immunogenic ', ' functional genomics ', ' Adverse effects ', ' Genomics ', ' Bioinformatics ', ' Bio-Informatics ', ' T-Cell Proliferation ', ' histone modification ', ' Address ', ' Detection ', ' Mature T-Lymphocyte ', ' Mature T-Cell ', ' Regulatory Element ', ' Retroviral Vector ', ' Retrovirus Vector ', ' in vivo ', ' Clonal Expansion ', ' epigenomics ', ' Advanced Development ', ' immunogenicity ', ' next generation ', ' Outcome ', ' Population ', ' Coupled ', ' therapeutic gene ', ' genes therapeutics ', ' genes therapeutic ', ' gene-based therapeutics ', ' gene therapeutics ', ' Oncogenic ', ' Cell model ', ' Cellular model ', ' human disease ', ' novel therapeutics ', ' novel therapy ', ' novel drugs ', ' novel drug treatments ', ' next generation therapeutics ', ' new therapy ', ' new therapeutics ', ' new drugs ', ' new drug treatments ', ' therapeutic development ', ' therapeutic agent development ', ' effective therapy ', ' effective treatment ', ' genome-wide ', ' genomewide ', ' genome scale ', ' safety testing ', ' comparative genomics ', ' T cell response ', ' adverse outcome ', ' adverse consequence ', ' transcriptome sequencing ', ' RNAseq ', ' RNA sequencing ', ' RNA Seq ', ' genome editing ', ' genomic editing ', ' learning strategy ', ' learning method ', ' learning activity ', ' Genomic medicine ', ' adaptive immune response ', ' Genetic Diseases ', ' genetic disorder ', ' genetic condition ', ' T-cell receptor repertoire ', ' TCR repertoire ', ' therapeutic genome editing ', ' genome editing-based therapeutics ', ' genome editing based therapy ', ' deep learning ', ' side effect ', ' safety assessment ', ' ']",NIBIB,ST. JUDE CHILDREN'S RESEARCH HOSPITAL,U01,2019,611358,TN-09,0.09653223666615235
"Reverse Sensitivity Analysis for Identifying Predictive Proteomics Signatures of Cancer Title: Reverse Sensitivity Analysis for Identifying Proteomics Signatures of Cancer Abstract Cancer is a complex disease in which genetic disruptions in cell signaling networks are known to play a significant role. A major aim of cancer systems biology is to build models that can predict the impact of these genetic disruptions to guide therapeutic interventions (i.e. personalized medicine). A prominent driver of cancer cell growth is signaling pathway deregulation from mutations in key regulatory nodes and loss/gain in gene copy number (CNV). However, current mathematical modeling approaches do not adequately capture the impact of these genetic changes. Reasons for this include the poorly understood layers of regulation between gene expression and protein activity, and limitations in most modeling and protein measurement technologies. In addition, there is a paucity of overarching hypotheses that can link specific gene expression or mutation patterns to the cancer phenotype. Recent work by our group has resolved some of the technical challenges that have hindered the application of proteomics technologies to cancer systems biology research. It has also suggested a new approach for using quantitative proteomics data to understand mechanisms driving cancer cell behavior. Using an ultrasensitive, targeted proteomics platform that can measure both abundance and phosphorylation of proteins present at only hundreds of copies per cell, we found that signaling pathways appeared to be controlled by only a limited number of key nodes whose activity is tightly regulated through low abundance and feedback phosphorylation. We propose to build on these findings by critically testing the hypothesis that CNV and genetic mutations dysregulate signaling pathways in cancer by shifting control from tightly regulated nodes to poorly regulated ones. This will be done by systematically identifying key regulatory nodes of normal and cancer cells using CRISPRa/i screens, determine the relationship between protein abundance and signaling pathway activities using ultrasensitive targeted proteomics and phosphoproteomics and then use these data to semi-automatically generate mathematical models of the functional topology of the signaling pathways. Specifically, we propose to: 1) Use targeted CRISPR gene perturbation libraries to identify the regulatory topologies of signaling pathways important in cancer and how they are disrupted by common cancer mutations, 2) Use the CRISPR perturbation and proteomics data to semi-automatically build predictive models of cancer cell signaling pathways, and 3) Combine modeling and perturbation screens to understand how feedback regulation in cancer contributes to drug resistance. This work will result in simplified, computationally tractable yet mechanistic models of signaling pathways and provide network maps of feedback and crosstalk circuits that can be used to rapidly map the regulatory state of cells. Most important, it will provide a generic platform for translating protein abundance and phosphorylation patterns into a state snapshot of cancers that can lead to predicting their response to specific drugs. Narrative Cancer is an extremely complex disease which is frequently caused by signaling pathway deregulation from genetic mutation or loss/gain in gene copy number. Modern analytical techniques have provided a wealth of data on the molecular changes associated with cancer mutations, but it has been extremely difficult to use this information to design targeted therapies. We propose a new methodology that combines CRISPR-based targeted screens, advanced proteomics technologies, and a new mathematical modeling approach for identifying proteomics signatures of altered signaling pathways in cancer that can be used to build predictive models and explore mechanisms of drug resistance.",Reverse Sensitivity Analysis for Identifying Predictive Proteomics Signatures of Cancer,9731187,U01CA227544,"['Affect ', ' Automobile Driving ', ' driving ', ' Behavior ', ' Malignant Neoplasms ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Cell Body ', ' Cells ', ' virtual simulation ', ' in silico ', ' computerized simulation ', ' computerized modeling ', ' computer based models ', ' computational simulation ', ' computational models ', ' computational modeling ', ' Mathematical Models and Simulations ', ' Mathematical Model Simulation ', ' Computerized Models ', ' Computer based Simulation ', ' Computer Models ', ' Computer Simulation ', ' Disorder ', ' Disease ', ' resistant to Drug ', ' resistance to Drug ', ' drug resistant ', ' Drug resistance ', ' drug/agent ', ' Pharmaceutic Preparations ', ' Medication ', ' Drugs ', ' Pharmaceutical Preparations ', ' Feedback ', ' flow cytophotometry ', ' Flow Microfluorometry ', ' Flow Microfluorimetry ', ' Flow Cytofluorometry ', ' Flow Cytofluorometries ', ' Flow Cytometry ', ' Gene Expression ', ' Genes ', ' heavy metal lead ', ' heavy metal Pb ', ' Pb element ', ' Lead ', ' Libraries ', ' Maps ', ' Malignant Melanoma ', ' melanoma ', ' Methods ', ' Methodology ', ' Model System ', ' Biologic Models ', ' Biological Models ', ' Modernization ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' Phenotype ', ' Protein Phosphorylation ', ' Phosphorylation ', ' Play ', ' Proteins ', ' Reagent ', ' Research ', ' social role ', ' Role ', ' Signal Pathway ', ' biological signal transduction ', ' Signaling ', ' Signal Transduction Systems ', ' Intracellular Communication and Signaling ', ' Cell Signaling ', ' Cell Communication and Signaling ', ' Signal Transduction ', ' Technology ', ' Testing ', ' Translating ', ' Work ', ' Generations ', ' Measures ', ' Proto-Oncogene Proteins c-akt ', ' related to A and C-protein ', ' rac protein kinase ', ' proto-oncogene protein akt ', ' proto-oncogene protein RAC ', ' c-akt protein ', ' RAC-PK protein ', ' Protein Kinase B ', ' Akt protein ', ' AKT ', ' base ', ' Gene Dosage ', ' Gene Copy Number ', ' Link ', ' Measurement ', ' Genetic ', ' cancer cell ', ' Malignant Cell ', ' tool ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Complex ', ' Pattern ', ' Techniques ', ' Gene Mutation ', ' Gene Alteration ', ' Gene Proteins ', ' Protein Gene Products ', ' Therapeutic Intervention ', ' intervention therapy ', ' Regulation ', ' Modeling ', ' response ', ' Proteomics ', ' mathematical model ', ' mathematical modeling ', ' mathematic model ', ' Math Models ', ' Normal Cell ', ' Address ', ' Systems Biology ', ' DNA Sequence Alteration ', ' genomic alteration ', ' Sequence Alteration ', ' Genetic mutation ', ' DNA mutation ', ' DNA Alteration ', ' Data ', ' Mutate ', ' Predictive Cancer Model ', ' Cancer Cell Growth ', ' Molecular ', ' Development ', ' developmental ', ' Pathway interactions ', ' pathway ', ' predictive modeling ', ' prognostic model ', ' prediction model ', ' computer based prediction ', ' design ', ' designing ', ' novel strategies ', ' novel strategy ', ' novel approaches ', ' new approaches ', ' cancer type ', ' Resistance ', ' resistant ', ' cell behavior ', ' cellular behavior ', ' screening ', ' Clustered Regularly Interspaced Short Palindromic Repeats ', ' CRISPR/Cas system ', ' CRISPR ', ' Breast Epithelial Cells ', ' mammary epithelial cells ', ' personalized medicine ', ' personalized treatment ', ' personalized therapy ', ' personalization of treatment ', ' targeted treatment ', ' targeted therapy ', ' targeted therapeutic agents ', ' targeted therapeutic ', ' targeted drug treatments ', ' targeted drug therapy ', ' Breast Cancer cell line ', ' Breast tumor cell line ', ' phosphoproteomics ', ' phospho-proteomics ', ' CRISPR library ', ' CRISPR/Cas9 library ', ' CRISPR-based library ', ' proteomic signature ', ' experimental study ', ' experimental research ', ' experiment ', ' ']",NCI,BATTELLE PACIFIC NORTHWEST LABORATORIES,U01,2019,608348,WA-04,0.06342842594713283
"Predicting and analyzing variation in cellular interactomes Project Summary Over the last two decades, significant experimental efforts have determined large sets of reference interactions for humans and other model organisms, along with substantial knowledge about the binding specificities of proteins, including for a large fraction of human transcription factors (TFs). The resulting data have proven to be an incredibly useful resource for understanding how cells function; nevertheless, they do not capture how molecular interactions and networks are different from the reference across individuals. Indeed, while human genomes in both healthy and disease populations are rapidly being sequenced, the corresponding individual-specific interaction networks remain largely unexamined; this represents a major gap in our knowledge, as mutations that alter molecular interactions underlie a wide range of human diseases. Further, the substantial amount of genetic variation across populations makes it infeasible in the near term to experimentally determine per-individual interaction networks. Thus our long-term goal is to develop computational methods to uncover whether and how mutations within coding and non-coding portions of the genome perturb cellular interactions and networks. Our specific aims are: (1) We will develop computational structure-based approaches to identify and catalog, at proteome-scale, variations within proteins that are likely to impact their ability to bind with DNA, RNA, small molecules, peptides or ions, thereby providing a comprehensive resource for analyzing protein interaction variation. (2) We will develop novel structure-based and probabilistic methods to predict how DNA-binding specificities are altered when a TF is mutated; since mutated TFs have been linked to numerous diseases, this will be a great aid in understanding disease networks and pathology. (3) We will develop new methods to uncover non-coding somatic mutations that alter human regulatory networks in cancer; this is a critical step towards ultimately uncovering patient-specific cancer networks. Overall by pursuing these aimswhich integrate mutational information with existing knowledge about reference interactions, interfaces and specificitieswe will develop novel computational methods that will significantly advance our understanding of molecular interactions perturbed in disease and healthy contexts. Narrative The proposed research will yield new software tools that predict whether specific genetic mutations alter molecular interactions and networks. Since many human diseases are caused by mutations that affect molecular interactions, this research will expand our understanding of the underlying basis of disease and will provide new avenues for diagnosis and treatment.",Predicting and analyzing variation in cellular interactomes,9740714,R01GM076275,"['Affect ', ' Alleles ', ' Allelomorphs ', ' Amino Acid Sequence ', ' protein sequence ', ' Primary Protein Structure ', ' Binding Sites ', ' Reactive Site ', ' Combining Site ', ' Malignant Neoplasms ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Subcellular Process ', ' Cellular Process ', ' Cellular Physiology ', ' Cellular Function ', ' Cell Process ', ' Cell Function ', ' Cell physiology ', ' computing method ', ' computer methods ', ' computer based method ', ' computational methods ', ' computational methodology ', ' Computing Methodologies ', ' Diagnosis ', ' Disorder ', ' Disease ', ' Deoxyribonucleic Acid ', ' DNA ', ' Gene Expression ', ' Genes ', ' trans acting element ', ' regulatory gene ', ' Transcriptional Regulatory Elements ', ' Regulator Genes ', ' Genome ', ' human whole genome ', ' Human Genome ', ' Goals ', ' Modern Man ', ' Human ', ' Ions ', ' Methods ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' living system ', ' Organism ', ' Pathology ', ' Patients ', ' Peptides ', ' Play ', ' Proteins ', ' genetic regulatory element ', ' Regulatory Regions ', ' Nucleic Acid Regulator Regions ', ' Nucleic Acid Regulatory Sequences ', ' Research ', ' Research Resources ', ' Resources ', ' Ribonucleic Acid ', ' RNA Gene Products ', ' Non-Polyadenylated RNA ', ' RNA ', ' Computer Software Tools ', ' Software Tools ', ' Specificity ', ' Transcription factor genes ', ' Transcription Factor Proto-Oncogene ', ' General Transcription Factors ', ' General Transcription Factor Gene ', ' Basal transcription factor genes ', ' Basal Transcription Factor ', ' transcription factor ', ' Genetic Diversity ', ' Genetic Variation ', ' Work ', ' Mutagenesis Molecular Biology ', ' Genetics-Mutagenesis ', ' Mutagenesis ', ' Zinc Finger Motifs ', ' Zinc Finger Domain ', ' Zinc Fingers ', ' Mediating ', ' Dataset ', ' Data Set ', ' base ', ' improved ', ' Site ', ' Variant ', ' Variation ', ' Biological ', ' Link ', ' Individual ', ' Binding Proteins ', ' bound protein ', ' Protein Binding ', ' Ligand Binding Protein Gene ', ' Ligand Binding Protein ', ' Biological Process ', ' Biological Function ', ' Internet ', ' world wide web ', ' web ', ' WWW ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Knowledge ', ' Catalogs ', ' Complex ', ' Pattern ', ' interest ', ' Somatic Mutation ', ' preference ', ' Animal Model ', ' model organism ', ' model of animal ', ' Animal Models and Related Studies ', ' knowledge base ', ' knowledgebase ', ' Structure ', ' novel ', ' Proteome ', ' Code ', ' Coding System ', ' Sampling ', ' Property ', ' software development ', ' developing computer software ', ' develop software ', ' Untranslated RNA ', ' noncoding ', ' Nontranslated RNA ', ' Noncoding RNA ', ' Non-translated RNA ', ' Non-Coding RNA ', ' Non-Coding ', ' Functional RNA ', ' Bioinformatics ', ' Bio-Informatics ', ' DNA Binding ', ' DNA bound ', ' DNA Binding Interaction ', ' Molecular Interaction ', ' Binding ', ' small molecule ', ' DNA-Protein Interaction ', ' DNA Sequence Alteration ', ' genomic alteration ', ' Sequence Alteration ', ' Genetic mutation ', ' DNA mutation ', ' DNA Alteration ', ' Data ', ' Mutate ', ' Protein Analysis ', ' Ligand Binding ', ' cancer genome ', ' tumor genome ', ' cancer cell genome ', ' virtual ', ' Population ', ' human disease ', ' tumor ', ' disease-causing mutation ', ' learning strategy ', ' learning method ', ' learning activity ', ' predictive tools ', ' experimental study ', ' experimental research ', ' experiment ', ' Infrastructure ', ' ']",NIGMS,PRINCETON UNIVERSITY,R01,2019,312660,NJ-12,0.12353103120853917
"Clinicopathologic and Genetic Profiling through Machine Learning and Natural Language Processing for Precision Lung Cancer Management PROJECT SUMMARY/ABSTRACT Lung cancer is the second-most common type of cancer and the leading cause of cancer death in men and women. Among the different types of lung cancer, non-small cell lung cancer (NSCLC) is the most common type and it constitutes 85% to 90% of all lung cancer cases. Current cancer research has shown that multiple somatic mutations affect the sensitivity of patients to various drugs used for NSCLC treatment. These mutations are essential factors for determining the most effective, personalized treatment for each NSCLC patient; however, most NSCLC patients develop resistance to these targeted therapies in their first year of treatment. Many mechanisms of this resistance are still unknown. Designing and prescribing better targeted therapies for NSCLC patients requires further understanding, particularly with respect to the relationship between NSCLC tumors pathological and clinical findings, genetic profiles, and targeted therapy responses/resistance. Currently, there is no computational method to connect observations and findings from pathology reports, medical records, somatic mutations, and the targeted therapy resistance. This project provides a plan to build a novel computational method to identify statistically significant associations between the pathological findings of NSCLC tumors and the presence of clinically-actionable somatic mutations. Furthermore, these associations, in combination with an innovative set of feature analysis from pathology reports and electronic medical records, will be leveraged to build and validate a machine-learning model to identify NSCLC patients with clinically-actionable somatic mutations. Finally, the associated clinical, pathological, and genetic findings for NSCLC patients will be used in a new machine-learning framework to predict patients time-to-resistance to targeted therapies. The required data to build and validate the proposed models in this project will be obtained through a collaboration with the Department of Pathologys Laboratory for Clinical Genomics and Advanced Technologies at Dartmouth-Hitchcock Medical Center. In addition to internal validation, the investigators in this proposal established a collaboration with the Department of Pathology at the University of Vermont Medical Center to apply and validate the developed models on an external data source. Upon successful implementation of this bioinformatics approach, the developed models will be able to reveal statistically significant links between clinical and pathological findings, clinically-actionable somatic mutations, and targeted-therapy responses for a better understanding of NSCLC tumor development and treatment. The proposed approach will provide an accurate, fast, and inexpensive pre- selection method for screening NSCLC patients with clinically-actionable mutations for translational research and precision medicine. Furthermore, the proposed machine-learning method to identify NSCLC patients resistance to targeted therapies will help healthcare providers to select the best treatment strategies for these patients, improve their health outcomes, and establish this precision medicine paradigm for other types of cancer. PROJECT NARRATIVE Resistance to targeted therapies severely limits the ability to treat non-small cell lung cancer (NSCLC) patients. This project proposes a novel computational approach to find statistically-significant links between pathological and clinical findings, clinically-actionable mutations, and targeted-therapy responses for NSCLC patients. The outcomes of this proposal can assist healthcare providers to identify the most effective strategy for NSCLC treatment, improve public health, and promote precision medicine.",Clinicopathologic and Genetic Profiling through Machine Learning and Natural Language Processing for Precision Lung Cancer Management,9726144,R01CA249758,"['Affect ', ' Architecture ', ' Engineering / Architecture ', ' Attention ', ' malignant breast neoplasm ', ' malignant breast tumor ', ' Breast Cancer ', ' Non-Small-Cell Lung Carcinoma ', ' nonsmall cell lung cancer ', ' Nonsmall Cell Lung Carcinoma ', ' Non-Small Cell Lung Cancer ', ' NSCLC - Non-Small Cell Lung Cancer ', ' NSCLC ', ' virtual simulation ', ' in silico ', ' computerized simulation ', ' computerized modeling ', ' computer based models ', ' computational simulation ', ' computational models ', ' computational modeling ', ' Mathematical Models and Simulations ', ' Mathematical Model Simulation ', ' Computerized Models ', ' Computer based Simulation ', ' Computer Models ', ' Computer Simulation ', ' computing method ', ' computer methods ', ' computer based method ', ' computational methods ', ' computational methodology ', ' Computing Methodologies ', ' Data Sources ', ' Death ', ' Cessation of life ', ' resistant to Drug ', ' resistance to Drug ', ' drug resistant ', ' Drug resistance ', ' drug/agent ', ' Pharmaceutic Preparations ', ' Medication ', ' Drugs ', ' Pharmaceutical Preparations ', ' Family ', ' Foundations ', ' spongioblastoma multiforme ', ' glioblastoma multiforme ', ' Grade IV Astrocytoma ', ' Grade IV Astrocytic Tumor ', ' Grade IV Astrocytic Neoplasm ', ' Glioblastoma ', ' Health ', ' treatment provider ', ' medical personnel ', ' healthcare personnel ', ' health workforce ', ' health provider ', ' health care worker ', ' health care personnel ', ' Healthcare worker ', ' Healthcare Providers ', ' Health Care Providers ', ' Health Personnel ', ' History ', ' Recording of previous events ', ' Laboratories ', ' Medical Records ', ' Malignant Melanoma ', ' melanoma ', "" men's "", ' men ', ' Methods ', ' Methodology ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' National Institutes of Health ', ' NIH ', ' United States National Institutes of Health ', ' natural language understanding ', ' Natural Language Processing ', ' Pathology ', ' Patients ', ' Public Health ', ' Recurrent ', ' Recurrence ', ' Researchers ', ' Investigators ', ' Research Personnel ', ' Semantics ', ' Technology ', ' Testing ', ' Time ', ' Body Tissues ', ' Tissues ', ' Tweens ', ' Universities ', ' Vermont ', ' Woman ', ' Work ', ' Electronic Medical Record ', ' Computerized Medical Record ', ' Measures ', ' health care ', ' Healthcare ', ' Dataset ', ' Data Set ', ' base ', ' improved ', ' Clinical ', ' Medical ', ' Link ', ' Malignant neoplasm of lung ', ' lung cancer ', ' Pulmonary malignant Neoplasm ', ' Pulmonary Cancer ', ' Malignant Tumor of the Lung ', ' Drug usage ', ' drug use ', ' Collaborations ', ' Genetic ', ' cancer cell ', ' Malignant Cell ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Knowledge ', ' Pattern ', ' Clinical Decision Support Systems ', ' Somatic Mutation ', ' Medical center ', ' Performance ', ' novel ', ' Second Primary Cancers ', ' secondary cancer ', ' Secondary Malignant Neoplasm ', ' Secondary Malignancy ', ' Second Cancer ', ' Pathology Report ', ' Statistical Methods ', ' Modeling ', ' response ', ' Genomics ', ' cancer therapy ', ' anticancer therapy ', ' anti-cancer therapy ', ' Malignant Neoplasm Treatment ', ' Malignant Neoplasm Therapy ', ' Cancer Treatment ', ' Bioinformatics ', ' Bio-Informatics ', ' DNA Sequence Alteration ', ' genomic alteration ', ' Sequence Alteration ', ' Genetic mutation ', ' DNA mutation ', ' DNA Alteration ', ' Data ', ' Cancer Etiology ', ' Cancer Cause ', ' Cancer Patient ', ' Clinical Data ', ' Ontology ', ' Smoking Status ', ' Translational Research ', ' translation research ', ' Translational Science ', ' Tumor Pathology ', ' Validation ', ' Pathologic ', ' Characteristics ', ' resistance mechanism ', ' resistant mechanism ', ' Development ', ' developmental ', ' Colorectal Cancer ', ' Colo-rectal Cancer ', ' electronic data ', ' Pathway interactions ', ' pathway ', ' genetic profiling ', ' anticancer research ', ' cancer research ', ' anti-cancer research ', ' design ', ' designing ', ' Outcome ', ' Resistance development ', ' developing resistance ', ' Resistant development ', ' cancer type ', ' innovation ', ' innovative ', ' innovate ', ' Resistance ', ' resistant ', ' demographics ', ' tumor ', ' treatment response ', ' therapeutic response ', ' response to treatment ', ' treatment strategy ', ' Biological Markers ', ' biomarker ', ' biologic marker ', ' bio-markers ', ' screening ', ' precision medicine ', ' precision-based medicine ', ' personalized medicine ', ' personalized treatment ', ' personalized therapy ', ' personalization of treatment ', ' targeted treatment ', ' targeted therapy ', ' targeted therapeutic agents ', ' targeted therapeutic ', ' targeted drug treatments ', ' targeted drug therapy ', ' targeted cancer therapy ', ' clinically actionable ', ' learning strategy ', ' learning method ', ' learning activity ', ' power analysis ', ' actionable mutation ', ' driver mutation ', ' actionable variants ', ' ']",NCI,DARTMOUTH COLLEGE,R01,2019,375150,NH-02,0.03444410556199578
"The adaptive potential of translational regulation Project Summary/Abstract  Our current understanding of the adaptive effects of mutation is largely limited to alterations in protein coding sequence and disruption of transcriptional cis-regulatory promoters. Very little is known about how mutations alter translation, or the role these mutations play in adaptation and evolution. This project seeks to address this gap by identifying the functional effect of mutations on translation. To accomplish this I will first identify mutations that arise from adaptation to various nutrient limited environments. I will then use expression profiling (e.g. RNA-seq, ribosome profiling, and RATE-seq) to identify the effect these mutations have on translation, as well as other levels of gene expression. This will provide insight into the magnitude of effect mutations have on translation and their relative rate. Furthermore, to fully characterize the role synonymous mutations have on fitness I will be using a deep scanning synonymous mutation library. To understand the role tRNA abundance plays in the fitness effect of a given synonymous mutations, I will also be evaluating fitness within tRNA under- and over-expression backgrounds. Because of the closely coupled nature of translation rates and mRNA decay, I will also characterize the effect synonymous mutations have on mRNA decay using RATE-seq. My analysis of the functional effects of these mutations on gene expression, particularly within the genetic background and environment in which they arose, will allow for the development of a machine learning algorithm that can use sequence and annotation features to predict the effect of a mutation on gene expression. This tool will aid future research into the effect mutations have of gene expression by allowing the identification of high-confidence candidates for further evaluation.  This project will be conducted at New York Universitys Center for Genomics and Systems Biology, whose mission is to answer otherwise intractable biological questions using applied experimental and computational approaches. The Center houses numerous facilities and cores that will be instrumental in the performance of this work. The collaborative atmosphere and multi-disciplinary nature of NYUs research communities that will enable me to stay abreast of developments in related fields and to rapidly communicate my research to interested parties. I will be trained under the guidance of Dr. David Gresham, an excellent researcher working on complementing long-term evolution experiments with gene expression studies to characterize the adaptive potential of the regulation of gene expression. Project Narrative The translation of mRNA into protein is a critical step in gene expression that is tightly regulated with mis-regulation of translation being a hallmark of many human pathologies. Understanding how mutations can alter the regulation of translation is an understudied but important aspect of adaptation and evolution. Ultimately, without an understanding of the adaptive potential of translation we have an incomplete, and imperfect, picture of the underlying genetic causes of numerous forms of cancer and genetic diseases.",The adaptive potential of translational regulation,9683394,F32GM131573,"['Affect ', ' Amino Acid Sequence ', ' protein sequence ', ' Primary Protein Structure ', ' Biological Assay ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' Biology ', ' Malignant Neoplasms ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Communities ', ' Complement Proteins ', ' Complement ', ' Disorder ', ' Disease ', ' Elements ', ' Environment ', ' Evolution ', ' Gene Expression ', ' Gene Regulation Process ', ' Gene Regulation ', ' Gene Action Regulation ', ' Gene Expression Regulation ', ' Genes ', ' trans acting element ', ' regulatory gene ', ' Transcriptional Regulatory Elements ', ' Regulator Genes ', ' Genome ', ' Goals ', ' Laboratories ', ' Libraries ', ' Literature ', ' Mission ', ' Modernization ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' New York ', ' Pathology ', ' Phenotype ', ' Play ', ' Proteins ', ' Research ', ' Researchers ', ' Investigators ', ' Research Personnel ', ' Ribosomes ', ' transfer Ribonucleic acids ', ' tRNA ', ' Triplet Codon-Amino Acid Adaptor ', ' Transfer RNA ', ' social role ', ' Role ', ' Software ', ' Computer software ', ' Stress ', ' Testing ', ' Transcription ', ' RNA Expression ', ' Gene Transcription ', ' Genetic Transcription ', ' mRNA Translation ', ' Genetic Translation ', ' Translations ', ' Universities ', ' Genetic Diversity ', ' Genetic Variation ', ' Work ', ' Generations ', ' Measures ', ' Protein Coding Region ', ' ORFs ', ' Open Reading Frames ', ' promotor ', ' promoter ', ' Site ', ' Variant ', ' Variation ', ' Biological ', ' Evaluation ', ' Training ', ' insight ', ' Genetic ', ' tool ', ' Nature ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Frequencies ', ' Scanning ', ' interest ', ' Nutrient ', ' novel ', ' cancer genetics ', ' Code ', ' Coding System ', ' Regulation ', ' Modeling ', ' response ', ' Untranslated RNA ', ' noncoding ', ' Nontranslated RNA ', ' Noncoding RNA ', ' Non-translated RNA ', ' Non-Coding RNA ', ' Non-Coding ', ' Functional RNA ', ' Genomics ', ' mRNA Decay ', ' mRNA Degradation ', ' mRNA Transcript Degradation ', ' work performance ', ' job performance ', ' Performance at work ', ' genome sequencing ', ' Address ', ' Systems Biology ', ' fitness ', ' Data ', ' Human Pathology ', ' Regulatory Element ', ' Translation Initiation ', ' Translational Regulation ', ' Development ', ' developmental ', ' environmental change ', ' Population ', ' Coupled ', ' analytical tool ', ' multidisciplinary ', ' transcriptome sequencing ', ' RNAseq ', ' RNA sequencing ', ' RNA Seq ', ' collaborative environment ', ' peer-group environment ', ' peer-group atmosphere ', ' interdisciplinary environment ', ' interdisciplinary atmosphere ', ' interactive environment ', ' interactive atmosphere ', ' collaborative atmosphere ', ' business-friendly environment ', ' Business-Friendly Atmosphere ', ' mutation screening ', ' mutation scanning ', ' actionable mutation ', ' driver mutation ', ' actionable variants ', ' whole genome ', ' full genome ', ' entire genome ', ' ribosome profiling ', ' ribosome footprint profiling ', ' Ribo-seq ', ' experimental study ', ' experimental research ', ' experiment ', ' Expression Profiling ', ' preservation ', ' Genetic Diseases ', ' genetic disorder ', ' genetic condition ', ' machine learning algorithm ', ' ']",NIGMS,NEW YORK UNIVERSITY,F32,2019,61226,NY-12,0.21917813221896407
"High-resolution map of human germline mutation patterns and inference of mutagenic mechanisms     DESCRIPTION (provided by applicant): Mutations are the ultimate source of genetic variation and one of the driving forces of evolution. Both the absolute mutation rate and the relative rate among mutation subtypes fluctuate along the genome, affected by adjacent nucleotide motifs and local features such as GC content and replication timing. Characterizing regional variation of mutation patterns is critical for understanding genome evolution and to identify variants causing genetic diseases. However, mutation rate and molecular spectrum are difficult to measure at high resolution, genomewide, and in an unbiased fashion. Estimates based on common variants and between- species substitutions are confounded by natural selection, population demographic history, and biased gene conversion (BGC). Methods relying on incidence rates of monogenic diseases or finding de novo variants by trio sequencing can inform global trends, but do not provide sufficient data to assess fine-scale local parameters. This study will overcome these limitations by using the extremely rare variants (ERVs) as a new data source to characterize patterns of recent germline variation in humans. ERVs, defined in this study as singletons in 30,000 samples, are becoming available via large-scale whole-genome sequencing (WGS) of population samples. Unlike common variants or substitutions, ERVs arose very recently and are largely unaffected by selection, BGC, etc. We will analyze 200-300 million singleton variants observed in 30,000 subjects at 20-30X coverage. The regional distribution of ERV subtypes will establish a quantitative atlas of the rate and spectrum of human germline mutations mostly unaltered by selection. We will share this resource with the research community and apply it to determine the impact of local genomic features and epigenomic attributes. We will use the systematic departures between ERVs and variants of higher frequencies (polymorphisms and substitutions) to infer local effects of selection, and this may uncover hitherto unknown functional regions of the genome. By comparing mutation signatures in ERVs with those in somatic variations observed in diverse cancers we will attribute distinct mutational signatures to known biochemical processes and thus infer the major contributors to new germline mutations in the human genome. This subtype-specific atlas will also be used to predict the probability of observing every possible single-base mutation in the genome, thus facilitating the interpretation of candidate causal variants of human diseases. We will assess mutation pattern differences among European Americans, African Americans and Latinos, and seek to discover genetic modifiers of germline mutation rate by finding functionally damaging mutations that show increased ERV counts in the surrounding genomic region, potentially identifying both known and previous unknown ""mutator"" genes that play a role in transmission fidelity in humans. This research will provide an essential resource to study the genesis and maintenance of germline mutations in humans. Understanding such a fundamental process will be the basis for a deeper understanding of human evolution and diseases. PUBLIC HEALTH RELEVANCE: We will study the patterns of inherited mutations in humans using approximately 250 million extremely rare DNA variants in human populations. Our results will allow the prediction of the rate of new mutations at every site in the genome based on features of the surrounding DNA sequence, thus providing a common resource to study the arrival and maintenance of mutations in humans. Understanding such a basic process is important for answering fundamental questions in human evolution, the cause of inherited diseases, and the role of DNA abnormality in cancer and aging.",High-resolution map of human germline mutation patterns and inference of mutagenic mechanisms,9702844,R01GM118928,"['Affect ', ' Aging ', ' Algorithms ', ' Alleles ', ' Allelomorphs ', ' Atlases ', ' Biological Factors ', ' Biologic Factor ', ' Biology ', ' Malignant Neoplasms ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' youngster ', "" childrens' "", ' children ', ' Children (0-21) ', ' Child Youth ', ' 0-11 years old ', ' Child ', ' Chromatin ', ' Communities ', ' data interpretation ', ' Data Analysis ', ' Data Analyses ', ' Data Sources ', ' Demographic Factors ', ' Disorder ', ' Disease ', ' Deoxyribonucleic Acid ', ' DNA ', ' Evolution ', ' Family ', ' Foundations ', ' Future ', ' Gene Conversion ', ' Genes ', ' Genome ', ' human whole genome ', ' Human Genome ', ' inherited genetic disorder ', ' inherited genetic disease ', ' inherited diseases ', ' inborn error ', ' hereditary disorder ', ' Inherited disorder ', ' Inborn Genetic Diseases ', ' Hereditary Disease ', ' History ', ' Recording of previous events ', ' Modern Man ', ' Human ', ' Human Genetics ', ' Incidence ', ' Maintenance ', ' Maps ', ' Methods ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' Nucleotides ', ' Parents ', ' Play ', ' polymorphism ', ' Genetic Polymorphism ', ' Probability ', ' Recombination ', ' DNA Recombination ', ' Genetic Recombination ', ' Research ', ' Research Resources ', ' Resources ', ' Rest ', ' social role ', ' Role ', ' Selection Bias ', ' Technology ', ' Body Tissues ', ' Tissues ', ' Genetic Diversity ', ' Genetic Variation ', ' Weight ', ' Generations ', ' Measures ', ' Mutagenesis Molecular Biology ', ' Genetics-Mutagenesis ', ' Mutagenesis ', ' black American ', ' Black Populations ', ' Afroamerican ', ' Afro American ', ' African American ', ' Latino ', ' Natural Selections ', ' Dataset ', ' Data Set ', ' DNA Sequence ', ' base ', ' density ', ' improved ', ' Site ', ' Variant ', ' Variation ', ' Germ-Line Mutation ', ' Hereditary Mutation ', ' Germline Mutation ', ' Individual ', ' European ', ' Biological Process ', ' Biological Function ', ' Genetic ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Frequencies ', ' Inherited ', ' Hereditary ', ' Complex ', ' Dependence ', ' Source ', ' Pattern ', ' Techniques ', ' Somatic Mutation ', ' American ', ' Environmental Risk Factor ', ' environmental risk ', ' Environmental Factor ', ' Positioning Attribute ', ' Position ', ' genetic analysis ', ' Genetic analyses ', ' Modeling ', ' Sampling ', ' repository ', ' Genomics ', ' Guanine + Cytosine Composition ', ' Guanine + Cytosine Content ', ' GC Content ', ' GC Composition ', ' G+C Content ', ' G+C Compositions ', ' Pathogenicity ', ' Mismatch Repair ', ' Post-Replication Mismatch Repair ', ' genome sequencing ', ' Address ', ' Biochemical Process ', ' Data ', ' Resolution ', ' Resource Sharing ', ' Genomic Segment ', ' genomic region ', ' transmission process ', ' Transmission ', ' trend ', ' Molecular ', ' Process ', ' epigenomics ', ' Population ', ' driving force ', ' human disease ', ' prototype ', ' public health relevance ', ' genome-wide ', ' genomewide ', ' genome scale ', ' data sharing ', ' next generation sequencing ', ' nextgen sequencing ', ' next gen sequencing ', ' NGS system ', ' NGS Method ', ' rare variant ', ' rare allele ', ' High-Throughput Nucleotide Sequencing ', ' High-Throughput Sequencing ', ' Mendelian disorder ', ' single-gene disorder ', ' single-gene disease ', ' monogenic disorder ', ' monogenic disease ', ' Mendelian genetic disorder ', ' Mendelian disease ', ' actionable mutation ', ' driver mutation ', ' actionable variants ', ' whole genome ', ' full genome ', ' entire genome ', ' Genetic Diseases ', ' genetic disorder ', ' genetic condition ', ' human model ', ' web server ', ' causal variant ', ' causative variant ', ' causative mutation ', ' causal mutation ', ' causal gene ', ' causal allele ', ' ']",NIGMS,UNIVERSITY OF MICHIGAN AT ANN ARBOR,R01,2019,300191,MI-12,0.19527015365396436
"Unraveling molecular and system-level mechanisms of human disease-associated protein mutations Project Summary Although a quickly expanding catalogue of protein mutations have been discovered, including those that cause human diseases or confer drug resistance, mechanistic understanding and prediction of functional consequences of these mutations remain rather limited. There is a critical need to develop novel, multiscale computational frameworks that are rigorous and generalizable to help close the ever-increasing gap between phenotypic data and mechanistic knowledge about the mutations and to develop effective therapeutic strategies.  My long-term research goals are two folds: (1) to unravel how a change in protein sequence ripples through various aspects of molecular and system-levels to a change in cellular function and cause human diseases or confer drug resistance; and (2) to translate learned mechanistic knowledge to effective drug-design strategies for human diseases and drug resistance. Toward these goals I propose to advance and combine the strengths of computational molecular biology (structural modeling and design for proteins or protein interactions) and computational systems biology (pathway/network-level topology and dynamics) and follow a novel, formal paradigm to develop methods that systematically identify mechanisms underlying various stages of consequence propagation (from conformation, molecular and system-level variables, to cellular functions, where intermediates can be skipped if necessary). In the forward direction of propagating consequences, I will determine, explain and understand mutational consequences at various levels with machine learning, causal analysis, and combinatorial optimization, starting with known or modelled changes at various levels. In the inverse direction of designing consequences, I will follow known or learned mechanistic hypotheses and develop efficient combinatorial optimization methods to design mutagenesis experiments or screen / design ligands for desired perturbations at various levels, which would test and refine corresponding hypotheses directly and translate mechanistic hypotheses to therapeutic strategies. Mechanisms underlying distal (potentially allosteric) mutations, multiple mutations within a protein or across proteins as well as systems pharmacology strategies will also be rigorously determined in the process.  The expected outcomes from the innovative project will include two main components. The first will be both biophysical principles of proteins and integrative understanding of biomedical systems, which will be organized in a database for public access. The second will be translating mechanistic insights into therapeutic intervention strategies to treat diseases. In particular, targeted experiments (mutagenesis or ligand-binding) will be designed following known or discovered mechanistic hypotheses. This project will involve close collaboration with structural biologists and clinician-scientists who are active collaborators of the PI. Project Narrative Genetic mutations, many of which lead to protein mutations, are often associated with human diseases: they often directly cause diseases or contribute to their progressions. Understanding mechanisms by which these mutations lead to significant functional consequences is of extreme importance to developing effective therapeutics to cure diseases and ameliorate drug resistance.",Unraveling molecular and system-level mechanisms of human disease-associated protein mutations,9774239,R35GM124952,"['Amino Acid Sequence ', ' protein sequence ', ' Primary Protein Structure ', ' Biophysics ', ' biophysical sciences ', ' biophysical principles ', ' biophysical foundation ', ' Subcellular Process ', ' Cellular Process ', ' Cellular Physiology ', ' Cellular Function ', ' Cell Process ', ' Cell Function ', ' Cell physiology ', ' Disorder ', ' Disease ', ' Drug Design ', ' resistant to Drug ', ' resistance to Drug ', ' drug resistant ', ' Drug resistance ', ' Goals ', ' heavy metal lead ', ' heavy metal Pb ', ' Pb element ', ' Lead ', ' Ligands ', ' Methods ', ' Structural Models ', ' conformational state ', ' conformation ', ' Molecular Stereochemistry ', ' Molecular Configuration ', ' Molecular Conformation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' Pharmacology ', ' protein design ', ' genetic protein engineering ', ' Protein Engineering ', ' Proteins ', ' Research ', ' Testing ', ' Translating ', ' Mutagenesis Molecular Biology ', ' Genetics-Mutagenesis ', ' Mutagenesis ', ' Distal ', ' insight ', ' Databases ', ' data base ', ' Data Bases ', ' Collaborations ', ' Therapeutic ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Knowledge ', ' Catalogs ', ' Scientist ', ' System ', ' novel ', ' Therapeutic Intervention ', ' intervention therapy ', ' Modeling ', ' Intervention ', ' interventional strategy ', ' Intervention Strategies ', ' Disease Resistance ', ' resistant to disease ', ' resistant disease ', ' resistance to disease ', ' Computational Molecular Biology ', ' Systems Biology ', ' DNA Sequence Alteration ', ' genomic alteration ', ' Sequence Alteration ', ' Genetic mutation ', ' DNA mutation ', ' DNA Alteration ', ' Structural Biologist ', ' Ligand Binding ', ' Molecular ', ' Process ', ' Pathway interactions ', ' pathway ', ' computer framework ', ' computational framework ', ' design ', ' designing ', ' Treatment Efficacy ', ' therapy efficacy ', ' therapeutically effective ', ' therapeutic efficacy ', ' intervention efficacy ', ' Outcome ', ' innovation ', ' innovative ', ' innovate ', ' human disease ', ' Combinatorial Optimization ', ' phenotypic data ', ' experimental study ', ' experimental research ', ' experiment ', ' ']",NIGMS,TEXAS ENGINEERING EXPERIMENT STATION,R35,2019,335245,TX-17,0.18895753745202024
"Molecular Characterization of Joubert Syndrome Project Summary Congenital ataxia presents in early childhood with non-progressive hypotonia, gross motor, fine motor and cognitive delays. These disorders are distinct from the progressive ataxias because of the presence of congenital cerebellar malformations and because they are typically inherited recessively. Joubert Syndrome and Related Disorders (JSRD) constitute a major subset of these conditions, consisting of a cerebellar midline (vermis) malformation, a nearly pathognomonic Molar Tooth sign on brain Imaging (MTI) and co-existent oculomotor apraxia and episodic breathing dysrhythmias. In our published data, we have: 1] Identified ten unique genetic causes of JSRD (nearly half of the published causes), 2] Generated genotype-phenotype correlations involving cerebellar, retinal, renal, hepatic, digit, and cerebral manifestations. 3] Identified common founder mutations that allow for population-based screening. 4] Discovered that JSRD encoded proteins frequently localize to the cilium. 5] Identified ciliary transition zone (TZ) defects in cells with JSRD mutations. 6] Performed siRNA cell-based screens for defective ciliogenesis to prioritize candidate JSRD genes. 7] Generated and characterized multiple zebrafish, mouse and human cell culture models for JSRD. 8] Defined the concept of Ciliary localization model, in which one JSRD gene is required for ciliary localization of other JSRD proteins. In our unpublished data we have: 1] Recruited an additional 200 JSRD patients without molecular diagnosis. 2] Performed whole exome (WES) and whole genome sequencing (WGS) on an additional 100 JSRD families. 3] Identified an additional 12 novel likely JSRD candidate genes. 4] Generated IPSCs and cerebellar organoids from mutation-positive and negative families to aid in functional analysis and gene discovery using RNAseq. 5] Begun functional validation of the putative mutations. 6] Developed methods to interrogate ciliary structure in a high-throughput fashion with electron microscopy (EM). The goal of this competing renewal is to identify the remaining discoverable genes that lead to JSRD when lost, functionally validate mutations within the pathogenetic framework, and test the hypothesis that mutations in JSRD genes lead to collapse of the ciliary TZ. Because the majority of patients still have unknown cause of disease, this renewal aims to advance knowledge through molecular characterization of new genes, using newly evolving high-throughput techniques, integrated bioinformatics, and a unique resource of consanguineous families recruited world-wide. We further aim to validate these mutations in patient cells, within a mechanistic framework that JSRD genes are required for essential ciliary structural components during cerebellar development. Project Narrative Joubert syndrome is a genetically and phenotypically heterogeneous neurodevelopmental disorder unified by defects of the cellular primary cilium. This work will identify new genetic causes and dissect ciliary defects associated with genetic mutations.",Molecular Characterization of Joubert Syndrome,9749889,R01NS048453,"['Termination of pregnancy ', ' Apraxias ', ' apraxia ', ' Dyspraxia ', ' Breathing ', ' inspiration ', ' Respiratory Inspiration ', ' Respiratory Aspiration ', ' Ataxia ', ' Dyssynergia ', ' Coordination Impairment ', ' Ataxy ', ' cell culture ', ' Cell Culture Techniques ', ' Cell Body ', ' Cells ', ' Cultured Cells ', ' Cilia ', ' granule ', ' Cytoplasmic Granules ', ' Disorder ', ' Disease ', ' Negatrons ', ' Negative Beta Particle ', ' Electrons ', ' Embryonic ', ' Embryo ', ' facial ', ' faces ', ' Face ', ' Family ', ' Genes ', ' Genotype ', ' Goals ', ' Gold ', ' Modern Man ', ' Human ', ' renal ', ' Kidney Urinary System ', ' Kidney ', ' heavy metal lead ', ' heavy metal Pb ', ' Pb element ', ' Lead ', ' Methods ', ' Electron Microscopy ', ' Scanning Electron Microscopy ', ' Middle East ', ' Molar tooth ', ' Morphogenesis ', ' Murine ', ' Mice Mammals ', ' Mice ', ' Mus ', ' Muscular Hypotonia ', ' Muscle Tone Poor ', ' Muscle Hypotony ', ' Hypotonia ', ' Hypomyotonia ', ' Decreased Muscle Tone ', ' Muscle hypotonia ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' Organoids ', ' Patients ', ' Phenotype ', ' Probability ', ' Proteins ', ' Publishing ', ' Research Resources ', ' Resources ', ' Risk ', ' biological signal transduction ', ' Signaling ', ' Signal Transduction Systems ', ' Intracellular Communication and Signaling ', ' Cell Signaling ', ' Cell Communication and Signaling ', ' Signal Transduction ', ' Sonication ', ' Mass Spectrum Analyses ', ' Mass Spectrum ', ' Mass Spectroscopy ', ' Mass Spectrometry ', ' Mass Photometry/Spectrum Analysis ', ' Mass Spectrum Analysis ', ' Syndrome ', ' Testing ', ' Work ', ' Zebra Fish ', ' Zebra Danio ', ' Danio rerio ', ' Brachydanio rerio ', ' Zebrafish ', ' base ', ' Brain imaging ', ' brain visualization ', ' Hepatic ', ' Clinical ', ' Microscopic ', ' Variant ', ' Variation ', ' Series ', ' Training ', ' Cerebellar vermis structure ', ' vermis ', ' insight ', ' Individual ', ' Cerebrum ', ' cerebral ', ' Databases ', ' data base ', ' Data Bases ', ' Congenital cerebellar hypoplasia ', ' Cerebellar hypoplasia ', ' Genetic ', ' Morphology ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Knowledge ', ' Joubert syndrome ', ' cerebelloparenchymal disorder IV ', ' cerebellar vermis agenesis ', ' Joubert-Boltshauser syndrome ', ' Inherited ', ' Hereditary ', ' Severities ', ' cell type ', ' Techniques ', ' fetal ', ' Digit structure ', ' Digit ', ' Gene Mutation ', ' Gene Alteration ', ' mutant ', ' early childhood ', ' cohort ', ' Transmission Electron Microscopy ', ' Structure ', ' Genetic screening method ', ' genetic testing ', ' gene-based testing ', ' gene testing ', ' novel ', ' Modeling ', ' affection ', ' oculomotor ', ' ocularmotor ', ' ocular motor ', ' disorder subtype ', ' disease subtype ', ' disease subgroups ', ' Small Interfering RNA ', ' siRNA ', ' Short interfering RNA ', ' Pathogenicity ', ' Bioinformatics ', ' Bio-Informatics ', ' cilium biogenesis ', ' ciliogenesis ', ' genome sequencing ', ' Candidate Disease Gene ', ' Candidate Gene ', ' Length ', ' Defect ', ' DNA Sequence Alteration ', ' genomic alteration ', ' Sequence Alteration ', ' Genetic mutation ', ' DNA mutation ', ' DNA Alteration ', ' Data ', ' Molecular Diagnosis ', ' Motor ', ' Protein Analysis ', ' Cognitive ', ' Enrollment ', ' enroll ', ' Validation ', ' WNT Signaling Pathway ', ' WNT signaling ', ' Molecular ', ' Knock-out ', ' Knockout ', ' Development ', ' developmental ', ' Neurodevelopmental Disorder ', ' Neurological Development Disorder ', ' Cerebellar malformation ', ' Cerebellum malformation ', ' reconstruction ', ' knock-down ', ' knockdown ', ' Three-dimensional analysis ', ' 3D analysis ', ' 3-dimensional analysis ', ' 3-D analysis ', ' Retinal ', ' loss of function mutation ', ' founder mutation ', ' malformation ', ' gene discovery ', ' discover genes ', ' population based ', ' stem cell biology ', ' genome-wide ', ' genomewide ', ' genome scale ', ' exome ', ' exomes ', ' transcriptome sequencing ', ' RNAseq ', ' RNA sequencing ', ' RNA Seq ', ' exome sequencing ', ' exome-seq ', ' screening ', ' Clustered Regularly Interspaced Short Palindromic Repeats ', ' CRISPR/Cas system ', ' CRISPR ', ' accurate diagnosis ', ' consanguineous family ', ' consanguineous\xa0kindreds ', ' consanguineous pedigree ', ' whole genome ', ' full genome ', ' entire genome ', ' recruit ', ' ']",NINDS,"UNIVERSITY OF CALIFORNIA, SAN DIEGO",R01,2019,510012,CA-52,0.20843462185098818
"Understanding modifiers of mendelian mutation penetrance using familial hypercholesterolemia as a model PROJECT SUMMARY / ABSTRACT Rare monogenic forms of common diseases have provided key fundamental insights about common disease. However, genetic, environmental, and stochastic elements influence risk for disease. Familial hypercholesterolemia (FH), an autosomal dominant disorder afflicting 1 in 250 linked to severe increases in LDL cholesterol and premature coronary heart disease (CHD) risk, is an ideal model to characterize modifiers of disease. Despite the presence of a strong genetic driver of hypercholesterolemia from FH mutations, we recently observed that half do not have the expected severe hypercholesterolemia. In this proposal, we outline several methods to discover and dissect the genetic and non-genetic factors influencing CHD risk conferred by FH mutations in humans and determine whether knowledge of these factors can improve risk discrimination among those with FH mutations. Our approach harnesses several multi-dimensional datasets: whole genome sequences, metabolomics, and cross-sectional and longitudinal cardiovascular phenotypes. In Aim 1, we will aggregate and curate 75,000 deep (30X) whole genome sequences and cardiovascular phenotypes. In Aim 2, we will discover genetic and non-genetic modifiers of LDL cholesterol and CHD risk in FH and evaluate their metabolomic consequences. In Aim 3, we will develop a method incorporating genetics and longitudinal non- genetic exposures for CHD risk stratification among ~4,000 with FH mutations in the Million Veteran Program. In addition to the proposed Aims, this five-year proposal outlines a comprehensive strategy for the principal investigator's (PI's) scientific and professional development in academic cardiovascular medicine. The research strategy builds upon the PI's prior research experience and clinical training. In addition to an undergraduate degree in Molecular Biology and master's degree in Biomedical Informatics, he completed post- graduate medical training in Internal Medicine and Cardiovascular Medicine. He recently developed a new preventive/genetic cardiology clinic focusing on the evaluation and management of those with or a family history of premature CHD, including those with FH, at Massachusetts General Hospital (MGH). This proposal now focuses on expanding his scientific skills in human genetics and genomics into new domains: integrative genomics, statistical genetics, clinical informatics, and risk modeling. The career development goals will be at achieved through a multi-faceted approach involving mentorship, collaboration, didactic coursework, conferences, and scientific investigation. This work will take place in a unique training environment comprised of MGH and the Broad Institute. Successful completion of this career development award will result in improved fundamental understanding of the determinants of CHD, result in the PI's transition to an independent physician-scientist, and provide a solid foundation from which he will apply for R01-level funding. PROJECT NARRATIVE / PUBLIC HEALTH RELEVANCE Cardiovascular disease, largely due to coronary heart disease (CHD), remains the leading cause of death in the United States and now worldwide despite current advances. Familial hypercholesterolemia is a relative common genetic disorder characterized by severe hypercholesterolemia and premature CHD but many carrying these mutations do not develop these consequences. This proposal seeks to define and characterize the factors modifying CHD risk among those with FH mutations; success has the potential to broadly identify new mechanisms of CHD and novel strategies for prevention.",Understanding modifiers of mendelian mutation penetrance using familial hypercholesterolemia as a model,9609507,K08HL140203,"['Adult ', ' adulthood ', ' Adult Human ', ' 21+ years old ', ' Affect ', ' Cardiology ', ' Cardiovascular Diseases ', ' cardiovascular disorder ', ' Cardiovascular system ', ' circulatory system ', ' Heart Vascular ', ' Cardiovascular Organ System ', ' Cardiovascular Body System ', ' Cardiovascular ', ' Cause of Death ', ' Clinical Informatics ', ' virtual simulation ', ' in silico ', ' computerized simulation ', ' computerized modeling ', ' computer based models ', ' computational simulation ', ' computational models ', ' computational modeling ', ' Mathematical Models and Simulations ', ' Mathematical Model Simulation ', ' Computerized Models ', ' Computer based Simulation ', ' Computer Models ', ' Computer Simulation ', ' coronary arterial disease ', ' atherosclerotic coronary disease ', ' Coronary Atherosclerosis ', ' Coronary Artery Disorder ', ' Coronary Artery Disease ', ' Coronary Arteriosclerosis ', ' coronary disorder ', ' atherosclerotic heart disease ', ' Coronary Disease ', ' Coronary heart disease ', ' Cognitive Discrimination ', ' Discrimination ', ' Disorder ', ' Disease ', ' Elements ', ' Environment ', ' Foundations ', ' Genetic Counseling ', ' Genotype ', ' Goals ', ' Gold ', ' General Hospitals ', ' Modern Man ', ' Human ', ' Human Genetics ', ' Hypercholesteremia ', ' hypercholesterolemia ', ' familial hyperlipoproteinemia type II ', ' familial hyperlipoproteinemia type 2 ', ' familial hypercholesteremia ', ' familial hyperbetalipoproteinemia ', ' Type II Hyperlipidemia ', ' Type 2 Hyperlipidemia ', ' Hyperlipoproteinemia Type II ', ' Hyperlipoproteinemia Type 2 ', ' Hyperbetalipoproteinemia ', ' Essential Hypercholesterolemia ', ' Familial Hypercholesterolemia ', ' Institutes ', ' Internal Medicine ', ' heavy metal lead ', ' heavy metal Pb ', ' Pb element ', ' Lead ', ' Leadership ', ' Lipids ', ' beta-Lipoproteins ', ' LDL Lipoproteins ', ' LDL ', ' Low-Density Lipoproteins ', ' beta-Lipoprotein Cholesterol ', ' Low Density Lipoprotein Cholesterol ', ' LDL Cholesterol ', ' LDL Cholesterol Lipoproteins ', ' Massachusetts ', ' Medicine ', ' Mentorship ', ' Methods ', ' statistical linear models ', ' statistical linear mixed models ', ' Probability Models ', ' Probabilistic Models ', ' Statistical Models ', ' DNA Molecular Biology ', ' Molecular Biology ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' National Institutes of Health ', ' NIH ', ' United States National Institutes of Health ', ' Phenotype ', ' Physicians ', ' Quality Control ', ' Research ', ' Risk ', ' Technology ', ' Testing ', ' Time ', ' United States ', ' Veterans ', ' Work ', ' Generations ', ' symposia ', ' summit ', ' convention ', ' conference ', ' symposium ', ' health care ', ' Healthcare ', ' Dataset ', ' Data Set ', ' base ', ' improved ', ' Solid ', ' Clinical ', ' premature ', ' prematurity ', ' Variant ', ' Variation ', ' Physiological ', ' Physiologic ', ' Biochemical ', ' Medical ', ' Link ', ' Evaluation ', ' Training ', ' insight ', ' Individual ', ' African ', ' Amish ', ' European ', ' Family history of ', ' Family Medical History Epidemiology ', ' Family Medical History ', ' Funding ', ' Ethnic Origin ', ' Ethnicity ', ' Collaborations ', ' Genetic ', ' Exposure to ', ' Knowledge ', ' Catalogs ', ' programs ', ' Scientist ', ' Investigation ', ' Clinic ', ' Penetrance ', ' experience ', ' Gene Mutation ', ' Gene Alteration ', ' success ', ' cohort ', ' trait ', ' skills ', ' novel ', ' Prevention strategy ', ' Preventive strategy ', ' Preventative strategy ', ' disorder risk ', ' disease risk ', ' Environmental Risk Factor ', ' environmental risk ', ' Environmental Factor ', ' Prevention ', ' Positioning Attribute ', ' Position ', ' genetic analysis ', ' Genetic analyses ', ' Pathway Analysis ', ' Network Analysis ', ' Modeling ', ' career development ', ' Genomics ', ' heart disease risk ', ' heart disorder risk ', ' cardiac disorder risk ', ' cardiac disease risk ', ' Pathogenicity ', ' metabonomics ', ' metabolism measurement ', ' metabolomics ', ' genome sequencing ', ' Mediator of activation protein ', ' Mediator of Activation ', ' Mediator ', ' Preventive ', "" Bachelor's Degree "", ' Undergraduate Degree ', ' Baccalaureate Degree ', ' Data ', ' Disease Pathway ', "" Master's Degree "", ' K-Series Research Career Programs ', ' Research Career Program ', ' K-Awards ', ' Career Development Programs K-Series ', ' Career Development Awards and Programs ', ' Career Development Awards ', ' in vivo ', ' lifestyle factors ', ' life-style factor ', ' Principal Investigator ', ' Development ', ' developmental ', ' Electronic Health Record ', ' electronic healthcare record ', ' electronic health care record ', ' Pathway interactions ', ' pathway ', ' National Heart, Lung, and Blood Institute ', ' NHLBI ', ' National Human Genome Research Institute ', ' National Center for Human Genome Research ', ' NHGRI ', ' biomedical informatics ', ' biomed informatics ', ' next generation ', ' novel strategies ', ' novel strategy ', ' novel approaches ', ' new approaches ', ' Population ', ' Prevalence ', ' Network-based ', ' human disease ', ' high risk ', ' public health relevance ', ' non-genetic ', ' nongenetic ', ' biobank ', ' biorepository ', ' Cloud Computing ', ' cloud computer ', ' Cloud Infrastructure ', ' cloud based ', ' precision medicine ', ' precision-based medicine ', ' genomic variation ', ' Mendelian disorder ', ' single-gene disorder ', ' single-gene disease ', ' monogenic disorder ', ' monogenic disease ', ' Mendelian genetic disorder ', ' Mendelian disease ', ' human genomics ', ' whole genome ', ' full genome ', ' entire genome ', ' Preventive therapy ', ' Preventative therapy ', ' Trans-Omics for Precision Medicine ', ' TOPMed ', ' Risk stratification ', ' DNA sequencing ', ' DNAseq ', ' DNA seq ', ' Genetic Diseases ', ' genetic disorder ', ' genetic condition ', ' machine learning algorithm ', ' risk prediction model ', ' ']",NHLBI,MASSACHUSETTS GENERAL HOSPITAL,K08,2019,170003,MA-08,0.12664327181676716
"Clinicopathologic and Genetic Profiling through Machine Learning and Natural Language Processing for Precision Lung Cancer Management PROJECT SUMMARY/ABSTRACT Lung cancer is the second-most common type of cancer and the leading cause of cancer death in men and women. Among the different types of lung cancer, non-small cell lung cancer (NSCLC) is the most common type and it constitutes 85% to 90% of all lung cancer cases. Current cancer research has shown that multiple somatic mutations affect the sensitivity of patients to various drugs used for NSCLC treatment. These mutations are essential factors for determining the most effective, personalized treatment for each NSCLC patient; however, most NSCLC patients develop resistance to these targeted therapies in their first year of treatment. Many mechanisms of this resistance are still unknown. Designing and prescribing better targeted therapies for NSCLC patients requires further understanding, particularly with respect to the relationship between NSCLC tumors pathological and clinical findings, genetic profiles, and targeted therapy responses/resistance. Currently, there is no computational method to connect observations and findings from pathology reports, medical records, somatic mutations, and the targeted therapy resistance. This project provides a plan to build a novel computational method to identify statistically significant associations between the pathological findings of NSCLC tumors and the presence of clinically-actionable somatic mutations. Furthermore, these associations, in combination with an innovative set of feature analysis from pathology reports and electronic medical records, will be leveraged to build and validate a machine-learning model to identify NSCLC patients with clinically-actionable somatic mutations. Finally, the associated clinical, pathological, and genetic findings for NSCLC patients will be used in a new machine-learning framework to predict patients time-to-resistance to targeted therapies. The required data to build and validate the proposed models in this project will be obtained through a collaboration with the Department of Pathologys Laboratory for Clinical Genomics and Advanced Technologies at Dartmouth-Hitchcock Medical Center. In addition to internal validation, the investigators in this proposal established a collaboration with the Department of Pathology at the University of Vermont Medical Center to apply and validate the developed models on an external data source. Upon successful implementation of this bioinformatics approach, the developed models will be able to reveal statistically significant links between clinical and pathological findings, clinically-actionable somatic mutations, and targeted-therapy responses for a better understanding of NSCLC tumor development and treatment. The proposed approach will provide an accurate, fast, and inexpensive pre- selection method for screening NSCLC patients with clinically-actionable mutations for translational research and precision medicine. Furthermore, the proposed machine-learning method to identify NSCLC patients resistance to targeted therapies will help healthcare providers to select the best treatment strategies for these patients, improve their health outcomes, and establish this precision medicine paradigm for other types of cancer. PROJECT NARRATIVE Resistance to targeted therapies severely limits the ability to treat non-small cell lung cancer (NSCLC) patients. This project proposes a novel computational approach to find statistically-significant links between pathological and clinical findings, clinically-actionable mutations, and targeted-therapy responses for NSCLC patients. The outcomes of this proposal can assist healthcare providers to identify the most effective strategy for NSCLC treatment, improve public health, and promote precision medicine.",Clinicopathologic and Genetic Profiling through Machine Learning and Natural Language Processing for Precision Lung Cancer Management,10023259,R01CA249758,"['Affect ', ' Architecture ', ' Engineering / Architecture ', ' Attention ', ' malignant breast neoplasm ', ' Breast Cancer ', ' malignant breast tumor ', ' Non-Small-Cell Lung Carcinoma ', ' NSCLC ', ' NSCLC - Non-Small Cell Lung Cancer ', ' Non-Small Cell Lung Cancer ', ' Nonsmall Cell Lung Carcinoma ', ' nonsmall cell lung cancer ', ' Computing Methodologies ', ' computational methodology ', ' computational methods ', ' computer based method ', ' computer methods ', ' computing method ', ' Data Sources ', ' Cessation of life ', ' Death ', ' Drug resistance ', ' drug resistant ', ' resistance to Drug ', ' resistant to Drug ', ' Pharmaceutical Preparations ', ' Drugs ', ' Medication ', ' Pharmaceutic Preparations ', ' drug/agent ', ' Family ', ' Foundations ', ' Glioblastoma ', ' Grade IV Astrocytic Neoplasm ', ' Grade IV Astrocytic Tumor ', ' Grade IV Astrocytoma ', ' glioblastoma multiforme ', ' spongioblastoma multiforme ', ' Health ', ' Health Personnel ', ' Health Care Providers ', ' Healthcare Providers ', ' Healthcare worker ', ' health care personnel ', ' health care worker ', ' health provider ', ' health workforce ', ' healthcare personnel ', ' medical personnel ', ' treatment provider ', ' Recording of previous events ', ' History ', ' Laboratories ', ' Medical Records ', ' melanoma ', ' Malignant Melanoma ', ' men ', "" men's "", ' Methods ', ' Methodology ', ' Mutation ', ' Genetic Alteration ', ' Genetic Change ', ' Genetic defect ', ' genome mutation ', ' United States National Institutes of Health ', ' NIH ', ' National Institutes of Health ', ' Natural Language Processing ', ' natural language understanding ', ' Pathology ', ' Patients ', ' Public Health ', ' Recurrence ', ' Recurrent ', ' Research Personnel ', ' Investigators ', ' Researchers ', ' Semantics ', ' Technology ', ' Testing ', ' Time ', ' Tissues ', ' Body Tissues ', ' Universities ', ' Vermont ', ' Woman ', ' Work ', ' Computerized Medical Record ', ' Electronic Medical Record ', ' Information Retrieval ', ' Information extraction ', ' Measures ', ' health care ', ' Healthcare ', ' Dataset ', ' Data Set ', ' base ', ' improved ', ' Clinical ', ' Medical ', ' Link ', ' Malignant Tumor of the Lung ', ' Pulmonary Cancer ', ' Pulmonary malignant Neoplasm ', ' lung cancer ', ' Malignant neoplasm of lung ', ' drug use ', ' Drug usage ', ' Collaborations ', ' Genetic ', ' Malignant Cell ', ' cancer cell ', ' machine learned ', ' Machine Learning ', ' Knowledge ', ' Pattern ', ' Clinical Decision Support Systems ', ' Somatic Mutation ', ' Medical center ', ' Performance ', ' novel ', ' Second Cancer ', ' Secondary Malignancy ', ' Secondary Malignant Neoplasm ', ' secondary cancer ', ' Second Primary Cancers ', ' Pathology Report ', ' Statistical Methods ', ' Modeling ', ' response ', ' Genomics ', ' Cancer Treatment ', ' Malignant Neoplasm Therapy ', ' Malignant Neoplasm Treatment ', ' anti-cancer therapy ', ' anticancer therapy ', ' cancer therapy ', ' Bio-Informatics ', ' Bioinformatics ', ' DNA Alteration ', ' DNA mutation ', ' Genetic mutation ', ' Sequence Alteration ', ' genomic alteration ', ' DNA Sequence Alteration ', ' Data ', ' Cancer Cause ', ' Cancer Etiology ', ' Cancer Patient ', ' Clinical Data ', ' Ontology ', ' Smoking Status ', ' Translational Science ', ' translation research ', ' Translational Research ', ' Tumor Pathology ', ' Validation ', ' Pathologic ', ' Characteristics ', ' resistant mechanism ', ' resistance mechanism ', ' developmental ', ' Development ', ' Colo-rectal Cancer ', ' Colorectal Cancer ', ' electronic data ', ' pathway ', ' Pathway interactions ', ' genetic profiling ', ' anti-cancer research ', ' cancer research ', ' anticancer research ', ' designing ', ' design ', ' Outcome ', ' Resistant development ', ' developing resistance ', ' Resistance development ', ' cancer type ', ' innovate ', ' innovative ', ' innovation ', ' resistant ', ' Resistance ', ' demographics ', ' tumor ', ' response to treatment ', ' therapeutic response ', ' treatment response ', ' treatment strategy ', ' bio-markers ', ' biologic marker ', ' biomarker ', ' Biological Markers ', ' screening ', ' precision-based medicine ', ' precision medicine ', ' personalization of treatment ', ' personalized therapy ', ' personalized treatment ', ' personalized medicine ', ' targeted drug therapy ', ' targeted drug treatments ', ' targeted therapeutic ', ' targeted therapeutic agents ', ' targeted therapy ', ' targeted treatment ', ' targeted cancer therapy ', ' clinically actionable ', ' power analysis ', ' actionable variants ', ' actionable mutation ', ' Computerized Models ', ' computational modeling ', ' computational models ', ' computer based models ', ' computerized modeling ', ' Computer Models ', ' machine learning method ', ' ']",NCI,DARTMOUTH COLLEGE,R01,2020,375150,NH-02,0.03444410556199578
"Predicting Transcriptional and Epigenetic Networks in Cancer from Sequencing Data Limitless replicative potential is a key hallmark of cancer and critically depends on telomere maintenance. Many cancers thus aberrantly reactivate the telomerase reverse transcriptase (TERT), a catalytic subunit of the telomerase complex that elongates telomere. It has been recently discovered that this common path to immortality in multiple cancers is through two activating point mutations in the TERT promoter (TERTp), found in more than 50 different cancer types, often at strikingly high frequencies, e.g. roughly 83% in glioblastomas (GBM) and 71% in melanomas. In the previous funding period, the PI has identified the molecular function of these highly recurrent mutations, demonstrating that the transcription factor (TF) GABP binds the mutant TERTp with exquisite specificity, but not the wild-type TERTp. The high prevalence of TERTp mutations across multiple cancer types and the selectivity of GABP recruitment to mutant TERTp thus provide an unprecedented opportunity for treating a large number of cancer patients with minimal toxicity to healthy cells. Despite the clear significance of this opportunity, however, several important questions surrounding the molecular functions and modulators of TERTp mutations remain poorly understood, hindering the development of effective and safe therapeutic strategies.  Our long-term goal is to establish a rigorous computational framework for understanding the aberrant transcriptional and epigenetic networks in cancers and to apply the resulting knowledge to devise novel therapeutic strategies that account for the genetic background of individual patients and that can a priori predict and avoid potential resistance mechanisms. The objective of our current renewal proposal is to develop powerful computational methods for transforming our knowledge about the non-coding TERTp mutations into an effective and safe molecular target. At the same time, the resulting methods will help resolve several outstanding challenges in the field of transcriptional gene regulation and have broad applications in cancer genomics. We will accomplish our objective my pursuing the following Aims: (1) Develop and test a computational framework for inferring sequence features that determine the distinct and shared binding patterns of paralogous TFs; (2) Develop and validate integrative tools for discovering the molecular basis of genetic interactions between germline variations and oncogenic mutations; (3) Develop and apply computational methods for studying the role of DNA helical phase between adjacent binding motifs in recruiting ETS factors to chromatin; (4) Perform a systematic genomic characterization of the effects of knocking out GABPB1L in TERTp-mutant cancer cells and healthy cells. The results of this proposal will have a broad impact on cancer research by providing powerful tools for studying paralogous oncogenic TFs and revealing novel insights into a highly promising therapeutic strategy. The proposed research will provide computational and bioinformatic resources for studying the binding pattern of paralogous oncogenic transcription factors. It will provide a computational framework for inferring the function of non-coding regulatory mutations and studying their interaction with common genetic variants. As an important application, we will systematically analyze a novel therapeutic strategy that has the potential to treat effectively a large number of patients across multiple cancer types harboring the recently discovered TERT promoter mutations.",Predicting Transcriptional and Epigenetic Networks in Cancer from Sequencing Data,9831048,R01CA163336,"['cancer research ', ' anticancer research ', ' computational framework ', ' computer framework ', ' cancer type ', ' Oncogenic ', ' computational resources ', ' computing resources ', ' new drug treatments ', ' new drugs ', ' new therapeutics ', ' new therapy ', ' next generation therapeutics ', ' novel drug treatments ', ' novel drugs ', ' novel therapy ', ' novel therapeutics ', ' therapeutic target ', ' response to treatment ', ' therapeutic response ', ' treatment response ', ' genome scale ', ' genomewide ', ' genome-wide ', ' individual patient ', ' recruit ', ' bio-informatics resource ', ' bioinformatics resource ', ' deep learning ', ' Binding Sites ', ' Combining Site ', ' Reactive Site ', ' Malignant Neoplasms ', ' Cancers ', ' Malignant Tumor ', ' malignancy ', ' neoplasm/cancer ', ' Cells ', ' Cell Body ', ' Chromatin ', ' Computing Methodologies ', ' computational methodology ', ' computational methods ', ' computer based method ', ' computer methods ', ' computing method ', ' DNA ', ' Deoxyribonucleic Acid ', ' Drug resistance ', ' drug resistant ', ' resistance to Drug ', ' resistant to Drug ', ' Family ', ' Gene Expression Regulation ', ' Gene Action Regulation ', ' Gene Regulation ', ' Gene Regulation Process ', ' Genome ', ' Glioblastoma ', ' Grade IV Astrocytic Neoplasm ', ' Grade IV Astrocytic Tumor ', ' Grade IV Astrocytoma ', ' glioblastoma multiforme ', ' spongioblastoma multiforme ', ' Goals ', ' knowledge of results ', ' melanoma ', ' Malignant Melanoma ', ' Methods ', ' Mutation ', ' Genetic Alteration ', ' Genetic Change ', ' Genetic defect ', ' genome mutation ', ' Patients ', ' Recurrence ', ' Recurrent ', ' Research ', ' RNA-Directed DNA Polymerase ', ' EC 2.7.7.49 ', ' RNA Transcriptase ', ' RNA-Dependent DNA Polymerase ', ' Reverse Transcriptase ', ' Revertase ', ' Role ', ' social role ', ' Specificity ', ' Testing ', ' Time ', ' transcription factor ', ' Basal Transcription Factor ', ' Basal transcription factor genes ', ' General Transcription Factor Gene ', ' General Transcription Factors ', ' Transcription Factor Proto-Oncogene ', ' Transcription factor genes ', ' Genetic Transcription ', ' Gene Transcription ', ' RNA Expression ', ' Transcription ', ' Work ', ' c-myc Genes ', ' c myc ', ' cmyc ', ' v-myc Avian Myelocytomatosis Viral Oncogene Cellular Homolog ', ' telomere ', ' Family member ', ' Mediating ', ' promotor ', ' promoter ', ' Telomerase ', ' Point Mutation ', ' base ', ' Phase ', ' Variation ', ' Variant ', ' Link ', ' insight ', ' Individual ', ' Funding ', ' Therapeutic ', ' Genetic ', ' Malignant Cell ', ' cancer cell ', ' tool ', ' Nature ', ' machine learned ', ' Machine Learning ', ' Knowledge ', ' Frequencies ', ' Complex ', ' Pattern ', ' Techniques ', ' Somatic Mutation ', ' dimer ', ' mutant ', ' Isoforms ', ' Protein Isoforms ', ' Toxicities ', ' Toxic effect ', ' novel ', ' member ', ' Functional RNA ', ' Non-Coding ', ' Non-Coding RNA ', ' Non-translated RNA ', ' Noncoding RNA ', ' Nontranslated RNA ', ' noncoding ', ' Untranslated RNA ', ' Genomics ', ' Telomere Maintenance ', ' Transcription Regulation ', ' Transcriptional Control ', ' Transcriptional Regulation ', ' Molecular Interaction ', ' Binding ', ' EST2 ', ' TCS1 ', ' Telomere Reverse Transcriptase ', ' telomerase catalytic subunit ', ' TERT gene ', ' Address ', ' DNA Alteration ', ' DNA mutation ', ' Genetic mutation ', ' Sequence Alteration ', ' genomic alteration ', ' DNA Sequence Alteration ', ' Data ', ' High Prevalence ', ' Molecular Target ', ' Cancer Patient ', ' Epigenetic ', ' Epigenetic Change ', ' Epigenetic Mechanism ', ' Epigenetic Process ', ' Validation ', ' Molecular ', ' Knockout ', ' Knock-out ', ' resistant mechanism ', ' resistance mechanism ', ' developmental ', ' Development ', ' oncogenomics ', ' cancer genomics ', ' Gene variant ', ' allele variant ', ' allelic variant ', ' genomic variant ', ' genetic variant ', ' anti-cancer research ', ' ']",NCI,UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN,R01,2020,326848,IL-13,0.14913333291555572
"A combined computational and experimental approach to the evolution and role of the DNA sequence environment in targeting mutations to antibody V regions Project summary There is a fundamental gap in our understanding of how mutations are preferentially targeted to the variable (V) regions of the Immunoglobulin (Ig) loci during somatic hypermutation (SHM). The persistence of this gap has limited our understanding of the mutagenic mechanisms involving activation-induced deaminase (AID) in the immune response and in the role of AID in mis-targeting mutations leading to B-cell lymphomas and other cancers. The long-term goal of the proposed research is to understand the global targeting of mutations in immunity that are required to protect us from infections. As high-throughput data from human antibody immune responses became available, it provided us with new opportunities to generate hypotheses to explain the underlying mechanisms of SHM. We now propose to generate further hypotheses using computational models applied to additional databases and to validate these hypotheses using cellular and animal experiments. Our objective is to understand what directs SHM across the many human Ig heavy chain V-regions. Our central hypothesis is that the V-region SHM process is highly dependent on a DNA sequence signature(s) that drives mutations in a largely deterministic fashion. This hypothesis is supported by our preliminary results using human in vivo data from a few human V region genes and has begun to be validated using independent databases and experiments in human B cell lines. The rationale is that evaluations of computational data based upon biological mechanisms, together with appropriate biological experiments, will reveal the key differences between IGHV regions (IGHV 3-23, 4-34, 1-18, 1-02, etc.) that lead to the dominance of each of those V regions in the responses to medically important antigens. Our hypothesis will be tested by pursuing two specific aims: 1) identify the extent to which a DNA signature determines the mutation process in four individual human IGHV genes that are important in disease responses; 2) examine the relationship between AID hotspots and Pol hotspots across all the other human V region genes, thus rigorously defining a mutation targeting signature. Both aims will also entail studying human V region genes and modifications of them in human cell lines and in mice expressing a human V region to further confirm the signature and identify molecular mechanisms in vivo. Our approach is innovative because the computational models we are proposing will be mechanistically motivated focusing on the interaction between AID and Pol hotspots, thus testing molecular mechanisms as opposed to classic statistical models using whole V region sequences that ignore the underlying biology. In addition, to focus on mechanisms we will leverage new high-throughput data from human V regions that have not undergone antigen selection. Our results will be highly relevant to human IgV repertoire analyses from immune responses that are currently hard to interpret and will help future vaccine and therapeutic antibody development, as well as help to understand mutations in human malignancies where AID plays a key role. Project narrative The proposed research is relevant to public health because understanding the targeting of AID-mediated mutations across many human heavy chain V-regions will make it possible to develop vaccines that will lead more rapidly to better and more broadly protective antibodies to infectious agents and reveal the risk factors in the development of B-cell malignancies and gastric and other solid tumors where AID is implicated.",A combined computational and experimental approach to the evolution and role of the DNA sequence environment in targeting mutations to antibody V regions,9882227,R01AI132507,"['Affect ', ' Alleles ', ' Allelomorphs ', ' Antibodies ', ' Antibody Affinity ', ' antigen antibody affinity ', ' Antigens ', ' immunogen ', ' Autoimmunity ', ' Autoimmune Status ', ' B-Lymphocytes ', ' B blood cells ', ' B cell ', ' B cells ', ' B-Cells ', ' B-cell ', ' Biology ', ' Malignant Neoplasms ', ' Cancers ', ' Malignant Tumor ', ' malignancy ', ' neoplasm/cancer ', ' Cell Line ', ' CellLine ', ' Strains Cell Lines ', ' cultured cell line ', ' Chromatin ', ' Disease ', ' Disorder ', ' DNA ', ' Deoxyribonucleic Acid ', ' Environment ', ' Enzyme Activation ', ' Evolution ', ' Family ', ' Feedback ', ' Future ', ' Genes ', ' Goals ', ' HIV ', ' AIDS Virus ', ' Acquired Immune Deficiency Syndrome Virus ', ' Acquired Immunodeficiency Syndrome Virus ', ' Human Immunodeficiency Viruses ', ' LAV-HTLV-III ', ' Lymphadenopathy-Associated Virus ', ' Virus-HIV ', ' Human ', ' Modern Man ', ' Immunity ', ' Complementarity Determining Regions ', ' Complimentarity Determining Region ', ' Hypervariable Loop ', ' Hypervariable Regions ', ' Immunoglobulin Hypervariable Region ', ' Immunoglobulins ', ' Immune Globulins ', ' Heavy-Chain Immunoglobulins ', ' Infection ', ' Influenza ', ' Grippe ', ' flu infection ', ' influenza infection ', ' Lead ', ' Pb element ', ' heavy metal Pb ', ' heavy metal lead ', ' Transgenic Mice ', ' Statistical Models ', ' Probabilistic Models ', ' Probability Models ', ' statistical linear mixed models ', ' statistical linear models ', ' Mus ', ' Mice ', ' Mice Mammals ', ' Murine ', ' Mutation ', ' Genetic Alteration ', ' Genetic Change ', ' Genetic defect ', ' genome mutation ', ' Play ', ' Public Health ', ' Research ', ' Risk Factors ', ' Role ', ' social role ', ' Stomach ', ' gastric ', ' Testing ', ' Time ', ' Vaccines ', ' B-Cell Lymphomas ', ' B lymphoma ', ' Mediating ', ' G(s), alpha Subunit ', ' G(s),  Subunit ', ' G(s)alpha ', ' G(s) ', ' GTP-Binding Protein  Subunits, Gs ', ' Gs alpha Family G-Protein ', ' Gs ', ' Gs ', ' Regulatory Ns Protein ', ' Stimulatory Gs G-Protein ', ' alpha Subunit Stimulatory GTP-Binding Protein ', ' alpha-Gs ', ' -Gs ', ' GTP-Binding Protein alpha Subunits, Gs ', ' DNA Sequence ', ' base ', ' density ', ' Site ', ' Variation ', ' Variant ', ' Biological ', ' Medical ', ' Animal Experiments ', ' Evaluation ', ' Individual ', ' Data Bases ', ' data base ', ' Databases ', ' Solid Tumor ', ' Solid Neoplasm ', ' Germinal Center ', ' Structure of germinal center of lymph node ', ' Immunological response ', ' host response ', ' immunoresponse ', ' Immune response ', ' infectious organism ', ' Infectious Agent ', ' machine learned ', ' Machine Learning ', ' Frequencies ', ' Event ', ' Pattern ', ' Techniques ', ' Location ', ' neutralizing antibody ', ' human data ', ' repair endonuclease ', ' repair enzyme ', ' Human Cell Line ', ' response ', ' Ig Somatic Hypermutation ', ' somatic hypermutation ', ' Immunoglobulin Somatic Hypermutation ', ' AICDA ', ' AICDA protein ', ' AID gene ', ' AID protein ', ' CDA2 protein ', ' activation-induced deaminase ', ' activation-induced cytidine deaminase ', ' Post-Replication Mismatch Repair ', ' Mismatch Repair ', ' chromatin modification ', ' Polymerase ', ' B-Cell Development ', ' Data ', ' Mutate ', ' in vivo ', ' in vivo Model ', ' computational analyses ', ' computational analysis ', ' computer analyses ', ' Computer Analysis ', ' gene modification ', ' Gene-Modified ', ' Validation ', ' Molecular ', ' Process ', ' developmental ', ' Development ', ' Gene variant ', ' allele variant ', ' allelic variant ', ' genomic variant ', ' genetic variant ', ' B cell malignancy ', ' B lymphoid malignancy ', ' Outcome ', ' innovate ', ' innovative ', ' innovation ', ' Influenza HA ', ' flu HA ', ' flu hemagglutinin ', ' influenza virus HA ', ' influenza virus hemagglutinin ', ' Influenza Hemagglutinin ', ' Therapeutic antibodies ', ' spatial relationship ', ' vaccine response ', ' knockin ', ' Knock-in ', ' experiment ', ' experimental research ', ' experimental study ', ' recruit ', ' Computerized Models ', ' computational modeling ', ' computational models ', ' computer based models ', ' computerized modeling ', ' Computer Models ', ' ']",NIAID,ALBERT EINSTEIN COLLEGE OF MEDICINE,R01,2020,591815,NY-14,0.15887011747240132
"A statistical framework to systematically characterize cancer driver mutations in noncoding genomic regions PROJECT SUMMARY Cancer genomes typically harbor a substantial number of somatic mutations. Relatively few driver mutations actually alter the function of proteins in tumor cells, whereas most mutations are considered to be functionally neutral passenger mutations. Over the past decade, the search for cancer driver mutations has focused on coding regions and several mutational significance algorithms have been developed for coding mutations. The contribution of mutations in noncoding regulatory regions to tumor formation largely remains unknown and current mutational significance algorithms are not designed to detect driver mutations in noncoding regions, due to biological differences between coding and noncoding mutations. The emerging availability of large whole- genome sequencing datasets (e.g. PCAWG and HMF datasets) creates an ample opportunity to develop new mutational significance algorithms that are particularly designed for the interpretation of noncoding regions. Recently, we have developed a new statistical approach that identifies driver mutations in coding regions based on the nucleotide context. Critically, consideration of the nucleotide context around mutations does not require prior knowledge for functional consequences associated with these mutations. Hence, we hypothesize that generalizing our nucleotide context model to noncoding regions will uncover novel noncoding driver mutations that cannot be detected using the mutational significance approaches currently available. For this purpose, we will develop a statistical framework that incorporates the biological differences between coding and noncoding mutations and that is specifically designed to detect driver mutations in noncoding regions. Specifically, we will consider the context-dependent distribution of passenger mutations, modeling of the background mutation rate, accurately partition the background mutation rate, model the sequence composition of the reference genome, and account for coverage fluctuation. We will then combine these statistical components by computing an independent product of their underlying probabilities. We will derive a significance p-value using a Monte-Carlo simulation approach, and use FDR for multiple hypothesis test correction. This strategy will allow us to accurately estimate the significance of somatic mutations in noncoding genomic regions. We will next apply this statistical framework to whole-genome sequencing data of 5,523 tumor patients, thereby deriving a comprehensive list of candidate driver mutations in noncoding regions. Finally, we will investigate whether noncoding mutations are overrepresented in transcription factor binding sites, regulate gene expression levels, induce alternative splicing, or affect epigenomic states. Upon the completion of this project, we will have developed and applied a statistical framework for discovery of significant somatic mutations in noncoding regions, and defined the mutational landscape of the non-coding cancer genome. All aspects of the methods developed and applied in this project will be made open source and developed in an online platform. PROJECT NARRATIVE While coding cancer driver mutations have been characterized in detail over the past decade, the contribution of noncoding mutations to tumor formation remains - apart from few examples (e.g. mutations in TERT promoters) - largely unknown. Recently, large-scale whole-genome sequencing datasets have been made available, but a major bottleneck for the biological and clinical interpretation of these cancer whole-genome cohorts is the lack of statistical models that identify driver mutations in noncoding regions. We developed a new statistical approach that characterizes driver mutations based on their surrounding nucleotide context in coding regions, and herein we propose a concrete plan to generalize our computational model to noncoding regions, apply our model to aggregated whole-genome sequencing data of 5,523 tumor patients (PCAWG, HMF datasets), and define the noncoding driver and passenger mutational landscape for biological discovery and focused clinical application.",A statistical framework to systematically characterize cancer driver mutations in noncoding genomic regions,10260680,R21CA242861,"['cancer cell genome ', ' tumor genome ', ' cancer genome ', ' immunogenicity ', ' designing ', ' design ', ' Outcome ', ' clinical effect ', ' clinical applicability ', ' clinical application ', ' open source ', ' tumor ', ' genome scale ', ' genomewide ', ' genome-wide ', ' TCGA ', ' The Cancer Genome Atlas ', ' exome-seq ', ' exome sequencing ', ' targeted drug therapy ', ' targeted drug treatments ', ' targeted therapeutic ', ' targeted therapeutic agents ', ' targeted therapy ', ' targeted treatment ', ' prediction of response ', ' predictive response ', ' predictor of response ', ' response prediction ', ' predicting response ', ' reference assembly ', ' reference genome ', ' entire genome ', ' full genome ', ' whole genome ', ' check point immunotherapy ', ' check point inhibitor therapy ', ' check point inhibitory therapy ', ' check point therapy ', ' checkpoint immunotherapy ', ' checkpoint inhibitor therapy ', ' checkpoint inhibitory therapy ', ' immune check point therapy ', ' immune checkpoint therapy ', ' checkpoint therapy ', ' check point blockade ', ' checkpoint blockade ', ' immune check point blockade ', ' immune checkpoint blockade ', ' neo-antigen ', ' neo-epitopes ', ' neoepitopes ', ' neoantigens ', ' Computerized Models ', ' computational modeling ', ' computational models ', ' computer based models ', ' computerized modeling ', ' Computer Models ', ' large data sets ', ' large datasets ', ' driver mutation ', ' Affect ', ' Algorithms ', ' Alternative Splicing ', ' Alternate Splicing ', ' Alternative RNA Splicing ', ' Attention ', ' Binding Sites ', ' Combining Site ', ' Reactive Site ', ' Biology ', ' malignant breast neoplasm ', ' Breast Cancer ', ' malignant breast tumor ', ' Malignant Neoplasms ', ' Cancers ', ' Malignant Tumor ', ' malignancy ', ' neoplasm/cancer ', ' Communities ', ' Gene Expression ', ' Gene Expression Regulation ', ' Gene Action Regulation ', ' Gene Regulation ', ' Gene Regulation Process ', ' Immunotherapy ', ' Immune mediated therapy ', ' Immunologically Directed Therapy ', ' immune therapeutic approach ', ' immune therapeutic interventions ', ' immune therapeutic regimens ', ' immune therapeutic strategy ', ' immune therapy ', ' immune-based therapies ', ' immune-based treatments ', ' immuno therapy ', ' melanoma ', ' Malignant Melanoma ', ' Methods ', ' Statistical Models ', ' Probabilistic Models ', ' Probability Models ', ' statistical linear mixed models ', ' statistical linear models ', ' Monte Carlo Method ', ' Monte Carlo algorithm ', ' Monte Carlo calculation ', ' Monte Carlo procedure ', ' Monte Carlo simulation ', ' Mutation ', ' Genetic Alteration ', ' Genetic Change ', ' Genetic defect ', ' genome mutation ', ' Nucleotides ', ' Patients ', ' Play ', ' Probability ', ' Nucleic Acid Regulatory Sequences ', ' Nucleic Acid Regulator Regions ', ' Regulatory Regions ', ' genetic regulatory element ', ' Role ', ' social role ', ' Testing ', ' transcription factor ', ' Basal Transcription Factor ', ' Basal transcription factor genes ', ' General Transcription Factor Gene ', ' General Transcription Factors ', ' Transcription Factor Proto-Oncogene ', ' Transcription factor genes ', ' Mediating ', ' promotor ', ' promoter ', ' Dataset ', ' Data Set ', ' base ', ' Clinical ', ' Biological ', ' Biological Function ', ' Biological Process ', ' anti-cancer immunotherapy ', ' anticancer immunotherapy ', ' immune-based cancer therapies ', ' immunotherapy for cancer ', ' immunotherapy of cancer ', ' cancer immunotherapy ', ' machine learned ', ' Machine Learning ', ' computer biology ', ' Computational Biology ', ' Knowledge ', ' Pattern ', ' Somatic Mutation ', ' mutant ', ' Tumor Cell ', ' neoplastic cell ', ' cohort ', ' novel ', ' Position ', ' Positioning Attribute ', ' Coding System ', ' Code ', ' Modeling ', ' response ', ' Functional RNA ', ' Non-Coding ', ' Non-Coding RNA ', ' Non-translated RNA ', ' Noncoding RNA ', ' Nontranslated RNA ', ' noncoding ', ' Untranslated RNA ', ' Microsatellite Instability ', ' genome sequencing ', ' Address ', ' Data ', ' Stratification ', ' genomic region ', ' Genomic Segment ', ' Process ', ' protein function ', ' developmental ', ' Development ', ' epigenomics ', ' ']",NCI,DANA-FARBER CANCER INST,R21,2020,177000,MA-07,0.2587934284878348
"Predicting and analyzing variation in cellular interactomes Project Summary Over the last two decades, significant experimental efforts have determined large sets of reference interactions for humans and other model organisms, along with substantial knowledge about the binding specificities of proteins, including for a large fraction of human transcription factors (TFs). The resulting data have proven to be an incredibly useful resource for understanding how cells function; nevertheless, they do not capture how molecular interactions and networks are different from the reference across individuals. Indeed, while human genomes in both healthy and disease populations are rapidly being sequenced, the corresponding individual-specific interaction networks remain largely unexamined; this represents a major gap in our knowledge, as mutations that alter molecular interactions underlie a wide range of human diseases. Further, the substantial amount of genetic variation across populations makes it infeasible in the near term to experimentally determine per-individual interaction networks. Thus our long-term goal is to develop computational methods to uncover whether and how mutations within coding and non-coding portions of the genome perturb cellular interactions and networks. Our specific aims are: (1) We will develop computational structure-based approaches to identify and catalog, at proteome-scale, variations within proteins that are likely to impact their ability to bind with DNA, RNA, small molecules, peptides or ions, thereby providing a comprehensive resource for analyzing protein interaction variation. (2) We will develop novel structure-based and probabilistic methods to predict how DNA-binding specificities are altered when a TF is mutated; since mutated TFs have been linked to numerous diseases, this will be a great aid in understanding disease networks and pathology. (3) We will develop new methods to uncover non-coding somatic mutations that alter human regulatory networks in cancer; this is a critical step towards ultimately uncovering patient-specific cancer networks. Overall by pursuing these aimswhich integrate mutational information with existing knowledge about reference interactions, interfaces and specificitieswe will develop novel computational methods that will significantly advance our understanding of molecular interactions perturbed in disease and healthy contexts. Narrative The proposed research will yield new software tools that predict whether specific genetic mutations alter molecular interactions and networks. Since many human diseases are caused by mutations that affect molecular interactions, this research will expand our understanding of the underlying basis of disease and will provide new avenues for diagnosis and treatment.",Predicting and analyzing variation in cellular interactomes,9896829,R01GM076275,"['Affect ', ' Alleles ', ' Allelomorphs ', ' Amino Acid Sequence ', ' Primary Protein Structure ', ' protein sequence ', ' Binding Sites ', ' Combining Site ', ' Reactive Site ', ' Malignant Neoplasms ', ' Cancers ', ' Malignant Tumor ', ' malignancy ', ' neoplasm/cancer ', ' Cell physiology ', ' Cell Function ', ' Cell Process ', ' Cellular Function ', ' Cellular Physiology ', ' Cellular Process ', ' Subcellular Process ', ' Computing Methodologies ', ' computational methodology ', ' computational methods ', ' computer based method ', ' computer methods ', ' computing method ', ' Diagnosis ', ' Disease ', ' Disorder ', ' DNA ', ' Deoxyribonucleic Acid ', ' Gene Expression ', ' Genes ', ' Regulator Genes ', ' Transcriptional Regulatory Elements ', ' regulatory gene ', ' trans acting element ', ' Genome ', ' Human Genome ', ' human whole genome ', ' Goals ', ' Human ', ' Modern Man ', ' Ions ', ' Methods ', ' Mutation ', ' Genetic Alteration ', ' Genetic Change ', ' Genetic defect ', ' genome mutation ', ' Organism ', ' living system ', ' Pathology ', ' Patients ', ' Peptides ', ' Play ', ' Proteins ', ' Nucleic Acid Regulatory Sequences ', ' Nucleic Acid Regulator Regions ', ' Regulatory Regions ', ' genetic regulatory element ', ' Research ', ' Resources ', ' Research Resources ', ' RNA ', ' Non-Polyadenylated RNA ', ' RNA Gene Products ', ' Ribonucleic Acid ', ' Software Tools ', ' Computer Software Tools ', ' Specificity ', ' transcription factor ', ' Basal Transcription Factor ', ' Basal transcription factor genes ', ' General Transcription Factor Gene ', ' General Transcription Factors ', ' Transcription Factor Proto-Oncogene ', ' Transcription factor genes ', ' Genetic Variation ', ' Genetic Diversity ', ' Work ', ' Mutagenesis ', ' Genetics-Mutagenesis ', ' Mutagenesis Molecular Biology ', ' Zinc Fingers ', ' Zinc Finger Domain ', ' Zinc Finger Motifs ', ' Mediating ', ' Dataset ', ' Data Set ', ' base ', ' improved ', ' Site ', ' Variation ', ' Variant ', ' Biological ', ' Link ', ' Individual ', ' Ligand Binding Protein ', ' Ligand Binding Protein Gene ', ' Protein Binding ', ' bound protein ', ' Binding Proteins ', ' Biological Function ', ' Biological Process ', ' WWW ', ' web ', ' world wide web ', ' Internet ', ' Knowledge ', ' Catalogs ', ' Complex ', ' Pattern ', ' interest ', ' Somatic Mutation ', ' preference ', ' Animal Models and Related Studies ', ' model of animal ', ' model organism ', ' Animal Model ', ' knowledgebase ', ' knowledge base ', ' Structure ', ' novel ', ' Proteome ', ' Coding System ', ' Code ', ' Sampling ', ' Property ', ' develop software ', ' developing computer software ', ' software development ', ' Functional RNA ', ' Non-Coding ', ' Non-Coding RNA ', ' Non-translated RNA ', ' Noncoding RNA ', ' Nontranslated RNA ', ' noncoding ', ' Untranslated RNA ', ' Bio-Informatics ', ' Bioinformatics ', ' DNA Binding Interaction ', ' DNA bound ', ' DNA Binding ', ' Molecular Interaction ', ' Binding ', ' small molecule ', ' DNA-Protein Interaction ', ' DNA Alteration ', ' DNA mutation ', ' Genetic mutation ', ' Sequence Alteration ', ' genomic alteration ', ' DNA Sequence Alteration ', ' Data ', ' Mutate ', ' Protein Analysis ', ' Ligand Binding ', ' cancer cell genome ', ' tumor genome ', ' cancer genome ', ' virtual ', ' Population ', ' human disease ', ' tumor ', ' disease-causing mutation ', ' predictive tools ', ' experiment ', ' experimental research ', ' experimental study ', ' Infrastructure ', ' machine learning method ', ' ']",NIGMS,PRINCETON UNIVERSITY,R01,2020,312660,NJ-12,0.12353103120853917
"APPLYING ERROR-CORRECTED SEQUENCING TO DETECT MINIMAL RESIDUAL IN THE AAML 1031 STUDY Abstract  Acute myeloid leukemia (AML) accounts for half of all pediatric leukemia deaths and is the leading cause of leukemia-related death in adulthood. One reason for worse outcomes is the inability to properly assess for minimal residual disease (MRD) following therapy. Unlike ALL, AML presents with multiple subclonal populations without a singular clonal surface marker, and surface markers can change during therapy. The current gold standard for AML MRD is multi-parameter flow cytometry (MPFC), which is predictive of outcomes to frequencies of 0.001, yet 30% of MPFC-MRD-negative patients still relapse. Alternatively, every AML case harbors leukemia-specific mutations that could be markers of disease, except that next-generation sequencing has high error rate of ~1%. In this proposal, we will implement a novel, validated error-corrected sequencing (ECS) strategy, developed by the Druley lab in collaboration with Illumina, to improve MRD assessment of AML subclonal heterogeneity in 990 pediatric de novo AML cases from the Children's Oncology Group AAML1031 study. We hypothesize that using a highly sensitive sequencing method will improve identification of residual AML, provide important insights on subclonal heterogeneity in pediatric AML, improve understanding of the role of germline variability and gene function on relapses or refractory disease and facilitate personalized medicine. To interrogate this hypothesis, we propose the following aims: 1. Define subclonal heterogeneity at diagnosis and end of Induction 1 (EOI1) in 990 pediatric de novo  AML patients (n=1890). By using the largest prospective study of pediatric AML that has ever been  performed, we will perform ECS on 94 genes that are the most frequently mutated genes in pediatric and  adult AML at diagnosis and EOI1 to identify patterns of mutation associated with relapsed disease, FAB  subtypes or other cytogenetic features. 2. Correlate ECS-MRD with existing EOI1 MPFC-MRD for all participants in the COG AAML1031 study.  A major question is whether the different from normal cell population identified as residual disease by  MPFC is actually the same population(s) identified by ECS. We will define residual disease by ECS and  compare results to MPFC status (positive/negative), actual MPFC percentages (<0.001) and the clinical  outcomes (relapse risk, disease-free survival and overall survival) of study participants. 3. Integrate germline variation and all subclonal mutations into mechanistic groups that are frequently  mutated in pediatric AML and correlate with outcomes using unbiased machine learning  algorithms. Preliminary data tells us that every patient will have multiple subclones at diagnosis and EOI1  as well as germline variants in AML-associated genes, which may be important for outcome. In this aim, we  will take these mutations into account as well as MPFC, clinical features and cytogenetics for probabilistic  risk assessment using unsupervised machine learning algorithms for improved outcome prognostication. Narrative We have developed Error-Corrected Sequencing (ECS) that enables the highly accurate detection of leukemia- specific mutations in heterogeneous DNA samples to a limit of 0.0001. We will perform ECS with a panel of 94 frequently mutated genes in adult and pediatric AML in matched diagnostic and end of Induction 1 bone marrow samples from 990 pediatric de novo AML patients enrolled on the Children's Oncology Group AAML1031 protocol, which is the largest pediatric AML trial ever performed in North America. With these data, we can truly understand subclonal heterogeneity in pediatric AML, significantly improve minimal residual disease testing in pediatric AML, and integrate these data into an unbiased multivariate probability platform taking into account individual sequencing, flow cytometry, cytogenetic and clinical features to provide truly personalized cancer care.",APPLYING ERROR-CORRECTED SEQUENCING TO DETECT MINIMAL RESIDUAL IN THE AAML 1031 STUDY,9844413,R01CA211711,"['Adult ', ' 21+ years old ', ' Adult Human ', ' adulthood ', ' Alleles ', ' Allelomorphs ', ' Bone Marrow ', ' Bone Marrow Reticuloendothelial System ', ' Cytogenetics ', ' Cessation of life ', ' Death ', ' Diagnosis ', ' Disease ', ' Disorder ', ' DNA ', ' Deoxyribonucleic Acid ', ' Exons ', ' Family ', ' Flow Cytometry ', ' Flow Cytofluorometries ', ' Flow Cytofluorometry ', ' Flow Microfluorimetry ', ' Flow Microfluorometry ', ' flow cytophotometry ', ' Future ', ' Genes ', ' Goals ', ' Gold ', ' Hematology ', ' leukemia ', ' Acute Myelocytic Leukemia ', ' AML - Acute Myeloid Leukemia ', ' Acute Myeloblastic Leukemia ', ' Acute Myelogenous Leukemia ', ' acute granulocytic leukemia ', ' acute myeloid leukemia ', ' Methods ', ' Methodology ', ' Mutation ', ' Genetic Alteration ', ' Genetic Change ', ' Genetic defect ', ' genome mutation ', ' United States National Institutes of Health ', ' NIH ', ' National Institutes of Health ', ' North America ', ' Oncogenes ', ' Cancer Genes ', ' Cancer-Promoting Gene ', ' Transforming Genes ', ' Patients ', ' Protein phosphatase ', ' Phosphoprotein Phosphatase ', ' Phosphoprotein Phosphatase-2C ', ' Phosphoprotein Phosphohydrolase ', ' Protein Phosphatase C ', ' Protein Phosphatase Gene ', ' Protein Phosphatase-1 ', ' Protein Phosphatase-2A ', ' Probability ', ' Prospective Studies ', ' Protein Tyrosine Kinase ', ' EPH- and ELK-Related Tyrosine Kinase ', ' EPH-and ELK-Related Kinase ', ' Ephrin Type-A Receptor 8 ', ' Ephrin Type-A Receptor 8 Precursor ', ' Protein Tyrosine Kinase EEK ', ' Tyrosine Kinase ', ' Tyrosine-Protein Kinase Receptor EEK ', ' Tyrosine-Specific Protein Kinase ', ' Tyrosylprotein Kinase ', ' hydroxyaryl protein kinase ', ' tyrosyl protein kinase ', ' Reagent ', ' Relapse ', ' Risk ', ' Role ', ' social role ', ' Testing ', ' Time ', ' transcription factor ', ' Basal Transcription Factor ', ' Basal transcription factor genes ', ' General Transcription Factor Gene ', ' General Transcription Factors ', ' Transcription Factor Proto-Oncogene ', ' Transcription factor genes ', ' Immunophenotyping ', ' Immunologic Subtyping ', ' immunophenotype ', ' Measures ', ' falls ', ' Risk Assessment ', ' Point Mutation ', ' Spliceosomes ', ' analytical method ', ' base ', ' improved ', ' Site ', ' Surface ', ' Clinical ', ' Residual ', ' Residual state ', ' Phase ', ' Variation ', ' Variant ', ' Adult AGL ', ' Adult AML ', ' Adult ANLL ', ' Adult Acute Granulocytic Leukemia ', ' Adult Acute Myelocytic Leukemia ', ' Adult Acute Myelogenous Leukemia ', ' Adult Acute Myeloid Leukemia ', ' Adult Acute Non-Lymphoblastic Leukemia ', ' Adult Acute Non-Lymphocytic Leukemia ', ' Adult Acute NonLymphoblastic Leukemia ', ' Adult Acute NonLymphocytic Leukemia ', ' Adult Acute Myeloblastic Leukemia ', ' Childhood AML ', ' Childhood Acute Granulocytic Leukemia ', ' Childhood Acute Myeloblastic Leukemia ', ' Childhood Acute Myelocytic Leukemia ', ' Childhood Acute Myelogeneous Leukemia ', ' Childhood Acute Myelogenous Leukemia ', ' Pediatric AML ', ' Pediatric Acute Myeloblastic Leukemia ', ' Pediatric Acute Myelocytic Leukemia ', ' Pediatric Acute Myelogeneous Leukemia ', ' Pediatric Acute Myelogenous Leukemia ', ' Pediatric Acute Myeloid Leukemia ', ' Childhood Acute Myeloid Leukemia ', ' prognostic ', ' pediatric ', ' Childhood ', ' insight ', ' Individual ', ' Detectable Residual Disease ', ' Minimal Residual Disease ', ' Residual Neoplasm ', ' Event-Free Survival ', ' Disease-Free Survival ', ' Relapsed Disease ', ' Recurrent disease ', ' Collaborations ', ' Genetic ', ' gene function ', ' Diagnostic ', ' Investigation ', ' Frequencies ', ' Complex ', ' Protocol ', ' Protocols documentation ', ' Pattern ', ' residual disease ', ' Residual Tumors ', ' tumor suppressor ', ' Tumor Suppressor Proteins ', ' cohesion ', ' functional group ', ' novel ', ' Participant ', ' Categories ', ' Sampling ', ' response ', ' Cell Nucleus Active Transport ', ' Nuclear Transport ', ' Nucleocytoplasmic Shuttling ', ' nucleocytoplasmic transport ', ' Bortezomib ', ' Normal Cell ', ' Pediatric Leukemia ', ' children with leukemia ', ' leukemia in children ', ' Childhood Leukemia ', ' FLK2 ', ' FLT3 ', ' Fms-Related Tyrosine Kinase 3 ', ' STK1 ', ' Stem Cell Tyrosine Kinase 1 ', ' FLT3 gene ', ' DNA Alteration ', ' DNA mutation ', ' Genetic mutation ', ' Sequence Alteration ', ' genomic alteration ', ' DNA Sequence Alteration ', ' Data ', ' Detection ', ' Disease Marker ', ' Mutate ', ' Refractory Disease ', ' Resolution ', ' Sorafenib ', ' BAY 54-9085 ', ' Clinical Data ', ' enroll ', ' Enrollment ', ' Epigenetic ', ' Epigenetic Change ', ' Epigenetic Mechanism ', ' Epigenetic Process ', "" Children's Oncology Group "", ' Pediatric Oncology Group ', ' Monitor ', ' digital ', ' designing ', ' design ', ' next generation ', ' intervention efficacy ', ' therapeutic efficacy ', ' therapeutically effective ', ' therapy efficacy ', ' Treatment Efficacy ', ' Outcome ', ' Population ', ' prospective ', ' chemotherapy ', ' bio-markers ', ' biologic marker ', ' biomarker ', ' Biological Markers ', ' Randomization trial ', ' randomized trial ', ' NGS Method ', ' NGS system ', ' next gen sequencing ', ' nextgen sequencing ', ' next generation sequencing ', ' personalization of treatment ', ' personalized therapy ', ' personalized treatment ', ' personalized medicine ', ' child patients ', ' pediatric patients ', ' leukemia treatment ', ' personalized cancer care ', ' predictive outcomes ', ' predictors of outcomes ', ' outcome prediction ', ' specific biomarkers ', ' improved outcome ', ' relapse risk ', ' sub-clonal heterogeneity ', ' subclonal heterogeneity ', ' Risk stratification ', ' DNA seq ', ' DNAseq ', ' DNA sequencing ', ' unsupervised machine learning ', ' unsupervised learning ', ' machine learned algorithm ', ' machine learning algorithm ', ' ']",NCI,WASHINGTON UNIVERSITY,R01,2020,352587,MO-01,0.07065056628137568
"ADPKD: Disease Spectrum & Genotype-Phenotype Correlations Autosomal dominant polycystic kidney disease (ADPKD) is a common monoallelic disorder associated with progressive cyst development and resulting in end stage renal failure (ESRD) in 50% of patients by 60y. However, there is considerable phenotypic variability, extending from in utero onset to patients with adequate renal function into old age. Autosomal dominant polycystic liver disease (ADPLD), as traditionally defined, results in PLD with minimal renal cysts. Classically there have been considered two ADPKD genes, PKD1 and PKD2, encoding PC1 and PC2, and two ADPLD genes, PRKCSH and SEC63, but in the past few years greater genetic heterogeneity has been described, with nine genes now implicated overall. Recent data also indicates an overlap in etiology and pathogenesis associated with ADPKD and ADPLD, with the efficient biogenesis and localization of the PC-complex central to both disorders. During the last funding period we identified a novel gene, GANAB, which is associated with both disorders, where the encoded protein, GII is involved in the maturation and trafficking of PC1.  In this proposal we will take advantage of advances in next generation sequencing (NGS) methodologies, and large populations of ADPKD and ADPLD patients that have been assembled and screened for the classic genes, to hunt for novel genes for these disorders (Aim 1). The phenotype associated with these genes will be characterized (Aim 3) along with their mechanism of action (Aim 2). NGS methods will be perfected to screen the segmentally duplicated locus, PKD1, and to identify missed mutations at the known loci, including those present in just some cells due to mosaicism (Aim 1). The significance of many PKD1 nontruncating variants has been difficult to evaluate (classed as variants of unknown significance; VUS), but recently evidence that some are incompletely penetrant alleles partially explains phenotypic variability in PKD1 populations. In Aim 2 improved in silico predictions, in combination with machine learning, will improve the understanding of the pathogenicity and penetrance of VUS. A cellular assay of the biogenesis and trafficking of this PC-complex will also be employed to quantify the penetrance of VUS. The mechanism of pathogenesis will be explored in animal models with ultralow penetrant (ULP) Pkd1 or Pkd2 alleles. Employing the large clinically, imaging, and genetically well-defined populations phenotypic groupings of patients will be defined that will then be compared to the genic and PKD1 allelic groups (Aim 3). This iterative process will allow the Variant Score (VS) associated with each PKD1 VUS to be refined. In a separate population the revised VS, alone and in combination with clinical, functional, and imaging data, will be employed to generate a comprehensive, predictive algorithm for ADPKD (Aim 3). Disease modifiers to severe disease, via biallelic ADPKD, and due to alleles at other loci will also be identified and characterized in the cellular assay and in vivo in combination with the Pkd1 hypomorphic, RC model. The final aim will exploit the newly identified information that some PKD1 and PKD2 VUS are rescuable, folding mutations that in a maturation-fostering environment can traffic and function appropriately. A screening scheme based on the level of cell surface PC1 will be improved and new chaperone drugs specific for the PC complex will be sought in collaboration with Sanford Burnham Prebys. A second mutation group that will be explored therapeutically are nonsense mutations. A cellular assay for readthrough efficiency is being developed and will be used for screening. Identified chaperone or readthrough drugs will be tested in available mouse models. Overall this proposal will better explain the etiology and the genetic causes of phenotypic variability in ADPKD/ADPLD, develop better prognostic tools for individual selection of patients for treatment that are now becoming available, and explore allele based treatments for ADPKD. ADPKD and ADPLD are genetic diseases associated with cyst development and loss of function in the kidney and liver cysts, where the disease severity varies greatly between patients. Here we will identify new genes that cause these disorders and evaluate mutations in silico, in a cellular assay, and in whole animals to better predict the disease course in each patient. Treatment options associated with the type of individual patient mutations will also be explored, bringing individualized medicine to these diseases.",ADPKD: Disease Spectrum & Genotype-Phenotype Correlations,10148997,R01DK058816,"['Age ', ' ages ', ' Alleles ', ' Allelomorphs ', ' Animals ', ' Biogenesis ', ' Origin of Life ', ' Budgets ', ' Cells ', ' Cell Body ', ' Cyst ', ' Disease ', ' Disorder ', ' Pharmaceutical Preparations ', ' Drugs ', ' Medication ', ' Pharmaceutic Preparations ', ' drug/agent ', ' Environment ', ' Family ', ' Genes ', ' Genotype ', ' Goals ', ' Kidney ', ' Kidney Urinary System ', ' renal ', ' Cystic kidney ', ' Kidney Cyst ', ' Renal Cyst ', ' Methods ', ' Methodology ', ' Mosaicism ', ' mosaic disorders ', ' Mutation ', ' Genetic Alteration ', ' Genetic Change ', ' Genetic defect ', ' genome mutation ', ' Patients ', ' Phenotype ', ' Proteins ', ' Role ', ' social role ', ' Signal Transduction ', ' Cell Communication and Signaling ', ' Cell Signaling ', ' Intracellular Communication and Signaling ', ' Signal Transduction Systems ', ' Signaling ', ' biological signal transduction ', ' Testing ', ' Proprotein Convertase 2 ', ' Endopeptidase PC2 ', ' Neuroendocrine Convertase PC2 ', ' PC2 ', ' PC2 Endoprotease ', ' PC2 Prohormone Convertase ', ' PC2 Protein ', ' Prohormone Convertase 2 ', ' Proinsulin Convertase 2 ', ' Autosomal Dominant Polycystic Kidney ', ' ADPKD ', ' Adult Polycystic Kidney Disease ', ' Autosomal Dominant Polycystic Kidney Disease ', ' Dominant Polycystic Kidney Disease ', ' Neuroendocrine Convertase PC1 ', ' PC1 ', ' PC1 Endoprotease ', ' PC1 Prohormone Convertase ', ' PC3 Endoprotease ', ' PC3 Prohormone Convertase ', ' Prohormone Convertase 1 ', ' Prohormone Convertase 3 ', ' Proinsulin Convertase 1 ', ' Proprotein Convertase SPC3 ', ' Proprotein Convertase 1 ', ' Congenital cystic liver disease ', ' Cystic disease of liver ', ' Fibrocystic liver disease ', ' polycystic liver disease ', ' protein folding ', ' base ', ' dosage ', ' improved ', ' Hepatic ', ' Clinical ', ' Variation ', ' Variant ', ' Biological ', ' Biochemical ', ' Germline Mutation ', ' Hereditary Mutation ', ' Germ-Line Mutation ', ' prognostic ', ' kidney function ', ' Renal function ', ' insight ', ' Individual ', ' Fostering ', ' Patient Selection ', ' Genetic Heterogeneity ', ' Chaperone ', ' Molecular Chaperones ', ' Funding ', ' Liver Cyst ', ' Hepatic Cyst ', ' Collaborations ', ' Therapeutic ', ' Genetic ', ' Diagnostic ', ' machine learned ', ' Machine Learning ', ' Knowledge ', ' Severities ', ' Complex ', ' Event ', ' disease severity ', ' Severity of illness ', ' Penetrance ', ' 80K-H protein ', ' FGF-stimulated p90 ', ' G19P1 protein ', ' PRKCSH ', ' protein kinase substrate 80K-H ', ' protein kinase substrate 80KD protein, heavy chain ', ' PRKCSH protein ', ' non-sense mutation ', ' Nonsense Mutation ', ' mutant ', ' Animal Models and Related Studies ', ' model of animal ', ' model organism ', ' Animal Model ', ' trafficking ', ' novel ', ' Cell surface ', ' Pathogenesis ', ' Modeling ', ' Pathogenicity ', ' ESRD ', ' End-Stage Kidney Disease ', ' End-Stage Renal Disease ', ' End stage renal failure ', ' Causality ', ' causation ', ' disease causation ', ' Etiology ', ' Defect ', ' Data ', ' in vitro Assay ', ' in vivo ', ' cell assay ', ' Cellular Assay ', ' Physiologic Imaging ', ' physiological imaging ', ' Functional Imaging ', ' Other Genetics ', ' Scheme ', ' Process ', ' groupings ', ' Grouping ', ' developmental ', ' Development ', ' imaging ', ' Image ', ' in utero ', ' early onset ', ' disease phenotype ', ' Population ', ' murine model ', ' mouse model ', ' loss of function ', ' develop therapy ', ' intervention development ', ' treatment development ', ' therapy development ', ' NGS Method ', ' NGS system ', ' next gen sequencing ', ' nextgen sequencing ', ' next generation sequencing ', ' exome-seq ', ' exome sequencing ', ' screening ', ' customized therapy ', ' customized treatment ', ' individualized patient treatment ', ' individualized therapy ', ' individualized treatment ', ' patient specific therapies ', ' patient specific treatment ', ' tailored medical treatment ', ' tailored therapy ', ' tailored treatment ', ' unique treatment ', ' individualized medicine ', ' unclassified variant ', ' variant of uncertain clinical significance ', ' variant of uncertain significance ', ' variant of undetermined significance ', ' variant of unknown significance ', ' prognostic tool ', ' mutation scanning ', ' mutation screening ', ' individual patient ', ' molecular diagnostics ', ' predictive algorithm ', ' predictor algorithm ', ' prediction algorithm ', ' genetic condition ', ' genetic disorder ', ' Genetic Diseases ', ' in silico ', ' large data sets ', ' large datasets ', ' ']",NIDDK,MAYO CLINIC ROCHESTER,R01,2020,15035,MN-01,0.10158678176448475
"Physics-based precision medicine: computationally phenotyping myosin isoforms and cardiomyopathy mutations PROJECT SUMMARY/ABSTRACT  Myosins are a diverse and ubiquitous class of molecular motors that are responsible for generating much of the macroscopic force in the human body. The human genome encodes 38 different isoforms of myosin, and members of this group act as force sensors or generators for a diverse set of processes throughout the body. To serve this wide array of functions, each myosin isoform has been biophysically tuned for its physiological role. In fact, the tuning is so precise that missense variants in one myosin isoform, !-cardiac myosin, can cause a congenital cardiomyopathy that is the leading cause of sudden cardiac death in people under 30. And yet, it is unknown how particular variants cause disease, or how to infer the pathogenic potential for novel mutations.  Large differences in functional properties between myosin isoforms are not the result of large differences in coding sequence or overall topology. Neither foreknowledge of phylogeny nor crystal structure is sufcient to predict an isoform's biophysical properties. Furthermore, mutations causing disease frequently occur in regions of the protein far from the site of their deleterious effects. Poor understanding of the biophysical regulation of motor function has hampered the development of pharmaceuticals and the interpretation of human genomic data.  My goal is to establish a mechanistic understanding of myosin motors that is capable of predicting if and how sequence variation changes biophysical properties and can cause cardiac disease. Since myosin kinetics are not apparent from sequence or overall structure, they must be determined by other factors. I hypothesize that kinetic differences result from differences in the allosteric networks in these proteins. Allosteric network in this context refers to the coordinated conformational uctuations that give protein regulation the appearance of action at a distance. To test this hypothesis, we will use our unique combination of enormous computational power for molecular simulation and cutting-edge machine learning tools for analyzing protein allostery.  Aim 1 is to identify the biophysical determinants of myosin isoforms' differing speeds. To test our hypothesis that allosteric networks are responsible for modulating dynamics, I will use molecular simulations of different myosin isoforms and compare their allosteric networks with biochemical data about their properties. Aim 1 directly addresses outstanding questions about normal molecular-biological function of the heart, putting it in line with NHLBI overarching objective #1.  Aim 2 is to determine the difference, at atomic resolution, between healthy and diseased !-cardiac myosin. I hypothesize that the pathogenicity of variants with an unknown molecular etiology is a consequence of allosteric disruption, and will use our computational tools to test this hypothesis by simulating a set of known-pathogenic variants. This aim uses techniques from data science to understand the genetic determinants of health, and will apply equally well to rare alleles in under-represented groups as to majority groups. It is directly addresses NHLBI overarching objectives #3, #4, and #7. PROJECT NARRATIVE  Myosins are a closely-related group of molecules that are responsible for generating much of the force in the human body, including the heartbeat, the movement of limbs, and driving food through the stomach and intestines. Small changes to the myosin genes can have large effects: in healthy people, these give rise to different myosins that perform different functions, and mutations in some myosin genes can give rise to diseases that cause of sudden cardiac death. This proposal aims to learn, at the level of atoms and interatomic bonds, why and how these subtle changes to the myosin gene can create such large effects in the protein's function.",Physics-based precision medicine: computationally phenotyping myosin isoforms and cardiomyopathy mutations,9881184,F30HL146052,"['Actins ', ' Automobile Driving ', ' driving ', ' Behavior ', ' Binding Sites ', ' Combining Site ', ' Reactive Site ', ' Biophysics ', ' biophysical foundation ', ' biophysical principles ', ' biophysical sciences ', ' Catalysis ', ' Chemistry ', ' Crystallization ', ' Disease ', ' Disorder ', ' Food ', ' Food or Food Product ', ' Genes ', ' Human Genome ', ' human whole genome ', ' Goals ', ' Health ', ' Heart Diseases ', ' Cardiac Diseases ', ' Cardiac Disorders ', ' heart disorder ', ' Human ', ' Modern Man ', ' Intestines ', ' Intestinal ', ' bowel ', ' Kinetics ', ' Learning ', ' Membrane Proteins ', ' Membrane Protein Gene ', ' Membrane-Associated Proteins ', ' Surface Proteins ', ' Methods ', ' Molecular Conformation ', ' Molecular Configuration ', ' Molecular Stereochemistry ', ' conformation ', ' conformational state ', ' Mutation ', ' Genetic Alteration ', ' Genetic Change ', ' Genetic defect ', ' genome mutation ', ' Myosin ATPase ', ' Actin-Activated ATPase ', ' Myosin Adenosine Triphosphatase ', ' Myosin Adenosinetriphosphatase ', ' Myosins ', ' Phenotype ', ' Phylogeny ', ' Physics ', ' Proteins ', ' Relaxation ', ' Role ', ' social role ', ' Signal Transduction ', ' Cell Communication and Signaling ', ' Cell Signaling ', ' Intracellular Communication and Signaling ', ' Signal Transduction Systems ', ' Signaling ', ' biological signal transduction ', ' Solvents ', ' Stomach ', ' gastric ', ' Testing ', ' Time ', ' Genetic Variation ', ' Genetic Diversity ', ' Measures ', ' sudden cardiac death ', ' base ', ' improved ', ' Site ', ' Surface ', ' Clinical ', ' Variation ', ' Variant ', ' Physiologic ', ' Physiological ', ' Biochemical ', ' cardiac function ', ' function of the heart ', ' heart function ', ' insight ', ' Human Figure ', ' Human body ', ' Biological Function ', ' Biological Process ', ' tool ', ' machine learned ', ' Machine Learning ', ' Msec ', ' millisecond ', ' Techniques ', ' limb movement ', ' Molecular Dynamics Simulation ', ' molecular dynamics ', ' Isoforms ', ' Protein Isoforms ', ' Molecular Motors ', ' Ran 2 ', ' rat Ran-2 antigen ', ' rat Ran 2 protein ', ' Speed ', ' Structure ', ' simulation ', ' novel ', ' member ', ' Appearance ', ' Coding System ', ' Code ', ' Regulation ', ' Modeling ', ' Property ', ' Myocardial Diseases ', ' Myocardial Disorder ', ' Myocardiopathies ', ' myocardium disease ', ' myocardium disorder ', ' Cardiomyopathies ', ' genetic determinant ', ' Genetic Determinism ', ' Cardiac Muscle Myosins ', ' Cardiac Myosins ', ' Pathogenicity ', ' Molecular Interaction ', ' Binding ', ' Pharmaceutical Agent ', ' Pharmaceuticals ', ' Pharmacological Substance ', ' Pharmacologic Substance ', ' Causality ', ' causation ', ' disease causation ', ' Etiology ', ' Address ', ' Affinity ', ' Data ', ' Drug Binding Site ', ' Motor ', ' Protein Analysis ', ' Protein Region ', ' Resolution ', ' Molecular ', ' Process ', ' protein function ', ' developmental ', ' Development ', ' NHLBI ', ' National Heart, Lung, and Blood Institute ', ' computational tools ', ' computerized tools ', ' prototype ', ' disease-causing mutation ', ' rare allele ', ' rare variant ', ' biophysical characteristics ', ' biophysical characterization ', ' biophysical measurement ', ' biophysical parameters ', ' biophysical properties ', ' precision-based medicine ', ' precision medicine ', ' Patient risk ', ' Data Science ', ' Congenital cardiomyopathy ', ' Underrepresented Groups ', ' entire genome ', ' full genome ', ' whole genome ', ' genomic data-set ', ' genomic dataset ', ' genomic data ', ' Risk stratification ', ' force sensor ', ' ']",NHLBI,WASHINGTON UNIVERSITY,F30,2020,48719,MO-01,0.03642626328894276
"Imaging signatures of genetic mutations in glioblastoma using machine learning Glioblastoma (GB) is the most common and aggressive malignant adult brain tumor, with grim prognosis and heterogeneous molecular and imaging profiles. Although the currently applicable treatment options (i.e., surgery, radiotherapy, chemotherapy) have expanded during the last 20 years, there is no substantial improvement in the OS rates. The major obstacle in treating GBM patients is the heterogeneity of their molecular landscape. Determination of molecular targets requires ex vivo postoperative tissue analyses, which are limited in assessing the tumor's spatial heterogeneity (sampling error due to single sample histopathological and molecular analysis) and temporal heterogeneity (not possible to continuously assess the molecular transformation of the tumor during treatment). Herein we propose to develop quantitative imaging phenomic (QIP) markers of a range of mutations of interest in GB. We will build on prior work on EGFR, IDH1 mutations and MGMT methylation QIP signatures, and develop an extensive panel of imaging signatures of 10 gene mutations, as well as MGMT promoter methylation, using machine learning methods applied to relatively routine clinical mpMRI (standard plus diffusion tensor and perfusion protocols). Availability of such biomarkers can contribute to non-invasive i) patient stratification into appropriate treatments, ii) measurement of individual molecular characteristics. In particular, we propose to carry out the following specific aims: Specific Aim 1 (SA1): To develop the enabling methodologies for constructing Quantitative Imaging Phenomic signatures of GB mutations Specific Aim 2 (SA2): Establish QIP signatures of 10 mutations of interest in gliomas, plus MGMT promoter status, using next generation sequencing (NGS). We will use 709 datasets. Specific Aim 3 (SA3): Characterize the molecular heterogeneity of GB using QIP signatures, leveraging the NGS samples of SA1, as well as a new sample that we will genotype, adding to a total of 600 tumor samples obtained from 4 different locations per patient from 150 patients. The first 150 tissue samples are already analyzed as part of ongoing work. Specific Aim 4 (SA4): Integrate our methods into the Cancer Imaging Phenomics Toolkit (CaPTk), in order to allow easy access to them by users This project will investigate the relationship between imaging characteristics of glioblastoma and its underlying genetic mutations/variants. As such, it aims to develop a number of imaging signatures of mutations that are important in GBM, using 1,159 (709 patients plus an additional 450 tissue samples of 150 of these patients obtained from different locations in the tumor) analyzed via next generation sequencing. The primary motivation of this work is to develop the imaging analytics methodologies and associated biomarkers that will allow us to evaluate the spatial, temporal and molecular heterogeneity of glioblastoma, thereby assisting in patient stratification and treatment.",Imaging signatures of genetic mutations in glioblastoma using machine learning,9893291,R01NS042645,"['Adult ', ' 21+ years old ', ' Adult Human ', ' adulthood ', ' Atlases ', ' Biophysics ', ' biophysical foundation ', ' biophysical principles ', ' biophysical sciences ', ' Biopsy ', ' Brain Neoplasms ', ' Brain Neoplasia ', ' Brain Tumors ', ' tumors in the brain ', ' Malignant Neoplasms ', ' Cancers ', ' Malignant Tumor ', ' malignancy ', ' neoplasm/cancer ', ' Diagnosis ', ' Diffusion ', ' Genes ', ' Genotype ', ' Glioblastoma ', ' Grade IV Astrocytic Neoplasm ', ' Grade IV Astrocytic Tumor ', ' Grade IV Astrocytoma ', ' glioblastoma multiforme ', ' spongioblastoma multiforme ', ' Glioma ', ' Glial Cell Tumors ', ' Glial Neoplasm ', ' Glial Tumor ', ' Neuroglial Neoplasm ', ' Neuroglial Tumor ', ' glial-derived tumor ', ' neuroglia neoplasm ', ' neuroglia tumor ', ' Growth ', ' Generalized Growth ', ' Tissue Growth ', ' ontogeny ', ' Heterogeneity ', ' Magnetic Resonance Imaging ', ' MR Imaging ', ' MR Tomography ', ' MRI ', ' Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance ', ' NMR Imaging ', ' NMR Tomography ', ' Nuclear Magnetic Resonance Imaging ', ' Zeugmatography ', ' Methods ', ' Methodology ', ' Methylation ', ' Motivation ', ' Mutation ', ' Genetic Alteration ', ' Genetic Change ', ' Genetic defect ', ' genome mutation ', ' Patients ', ' Perfusion ', ' Phenotype ', ' Postoperative Period ', ' Post-Operative ', ' Postoperative ', ' outcome forecast ', ' Prognosis ', ' Radiation therapy ', ' Radiotherapeutics ', ' Radiotherapy ', ' radiation treatment ', ' radio-therapy ', ' treatment with radiation ', ' Epidermal Growth Factor Receptor ', ' EGF Receptor ', ' EGFR ', ' ERBB Protein ', ' Epidermal Growth Factor Receptor Kinase ', ' Epidermal Growth Factor Receptor Protein-Tyrosine Kinase ', ' Epidermal Growth Factor-Urogastrone Receptors ', ' HER1 ', ' TGF-alpha Receptor ', ' Transforming Growth Factor alpha Receptor ', ' Urogastrone Receptor ', ' c-erbB-1 ', ' c-erbB-1 Protein ', ' erbB-1 ', ' erbB-1 Proto-Oncogene Protein ', ' erbBl ', ' proto-oncogene protein c-erbB-1 ', ' Sampling Errors ', ' Signal Transduction ', ' Cell Communication and Signaling ', ' Cell Signaling ', ' Intracellular Communication and Signaling ', ' Signal Transduction Systems ', ' Signaling ', ' biological signal transduction ', ' Spatial Distribution ', ' Survival Rate ', ' Testing ', ' Tissues ', ' Body Tissues ', ' Work ', ' Measures ', ' promotor ', ' promoter ', ' Dataset ', ' Data Set ', ' base ', ' Image Analyses ', ' image evaluation ', ' image interpretation ', ' Image Analysis ', ' Clinical ', ' Malignant ', ' Malignant - descriptor ', ' Variation ', ' Variant ', ' Evaluation ', ' Individual ', ' Measurement ', ' Descriptor ', ' Morphology ', ' Infiltration ', ' machine learned ', ' Machine Learning ', ' programs ', ' Complex ', ' Protocol ', ' Protocols documentation ', ' Texture ', ' Pattern ', ' Location ', ' Operative Procedures ', ' Surgical ', ' Surgical Interventions ', ' Surgical Procedure ', ' surgery ', ' Operative Surgical Procedures ', ' interest ', ' Gene Alteration ', ' Gene Mutation ', ' Receptor Protein ', ' receptor ', ' tumor growth ', ' Modeling ', ' Sampling ', ' Tissue Sample ', ' DNA-6-O-Methylguanine[protein]-L-Cysteine S-Methyltransferase ', ' EC 2.1.1.63 ', ' Guanine-O(6)-Alkyltransferase ', ' MGMT ', ' Methylated-DNA Protein-Cysteine Methyltransferase ', ' Methylated-DNA-Protein-Cysteine S-Methyltransferase ', ' Methylguanine-DNA Methyltransferase Gene ', ' O(6)-AGT ', ' O(6)-Alkylguanine-DNA Alkyltransferase ', ' O(6)-MeG-DNA Methyltransferase ', ' O(6)-Methylguanine DNA Transmethylase ', ' O(6)-Methylguanine Methyltransferase ', ' O(6)-Methylguanine-DNA Methyltransferase ', ' O6-Alkylguanine DNA Alkyltransferase ', ' alkylguanine DNA alkyltransferase ', ' methylguanine DNA methyltransferase ', ' MGMT gene ', ' DNA Alteration ', ' DNA mutation ', ' Genetic mutation ', ' Sequence Alteration ', ' genomic alteration ', ' DNA Sequence Alteration ', ' Data ', ' Molecular Analysis ', ' Molecular Fingerprinting ', ' molecular profile ', ' molecular signature ', ' Molecular Profiling ', ' Molecular Target ', ' Stratification ', ' Subgroup ', ' Therapeutic Clinical Trial ', ' in vivo ', ' Ligand Binding ', ' Characteristics ', ' Molecular ', ' molecule imaging ', ' molecular imaging ', ' imaging ', ' Image ', ' pathway ', ' Pathway interactions ', ' clinical phenotype ', ' rapid growth ', ' designing ', ' design ', ' oncologic imaging ', ' oncology imaging ', ' tumor imaging ', ' cancer imaging ', ' clinical relevance ', ' clinically relevant ', ' chemotherapy ', ' tumor ', ' standard of care ', ' bio-markers ', ' biologic marker ', ' biomarker ', ' Biological Markers ', ' phenomics ', ' NGS Method ', ' NGS system ', ' next gen sequencing ', ' nextgen sequencing ', ' next generation sequencing ', ' Radiogenomics ', ' personalized diagnosis ', ' precise diagnostics ', ' precision diagnostics ', ' personalized diagnostics ', ' quantitative imaging ', ' clinically actionable ', ' gene signatures ', ' genetic signature ', ' individual patient ', ' stratified patient ', ' patient stratification ', ' Intratumoral heterogeneity ', ' heterogeneity in tumors ', ' intra-tumoral heterogeneity ', ' intratumor heterogeneity ', ' tumor heterogeneity ', ' radiomics ', ' predictive signature ', ' clinical imaging ', ' routine imaging ', ' Individualized Predictors ', ' individualized predictions ', ' personalized predictors ', ' personalized predictions ', ' deep learning ', ' machine learning method ', ' ']",NINDS,UNIVERSITY OF PENNSYLVANIA,R01,2020,670422,PA-03,0.050029415968633466
"A novel human T-cell platform to define biological effects of genome editing PROJECT SUMMARY Genome editing technologies have extraordinary potential as new genomic medicines that address underlying genetic causes of human disease; however, it remains challenging to predict their long-term safety, because we do not know the consequences of potential side effects of genome editing such as off-target mutations or immunogenicity. Our long-term goal is to understand and predict such unintended biological effects to advance the development of safe and effective therapies. T-cells are an ideal cellular model because: 1) they are highly relevant as the most widely used cells for development of therapeutic genome editing strategies (such as cell-based treatments for HIV and cancer) and 2) mature T-cells encode a diverse T-cell receptor repertoire that can be exploited as built-in cellular barcodes for quantifying clonal expansion or depletion in response to specific treatments. We, therefore, propose the following specific aims: 1) to predict which unintended editing sites have biological effects on human T-cells by integrating large-scale genome-wide activity and epigenomic profiles with state-of-the-art deep learning models and 2) to develop a human primary T-cell platform to detect functional effects of genome editing by measuring clonal representation, off-target mutation frequencies, immunogenicity, or gene expression. If successful, our experimental and predictive framework will profoundly increase confidence in the safety of the next generation of promising genome editing therapies. PROJECT NARRATIVE Genome editing technologies have extraordinary potential as the basis of new genomic medicines that address the underlying genetic causes of human disease; however, it is challenging to predict their long-term safety, because we do not know the consequences of potential unintended side effects of genome editing such as off-target mutations or immunogenicity. To define the biological effects of genome editing strategies, we will develop a human primary T-cell platform to sensitively detect functional effects coupled with an empirically-trained artificial intelligence models to predict them. Together, our platform will significantly improve confidence in safety assessments of promising genome editing therapeutics.",A novel human T-cell platform to define biological effects of genome editing,10016298,U01AI157189,"['Affect ', ' Epitopes ', ' Antigenic Determinants ', ' Binding Determinants ', ' Artificial Intelligence ', ' AI system ', ' Computer Reasoning ', ' Machine Intelligence ', ' Bar Codes ', ' barcode ', ' Biological Assay ', ' Assay ', ' Bioassay ', ' Biologic Assays ', ' Malignant Neoplasms ', ' Cancers ', ' Malignant Tumor ', ' malignancy ', ' neoplasm/cancer ', ' Cell physiology ', ' Cell Function ', ' Cell Process ', ' Cellular Function ', ' Cellular Physiology ', ' Cellular Process ', ' Subcellular Process ', ' Cells ', ' Cell Body ', ' Chromatin ', ' Engineering ', ' Gene Expression ', ' gene therapy ', ' DNA Therapy ', ' Gene Transfer Clinical ', ' Genetic Intervention ', ' gene-based therapy ', ' genetic therapy ', ' genomic therapy ', ' Genes ', ' Human Genome ', ' human whole genome ', ' Goals ', ' HIV ', ' AIDS Virus ', ' Acquired Immune Deficiency Syndrome Virus ', ' Acquired Immunodeficiency Syndrome Virus ', ' Human Immunodeficiency Viruses ', ' LAV-HTLV-III ', ' Lymphadenopathy-Associated Virus ', ' Virus-HIV ', ' Human ', ' Modern Man ', ' Human Genetics ', ' Immunologic Deficiency Syndromes ', ' Immunodeficiency Disorder ', ' Immunodeficiency Syndrome ', ' Immunological Deficiency Syndromes ', ' hypoimmunity ', ' immune deficiency disorder ', ' immunodeficiency ', ' In Vitro ', ' Maps ', ' Methods ', ' Mutation ', ' Genetic Alteration ', ' Genetic Change ', ' Genetic defect ', ' genome mutation ', ' Phenotype ', ' Proto-Oncogenes ', ' Cellular Oncogene ', ' c-ONC ', ' protooncogene ', ' T-Cell Receptor ', ' MHC Receptor ', ' Major Histocompatibility Complex Receptor ', ' Receptors, Antigen, T-Cell ', ' Ribonucleoproteins ', ' Safety ', ' Standardization ', ' Streptococcus pyogenes ', ' S pyogenes ', ' S. pyogenes ', ' Streptococcus Group A ', ' T-Lymphocyte ', ' T-Cells ', ' thymus derived lymphocyte ', ' Technology ', ' Testing ', ' Genetic Transcription ', ' Gene Transcription ', ' RNA Expression ', ' Transcription ', ' Genetic Variation ', ' Genetic Diversity ', ' cytokine ', ' Measures ', ' Site-Directed Mutagenesis ', ' Site-Specific Mutagenesis ', ' Targeted DNA Modification ', ' Targeted Modification ', ' Organizational Change ', ' base ', ' improved ', ' Site ', ' Benign ', ' Variation ', ' Variant ', ' Biological ', ' Biochemical ', ' Training ', ' Therapeutic ', ' Genetic ', ' Peptide Library ', ' DNA Methylation ', ' Frequencies ', ' Hereditary ', ' Inherited ', ' Complex ', ' genotoxicity ', ' PBMC ', ' Peripheral Blood Mononuclear Cell ', ' novel ', ' Modeling ', ' response ', ' immunogenic ', ' functional genomics ', ' Adverse effects ', ' Genomics ', ' Bio-Informatics ', ' Bioinformatics ', ' T-Cell Proliferation ', ' histone modification ', ' Address ', ' Detection ', ' Mature T-Cell ', ' Mature T-Lymphocyte ', ' Regulatory Element ', ' Retrovirus Vector ', ' Retroviral Vector ', ' in vivo ', ' Clonal Expansion ', ' epigenomics ', ' Advanced Development ', ' immunogenicity ', ' next generation ', ' Outcome ', ' Population ', ' Coupled ', ' gene therapeutics ', ' gene-based therapeutic ', ' gene-based therapeutics ', ' genes therapeutic ', ' genes therapeutics ', ' therapeutic gene ', ' Oncogenic ', ' Cellular model ', ' Cell model ', ' human disease ', ' new drug treatments ', ' new drugs ', ' new therapeutics ', ' new therapy ', ' next generation therapeutics ', ' novel drug treatments ', ' novel drugs ', ' novel therapy ', ' novel therapeutics ', ' therapeutic agent development ', ' therapeutic development ', ' effective treatment ', ' effective therapy ', ' genome scale ', ' genomewide ', ' genome-wide ', ' safety testing ', ' comparative genomics ', ' T cell response ', ' adverse consequence ', ' adverse outcome ', ' RNA Seq ', ' RNA sequencing ', ' RNAseq ', ' transcriptome sequencing ', ' genomic editing ', ' genome editing ', ' Genomic medicine ', ' adaptive immune response ', ' genetic condition ', ' genetic disorder ', ' Genetic Diseases ', ' TCR repertoire ', ' T-cell receptor repertoire ', ' gene-editing therapy ', ' genome editing based therapy ', ' genome editing therapy ', ' genome editing treatment ', ' genome editing-based therapeutics ', ' therapeutic editing ', ' therapeutic genome editing ', ' deep learning ', ' side effect ', ' safety assessment ', ' machine learning method ', ' off-target site ', ' off-target mutation ', ' ']",NIAID,ST. JUDE CHILDREN'S RESEARCH HOSPITAL,U01,2020,610710,TN-09,0.09653223666615235
"Unraveling molecular and system-level mechanisms of human disease-associated protein mutations Project Summary Although a quickly expanding catalogue of protein mutations have been discovered, including those that cause human diseases or confer drug resistance, mechanistic understanding and prediction of functional consequences of these mutations remain rather limited. There is a critical need to develop novel, multiscale computational frameworks that are rigorous and generalizable to help close the ever-increasing gap between phenotypic data and mechanistic knowledge about the mutations and to develop effective therapeutic strategies.  My long-term research goals are two folds: (1) to unravel how a change in protein sequence ripples through various aspects of molecular and system-levels to a change in cellular function and cause human diseases or confer drug resistance; and (2) to translate learned mechanistic knowledge to effective drug-design strategies for human diseases and drug resistance. Toward these goals I propose to advance and combine the strengths of computational molecular biology (structural modeling and design for proteins or protein interactions) and computational systems biology (pathway/network-level topology and dynamics) and follow a novel, formal paradigm to develop methods that systematically identify mechanisms underlying various stages of consequence propagation (from conformation, molecular and system-level variables, to cellular functions, where intermediates can be skipped if necessary). In the forward direction of propagating consequences, I will determine, explain and understand mutational consequences at various levels with machine learning, causal analysis, and combinatorial optimization, starting with known or modelled changes at various levels. In the inverse direction of designing consequences, I will follow known or learned mechanistic hypotheses and develop efficient combinatorial optimization methods to design mutagenesis experiments or screen / design ligands for desired perturbations at various levels, which would test and refine corresponding hypotheses directly and translate mechanistic hypotheses to therapeutic strategies. Mechanisms underlying distal (potentially allosteric) mutations, multiple mutations within a protein or across proteins as well as systems pharmacology strategies will also be rigorously determined in the process.  The expected outcomes from the innovative project will include two main components. The first will be both biophysical principles of proteins and integrative understanding of biomedical systems, which will be organized in a database for public access. The second will be translating mechanistic insights into therapeutic intervention strategies to treat diseases. In particular, targeted experiments (mutagenesis or ligand-binding) will be designed following known or discovered mechanistic hypotheses. This project will involve close collaboration with structural biologists and clinician-scientists who are active collaborators of the PI. Project Narrative Genetic mutations, many of which lead to protein mutations, are often associated with human diseases: they often directly cause diseases or contribute to their progressions. Understanding mechanisms by which these mutations lead to significant functional consequences is of extreme importance to developing effective therapeutics to cure diseases and ameliorate drug resistance.",Unraveling molecular and system-level mechanisms of human disease-associated protein mutations,10007852,R35GM124952,"['Amino Acid Sequence ', ' Primary Protein Structure ', ' protein sequence ', ' Biophysics ', ' biophysical foundation ', ' biophysical principles ', ' biophysical sciences ', ' Cell physiology ', ' Cell Function ', ' Cell Process ', ' Cellular Function ', ' Cellular Physiology ', ' Cellular Process ', ' Subcellular Process ', ' Disease ', ' Disorder ', ' Drug Design ', ' Drug resistance ', ' drug resistant ', ' resistance to Drug ', ' resistant to Drug ', ' Goals ', ' Lead ', ' Pb element ', ' heavy metal Pb ', ' heavy metal lead ', ' Ligands ', ' Methods ', ' Structural Models ', ' Molecular Conformation ', ' Molecular Configuration ', ' Molecular Stereochemistry ', ' conformation ', ' conformational state ', ' Mutation ', ' Genetic Alteration ', ' Genetic Change ', ' Genetic defect ', ' genome mutation ', ' Pharmacology ', ' Protein Engineering ', ' genetic protein engineering ', ' protein design ', ' Proteins ', ' Research ', ' Testing ', ' Translating ', ' Mutagenesis ', ' Genetics-Mutagenesis ', ' Mutagenesis Molecular Biology ', ' Distal ', ' insight ', ' Data Bases ', ' data base ', ' Databases ', ' Collaborations ', ' Therapeutic ', ' machine learned ', ' Machine Learning ', ' Knowledge ', ' Catalogs ', ' Scientist ', ' System ', ' novel ', ' intervention therapy ', ' Therapeutic Intervention ', ' Modeling ', ' Intervention Strategies ', ' interventional strategy ', ' Intervention ', ' resistance to disease ', ' resistant disease ', ' resistant to disease ', ' Disease Resistance ', ' Computational Molecular Biology ', ' Systems Biology ', ' DNA Alteration ', ' DNA mutation ', ' Genetic mutation ', ' Sequence Alteration ', ' genomic alteration ', ' DNA Sequence Alteration ', ' Structural Biologist ', ' Ligand Binding ', ' Molecular ', ' Process ', ' pathway ', ' Pathway interactions ', ' computational framework ', ' computer framework ', ' designing ', ' design ', ' intervention efficacy ', ' therapeutic efficacy ', ' therapeutically effective ', ' therapy efficacy ', ' Treatment Efficacy ', ' Outcome ', ' innovate ', ' innovative ', ' innovation ', ' human disease ', ' Combinatorial Optimization ', ' phenotypic data ', ' experiment ', ' experimental research ', ' experimental study ', ' ']",NIGMS,TEXAS ENGINEERING EXPERIMENT STATION,R35,2020,335245,TX-17,0.18895753745202024
"Synergistic integration of topology and machine learning for the predictions of protein-ligand binding affinities and mutation impacts Project Summary The success of the ongoing battle with coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) depends crucially on the availability of effective diagnostics, vaccines, antibody therapeutics, and small-molecular drugs. Although SARS-CoV-2 mutates slower than the viruses that cause the flu and the common cold, it has had more than 8300 observed single mutations on its genome of 29,900 nucleotides by June 1, 2020. We show that these mutations might have devastating effects on COVID-19 diagnostics, vaccines, antibody therapeutics, and small-molecular drugs (J. Chem. Inf. Model. In press). We will develop new artificial intelligence (AI) to forecast SARS-CoV-2 future mutations. Leveraging on state-of-art methods developed under the present R01 award, we will design mutation- resistant vaccines, antibody therapeutics, and small-molecular drugs. The CPUs and GPUs requested in this supplement will be essential for my lab to continue the research of the present R01 award and to apply the methods developed in this award to attack fundamental problems in combating COVID-19. Project Narrative The project concerns the forecasting of SARS-CoV-2 mutations and the design of mutation- resistant vaccines, antibody therapeutics, and small-molecular drugs using artificial intelligence (AI) and advanced mathematics. The requested CPUs and GPUs will enable us to addresses potential threats in combating COVID-19.",Synergistic integration of topology and machine learning for the predictions of protein-ligand binding affinities and mutation impacts,10189006,R01GM126189,"['inhibitor/antagonist ', ' inhibitor ', ' Antibodies ', ' Antibody Affinity ', ' antigen antibody affinity ', ' Artificial Intelligence ', ' AI system ', ' Computer Reasoning ', ' Machine Intelligence ', ' Attention ', ' Award ', ' Cells ', ' Cell Body ', ' Common Cold ', ' Acute Nasopharyngitis ', ' Conflict (Psychology) ', ' Conflict ', ' Crystallization ', ' Drug resistance ', ' drug resistant ', ' resistance to Drug ', ' resistant to Drug ', ' Pharmaceutical Preparations ', ' Drugs ', ' Medication ', ' Pharmaceutic Preparations ', ' drug/agent ', ' Evolution ', ' Future ', ' Genome ', ' Goals ', ' Grant ', ' Heterogeneity ', ' Peptidyl-Dipeptidase A ', ' Angiotensin Converting Enzyme ', ' Angiotensin I-Converting Enzyme ', ' CD143 Antigens ', ' Carboxycathepsin ', ' Dipeptidyl Peptidase A ', ' Kininase A ', ' Kininase II ', ' Mathematics ', ' Math ', ' Medicine ', ' Methods ', ' Mission ', ' Mutation ', ' Genetic Alteration ', ' Genetic Change ', ' Genetic defect ', ' genome mutation ', ' Nucleotides ', ' Proteins ', ' Recurrence ', ' Recurrent ', ' Research ', ' Rhinovirus ', ' RNA Viruses ', ' Time ', ' Genetic Transcription ', ' Gene Transcription ', ' RNA Expression ', ' Transcription ', ' Vaccines ', ' Virulence ', ' Virus ', ' Work ', ' Diagnostic tests ', ' protein folding ', ' base ', ' improved ', ' Site ', ' Phase ', ' Coronaviridae ', ' corona virus ', ' Coronavirus ', ' Failure ', ' Ligand Binding Protein ', ' Ligand Binding Protein Gene ', ' Protein Binding ', ' bound protein ', ' Binding Proteins ', ' drug use ', ' Drug usage ', ' news ', ' Therapeutic ', ' Diagnostic ', ' machine learned ', ' Machine Learning ', ' Adopted ', ' Viral ', ' experience ', ' Receptor Protein ', ' receptor ', ' receptor bound ', ' receptor binding ', ' success ', ' develop a vaccine ', ' development of a vaccine ', ' vaccine formulation ', ' vaccine development ', ' antigen antibody binding ', ' Manuscripts ', ' Structure ', ' Reporting ', ' Modeling ', ' Influenza A ', ' Influenza Viruses Type A ', ' Influenzavirus A ', ' Orthomyxovirus Type A ', ' Type A Influenza ', ' Influenza A virus ', ' Molecular Interaction ', ' Binding ', ' SARS ', ' SARS coronavirus disease ', ' SARS-CoV disease ', ' Severe Acute Respiratory Syndrome CoV disease ', ' Severe Acute Respiratory Syndrome coronavirus disease ', ' Severe Acute Respiratory Syndrome ', ' SARS Virus ', ' SARS corona virus ', ' SARS-Associated Coronavirus ', ' SARS-CoV ', ' SARS-Related Coronavirus ', ' Severe Acute Respiratory Syndrome Virus ', ' Severe Acute Respiratory Syndrome corona virus ', ' Severe Acute Respiratory Syndrome coronavirus ', ' severe acute respiratory syndrome-CoV ', ' SARS coronavirus ', ' Address ', ' Affinity ', ' Diagnostic Reagent ', ' Induced DNA Alteration ', ' Induced Sequence Alteration ', ' Induced Mutation ', ' Mutate ', ' NIGMS ', ' National Institute of General Medical Sciences ', ' Molecular ', ' Process ', ' Modification ', ' developmental ', ' Development ', ' pandemic ', ' pandemic disease ', ' reconstruction ', ' designing ', ' design ', ' flu ', ' Therapeutic antibodies ', ' combat ', ' resistant mutation ', ' resistance mutation ', ' Preventative measure ', ' Preventive measure ', ' Preventative vaccine ', ' Prophylactic vaccine ', ' Preventive vaccine ', ' autoencoding neural network ', ' autoencoder ', ' COVID19 ', ' corona virus disease 2019 ', ' coronavirus disease 2019 ', ' COVID-19 ', ' 2019 novel coronavirus ', ' SARS-CoV-2 ', ' SARS-CoV2 ', ' SARS-associated coronavirus 2 ', ' SARS-coronavirus-2 ', ' SARS-related coronavirus 2 ', ' Severe acute respiratory syndrome coronavirus 2 ', ' Wuhan coronavirus ', ' 2019-nCoV ', ' COVID19 vaccine ', ' corona virus disease 2019 vaccine ', ' coronavirus disease 2019 vaccine ', ' COVID-19 vaccine ', ' ']",NIGMS,MICHIGAN STATE UNIVERSITY,R01,2020,116389,MI-08,0.08767535367094402
"A statistical framework to systematically characterize cancer driver mutations in noncoding genomic regions PROJECT SUMMARY Cancer genomes typically harbor a substantial number of somatic mutations. Relatively few driver mutations actually alter the function of proteins in tumor cells, whereas most mutations are considered to be functionally neutral passenger mutations. Over the past decade, the search for cancer driver mutations has focused on coding regions and several mutational significance algorithms have been developed for coding mutations. The contribution of mutations in noncoding regulatory regions to tumor formation largely remains unknown and current mutational significance algorithms are not designed to detect driver mutations in noncoding regions, due to biological differences between coding and noncoding mutations. The emerging availability of large whole- genome sequencing datasets (e.g. PCAWG and HMF datasets) creates an ample opportunity to develop new mutational significance algorithms that are particularly designed for the interpretation of noncoding regions. Recently, we have developed a new statistical approach that identifies driver mutations in coding regions based on the nucleotide context. Critically, consideration of the nucleotide context around mutations does not require prior knowledge for functional consequences associated with these mutations. Hence, we hypothesize that generalizing our nucleotide context model to noncoding regions will uncover novel noncoding driver mutations that cannot be detected using the mutational significance approaches currently available. For this purpose, we will develop a statistical framework that incorporates the biological differences between coding and noncoding mutations and that is specifically designed to detect driver mutations in noncoding regions. Specifically, we will consider the context-dependent distribution of passenger mutations, modeling of the background mutation rate, accurately partition the background mutation rate, model the sequence composition of the reference genome, and account for coverage fluctuation. We will then combine these statistical components by computing an independent product of their underlying probabilities. We will derive a significance p-value using a Monte-Carlo simulation approach, and use FDR for multiple hypothesis test correction. This strategy will allow us to accurately estimate the significance of somatic mutations in noncoding genomic regions. We will next apply this statistical framework to whole-genome sequencing data of 5,523 tumor patients, thereby deriving a comprehensive list of candidate driver mutations in noncoding regions. Finally, we will investigate whether noncoding mutations are overrepresented in transcription factor binding sites, regulate gene expression levels, induce alternative splicing, or affect epigenomic states. Upon the completion of this project, we will have developed and applied a statistical framework for discovery of significant somatic mutations in noncoding regions, and defined the mutational landscape of the non-coding cancer genome. All aspects of the methods developed and applied in this project will be made open source and developed in an online platform. PROJECT NARRATIVE While coding cancer driver mutations have been characterized in detail over the past decade, the contribution of noncoding mutations to tumor formation remains - apart from few examples (e.g. mutations in TERT promoters) - largely unknown. Recently, large-scale whole-genome sequencing datasets have been made available, but a major bottleneck for the biological and clinical interpretation of these cancer whole-genome cohorts is the lack of statistical models that identify driver mutations in noncoding regions. We developed a new statistical approach that characterizes driver mutations based on their surrounding nucleotide context in coding regions, and herein we propose a concrete plan to generalize our computational model to noncoding regions, apply our model to aggregated whole-genome sequencing data of 5,523 tumor patients (PCAWG, HMF datasets), and define the noncoding driver and passenger mutational landscape for biological discovery and focused clinical application.",A statistical framework to systematically characterize cancer driver mutations in noncoding genomic regions,9957082,R21CA242861,"['Affect ', ' Algorithms ', ' Alternative Splicing ', ' Alternate Splicing ', ' Alternative RNA Splicing ', ' Attention ', ' Binding Sites ', ' Combining Site ', ' Reactive Site ', ' Biology ', ' malignant breast neoplasm ', ' Breast Cancer ', ' malignant breast tumor ', ' Malignant Neoplasms ', ' Cancers ', ' Malignant Tumor ', ' malignancy ', ' neoplasm/cancer ', ' Communities ', ' Gene Expression ', ' Gene Expression Regulation ', ' Gene Action Regulation ', ' Gene Regulation ', ' Gene Regulation Process ', ' Immunotherapy ', ' Immune mediated therapy ', ' Immunologically Directed Therapy ', ' immune therapeutic approach ', ' immune therapeutic interventions ', ' immune therapeutic regimens ', ' immune therapeutic strategy ', ' immune therapy ', ' immune-based therapies ', ' immune-based treatments ', ' immuno therapy ', ' melanoma ', ' Malignant Melanoma ', ' Methods ', ' Statistical Models ', ' Probabilistic Models ', ' Probability Models ', ' statistical linear mixed models ', ' statistical linear models ', ' Monte Carlo Method ', ' Monte Carlo algorithm ', ' Monte Carlo calculation ', ' Monte Carlo procedure ', ' Monte Carlo simulation ', ' Mutation ', ' Genetic Alteration ', ' Genetic Change ', ' Genetic defect ', ' genome mutation ', ' Nucleotides ', ' Patients ', ' Play ', ' Probability ', ' Nucleic Acid Regulatory Sequences ', ' Nucleic Acid Regulator Regions ', ' Regulatory Regions ', ' genetic regulatory element ', ' Role ', ' social role ', ' Testing ', ' transcription factor ', ' Basal Transcription Factor ', ' Basal transcription factor genes ', ' General Transcription Factor Gene ', ' General Transcription Factors ', ' Transcription Factor Proto-Oncogene ', ' Transcription factor genes ', ' Mediating ', ' promotor ', ' promoter ', ' Dataset ', ' Data Set ', ' base ', ' Clinical ', ' Biological ', ' Biological Function ', ' Biological Process ', ' anti-cancer immunotherapy ', ' anticancer immunotherapy ', ' immune-based cancer therapies ', ' immunotherapy for cancer ', ' immunotherapy of cancer ', ' cancer immunotherapy ', ' machine learned ', ' Machine Learning ', ' computer biology ', ' Computational Biology ', ' Knowledge ', ' Pattern ', ' Somatic Mutation ', ' mutant ', ' Tumor Cell ', ' neoplastic cell ', ' cohort ', ' novel ', ' Position ', ' Positioning Attribute ', ' Coding System ', ' Code ', ' Modeling ', ' response ', ' Functional RNA ', ' Non-Coding ', ' Non-Coding RNA ', ' Non-translated RNA ', ' Noncoding RNA ', ' Nontranslated RNA ', ' noncoding ', ' Untranslated RNA ', ' Microsatellite Instability ', ' genome sequencing ', ' Address ', ' Data ', ' Stratification ', ' genomic region ', ' Genomic Segment ', ' Process ', ' protein function ', ' developmental ', ' Development ', ' epigenomics ', ' cancer cell genome ', ' tumor genome ', ' cancer genome ', ' immunogenicity ', ' designing ', ' design ', ' Outcome ', ' clinical effect ', ' clinical applicability ', ' clinical application ', ' open source ', ' tumor ', ' genome scale ', ' genomewide ', ' genome-wide ', ' TCGA ', ' The Cancer Genome Atlas ', ' exome-seq ', ' exome sequencing ', ' targeted drug therapy ', ' targeted drug treatments ', ' targeted therapeutic ', ' targeted therapeutic agents ', ' targeted therapy ', ' targeted treatment ', ' prediction of response ', ' predictive response ', ' predictor of response ', ' response prediction ', ' predicting response ', ' reference assembly ', ' reference genome ', ' entire genome ', ' full genome ', ' whole genome ', ' check point immunotherapy ', ' check point inhibitor therapy ', ' check point inhibitory therapy ', ' check point therapy ', ' checkpoint immunotherapy ', ' checkpoint inhibitor therapy ', ' checkpoint inhibitory therapy ', ' immune check point therapy ', ' immune checkpoint therapy ', ' checkpoint therapy ', ' check point blockade ', ' checkpoint blockade ', ' immune check point blockade ', ' immune checkpoint blockade ', ' neo-antigen ', ' neo-epitopes ', ' neoepitopes ', ' neoantigens ', ' Computerized Models ', ' computational modeling ', ' computational models ', ' computer based models ', ' computerized modeling ', ' Computer Models ', ' large data sets ', ' large datasets ', ' driver mutation ', ' ']",NCI,DANA-FARBER CANCER INST,R21,2020,193576,MA-07,0.2587934284878348
"Reverse Sensitivity Analysis for Identifying Predictive Proteomics Signatures of Cancer Title: Reverse Sensitivity Analysis for Identifying Proteomics Signatures of Cancer Abstract Cancer is a complex disease in which genetic disruptions in cell signaling networks are known to play a significant role. A major aim of cancer systems biology is to build models that can predict the impact of these genetic disruptions to guide therapeutic interventions (i.e. personalized medicine). A prominent driver of cancer cell growth is signaling pathway deregulation from mutations in key regulatory nodes and loss/gain in gene copy number (CNV). However, current mathematical modeling approaches do not adequately capture the impact of these genetic changes. Reasons for this include the poorly understood layers of regulation between gene expression and protein activity, and limitations in most modeling and protein measurement technologies. In addition, there is a paucity of overarching hypotheses that can link specific gene expression or mutation patterns to the cancer phenotype. Recent work by our group has resolved some of the technical challenges that have hindered the application of proteomics technologies to cancer systems biology research. It has also suggested a new approach for using quantitative proteomics data to understand mechanisms driving cancer cell behavior. Using an ultrasensitive, targeted proteomics platform that can measure both abundance and phosphorylation of proteins present at only hundreds of copies per cell, we found that signaling pathways appeared to be controlled by only a limited number of key nodes whose activity is tightly regulated through low abundance and feedback phosphorylation. We propose to build on these findings by critically testing the hypothesis that CNV and genetic mutations dysregulate signaling pathways in cancer by shifting control from tightly regulated nodes to poorly regulated ones. This will be done by systematically identifying key regulatory nodes of normal and cancer cells using CRISPRa/i screens, determine the relationship between protein abundance and signaling pathway activities using ultrasensitive targeted proteomics and phosphoproteomics and then use these data to semi-automatically generate mathematical models of the functional topology of the signaling pathways. Specifically, we propose to: 1) Use targeted CRISPR gene perturbation libraries to identify the regulatory topologies of signaling pathways important in cancer and how they are disrupted by common cancer mutations, 2) Use the CRISPR perturbation and proteomics data to semi-automatically build predictive models of cancer cell signaling pathways, and 3) Combine modeling and perturbation screens to understand how feedback regulation in cancer contributes to drug resistance. This work will result in simplified, computationally tractable yet mechanistic models of signaling pathways and provide network maps of feedback and crosstalk circuits that can be used to rapidly map the regulatory state of cells. Most important, it will provide a generic platform for translating protein abundance and phosphorylation patterns into a state snapshot of cancers that can lead to predicting their response to specific drugs. Narrative Cancer is an extremely complex disease which is frequently caused by signaling pathway deregulation from genetic mutation or loss/gain in gene copy number. Modern analytical techniques have provided a wealth of data on the molecular changes associated with cancer mutations, but it has been extremely difficult to use this information to design targeted therapies. We propose a new methodology that combines CRISPR-based targeted screens, advanced proteomics technologies, and a new mathematical modeling approach for identifying proteomics signatures of altered signaling pathways in cancer that can be used to build predictive models and explore mechanisms of drug resistance.",Reverse Sensitivity Analysis for Identifying Predictive Proteomics Signatures of Cancer,9923630,U01CA227544,"['Affect ', ' Automobile Driving ', ' driving ', ' Behavior ', ' Malignant Neoplasms ', ' Cancers ', ' Malignant Tumor ', ' malignancy ', ' neoplasm/cancer ', ' Cells ', ' Cell Body ', ' Disease ', ' Disorder ', ' Drug resistance ', ' drug resistant ', ' resistance to Drug ', ' resistant to Drug ', ' Pharmaceutical Preparations ', ' Drugs ', ' Medication ', ' Pharmaceutic Preparations ', ' drug/agent ', ' Feedback ', ' Flow Cytometry ', ' Flow Cytofluorometries ', ' Flow Cytofluorometry ', ' Flow Microfluorimetry ', ' Flow Microfluorometry ', ' flow cytophotometry ', ' Gene Expression ', ' Genes ', ' Lead ', ' Pb element ', ' heavy metal Pb ', ' heavy metal lead ', ' Libraries ', ' Maps ', ' melanoma ', ' Malignant Melanoma ', ' Methods ', ' Methodology ', ' Biological Models ', ' Biologic Models ', ' Model System ', ' Modernization ', ' Mutation ', ' Genetic Alteration ', ' Genetic Change ', ' Genetic defect ', ' genome mutation ', ' Phenotype ', ' Phosphorylation ', ' Protein Phosphorylation ', ' Play ', ' Proteins ', ' Reagent ', ' Research ', ' Role ', ' social role ', ' Signal Pathway ', ' Signal Transduction ', ' Cell Communication and Signaling ', ' Cell Signaling ', ' Intracellular Communication and Signaling ', ' Signal Transduction Systems ', ' Signaling ', ' biological signal transduction ', ' Technology ', ' Testing ', ' Translating ', ' Work ', ' Generations ', ' Measures ', ' AKT ', ' Akt protein ', ' Protein Kinase B ', ' RAC-PK protein ', ' c-akt protein ', ' proto-oncogene protein RAC ', ' proto-oncogene protein akt ', ' rac protein kinase ', ' related to A and C-protein ', ' Proto-Oncogene Proteins c-akt ', ' base ', ' Gene Copy Number ', ' Gene Dosage ', ' Link ', ' Measurement ', ' Genetic ', ' Malignant Cell ', ' cancer cell ', ' tool ', ' machine learned ', ' Machine Learning ', ' Complex ', ' Pattern ', ' Techniques ', ' Gene Alteration ', ' Gene Mutation ', ' Protein Gene Products ', ' Gene Proteins ', ' intervention therapy ', ' Therapeutic Intervention ', ' Regulation ', ' Modeling ', ' response ', ' Proteomics ', ' Math Models ', ' mathematic model ', ' mathematical modeling ', ' mathematical model ', ' Normal Cell ', ' Address ', ' Systems Biology ', ' DNA Alteration ', ' DNA mutation ', ' Genetic mutation ', ' Sequence Alteration ', ' genomic alteration ', ' DNA Sequence Alteration ', ' Data ', ' Mutate ', ' Predictive Cancer Model ', ' Cancer Cell Growth ', ' Molecular ', ' developmental ', ' Development ', ' pathway ', ' Pathway interactions ', ' computer based prediction ', ' prediction model ', ' prognostic model ', ' predictive modeling ', ' designing ', ' design ', ' new approaches ', ' novel approaches ', ' novel strategy ', ' novel strategies ', ' cancer type ', ' resistant ', ' Resistance ', ' cellular behavior ', ' cell behavior ', ' screening ', ' CRISPR ', ' CRISPR/Cas system ', ' Clustered Regularly Interspaced Short Palindromic Repeats ', ' mammary epithelial cells ', ' Breast Epithelial Cells ', ' personalization of treatment ', ' personalized therapy ', ' personalized treatment ', ' personalized medicine ', ' targeted drug therapy ', ' targeted drug treatments ', ' targeted therapeutic ', ' targeted therapeutic agents ', ' targeted therapy ', ' targeted treatment ', ' Breast tumor cell line ', ' Breast Cancer cell line ', ' phospho-proteomics ', ' phosphoproteomics ', ' CRISPR-based library ', ' CRISPR/Cas9 library ', ' Clustered Regularly Interspaced Short Palindromic Repeats library ', ' CRISPR library ', ' proteomic signature ', ' experiment ', ' experimental research ', ' experimental study ', ' Computerized Models ', ' computational modeling ', ' computational models ', ' computer based models ', ' computerized modeling ', ' Computer Models ', ' ']",NCI,BATTELLE PACIFIC NORTHWEST LABORATORIES,U01,2020,715682,WA-04,0.06342842594713283
"Functional Annotation of Natural and Disease Variants in Tryosine Kinases     DESCRIPTION (provided by applicant): Protein tyrosine kinases are dynamic molecular switches that toggle between a catalytically ""on"" and ""off"" state to turn on and off signals responsible for cell growth and survival. While the tyrosine kinase switch is tightly regulated by  diverse array of structural mechanisms in normal states, in many disease states, the switch is permanently turned on or off due, in part, to mutations in the tyrosine kinase domain. Although genome sequencing studies have revealed the mutational patterns of tyrosine kinases from many different disease types, understanding the structural and functional impact of these mutations is a challenge because many recurrent mutations occur far from the active site (distal mutations) and the residue networks that contribute to the complex modes of tyrosine kinase allosteric regulation are not fully understood. Our long term goal is to understand the relationships connecting sequence, structure, function, regulation and disease in protein kinases using a combination of computational and experimental approaches. Our objective in this proposal, which is the next logical step toward attainment of our long-term goal, is to delineate the residue interaction networks that contribute to the unique modes of allosteric regulation in tyrosine kinases, and to develop a computational framework for predicting mutation impact using the evolutionary and allosteric properties encoded in three dimensional structures. The central hypothesis is that distal mutations alter evolutionarily conserved allosteric networks in tyrosine kinases, and delineating the allosteric networks unique to tyrosine kinases will provide context for predicting and testing disease mutation impact. The specific aims are: * To identify and characterize natural sequence and structural variants associated with tight  allosteric control of tyrosine kinase activity * To develop a computational framework for predicting mutation impact on kinase activation and to  experimentally validate computational predictions using selected receptor tyrosine kinases as  model systems Successful completion of these aims is expected to reveal novel activating mutations in putative allosteric sites in the tyrosine kinase domain, and pinpoint key residues and interactions for functional studies. These outcomes, in turn, are expected to have major biomedical impact by accelerating the functional characterization of the mutated tyrosine kinome, which is emerging as a major target for personalized medicine. Finally, by providing detailed mechanistic annotation of mutations identified in genome sequencing studies, this proposal will address a fundamental NIH roadmap problem in translational medicine of converting genomic discoveries into therapeutic strategies. PUBLIC HEALTH RELEVANCE: Protein tyrosine kinases are a biomedically important class of proteins that are abnormally regulated in many human diseases including cancer, diabetes, and inflammatory disorders, to name but a few. They have been the focus of many drug discovery efforts and genome sequencing studies because of the therapeutic potential of targeting mutated tyrosine kinases for personalized therapy. By providing functional annotation of natural and disease mutations in tyrosine kinases, the proposed studies will accelerate the targeting of mutated tyrosine kinases for drug discovery and personalized therapy.",Functional Annotation of Natural and Disease Variants in Tryosine Kinases,10145865,R01GM114409,"['Allosteric Regulation ', ' Allosteric Site ', ' Antineoplastic Agents ', ' Anti-Cancer Agents ', ' Antineoplastic Drugs ', ' Antineoplastics ', ' Cancer Drug ', ' Neoplastic Disease Chemotherapeutic Agents ', ' Tumor-Specific Treatment Agents ', ' anti-cancer drug ', ' anticancer agent ', ' anticancer drug ', ' Biological Assay ', ' Assay ', ' Bioassay ', ' Biologic Assays ', ' Malignant Neoplasms ', ' Cancers ', ' Malignant Tumor ', ' malignancy ', ' neoplasm/cancer ', ' cell growth ', ' Cellular Expansion ', ' Cellular Growth ', ' Cell Survival ', ' Cell Viability ', ' Communities ', ' Diabetes Mellitus ', ' diabetes ', ' Disease ', ' Disorder ', ' Drug resistance ', ' drug resistant ', ' resistance to Drug ', ' resistant to Drug ', ' Pharmaceutical Preparations ', ' Drugs ', ' Medication ', ' Pharmaceutic Preparations ', ' drug/agent ', ' Foundations ', ' Genes ', ' Human Genome ', ' human whole genome ', ' Goals ', ' In Vitro ', ' Biological Models ', ' Biologic Models ', ' Model System ', ' Mutation ', ' Genetic Alteration ', ' Genetic Change ', ' Genetic defect ', ' genome mutation ', ' Names ', ' United States National Institutes of Health ', ' NIH ', ' National Institutes of Health ', ' Organism ', ' living system ', ' Peptides ', ' Phosphotransferases ', ' Kinases ', ' Phosphotransferase Gene ', ' Transphosphorylases ', ' Protein Kinase ', ' ATP-protein phosphotransferase ', ' Kinase Family Gene ', ' glycogen synthase a kinase ', ' hydroxyalkyl protein kinase ', ' phosphorylase b kinase kinase ', ' Protein Tyrosine Kinase ', ' EPH- and ELK-Related Tyrosine Kinase ', ' EPH-and ELK-Related Kinase ', ' Ephrin Type-A Receptor 8 ', ' Ephrin Type-A Receptor 8 Precursor ', ' Protein Tyrosine Kinase EEK ', ' Tyrosine Kinase ', ' Tyrosine-Protein Kinase Receptor EEK ', ' Tyrosine-Specific Protein Kinase ', ' Tyrosylprotein Kinase ', ' hydroxyaryl protein kinase ', ' tyrosyl protein kinase ', ' Proteins ', ' Publishing ', ' Recurrence ', ' Recurrent ', ' Signal Transduction ', ' Cell Communication and Signaling ', ' Cell Signaling ', ' Intracellular Communication and Signaling ', ' Signal Transduction Systems ', ' Signaling ', ' biological signal transduction ', ' Testing ', ' Tyrosine ', ' Protein-Serine-Threonine Kinases ', ' Protein-Serine Kinase ', ' Protein-Threonine Kinase ', ' Serine Kinase ', ' Serine-Threonine Kinases ', ' Serine/Threonine Protein Kinase Gene ', ' Threonine Kinase ', ' base ', ' improved ', ' Distal ', ' Site ', ' Variation ', ' Variant ', ' Active Sites ', ' PTK Receptors ', ' Receptor Tyrosine Kinase Gene ', ' Transmembrane Receptor Protein Tyrosine Kinase ', ' Tyrosine Kinase Linked Receptors ', ' Tyrosine Kinase Receptors ', ' Receptor Protein-Tyrosine Kinases ', ' insight ', ' Therapeutic ', ' Inflammatory ', ' machine learned ', ' Machine Learning ', ' Complex ', ' Pattern ', ' System ', ' Molecular Dynamics Simulation ', ' molecular dynamics ', ' mutant ', ' Structure ', ' novel ', ' Regulation ', ' Modeling ', ' Property ', ' Genomics ', ' drug discovery ', ' Pathogenicity ', ' Molecular Interaction ', ' Binding ', ' genome sequencing ', ' Address ', ' Drug Binding Site ', ' Mutate ', ' Ontology ', ' Tyrosine Kinase Domain ', ' Molecular ', ' non-synonymous mutation ', ' nonsynonymous mutation ', ' computational framework ', ' computer framework ', ' Outcome ', ' 3-D structure ', ' 3-dimensional structure ', ' 3D structure ', ' three dimensional structure ', ' translational medicine ', ' human disease ', ' public health relevance ', ' personalization of treatment ', ' personalized therapy ', ' personalized treatment ', ' personalized medicine ', ' predictive assay ', ' predictive test ', ' learning classifier ', ' ']",NIGMS,UNIVERSITY OF GEORGIA,R01,2020,9815,GA-10,0.253183175078445
"Advancing Protein Engineering Using Artificial Intelligence and the ProtaBank Mutation Database PROJECT SUMMARY Therapeutic antibodies, specialized enzymes for drug manufacturing, small molecule drug screening agents, and other proteins have been instrumental in advancing biotechnology and medicine. Protein therapeutics alone represents a rapidly growing $100+ billion market with broad applications in the treatment of cancer, inflammatory and metabolic diseases, and numerous other disorders. Most of the antibodies and other protein therapeutics developed in the last several years have been engineered, leading to improvements in important properties such as efficacy, binding affinity, expression, stability, and immunogenicity. However, improving protein properties through sequence modification remains a challenging task. Artificial intelligence (AI), which has been enormously successful in several fields (e.g., image recognition, self-driving cars, natural language processing), is now being applied to protein engineering and has the potential to transform this field as well. AI and machine learning (ML) can take advantage of large and diverse datasets to identify correlations, predict beneficial mutations, and explore novel protein sequences in ways that are not possible using other techniques. Other advantages include the ability to simultaneously optimize multiple protein properties and explore sequence space more efficiently. In Phases I and II of this project, we developed the ProtaBank database as a central repository to store, organize, and annotate protein mutation data spanning a broad range of properties. ProtaBank is the largest and only database actively collecting such a comprehensive set of sequence mutation data and is growing rapidly due to the wealth of data being generated with advanced automation and next-generation sequencing techniques. ProtaBank's depth and breadth makes it an ideal data source to train ML models. This proposal aims to create the ProtaBank AI Platform to enable the use of AI and ML tools to apply the data in ProtaBank to engineer proteins. The platform will provide fully customizable computational tools and will invoke protein-specific knowledge to properly prepare data for use with ML models. An interface to popular ML frameworks will be provided so that scientists can use these techniques to discover new predictive algorithms and enhance their ability to design proteins with the desired properties. Specific aims include: (1) integrating peer validated ML methods and proprietary technology for protein engineering into the ProtaBank AI Platform, (2) developing dynamic ML dataset creation tools, (3) expanding and improving the ProtaBank database by reaching out to scientists to contribute data, (4) enhancing our data deposition tools, and (5) integrating ProtaBank with the Protein Data Bank structure database and other databases. ! Project Narrative Protein engineering has enabled significant advances in health care by playing a key role in the development of antibodies and other protein therapeutics (e.g., for the treatment of cancer, inflammatory and metabolic diseases, and other disorders), highly selective enzymes for drug manufacturing, and novel proteins for use in diagnostics and the identification of new small molecule drugs. This project will enable the power of artificial intelligence (AI) to be applied to accelerate the engineering of proteins with new and improved properties. AI approaches can capitalize on the large amounts of protein mutation data being generated and stored in our recently developed ProtaBank protein mutation database to transform the way in which protein therapeutics and reagents are discovered and developed.!",Advancing Protein Engineering Using Artificial Intelligence and the ProtaBank Mutation Database,9994932,R44GM117961,"['Amino Acid Sequence ', ' Primary Protein Structure ', ' protein sequence ', ' Antibodies ', ' Artificial Intelligence ', ' AI system ', ' Computer Reasoning ', ' Machine Intelligence ', ' Automation ', ' Automobile Driving ', ' driving ', ' Base Sequence ', ' Nucleotide Sequence ', ' nucleic acid sequence ', ' Biological Assay ', ' Assay ', ' Bioassay ', ' Biologic Assays ', ' Biotechnology ', ' Biotech ', ' Communities ', ' Data Sources ', ' Disease ', ' Disorder ', ' Pharmaceutical Preparations ', ' Drugs ', ' Medication ', ' Pharmaceutic Preparations ', ' drug/agent ', ' Engineering ', ' Enzymes ', ' Enzyme Gene ', ' Medicine ', ' Metabolic Diseases ', ' Metabolic Disorder ', ' Thesaurismosis ', ' metabolism disorder ', ' Mutation ', ' Genetic Alteration ', ' Genetic Change ', ' Genetic defect ', ' genome mutation ', ' Natural Language Processing ', ' natural language understanding ', ' Play ', ' Protein Engineering ', ' genetic protein engineering ', ' protein design ', ' Proteins ', ' Reagent ', ' Research Personnel ', ' Investigators ', ' Researchers ', ' Standardization ', ' Technology ', ' Generations ', ' health care ', ' Healthcare ', ' Dataset ', ' Data Set ', ' base ', ' improved ', ' Phase ', ' Link ', ' Training ', ' insight ', ' Data Bases ', ' data base ', ' Databases ', ' Meteor ', ' Inflammatory ', ' Deposit ', ' Deposition ', ' tool ', ' Diagnostic ', ' machine learned ', ' Machine Learning ', ' Knowledge ', ' Scientist ', ' Protocol ', ' Protocols documentation ', ' Techniques ', ' Structure ', ' novel ', ' peer ', ' Modeling ', ' Sampling ', ' Property ', ' depository ', ' repository ', ' native protein drug ', ' pharmaceutical protein ', ' protein drug agent ', ' therapeutic protein ', ' Cancer Treatment ', ' Malignant Neoplasm Therapy ', ' Malignant Neoplasm Treatment ', ' anti-cancer therapy ', ' anticancer therapy ', ' cancer therapy ', ' Molecular Interaction ', ' Binding ', ' small molecule ', ' protein structures ', ' proteins structure ', ' protein structure ', ' Affinity ', ' Data ', ' Collection ', ' Preparation ', ' Modification ', ' developmental ', ' Development ', ' imaging ', ' Image ', ' computational tools ', ' computerized tools ', ' immunogenicity ', ' designing ', ' design ', ' Coupled ', ' Therapeutic antibodies ', ' multi-task ', ' multitask ', ' data base structure ', ' database structure ', ' flexible ', ' flexibility ', ' NGS Method ', ' NGS system ', ' next gen sequencing ', ' nextgen sequencing ', ' next generation sequencing ', ' learning activity ', ' learning method ', ' learning strategy ', ' predictive algorithm ', ' predictor algorithm ', ' prediction algorithm ', ' Drug Screening ', ' Data Banks ', ' Databanks ', ' data depository ', ' data repository ', ' data warehouse ', ' data deposition ', ' data submission ', ' deep learning ', ' machine learning method ', ' ']",NIGMS,"PROTABIT, LLC",R44,2020,495160,CA-27,0.0816111822418586
"The Evolution of Gene Regulation and Human Disease PROJECT SUMMARY Genetic variants that disrupt the functionality of regulatory sequences, and thereby alter gene expression levels, are major contributors to both evolutionary divergence between species and differences in risk for complex disease among humans. However, due to the complexity of the gene regulatory programs encoded in mammalian genomes and their rapid turnover between species, evaluating the function of non-protein-coding mutations is challenging. This is a major roadblock to tracing the evolution of human-specific biology. In addition, since the majority of disease-associated variants are non-coding, it impairs our ability to map the genetics of complex disease.  The long-term mission of my lab is to interpret the complex gene regulatory programs encoded in the human genome and accurately model the effects of genetic mutations to these elements on phenotypes relevant to disease and human evolution. We work toward these goals by integrating cutting-edge machine learning, statistical modeling of evolution, and the analysis of genotypes and phenotypes from large-scale clinical biobanks. In particular, my lab is uniquely well positioned to build on our previous work to address the following fundamental questions:  1. How have evolutionary transitions on the human-lineage modified the genomein particular gene  regulatory programsto produce human-specific biology? And how do these modifications relate to  human-specific disease risk?  2. What are the combinatorial rules underlying how TF binding patterns specify precise control of gene  regulation? And how do these gene regulatory programs evolve between species?  3. How do genetic and epigenetic mechanisms interact to specify the dynamic gene regulatory programs  that drive cellular development? And how are these programs perturbed in disease?  4. How can we interpret non-protein-coding mutations identified in patient genomes to inform treatment  and preventative care? Our work will produce much-needed methods for understanding the effects of mutations to gene regulatory regions and identify mutations responsible for differences in disease risk between human populations. PROJECT NARRATIVE The genetic mutations that distinguish humans from other great apes and that influence risk for complex disease are mostly found outside of genes. Many of these mutations influence when and where genes are expressed. However, we do not know how to interpret the effects of most such mutations on gene regulation, disease risk, or human evolution, we will develop computational models that leverage machine learning, evolutionary patterns, and large-scale clinical biobanks to identify mutations that disrupt proper control of genes and lead to disease.",The Evolution of Gene Regulation and Human Disease,9904747,R35GM127087,"['Biology ', ' Disease ', ' Disorder ', ' Elements ', ' Evolution ', ' Gene Expression ', ' Gene Expression Regulation ', ' Gene Action Regulation ', ' Gene Regulation ', ' Gene Regulation Process ', ' Genes ', ' Regulator Genes ', ' Transcriptional Regulatory Elements ', ' regulatory gene ', ' trans acting element ', ' Genome ', ' Human Genome ', ' human whole genome ', ' Genotype ', ' Goals ', ' Human ', ' Modern Man ', ' Lead ', ' Pb element ', ' heavy metal Pb ', ' heavy metal lead ', ' Maps ', ' Methods ', ' Mission ', ' Statistical Models ', ' Probabilistic Models ', ' Probability Models ', ' statistical linear mixed models ', ' statistical linear models ', ' Mutation ', ' Genetic Alteration ', ' Genetic Change ', ' Genetic defect ', ' genome mutation ', ' Patients ', ' Phenotype ', ' Pongidae ', ' Apes ', ' great ape ', ' Nucleic Acid Regulatory Sequences ', ' Nucleic Acid Regulator Regions ', ' Regulatory Regions ', ' genetic regulatory element ', ' Risk ', ' Work ', ' species difference ', ' Clinical ', ' Specified ', ' Specific qualifier value ', ' Variation ', ' Variant ', ' Genetic ', ' machine learned ', ' Machine Learning ', ' programs ', ' Complex ', ' Pattern ', ' disease risk ', ' disorder risk ', ' Position ', ' Positioning Attribute ', ' Coding System ', ' Code ', ' Modeling ', ' Functional RNA ', ' Non-Coding ', ' Non-Coding RNA ', ' Non-translated RNA ', ' Noncoding RNA ', ' Nontranslated RNA ', ' noncoding ', ' Untranslated RNA ', ' Molecular Interaction ', ' Binding ', ' Address ', ' DNA Alteration ', ' DNA mutation ', ' Genetic mutation ', ' Sequence Alteration ', ' genomic alteration ', ' DNA Sequence Alteration ', ' Epigenetic ', ' Epigenetic Change ', ' Epigenetic Mechanism ', ' Epigenetic Process ', ' To specify ', ' Modification ', ' Gene variant ', ' allele variant ', ' allelic variant ', ' genomic variant ', ' genetic variant ', ' Population ', ' Impairment ', ' combinatorial ', ' mammalian genome ', ' human disease ', ' cellular development ', ' biorepository ', ' biobank ', ' Preventative care ', ' Preventive care ', ' Computerized Models ', ' computational modeling ', ' computational models ', ' computer based models ', ' computerized modeling ', ' Computer Models ', ' ']",NIGMS,VANDERBILT UNIVERSITY,R35,2020,86356,TN-05,0.11439979874233072
"The adaptive potential of translational regulation Project Summary/Abstract  Our current understanding of the adaptive effects of mutation is largely limited to alterations in protein coding sequence and disruption of transcriptional cis-regulatory promoters. Very little is known about how mutations alter translation, or the role these mutations play in adaptation and evolution. This project seeks to address this gap by identifying the functional effect of mutations on translation. To accomplish this I will first identify mutations that arise from adaptation to various nutrient limited environments. I will then use expression profiling (e.g. RNA-seq, ribosome profiling, and RATE-seq) to identify the effect these mutations have on translation, as well as other levels of gene expression. This will provide insight into the magnitude of effect mutations have on translation and their relative rate. Furthermore, to fully characterize the role synonymous mutations have on fitness I will be using a deep scanning synonymous mutation library. To understand the role tRNA abundance plays in the fitness effect of a given synonymous mutations, I will also be evaluating fitness within tRNA under- and over-expression backgrounds. Because of the closely coupled nature of translation rates and mRNA decay, I will also characterize the effect synonymous mutations have on mRNA decay using RATE-seq. My analysis of the functional effects of these mutations on gene expression, particularly within the genetic background and environment in which they arose, will allow for the development of a machine learning algorithm that can use sequence and annotation features to predict the effect of a mutation on gene expression. This tool will aid future research into the effect mutations have of gene expression by allowing the identification of high-confidence candidates for further evaluation.  This project will be conducted at New York Universitys Center for Genomics and Systems Biology, whose mission is to answer otherwise intractable biological questions using applied experimental and computational approaches. The Center houses numerous facilities and cores that will be instrumental in the performance of this work. The collaborative atmosphere and multi-disciplinary nature of NYUs research communities that will enable me to stay abreast of developments in related fields and to rapidly communicate my research to interested parties. I will be trained under the guidance of Dr. David Gresham, an excellent researcher working on complementing long-term evolution experiments with gene expression studies to characterize the adaptive potential of the regulation of gene expression. Project Narrative The translation of mRNA into protein is a critical step in gene expression that is tightly regulated with mis-regulation of translation being a hallmark of many human pathologies. Understanding how mutations can alter the regulation of translation is an understudied but important aspect of adaptation and evolution. Ultimately, without an understanding of the adaptive potential of translation we have an incomplete, and imperfect, picture of the underlying genetic causes of numerous forms of cancer and genetic diseases.",The adaptive potential of translational regulation,9893712,F32GM131573,"['Affect ', ' Amino Acid Sequence ', ' Primary Protein Structure ', ' protein sequence ', ' Biological Assay ', ' Assay ', ' Bioassay ', ' Biologic Assays ', ' Biology ', ' Malignant Neoplasms ', ' Cancers ', ' Malignant Tumor ', ' malignancy ', ' neoplasm/cancer ', ' Communities ', ' Complement ', ' Complement Proteins ', ' Disease ', ' Disorder ', ' Elements ', ' Environment ', ' Evolution ', ' Gene Expression ', ' Gene Expression Regulation ', ' Gene Action Regulation ', ' Gene Regulation ', ' Gene Regulation Process ', ' Genes ', ' Regulator Genes ', ' Transcriptional Regulatory Elements ', ' regulatory gene ', ' trans acting element ', ' Genome ', ' Goals ', ' Laboratories ', ' Libraries ', ' Literature ', ' Mission ', ' Modernization ', ' Mutation ', ' Genetic Alteration ', ' Genetic Change ', ' Genetic defect ', ' genome mutation ', ' New York ', ' Pathology ', ' Phenotype ', ' Play ', ' Proteins ', ' Research ', ' Research Personnel ', ' Investigators ', ' Researchers ', ' Ribosomes ', ' Transfer RNA ', ' Triplet Codon-Amino Acid Adaptor ', ' tRNA ', ' transfer Ribonucleic acids ', ' Role ', ' social role ', ' Computer software ', ' Software ', ' Stress ', ' Testing ', ' Genetic Transcription ', ' Gene Transcription ', ' RNA Expression ', ' Transcription ', ' Genetic Translation ', ' mRNA Translation ', ' Translations ', ' Universities ', ' Genetic Variation ', ' Genetic Diversity ', ' Work ', ' Generations ', ' Measures ', ' Open Reading Frames ', ' ORFs ', ' Protein Coding Region ', ' promotor ', ' promoter ', ' Site ', ' Variation ', ' Variant ', ' Biological ', ' Evaluation ', ' Training ', ' insight ', ' Genetic ', ' tool ', ' Nature ', ' machine learned ', ' Machine Learning ', ' Frequencies ', ' Scanning ', ' interest ', ' Nutrient ', ' novel ', ' cancer genetics ', ' Coding System ', ' Code ', ' Regulation ', ' Modeling ', ' response ', ' Functional RNA ', ' Non-Coding ', ' Non-Coding RNA ', ' Non-translated RNA ', ' Noncoding RNA ', ' Nontranslated RNA ', ' noncoding ', ' Untranslated RNA ', ' Genomics ', ' mRNA Decay ', ' mRNA Degradation ', ' mRNA Transcript Degradation ', ' job performance ', ' work performance ', ' Performance at work ', ' genome sequencing ', ' Address ', ' Systems Biology ', ' fitness ', ' Data ', ' Human Pathology ', ' Regulatory Element ', ' Translation Initiation ', ' Translational Regulation ', ' developmental ', ' Development ', ' environmental change ', ' Population ', ' Coupled ', ' analytical tool ', ' multidisciplinary ', ' RNA Seq ', ' RNA sequencing ', ' RNAseq ', ' transcriptome sequencing ', ' Business-Friendly Atmosphere ', ' business-friendly environment ', ' collaborative atmosphere ', ' interactive atmosphere ', ' interactive environment ', ' interdisciplinary atmosphere ', ' interdisciplinary environment ', ' peer-group atmosphere ', ' peer-group environment ', ' collaborative environment ', ' mutation scanning ', ' mutation screening ', ' entire genome ', ' full genome ', ' whole genome ', ' Ribo-seq ', ' ribosome footprint profiling ', ' ribosome profiling ', ' experiment ', ' experimental research ', ' experimental study ', ' Expression Profiling ', ' preservation ', ' genetic condition ', ' genetic disorder ', ' Genetic Diseases ', ' machine learned algorithm ', ' machine learning algorithm ', ' driver mutation ', ' ']",NIGMS,NEW YORK UNIVERSITY,F32,2020,65310,NY-12,0.21917813221896407
"A combined computational and experimental approach to the evolution and role of the DNA sequence environment in targeting mutations to antibody V regions Project summary There is a fundamental gap in our understanding of how mutations are preferentially targeted to the variable (V) regions of the Immunoglobulin (Ig) loci during somatic hypermutation (SHM). The persistence of this gap has limited our understanding of the mutagenic mechanisms involving activation-induced deaminase (AID) in the immune response and in the role of AID in mis-targeting mutations leading to B-cell lymphomas and other cancers. The long-term goal of the proposed research is to understand the global targeting of mutations in immunity that are required to protect us from infections. As high-throughput data from human antibody immune responses became available, it provided us with new opportunities to generate hypotheses to explain the underlying mechanisms of SHM. We now propose to generate further hypotheses using computational models applied to additional databases and to validate these hypotheses using cellular and animal experiments. Our objective is to understand what directs SHM across the many human Ig heavy chain V-regions. Our central hypothesis is that the V-region SHM process is highly dependent on a DNA sequence signature(s) that drives mutations in a largely deterministic fashion. This hypothesis is supported by our preliminary results using human in vivo data from a few human V region genes and has begun to be validated using independent databases and experiments in human B cell lines. The rationale is that evaluations of computational data based upon biological mechanisms, together with appropriate biological experiments, will reveal the key differences between IGHV regions (IGHV 3-23, 4-34, 1-18, 1-02, etc.) that lead to the dominance of each of those V regions in the responses to medically important antigens. Our hypothesis will be tested by pursuing two specific aims: 1) identify the extent to which a DNA signature determines the mutation process in four individual human IGHV genes that are important in disease responses; 2) examine the relationship between AID hotspots and Pol hotspots across all the other human V region genes, thus rigorously defining a mutation targeting signature. Both aims will also entail studying human V region genes and modifications of them in human cell lines and in mice expressing a human V region to further confirm the signature and identify molecular mechanisms in vivo. Our approach is innovative because the computational models we are proposing will be mechanistically motivated focusing on the interaction between AID and Pol hotspots, thus testing molecular mechanisms as opposed to classic statistical models using whole V region sequences that ignore the underlying biology. In addition, to focus on mechanisms we will leverage new high-throughput data from human V regions that have not undergone antigen selection. Our results will be highly relevant to human IgV repertoire analyses from immune responses that are currently hard to interpret and will help future vaccine and therapeutic antibody development, as well as help to understand mutations in human malignancies where AID plays a key role. Project narrative The proposed research is relevant to public health because understanding the targeting of AID-mediated mutations across many human heavy chain V-regions will make it possible to develop vaccines that will lead more rapidly to better and more broadly protective antibodies to infectious agents and reveal the risk factors in the development of B-cell malignancies and gastric and other solid tumors where AID is implicated.",A combined computational and experimental approach to the evolution and role of the DNA sequence environment in targeting mutations to antibody V regions,10090262,R01AI132507,"['Affect ', ' Alleles ', ' Allelomorphs ', ' Antibodies ', ' Antibody Affinity ', ' antigen antibody affinity ', ' Antigens ', ' immunogen ', ' Autoimmunity ', ' Autoimmune Status ', ' B-Lymphocytes ', ' B blood cells ', ' B cell ', ' B cells ', ' B-Cells ', ' B-cell ', ' Biology ', ' Malignant Neoplasms ', ' Cancers ', ' Malignant Tumor ', ' malignancy ', ' neoplasm/cancer ', ' Cell Line ', ' CellLine ', ' Strains Cell Lines ', ' cultured cell line ', ' Chromatin ', ' Disease ', ' Disorder ', ' DNA ', ' Deoxyribonucleic Acid ', ' Environment ', ' Enzyme Activation ', ' Evolution ', ' Family ', ' Feedback ', ' Future ', ' Genes ', ' Goals ', ' HIV ', ' AIDS Virus ', ' Acquired Immune Deficiency Syndrome Virus ', ' Acquired Immunodeficiency Syndrome Virus ', ' Human Immunodeficiency Viruses ', ' LAV-HTLV-III ', ' Lymphadenopathy-Associated Virus ', ' Virus-HIV ', ' Human ', ' Modern Man ', ' Immunity ', ' Complementarity Determining Regions ', ' Complimentarity Determining Region ', ' Hypervariable Loop ', ' Hypervariable Regions ', ' Immunoglobulin Hypervariable Region ', ' Immunoglobulins ', ' Immune Globulins ', ' Heavy-Chain Immunoglobulins ', ' Infection ', ' Influenza ', ' Grippe ', ' flu infection ', ' influenza infection ', ' Lead ', ' Pb element ', ' heavy metal Pb ', ' heavy metal lead ', ' Transgenic Mice ', ' Statistical Models ', ' Probabilistic Models ', ' Probability Models ', ' statistical linear mixed models ', ' statistical linear models ', ' Mus ', ' Mice ', ' Mice Mammals ', ' Murine ', ' Mutation ', ' Genetic Alteration ', ' Genetic Change ', ' Genetic defect ', ' genome mutation ', ' Play ', ' Public Health ', ' Research ', ' Risk Factors ', ' Role ', ' social role ', ' Stomach ', ' gastric ', ' Testing ', ' Time ', ' Vaccines ', ' B-Cell Lymphomas ', ' B lymphoma ', ' Mediating ', ' G(s), alpha Subunit ', ' G(s),  Subunit ', ' G(s)alpha ', ' G(s) ', ' GTP-Binding Protein  Subunits, Gs ', ' Gs alpha Family G-Protein ', ' Gs ', ' Gs ', ' Regulatory Ns Protein ', ' Stimulatory Gs G-Protein ', ' alpha Subunit Stimulatory GTP-Binding Protein ', ' alpha-Gs ', ' -Gs ', ' GTP-Binding Protein alpha Subunits, Gs ', ' DNA Sequence ', ' base ', ' density ', ' Site ', ' Variation ', ' Variant ', ' Biological ', ' Medical ', ' Animal Experiments ', ' Evaluation ', ' Individual ', ' Data Bases ', ' data base ', ' Databases ', ' Solid Tumor ', ' Solid Neoplasm ', ' Germinal Center ', ' Structure of germinal center of lymph node ', ' Immunological response ', ' host response ', ' immunoresponse ', ' Immune response ', ' infectious organism ', ' Infectious Agent ', ' machine learned ', ' Machine Learning ', ' Frequencies ', ' Event ', ' Pattern ', ' Techniques ', ' Location ', ' neutralizing antibody ', ' human data ', ' repair endonuclease ', ' repair enzyme ', ' Human Cell Line ', ' response ', ' Ig Somatic Hypermutation ', ' somatic hypermutation ', ' Immunoglobulin Somatic Hypermutation ', ' AICDA ', ' AICDA protein ', ' AID gene ', ' AID protein ', ' CDA2 protein ', ' activation-induced deaminase ', ' activation-induced cytidine deaminase ', ' Post-Replication Mismatch Repair ', ' Mismatch Repair ', ' chromatin modification ', ' Polymerase ', ' B-Cell Development ', ' Data ', ' Mutate ', ' in vivo ', ' in vivo Model ', ' computational analyses ', ' computational analysis ', ' computer analyses ', ' Computer Analysis ', ' gene modification ', ' Gene-Modified ', ' Validation ', ' Molecular ', ' Process ', ' developmental ', ' Development ', ' Gene variant ', ' allele variant ', ' allelic variant ', ' genomic variant ', ' genetic variant ', ' B cell malignancy ', ' B lymphoid malignancy ', ' Outcome ', ' innovate ', ' innovative ', ' innovation ', ' Influenza HA ', ' flu HA ', ' flu hemagglutinin ', ' influenza virus HA ', ' influenza virus hemagglutinin ', ' Influenza Hemagglutinin ', ' Therapeutic antibodies ', ' spatial relationship ', ' vaccine response ', ' knockin ', ' Knock-in ', ' experiment ', ' experimental research ', ' experimental study ', ' recruit ', ' Computerized Models ', ' computational modeling ', ' computational models ', ' computer based models ', ' computerized modeling ', ' Computer Models ', ' ']",NIAID,ALBERT EINSTEIN COLLEGE OF MEDICINE,R01,2020,38074,NY-14,0.15887011747240132
"The interaction of myosin and the thin filament: how mutations cause allosteric dysfunction and their connection to genetic cardiomyopathy Project Summary: The long-term goal of this research program is to develop a rigorously experimentally validated all-atom computational model of the cardiac thin filament (CTF) bound to myosin S1 which provides a unique and accessible platform to identify novel, high resolution disease mechanisms linked to Hypertrophic Cardiomyopathy (HCM). In the prior funding period, we refined and extended our existing CTF computational model and successfully employed it to identify unique and clinically relevant allosteric disease mechanisms including HCM mutation-induced changes in myofilament Ca2+ kinetics, mutation-specific molecular causes of differential cardiac remodeling and disease progression. This included an in vivo validation via the development of a novel transgenic mouse model of cTnT-linked dilated cardiomyopathy and a predictive algorithm to determine the pathogenicity of cTnT mutations that out-performed existing computational approaches in a preliminary test. The key to these advances has been the ability of the current model to precisely identify and locate allosteric changes caused by mutations throughout all components of the CTF followed by closely coupled experimental validation and eventual in vivo model correlation. We now propose to significantly expand the biological complexity of the model to include myosin S1, the molecular motor that drives contraction and the second most common genetic cause of HCM. This important and challenging advance will facilitate a deeper understanding of disease pathogenesis by, for the first time, incorporating the role of molecular allosteric mechanisms between myosin S1 and thin filament. This new computational  experimental platform will be used for both mechanistic insight (for example used for the identification of novel myofilament disease targets,) and the development of a comprehensive deep-learning predictive algorithm to assign pathogenicity to both myosin and thin filament HCM mutations. The latter represents the first use of high-resolution structure, dynamics and function to predict HCM disease allele pathogenicity, a central challenge in the clinical management of these complex patients. Both the training and testing components of the deep learning development will utilize data from the highly annotated and curated SHaRe HCM registry thus greatly improving translational power. Two Specific Aims will be pursued: Aim 1 will utilize state of the art rare event simulation methods developed in one of our groups and refinement of existing unstructured domains of the CTF via FRET to establish the new model. Aim 2 will employ an extensive program of computational analysis and subsequent in vitro validation using pathogenic, variants of unknown significance and non- pathogenic HCM alleles derived from SHaRe to provide inputs to the machine learning environment for algorithm development. Novel disease mechanisms for myosin and thin filament HCM that include crosstalk between the two components will also be explored. Elucidation of these mechanisms can be the basis for robust molecular approaches to disease. Precision medicine and molecular medicine are concepts that aim to employ a patients genetic structure to discern the best medical treatments for disease. Hypertrophic cardiomyopathy is a genetic disease that afflicts 1/500 people. This application translates our knowledge of the molecular level effects of cardiac tissue mutation to disease and will aim to lead to eventual treatment.",The interaction of myosin and the thin filament: how mutations cause allosteric dysfunction and their connection to genetic cardiomyopathy,10071638,R01HL107046,"['Alleles ', ' Allelomorphs ', ' Artificial Intelligence ', ' AI system ', ' Computer Reasoning ', ' Machine Intelligence ', ' Biological Assay ', ' Assay ', ' Bioassay ', ' Biologic Assays ', ' Biology ', ' Biophysics ', ' biophysical foundation ', ' biophysical principles ', ' biophysical sciences ', ' Breath Tests ', ' breath analysis ', ' Differential Scanning Calorimetry ', ' Calorimetric Differential Thermal Analysis ', ' Dilated Cardiomyopathy ', ' Congestive Cardiomyopathy ', ' Translating ', ' Work ', ' Generations ', ' Anisotropy ', ' Fluorescence Anisotropy ', ' Dataset ', ' Data Set ', ' base ', ' improved ', ' Site ', ' Variation ', ' Variant ', ' Biological ', ' Physiologic ', ' Physiological ', ' Medical ', ' Link ', ' Training ', ' insight ', ' Individual ', ' Disease Progression ', ' Funding ', ' Dysfunction ', ' Physiopathology ', ' pathophysiology ', ' Functional disorder ', ' Descriptor ', ' Genetic ', ' Contracting Opportunities ', ' Contracts ', ' machine learned ', ' Machine Learning ', ' Knowledge ', ' programs ', ' Complex ', ' Event ', ' Distant ', ' Techniques ', ' System ', ' computational quantum chemistry ', ' quantum chemistry ', ' success ', ' FRET ', ' Frster Resonance Energy Transfer ', ' Fluorescence Resonance Energy Transfer ', ' Molecular Motors ', ' Structure ', ' simulation ', ' novel ', ' Pathogenesis ', ' Modeling ', ' Sampling ', ' response ', ' Pathogenicity ', ' Genetic Structures ', ' Thick Filament ', ' Thin Filament ', ' Address ', ' Data ', ' Induced DNA Alteration ', ' Induced Sequence Alteration ', ' Induced Mutation ', ' Molecular Medicine ', ' Motor ', ' Protein Dynamics ', ' Resolution ', ' in vivo ', ' in vivo Model ', ' Clinical Management ', ' computational analyses ', ' computational analysis ', ' computer analyses ', ' Computer Analysis ', ' Validation ', ' Molecular ', ' Cardiac ', ' developmental ', ' Development ', ' next generation ', ' Coupled ', ' C-terminal ', ' clinical relevance ', ' clinically relevant ', ' murine model ', ' mouse model ', ' stopped-flow fluorescence ', ' precision-based medicine ', ' precision medicine ', ' unclassified variant ', ' variant of uncertain clinical significance ', ' variant of uncertain significance ', ' variant of undetermined significance ', ' variant of unknown significance ', ' classroom environment ', ' college atmosphere ', ' collegial atmosphere ', ' collegiate atmosphere ', ' education atmosphere ', ' educational environment ', ' intellectual atmosphere ', ' learning atmosphere ', ' learning environment ', ' school atmosphere ', ' training atmosphere ', ' university atmosphere ', ' educational atmosphere ', ' predictive algorithm ', ' predictor algorithm ', ' prediction algorithm ', ' experiment ', ' experimental research ', ' experimental study ', ' genetic condition ', ' genetic disorder ', ' Genetic Diseases ', ' deep learning ', ' neural network ', ' machine learned algorithm ', ' machine learning algorithm ', ' automated analysis ', ' familial cardiomyopathy ', ' genetic cardiomyopathy ', ' hereditary cardiomyopathy ', ' inherited cardiomyopathy ', ' Computerized Models ', ' computational modeling ', ' computational models ', ' computer based models ', ' computerized modeling ', ' Computer Models ', ' algorithm development ', ' Hypertrophic Cardiomyopathy ', ' Asymmetric Septal Hypertrophy ', ' Cardiomyopathy familial hypertrophic ', ' Hereditary ventricular hypertrophy ', ' Hypertrophic Obstructive Cardiomyopathy ', ' Idiopathic Hypertrophic Subvalvular Stenosis ', ' Idiopathic hypertrophic subaortic stenosis ', ' hypertrophic myocardiopathy ', ' cell motility ', ' Cell Locomotion ', ' Cell Migration ', ' Cell Movement ', ' Cellular Migration ', ' Cellular Motility ', ' Motility ', ' Chemistry ', ' Disease ', ' Disorder ', ' Engineering ', ' Enzymes ', ' Enzyme Gene ', ' Goals ', ' Grant ', ' Hand ', ' Human ', ' Modern Man ', ' In Vitro ', ' Kinetics ', ' Lead ', ' Pb element ', ' heavy metal Pb ', ' heavy metal lead ', ' Manuals ', ' Methods ', ' Methodology ', ' Transgenic Mice ', ' Microfilaments ', ' Actin Filaments ', ' Myofilaments ', ' Molecular Conformation ', ' Molecular Configuration ', ' Molecular Stereochemistry ', ' conformation ', ' conformational state ', ' Mutation ', ' Genetic Alteration ', ' Genetic Change ', ' Genetic defect ', ' genome mutation ', ' Myosin ATPase ', ' Actin-Activated ATPase ', ' Myosin Adenosine Triphosphatase ', ' Myosin Adenosinetriphosphatase ', ' Myosins ', ' Patients ', ' Perception ', ' phosphorescence ', ' Play ', ' Protein Conformation ', ' Proteins ', ' Registries ', ' Research ', ' Resources ', ' Research Resources ', ' Role ', ' social role ', ' Sarcomeres ', ' Technology ', ' Testing ', ' Thinness ', ' Leanness ', ' Time ', ' Tissues ', ' Body Tissues ', ' ']",NHLBI,UNIVERSITY OF ARIZONA,R01,2020,585711,AZ-03,0.12229390151084266
"Molecular Characterization of Joubert Syndrome Project Summary Congenital ataxia presents in early childhood with non-progressive hypotonia, gross motor, fine motor and cognitive delays. These disorders are distinct from the progressive ataxias because of the presence of congenital cerebellar malformations and because they are typically inherited recessively. Joubert Syndrome and Related Disorders (JSRD) constitute a major subset of these conditions, consisting of a cerebellar midline (vermis) malformation, a nearly pathognomonic Molar Tooth sign on brain Imaging (MTI) and co-existent oculomotor apraxia and episodic breathing dysrhythmias. In our published data, we have: 1] Identified ten unique genetic causes of JSRD (nearly half of the published causes), 2] Generated genotype-phenotype correlations involving cerebellar, retinal, renal, hepatic, digit, and cerebral manifestations. 3] Identified common founder mutations that allow for population-based screening. 4] Discovered that JSRD encoded proteins frequently localize to the cilium. 5] Identified ciliary transition zone (TZ) defects in cells with JSRD mutations. 6] Performed siRNA cell-based screens for defective ciliogenesis to prioritize candidate JSRD genes. 7] Generated and characterized multiple zebrafish, mouse and human cell culture models for JSRD. 8] Defined the concept of Ciliary localization model, in which one JSRD gene is required for ciliary localization of other JSRD proteins. In our unpublished data we have: 1] Recruited an additional 200 JSRD patients without molecular diagnosis. 2] Performed whole exome (WES) and whole genome sequencing (WGS) on an additional 100 JSRD families. 3] Identified an additional 12 novel likely JSRD candidate genes. 4] Generated IPSCs and cerebellar organoids from mutation-positive and negative families to aid in functional analysis and gene discovery using RNAseq. 5] Begun functional validation of the putative mutations. 6] Developed methods to interrogate ciliary structure in a high-throughput fashion with electron microscopy (EM). The goal of this competing renewal is to identify the remaining discoverable genes that lead to JSRD when lost, functionally validate mutations within the pathogenetic framework, and test the hypothesis that mutations in JSRD genes lead to collapse of the ciliary TZ. Because the majority of patients still have unknown cause of disease, this renewal aims to advance knowledge through molecular characterization of new genes, using newly evolving high-throughput techniques, integrated bioinformatics, and a unique resource of consanguineous families recruited world-wide. We further aim to validate these mutations in patient cells, within a mechanistic framework that JSRD genes are required for essential ciliary structural components during cerebellar development. Project Narrative Joubert syndrome is a genetically and phenotypically heterogeneous neurodevelopmental disorder unified by defects of the cellular primary cilium. This work will identify new genetic causes and dissect ciliary defects associated with genetic mutations.",Molecular Characterization of Joubert Syndrome,9988508,R01NS048453,"['Termination of pregnancy ', ' Apraxias ', ' Dyspraxia ', ' apraxia ', ' Breathing ', ' Respiratory Aspiration ', ' Respiratory Inspiration ', ' inspiration ', ' Ataxia ', ' Ataxy ', ' Coordination Impairment ', ' Dyssynergia ', ' Cell Culture Techniques ', ' cell culture ', ' Cells ', ' Cell Body ', ' Cultured Cells ', ' Cilia ', ' Cytoplasmic Granules ', ' granule ', ' Disease ', ' Disorder ', ' Electrons ', ' Negative Beta Particle ', ' Negatrons ', ' Embryo ', ' Embryonic ', ' Face ', ' faces ', ' facial ', ' Family ', ' Genes ', ' Genotype ', ' Goals ', ' Gold ', ' Human ', ' Modern Man ', ' Kidney ', ' Kidney Urinary System ', ' renal ', ' Lead ', ' Pb element ', ' heavy metal Pb ', ' heavy metal lead ', ' Methods ', ' Electron Microscopy ', ' Scanning Electron Microscopy ', ' Middle East ', ' Molar tooth ', ' Morphogenesis ', ' morphogenetic process ', ' Mus ', ' Mice ', ' Mice Mammals ', ' Murine ', ' Muscle hypotonia ', ' Decreased Muscle Tone ', ' Hypomyotonia ', ' Hypotonia ', ' Muscle Hypotony ', ' Muscle Tone Poor ', ' Muscular Hypotonia ', ' Mutation ', ' Genetic Alteration ', ' Genetic Change ', ' Genetic defect ', ' genome mutation ', ' Organoids ', ' Patients ', ' Phenotype ', ' Probability ', ' Proteins ', ' Publishing ', ' Resources ', ' Research Resources ', ' Retina ', ' Risk ', ' Signal Transduction ', ' Cell Communication and Signaling ', ' Cell Signaling ', ' Intracellular Communication and Signaling ', ' Signal Transduction Systems ', ' Signaling ', ' biological signal transduction ', ' Sonication ', ' Mass Spectrum Analysis ', ' Mass Photometry/Spectrum Analysis ', ' Mass Spectrometry ', ' Mass Spectroscopy ', ' Mass Spectrum ', ' Mass Spectrum Analyses ', ' Syndrome ', ' Testing ', ' Work ', ' Zebrafish ', ' Brachydanio rerio ', ' Danio rerio ', ' Zebra Danio ', ' Zebra Fish ', ' base ', ' brain visualization ', ' Brain imaging ', ' Hepatic ', ' Clinical ', ' Microscopic ', ' Variation ', ' Variant ', ' Series ', ' Training ', ' vermis ', ' Cerebellar vermis structure ', ' insight ', ' Individual ', ' cerebral ', ' Cerebrum ', ' Data Bases ', ' data base ', ' Databases ', ' Cerebellar hypoplasia ', ' Congenital cerebellar hypoplasia ', ' Genetic ', ' Morphology ', ' machine learned ', ' Machine Learning ', ' Knowledge ', ' Joubert-Boltshauser syndrome ', ' cerebellar vermis agenesis ', ' cerebelloparenchymal disorder IV ', ' Joubert syndrome ', ' Hereditary ', ' Inherited ', ' Severities ', ' cell type ', ' Techniques ', ' fetal ', ' Digit ', ' Digit structure ', ' Gene Alteration ', ' Gene Mutation ', ' mutant ', ' early childhood ', ' cohort ', ' Transmission Electron Microscopy ', ' Structure ', ' novel ', ' Modeling ', ' affection ', ' ocular motor ', ' ocularmotor ', ' oculomotor ', ' disease subgroups ', ' disease subtype ', ' disorder subtype ', ' Short interfering RNA ', ' siRNA ', ' Small Interfering RNA ', ' Pathogenicity ', ' Bio-Informatics ', ' Bioinformatics ', ' ciliogenesis ', ' cilium biogenesis ', ' genome sequencing ', ' Candidate Gene ', ' Candidate Disease Gene ', ' Length ', ' Defect ', ' DNA Alteration ', ' DNA mutation ', ' Genetic mutation ', ' Sequence Alteration ', ' genomic alteration ', ' DNA Sequence Alteration ', ' Data ', ' Molecular Diagnosis ', ' Motor ', ' Protein Analysis ', ' Cognitive ', ' enroll ', ' Enrollment ', ' Validation ', ' WNT signaling ', ' WNT Signaling Pathway ', ' Molecular ', ' Knockout ', ' Knock-out ', ' developmental ', ' Development ', ' Neurological Development Disorder ', ' Neurodevelopmental Disorder ', ' Cerebellum malformation ', ' Cerebellar malformation ', ' reconstruction ', ' knockdown ', ' knock-down ', ' 3-D analysis ', ' 3-dimensional analysis ', ' 3D analysis ', ' Three-dimensional analysis ', ' loss of function mutation ', ' founder mutation ', ' malformation ', ' discover genes ', ' gene discovery ', ' population based ', ' stem cell biology ', ' genome scale ', ' genomewide ', ' genome-wide ', ' exomes ', ' exome ', ' RNA Seq ', ' RNA sequencing ', ' RNAseq ', ' transcriptome sequencing ', ' exome-seq ', ' exome sequencing ', ' screening ', ' CRISPR ', ' CRISPR/Cas system ', ' Clustered Regularly Interspaced Short Palindromic Repeats ', ' accurate diagnosis ', ' consanguineous kindreds ', ' consanguineous pedigree ', ' consanguineous family ', ' entire genome ', ' full genome ', ' whole genome ', ' recruit ', ' gene testing ', ' gene-based testing ', ' genetic testing ', ' ']",NINDS,"UNIVERSITY OF CALIFORNIA, SAN DIEGO",R01,2020,510012,CA-52,0.20843462185098818
"Evolutionary Human Genomics: Demography, Natural Selection, and Transcriptional Regulation To be fully understood, the human genome must be considered in the context of evolution. The activities that have dominated human genomics for three decades  such as genome sequencing and annotation, interrogation with high-throughput biochemical assays, and the identification of associations between genetic variants and diseases  have been enormously informative, but these descriptive studies must eventually be understood within the theoretical framework of evolutionary genetics. We must continue to press forward from the what? to the why? and how? of human genetics.  The goal of my laboratory is to interpret high-throughput genomic data from an evolutionary perspective. Drawing from ideas and techniques in molecular evolution, population genetics, statistics, and computer science, we aim both to understand the evolutionary forces that have shaped human genomes, and to use evolution to shed light on the phenotypic importance of particular sequences. Our recent activities have focused in three major areas: (1)  reconstruction  of  features  of  human  evolution  based  on  genome  sequences;  (2)  prediction  of  the  fitness consequences  of  human  mutations;  and  (3)  the  study  of  transcriptional  regulation  and  its  evolution  in primates.   We have reported major findings in each of these areas, including the existence of gene flow from early modern humans to Eastern Neandertals, a map of fitness consequences for mutations across the human genome, and an analysis showing that the architecture of transcription initiation is highly similar at enhancers and promoters in the human genome.  Here we propose to extend our research substantially in each of these areas, working together with a broad range  of  experimental  and  theoretical  collaborators.    Our  new  goals  include  the  development  of  improved methods for reconstructing human demography, with a focus on ancient gene flow; extensions of our ancestral recombination graph (ARG) sampling methods to accommodate much larger samples sizes, with applications in association mapping and the detection of natural selection; two complementary machine-learning approaches for  improving  the  prediction  of  fitness  consequences  from  sequence  data;  an  experimental  collaboration  to leverage CRISPR-Cas9 screens in characterizing noncoding mutations; a multi-pronged study of the sequence determinants of RNA stability and their implications for the evolution of transcription units; and development of a new probabilistic model for turnover of regulatory elements.  Together, these projects will address a wide variety of fundamental questions about the function and evolution of sequences in the human genome. Vast quantities of genomic data are now available to describe patterns of genetic variation within  human populations and across species, and various measures of biochemical activity along the human  genome. These data need to be interpreted in light of the fundamental forces of mutation,  recombination, natural selection, and genetic drift that have shaped genetic variation. This  proposal describes a series of projects that make use of new computational, statistical, and  theoretical methods to address fundamental questions in human evolutionary genetics, including how  humans arose   from our archaic hominin and ape cousins, how human populations diverged from one  another, how new mutations influence human health and fitness, and how regulatory sequences  contribute to unique aspects of human biology.","Evolutionary Human Genomics: Demography, Natural Selection, and Transcriptional Regulation",9876220,R35GM127070,"['Architecture ', ' Engineering / Architecture ', ' Biological Assay ', ' Assay ', ' Bioassay ', ' Biologic Assays ', ' Demography ', ' Evolution ', ' Genes ', ' Population Genetics ', ' Genome ', ' Human Genome ', ' human whole genome ', ' Goals ', ' Health ', ' Human ', ' Modern Man ', ' Human Genetics ', ' Laboratories ', ' Light ', ' Photoradiation ', ' Maps ', ' Methods ', ' Statistical Models ', ' Probabilistic Models ', ' Probability Models ', ' statistical linear mixed models ', ' statistical linear models ', ' Modernization ', ' Mutation ', ' Genetic Alteration ', ' Genetic Change ', ' Genetic defect ', ' genome mutation ', ' Phenotype ', ' Pongidae ', ' Apes ', ' great ape ', ' Primates ', ' Primates Mammals ', ' Genetic Recombination ', ' DNA Recombination ', ' Recombination ', ' Research ', ' statistics ', ' Genetic Transcription ', ' Gene Transcription ', ' RNA Expression ', ' Transcription ', ' Genetic Variation ', ' Genetic Diversity ', ' Measures ', ' Enhancers ', ' Natural Selections ', ' promotor ', ' promoter ', ' base ', ' improved ', ' Area ', ' Biochemical ', ' Series ', ' Sample Size ', ' Collaborations ', ' Molecular Evolution ', ' Genetic ', ' machine learned ', ' Machine Learning ', ' Pattern ', ' Techniques ', ' computer science ', ' Human Biology ', ' Graph ', ' Reporting ', ' RNA Stability ', ' Sampling ', ' Functional RNA ', ' Non-Coding ', ' Non-Coding RNA ', ' Non-translated RNA ', ' Noncoding RNA ', ' Nontranslated RNA ', ' noncoding ', ' Untranslated RNA ', ' Genetic Differentiation ', ' Genetic Divergence ', ' Genetic Drift ', ' Transcription Regulation ', ' Transcriptional Control ', ' Transcriptional Regulation ', ' Transcription Initiation ', ' genome sequencing ', ' Address ', ' fitness ', ' Data ', ' Detection ', ' Regulatory Element ', ' developmental ', ' Development ', ' reconstruction ', ' Gene variant ', ' allele variant ', ' allelic variant ', ' genomic variant ', ' genetic variant ', ' Population ', ' genome annotation ', ' genome analysis ', ' human genomics ', ' CRISPR editing screen ', ' CRISPR-based screen ', ' CRISPR/Cas9 screen ', ' clustered regularly interspaced short palindromic repeats screen ', ' CRISPR screen ', ' genomic data-set ', ' genomic dataset ', ' genomic data ', ' genetic condition ', ' genetic disorder ', ' Genetic Diseases ', ' ']",NIGMS,COLD SPRING HARBOR LABORATORY,R35,2020,479215,NY-03,0.07480630374161072
"Blood mitochondrial DNA biomarkers of midlife cognitive decline and adverse brain imaging changes - A longitudinal investigation in the CARDIA populationbased cohort study SUMMARY Alzheimers disease and related dementias (ADRDs) are typically the result of neurodegenerative processes that begin 15-20 years before clinical diagnosis. Despite this lengthy subclinical phase and advances in early diagnostic technologies including cerebrospinal fluid (CSF) biomarkers, brain MRIs, and positron emission tomography (PET) measures there are no scalable biomarkers to identify individuals with preclinical disease, which may offer the best time window for intervention. Specifically, because brain MRI and PET tests are resource-intensive and CSF sampling is invasive, there is urgent need for biomarkers based on blood samples, which can be non-invasively collected even in centers lacking highly specialized technology. The mitochondrial genome (mtDNA), unlike the stable nuclear genome, is dynamic and accumulates somatic mutations over the lifespan. Mutations in the mtDNA can be induced by oxidative stress and lead to declining mitochondrial function as we age; in turn, less functional mitochondria generate higher levels of oxidative stress, which induces chronic inflammation and tissue injury in specific organs including the brain. Yet, no study has investigated mtDNA mutations as early predictors of ADRD. We hypothesize that individuals with higher levels and faster accumulation of blood mtDNA mutations have greater cognitive decline and preclinical ADRD brain imaging changes during midlife, and that these mtDNA biomarkers will predict ADRD diagnosis in older adults. We will test our hypotheses by leveraging the NHLBI-funded Coronary Artery Risk Development In young Adults (CARDIA) study. CARDIA is a multicenter, community-based, longitudinal cohort that recruited 5,115 black and white young adults (mean age 25 years), followed them up at least every five years, and is preparing to conduct its examination Year 35 (Y35) visit in 2020/21 (mean age 60 years) when over 3,000 participants are expected to return. We will use state-of-the-art deep sequencing technology to measure mtDNA mutations in CARDIA blood samples collected at Y15, Y25, and Y35. In Aim 1, we will determine whether higher levels of mtDNA mutations and their accumulation over time are associated with greater cognitive decline in midlife. In Aim 2, we will determine whether mtDNA mutations are associated with structural, physiological, and functional MRI phenotypes of preclinical ADRD as well as with sensitive MRI-based markers of accelerated brain aging and preclinical ADRD constructed by our team using contemporary machine learning techniques. Finally, in Aim 3, we will test the clinical utility of these mtDNA mutation biomarkers in identifying individuals at risk of future ADRD in four older cohorts that have large numbers of longitudinally identified, clinically-diagnosed ADRD. Our focus on longitudinal measures of blood mtDNA, cognitive function, and MRI changes over a 10- year period during midlife, combined with characterization of their clinical utility in older populations, is highly innovative. If successful, our study may help initiate possible future interventions in early midlife and reduce the public health and medical burden of AD and dementia. PUBLIC HEALTH STATEMENT This study has high potential for characterizing novel blood-based biomarkers to identify preclinical ADRD and test their utility in predicting clinical ADRD. No other study has a similar design with repeated blood mtDNA mutations, cognitive assessments, and brain imaging data during midlife, a critical time window for interventions to prevent clinical ADRD development. By also using data from four large cohorts of older adults, we can determine the clinical utility of these mtDNA biomarkers to predict clinical ADRD and move the field closer toward the NIHs goal of personalized health interventions.",Blood mitochondrial DNA biomarkers of midlife cognitive decline and adverse brain imaging changes - A longitudinal investigation in the CARDIA populationbased cohort study,10055446,R01AG069120,"['Age ', ' ages ', ' Elderly ', ' advanced age ', ' elders ', ' geriatric ', ' late life ', ' later life ', ' older adult ', ' older person ', ' senior citizen ', ' Aging ', "" Alzheimer's Disease "", ' AD dementia ', ' Alzheimer ', ' Alzheimer Type Dementia ', ' Alzheimer disease ', ' Alzheimer sclerosis ', ' Alzheimer syndrome ', "" Alzheimer's "", "" Alzheimer's disease dementia "", ' Alzheimers Dementia ', ' Alzheimers disease ', ' Primary Senile Degenerative Dementia ', ' dementia of the Alzheimer type ', ' primary degenerative dementia ', ' senile dementia of the Alzheimer type ', ' Blood ', ' Blood Reticuloendothelial System ', ' Brain ', ' Brain Nervous System ', ' Encephalon ', ' Cerebrospinal Fluid ', ' cerebral spinal fluid ', ' spinal fluid ', ' Clinical Markers ', ' Cohort Studies ', ' Concurrent Studies ', ' Communities ', ' Diagnosis ', ' Disease ', ' Disorder ', ' Mitochondrial DNA ', ' mtDNA ', ' Future ', ' Genome ', ' Goals ', ' Health ', ' Inflammation ', ' Lead ', ' Pb element ', ' heavy metal Pb ', ' heavy metal lead ', ' Longevity ', ' Length of Life ', ' life span ', ' lifespan ', ' Magnetic Resonance Imaging ', ' MR Imaging ', ' MR Tomography ', ' MRI ', ' Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance ', ' NMR Imaging ', ' NMR Tomography ', ' Nuclear Magnetic Resonance Imaging ', ' Zeugmatography ', ' middle age ', ' mid life ', ' mid-life ', ' middle aged ', ' midlife ', ' Mitochondria ', ' mitochondrial ', ' Mutation ', ' Genetic Alteration ', ' Genetic Change ', ' Genetic defect ', ' genome mutation ', ' United States National Institutes of Health ', ' NIH ', ' National Institutes of Health ', ' Nerve Degeneration ', ' Neuron Degeneration ', ' neural degeneration ', ' neurodegeneration ', ' neurodegenerative ', ' neurological degeneration ', ' neuronal degeneration ', ' Patients ', ' Phenotype ', ' Positron-Emission Tomography ', ' PET ', ' PET Scan ', ' PET imaging ', ' PETSCAN ', ' PETT ', ' Positron Emission Tomography Medical Imaging ', ' Positron Emission Tomography Scan ', ' Rad.-PET ', ' positron emission tomographic (PET) imaging ', ' positron emission tomographic imaging ', ' positron emitting tomography ', ' Public Health ', ' Research ', ' Research Design ', ' Study Type ', ' study design ', ' Research Personnel ', ' Investigators ', ' Researchers ', ' Resources ', ' Research Resources ', ' Risk ', ' Role ', ' social role ', ' Technology ', ' Testing ', ' Time ', ' Work ', ' Measures ', ' base ', ' Organ ', ' Blood Sample ', ' Blood specimen ', ' brain visualization ', ' Brain imaging ', ' Chronic ', ' Solid ', ' Clinical ', ' Phase ', ' Physiologic ', ' Physiological ', ' Medical ', ' Link ', ' insight ', ' brain atrophy ', ' cortical atrophy ', ' cerebral atrophy ', ' Individual ', ' adult youth ', ' young adulthood ', ' young adult ', ' Oxidative Stress ', ' Funding ', ' clinical Diagnosis ', ' tool ', ' Cognitive Disturbance ', ' Cognitive Impairment ', ' Cognitive decline ', ' Cognitive function abnormal ', ' Disturbance in cognition ', ' cognitive dysfunction ', ' cognitive loss ', ' Impaired cognition ', ' Diagnostic ', ' machine learned ', ' Machine Learning ', ' Functional MRI ', ' fMRI ', ' Functional Magnetic Resonance Imaging ', ' programs ', ' cognitive function ', ' Investigation ', ' Pattern ', ' Techniques ', ' Nuclear ', ' Somatic Mutation ', ' Visit ', ' experience ', ' cohort ', ' Structure ', ' novel ', ' Participant ', ' Environmental Factor ', ' environmental risk ', ' Environmental Risk Factor ', ' Sampling ', ' Intervention Strategies ', ' interventional strategy ', ' Intervention ', ' mtDNA mutation ', ' mitochondrial DNA mutation ', ' preventing ', ' prevent ', ' genome sequencing ', ' Address ', ' Data ', ' Cognitive ', ' Older Population ', ' Process ', ' Active Follow-up ', ' active followup ', ' follow up ', ' followed up ', ' followup ', ' follow-up ', ' developmental ', ' Development ', ' preclinical ', ' pre-clinical ', ' mitochondrial genome ', ' NHLBI ', ' National Heart, Lung, and Blood Institute ', ' deep sequencing ', ' age dependent ', ' age related ', ' designing ', ' design ', ' aged ', ' prospective ', ' innovate ', ' innovative ', ' innovation ', ' aged brain ', ' aging brain ', ' Alzheimer risk factor ', ' alzheimer risk ', "" Alzheimer's disease risk "", ' Framingham Heart Study ', ' critical period ', ' population based ', ' bio-markers ', ' biologic marker ', ' biomarker ', ' Biological Markers ', ' clinical risk ', ' epigenome ', ' clinical predictors ', ' predictive biomarkers ', ' predictive molecular biomarker ', ' predictive marker ', ' cognitive assessment ', ' cognitive testing ', ' Coronary Artery Risk Development in Young Adults ', ' Coronary Artery Risk Development in Young Adults Study ', ' entire genome ', ' full genome ', ' whole genome ', ' TOPMed ', ' Trans-Omics for Precision Medicine ', ' blood-based marker ', ' blood-based biomarker ', ' Long-term cohort ', ' Longterm cohort ', ' Longitudinal cohort ', ' recruit ', ' AD related dementia ', ' ADRD ', ' Alzheimer related dementia ', "" Alzheimer's disease related dementia "", ' risk factor for dementia ', ' risk for dementia ', ' dementia risk ', ' injury to tissue ', ' tissue injury ', ' ']",NIA,COLUMBIA UNIVERSITY HEALTH SCIENCES,R01,2020,852784,NY-13,0.0930199859848389
